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 SUMMARY 
 
Mass spectrometry is the primary technology of proteomics. For the analysis of complex 
proteomes, protein identities and quantities are inferred from their peptides that are 
generated by cleaving all proteins with the endopeptidase trypsin. But there is one major 
disadvantage that is due to biophysical differences, different peptides cause different 
intensities. Miscellaneous approaches have been developed to circumvent this problem 
based on the chemical or metabolic introduction of heavy stable isotopes. This enables to 
monitor protein abundance differences of two or more samples on the same tryptic 
peptides that differ in mass only. Absolute quantification can be achieved similar by spiking-
in synthetic isotopical labeled counterparts of a sample’s tryptic peptides. However, labeling 
technics suffer from high prices, introduced biases, need for extensive manual control, 
laborious implementation and implementation restrictions. Therefore, a multiplicity of 
label-free approaches have been developed that profit from instrumental improvements 
targeting reliability of identifications and reproducibility of quantitative values. No extensive 
systematic comparison of label-free quantitative parameters has been published so far 
presumably because of the laborious implementation. An analysis of primary label-free 
parameters and associated normalization methods is presented here that compares 
dynamic and linear ranges and accuracies in the estimation of protein amounts. This 
facilitated the establishment of label-free procedures addressing three fundamental 
questions in proteomics: what is a sample’s composition, are proteins that share a specific 
property enriched and what are the differences between two (or more) samples. A new 
mathematic model is presented that defines and elucidates enrichment.  
The procedures were applied first to analyze and compare stem cell plasma membrane 
proteomes. This is an ambitious model for proteomics because of only small amounts of 
arduous to analyze, partial hydrophobic proteins in a complex proteomic and chemical 
background. It is of scientific relevance, as membrane proteins are the cell’s communication 
interface that enable cell type specific processes and hence can be used to define, isolate 
and quantify those. The success of cell surface proteome enrichment, the quantitative 
composition of the proteome and the proteomic difference between stem cells isolated 
from the dental pulp and cultivated in different media is shown. 
Secondly, the procedures were applied to the analysis of transient protein networks that 
assemble onto proteo-liposomes in a newly designed recruitment assay that fully 
recapitulates membrane sorting as seen in vivo. All transmembrane proteins need to be 
trafficked to other organelles’ membranes by vesicular trafficking. Sorting signals within the 
cytosolic regions of the protein cargos trigger the formation of trafficking complexes around 
those. The transient membrane complexes additionally recognize organelle or organelle-
domain specific membrane lipids, such as phosphatidylinositol phosphates. Different 
trafficking ways are characterized by different trafficking complexes. The elucidation of 
trafficking complexes that form around a transmembrane protein of interest discloses its 
trafficking routes and involved signaling processes. The synthetic proteo-liposomes were 
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prepared from chemically defined lipids and heterologous expressed cytosolic domains of 
type-I or type-II membrane receptors. The proteomic analyses of such samples are 
challenging because of huge proteomic backgrounds of proteins binding to the liposomes 
irrespective of the receptor and relatively small amounts and numbers of receptor-specific 
binders. Though the basic idea is to elucidate sorting machineries and study membrane 
trafficking processes, such experiments are untargeted and miscellaneous discoveries were 
achieved. We elucidated that the apical determinant crumbs 2 is a cargo of the retromer 
complex. This revealed a fameless level of control for the establishment of cell polarity. We 
found retromer along with the adapter complexes AP-4 and AP-5 trafficking the beta 
amyloid precursor protein APP. This confirmed recent publications and yielded new insights. 
Moreover, many more proteins and complexes appeared to associate with the cytosolic part 
of APP (AICD) in a membrane context-dependent or -independent manner. Among those, 
some were so far unknown to interact with AICD, like mTORC1 and the PIKFyve complex. 
 1. INTRODUCTION 
 
1.1 Prologue 
In the last twenty years, the biological sciences substantially changed with the 
introduction of -omics techniques. With the Human Genome Project and the publication of 
the first drafts of the human genome in 2001 (Lander, 2001; Venter, 2001), this process 
reached a milestone and a cornerstone for the system-wide analysis of the proteome. The 
basic technology of proteomics is mass spectrometry. A key step in the development of 
instruments for the analysis of proteins was the introduction of the soft-ionization 
techniques, matrix-assisted laser desorption ionization (MALDI) by Karas and Hillenkamp 
(Karas, 1988) as well as Tanaka (Tanaka, 1988), and electrospray ionization (ESI) by Fenn et 
al. (Fenn, 1989). The latter is the dominant ionization technique today in proteomics as it 
allows coupling a high-performance liquid chromatography system in front, for high content 
analysis (LC-MS). Additionally, the application of mass spectrometry for the study of the 
proteome reached several breakthroughs. One such was the use of trypsin to specifically 
cleave proteins in a subset of ‘tryptic peptides’ which masses were estimated to identify the 
protein they were generated from (Cottrell, 1994). This so-called peptide mass fingerprint 
relied on data bases with protein sequence data that were either experimentally yielded 
before or deduced from genome data. Nowadays, tryptic peptides are fragmented in the 
mass spectrometer to assess their partial or full sequence (LC-MS/MS). This increases the 
reliability of matching tryptic peptides to particular proteins and hence it allows studying a 
whole proteome in a single LC-MS run (Nagaraj, 2012). The analysis of such immense 
amounts of data benefits from the development of powerful and affordable computers. 
With the drastic increase in capacity and instrumental sensitivity, lists of identified proteins 
of samples and related controls became more and more interchangeable. This necessitated 
the development of quantitative approaches (Ong, 2005). Quantification is hindered by the 
fact that due to physicochemical distinctions different peptides cause different intensities. 
The introduction of heavy stable isotope labels circumvented this problem as it allows the 
quantitative study of proteins by the measurement of chemically identical peptides. Protein 
amounts can be estimated by peak comparison, either to a related sample or to a spike-in 
standard of synthetic tryptic peptide analogs. There was also a constant instrumental 
development that reduced the number of necessary protein fractionation steps and run to 
run deviations in LC-MS/MS, a prerequisite for a multitude of label-free methods that were 
developed in the last years. Label-free methods are attractive, because they omit long 
sample adaptation procedures, like the adaptation of a cell line to a specific medium to 
ensure high labeling efficiency and they omit implicated restrictions. Moreover they are 
cost-saving and hence reduce the entry barrier for work groups to make use of mass 
spectrometry services for their projects. 
In modern proteomics, holistic approaches are used to study system perturbations and 
reductionistic approaches are performed for validation of specific findings. Mass 
spectrometry is also a key technology for the analysis of the lipidome (Blanksby, 2010) and 
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metabolome (Villas-Bôas, 2005). We expect this holism in near future to not only 
encompass the proteome, but also the lipidome and metabolome when studying a single 
sample – a concept called systems biology which seems now at hand with modern mass 
spectrometry instruments and approaches. 
 
1.2 Mass spectrometry vocabulary 
Only charged peptides are measured in mass spectrometry. If protonated peptides are 
measured, the instrument is operated in the positive mode which is the also the standard 
mode. The instrument can also be operated in the negative mode, for instance when 
multiphosphorylated peptides are analyzed in special approaches. The measurement 
doesn’t directly yield masses, but mass to charge ratios instead. The unit is Thomson (Th) 
and is defined as one atomic unit per elementary charge: 1 Th = 1 u / e = 1.660540 10-27 kg / 
1.602177 10-19 C = 1.036426 10-8 kg C-1 . Peptides don’t appear as a single mass to charge 
ratio in the spectrum, but as a number of peaks instead, due to the probabilistic distributed 
presence of isotopes. This is mainly due to the 1.1% of naturally occurring 13C and 4.21% 34S. 
Such patterns are called isotopic clusters. Because the distance of the isotopic peaks is 
always one atomic unit divided by the charge, the charge can be inferred from that. The 
mass value which is assigned to a peptide then, is the monoisotopic mass which is inferred 
from the most abundant isotopes of each element. For peptides, it is the mass of the first 
(most left) isotopic peak. This differs from stoichiometric calculations where a compound’s 
mass (average mass) is calculated from the atomic weight, a weighted average of the atomic 
masses of the different isotopes of each element. For small peptides, below 1.5 kDa, the 
first isotopic peak is the most intensive one within the cluster. If peptides are bigger, it is 
more likely that at least one of the atoms within the peptide is a heavier isotope and the 
second isotopic peak is the most intensive one. For proteins, the monoisotopic peak cannot 
even be seen in the spectrum. The difference between the observed and a calculated 
monoisotopic mass is the mass accuracy which is expressed in parts per million (ppm). The 
ability of a mass analyzer to resolve peaks of ions with a small m/z difference is the 
resolution. It is commonly defined as m/Δm, with m=400 Th and Δm as the difference to the 
nearest (theoretical) peak at which the two peaks are separated by a valley with 10% of the 
smaller peaks height.  As this is troublesome to estimate, the resolving power can also be 
approximated by half of the full width at half maximum (FWHM) of a single peak. Isotopic 
resolution is achieved when the peaks of an isotopic cluster are resolved. The mass range is 
the limit of m/z over which the mass analyzer can measure ions and the scan speed is the 
rate at which the analyzer measures over a particular mass range. Beside the estimation of 
masses, the mass spectrometer also delivers intensity values from the ion detection devices. 
Within this thesis this intensity values will be investigated how they can be used best to 
assess protein abundance. Another measurement parameter in LC-MS is the retention time 
at which a specific peptide is been detected at its maximum intensity in the mass 
spectrometer. As routine in chromatography, a peptide’s intensity signal is integrated over 
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time and normalized by locally weighted polynomial regression (LOWESS) and the resulting 
paired retention time and intensity data that represents the respective peptide is called a 
peptide feature. The smallest quantity of compound yielding a definite signal-to noise ratio 
(10:1) is the sensitivity. The ratio of the number of ions reaching the detector and the 
number of ions entering the mass analyzer is the transmission of the mass analyzer and the 
part of ions of a particular m/z produced in the source that are effectively analyzed after 
passing the whole mass spectrometer is called the duty cycle of the instrument. The modern 
mass spectrometer is not only a balance and counter, but is also capable for fragmentation 
of the analytes and subsequent analysis of the fragments. The instrument which is used in 
this work is the LTQ Orbitrap XL (Thermo Fisher Scientific, Germany). It is capable for four 
different fragmentation technics: collision induced fragmentation (CID), pulsed Q- 
dissociation (PQD), high-energy collisional dissociation (HCD) and electron transfer 
dissociation (HCD). Here, we use solely CID which is described in the linear ion trap chapter 
of this introduction. The spectrum of the unfragmented peptide is called MS or MS1 
spectrum, the fragment ion spectrum is called MSMS or MS2 spectrum and when 
fragmentation is applied again on a specific fragment, the spectrum of the new fragments is 
called MS3 spectrum. When all MS1 peaks are added and this signal is plotted over the time, 
this chromatogram is called total ion chromatogram (TIC). When noise is filtered in the MS1 
spectra prior to this and a baseline correction is carried out, then the resulting 
chromatogram is called base peak chromatogram (BP). It is also possible to plot only the 
signals of a specific mass. Doing so leads to the extracted ion chromatogram (XIC). 
 
1.3 The mass spectrometer and its operation modes 
A mass spectrometer as it is used in proteomics consists of the following components: A 
source, were peptides are transferred into the gas phase, ion lenses to filter and constrict 
the ion cloud, multipoles as ion transport devices, a mass analyzer, a collision cell and 
detectors. Some components are realized as a combination of those, like linear ion traps 
that consists of quadrupoles and lenses and are used as a fragmentation cell and as a mass 
analyzer, or an orbitrap that represents a combination of a mass analyzer and detector.  
1.3.1 Electrospray ionization (ESI) is not the only source allowing online-coupling of a mass 
spectrometer to a chromatography system. Others are e.g. atmospheric pressure chemical 
ionization (APCI), thermo spray and gas chromatography-MS (GC-MS). These methods have 
specific preferences for the analytes’ molecular weight and polarity with respect to their 
operating efficiency (Figure 1.1-A) making electrospray ionization coupled to HPLC the 
method of choice for the analysis of peptides. Peptides elute from the reversed phase HPLC-
column, with an acidic water/acetonitrile gradient in a constant flow of around 200 nl/min 
and are transported to a metal coated needle (spray-tip). In between this needle coat and 
an appr. 5-10 mm distant orifice of the mass spectrometer, a voltage of about 2 kV is 
applied. Drops formed at the spray-tip are accelerated through this field and the low 
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pressure inside the mass spectrometer. On the way to the orifice, the solvent evaporates. 
When the surface- accumulated charges are too dense, the drop explodes leaving the 
charges remaining on the now gaseous peptides. The majority of peptides receive two or 
three charges (protons) in that way. However, the average number of charges increases 
with increasing size of the peptides. Proteins injected in that way receive 20, 30 or more 
charges (Figure 1.1-B). 
 
 
Figure 1.1: Electrospray ionization is the ion source in LC-MS based proteomics. A - Ionization capabilities of 
different source/mass spectrometer combinations with respect to the analytes’ molecular weight and polarity. 
Tryptic peptides occur as ions with a suitable mass range of 500 to 10000 dalton. This elucidates electrospray 
ionization as the source of choice when analyzing tryptic peptides (taken from de Hoffmann, 2007). 
B - Electrospray ionization showing the needle tip on the left and the orifice of the mass spectrometer on the 
right side between which a constant voltage of about 2kV is applied (modified from www.physik.hu-berlin.de). 
 
Only charged peptides can be analyzed in the mass spectrometer, which can be 
operated in two modes: negative, which means that peptides are negatively charged, or 
positive when peptides with one or more protons attached are analyzed. As protonated 
peptides are more stable than peptides with an overload on electrons, achievable intensities 
and resolutions are higher and the positive mode is the standard in proteomics. Cleaving 
proteins with trypsin ensures that, except the carboxy-terminal peptide, all tryptic peptides 
receive one or more basic residues, arginine or lysine, that stabilizes protons.  
1.3.2 Multipoles. Ions are transported inside the mass spectrometer by multipoles. Such 
multipoles commonly consist of either eight (octapole), six (hexapole) or four (quadrupole) 
metal rods with round, square or hyperbolic cross-sections. The transport characteristics of 
ion clouds depend on the design of the multipoles (Figure 1.2-A). To construct a linear ion 
trap a round quadrupole exhibits best ion filtering characteristics, whereas for the transport 
of ions from one component to another octapoles are suited best. Those transport ways are 
important, because they allow in combination with the separation of different instrumental 
compartments by electrical lenses to operate at different pressures, as it is the case for 
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instance with quadrupole filters and collision cells. Also, those components need to be 
separated to minimize overlapping of electric fields. 
 
 
Figure 1.2: Multipoles as ion guides and filters. A – Transport characteristics are depending on the number and 
profile of the rods (source: www.thermofisher.com). B – A constant voltage superposed with an alternating is 
applied with different polarities on neighboring rods (taken from Benedikt, 2012). C - Examples for ion 
trajectories. D – Mathieu stability diagram for a quadrupole. Right pane: zoom-in of the first stability region 
which is generally the operating region (C,D taken from Blaum, 2006). 
 
In addition to a constant voltage (U), an alternating voltage (V) is applied with opposite 
polarity on adjacent rods (Figure 1.2-B). Ions which are axially (z-direction) entering the 
multipoles, start to oscillate in the orthogonal x and y directions while continuing their axial 
movement resulting in a complex trajectory. The intensities and frequency of the applied 
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voltages determine the trajectories’ stability of a specific mass to charge ratio range of the 
ions. In addition to the constant movement of the ions in the z-direction, the mathematical 
deduction of ion motion in the x,y-pane lead to the following differential expressions of ion 
movement (Paul equations): 

 +	
2
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With x, y being the coordinates of an ion of mass m and charge z, e the elementary charge, 
r0 the inner space between the rods, t the time, ω the angular frequency and U and V the 
constant and alternating voltages applied to the rods as described above. These equations 
were seen in analogy to the former work of Mathieu (1866) on the propagation of waves in 
membranes and lead to two terms and parameters: 
 =  !"      and    # = 	
$%
 !"  
These terms describe a relationship between ion coordinates and time (de Hoffmann, 2007). 
Ions are instable when their x- or y-coordinates are reaching r0 and they thus touch the rods 
and discharge. The a- and q-parameters are used to draw a Mathieu stability diagram 
(Figure 1.2-D), showing regions of pairs of a- and q-values that lead to stable ion trajectories 
(Figure 1.2-C). The stability diagram is an overlay of calculations for the x-and y-direction. 
Ions with different masses (mass to charge ratios) can be positioned in the stability diagram 
by altering V and U. The right pane in figure 1.2-D shows a zoom-in representing the 
common operating region. At a q-value of 0.706 and an a-value of 0.237, the stability region 
narrows. When the voltages set a specific m/z-ion to that point, other ions are instable and 
get lost enabling to operate the quadrupole as a filter in that way. When multipoles are 
operated as an ion guide, the a-parameter is set to zero by switching the constant voltage U 
off. All ions with a higher m/z than the one that for a given voltage V holds a q-value of 
0.908 have stable trajectories and thus pass the quadrupole. However, ions with a very low 
q-value are poorly focused and hence also get lost. These are the reasons for the symmetric 
function shapes in figure 1.2-A. As a rule of thumb, for a quadrupole the lowest mass (m/z) 
observable (mmin) by adjusting V to yield a q-value of 0.908 for that m/z restricts the 
maximum observable mass to be mmax = 20 x mmin . 
1.3.3 Linear ion traps (LIT, LTQ) are constructed by superposing a potential well along the z-
axis to a quadrupole field. This can be achieved by additional lenses or segmentation of the 
rods and the application of a constant voltage between the outer rods/lenses and the 
central rods (Figure 1.3-A and –B). This potential well causes ions to oscillate along the z-
axis. Figure 1.3-A also depicts that the x-rods have slits for radial ejection of ions through the 
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x-rods to detectors. The Mathieu stability diagram of the linear ion trap favors the 
quadrupole’s, but is asymmetric with respect to the q-axis (Figure 1.3-C).  
 
Figure 1.3: The linear ion trap is a versatile component and mass analyzer. A – Diagram of a linear ion trap as it 
is implemented within the LTQ orbitrap system. The two x-rods are provided with slits to enable radial 
resonance ejection. B - The hyperbolic rods are divided into inner and outer sections to add a constant voltage 
in z-direction that causes trapping. C –Matthieu-stability diagram for the two dimensional Paul-trap and 
operating region, lower panel: zoom-in of the operating region. (A,B from Schwartz, 2002; C from Fernández, 
2007) 
 
Ions enter the linear ion trap with a dispersed translational energy, but can be 
synchronized by collisional cooling with helium gas. This can be directly observed by an 
increase in resolution.   
If the constant voltage U on the center rods is switched off, all ions are on the q-axis in 
the stability diagram. By ramping the alternating voltage V the ions are subsequently 
(smallest m/z values first) passing the q=0.908 instability barrier and are axially ejected. This 
is called the mass-selective instability mode. Ions are ejected as a function of the applied 
alternating voltage V (Fernández, 2007) and the mass spectrum can be obtained by 
rearranging the expression for q: 
	
 =	
4

# 
Another ejection mode is the resonance ion ejection. The basis of this method is the 
secular frequency with which all ions of a specific m/z oscillate along z. An alternating 
voltage applied to the end caps, or x-rods of the same frequency selectively increases the 
amplitude of this ions through resonance and causes those ions to be ejected axillary or 
radially in –x- or x-direction through the slits of the rods. Resonance ejection can be applied 
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to ions irrespective of their position within the stability diagram. An important application of 
axillary resonance ejection is the precursor isolation. It is conducted by ejection of all ions 
except the precursor. There is also a mass-selective stability mode, were the applied 
potentials U and V are selected that the a- und q-values are close to the apex of the stability 
diagram (Dass, 2007) and as described before for the multipoles, a single species is 
remaining stable und thus be isolated. Finally, the linear ion trap can be operated as an ion 
guide like ordinary multipoles. 
After precursor isolation, the precursor can be positioned at a low q-value (0.25) and 
axillary resonance can be applied at an intensity omitting ejection. The excited ions will 
collide with the helium atoms and collision induced fragmentation occurs. The disadvantage 
of this is that fragment ions with m/z values of 1/3 of the precursor m/z are outside the 
q=0.908 instability barrier and will thus be not detected. This is the reason why iTRAQ is not 
applicable to standard linear ion traps, because of the small size of the reporter ions.  
1.3.4 Orbitrap. The orbitrap is a combination of a high resolution mass analyzer and 
detector. It is composed of a central spindle electrode and an outer shell that consists of 
two electrical isolated halves. A constant voltage is applied between both shell halves on the 
one side and the spindle (electrostatic trap). Ions injected perpendicular to the spindle axis 
(z-axis) develop an intricate spiral trajectory composed of a circulation around and an 
oscillation along the spindle (Figure 1.4) due to the influence of the potential: 
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Where r and z are cylindrical coordinates with z as the axis of symmetry, k the field 
curvature, Rm the characteristic radius and C a constant. When integrating this equation 
with respect to z, this equation is reduced to k·z. The force that effects the z-oscillation is:  
0 =	−# ∙ 11  
And equals the force that has to be applied to an ion of mass m and charge q (don’t intermix 
with z, as z is the position along the spindle axis here) to move it: 
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This is the equation of movement for the oscillation of an ion of mass m and charge q along 
the z-axis. Solving this equation leads to a combined sinus and cosinus function (de 
Hoffmann, 2007) with the angular frequency term: 
 =	3 #	 ∙ ( 
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This means that the frequency of the oscillation along the z-axis depends only on the mass 
to charge ratio of the ions (k is a constant). This oscillation results in an induced electric field 
which can be measured as a potential difference between the orbitrap’s outer shell halves. 
A Fourier transformation of this image current yields all angular frequencies and hence mass 
to charge ratios inside the orbitrap, along with the respective intensity proportions. 
 
Figure 1.4: An orbitrap is an electrostatic trap. After radial injection, the ions start to oscillate around and along 
the inner spindle electrode (taken from de Hofmann, 2007; Makarov, 2000). 
 
1.3.5 Secondary electron multipliers. As the orbitrap has intrinsic ion detection, the linear 
ion trap has not and is hence equipped with two secondary electron multipliers to detect 
ions that are radially ejected through the slits of the respective rods in x- and opposite 
direction. Ions are hitting a conversion  dynode  and  release  electrons  that  are  
accelerated  by  a  static  electric  field, hitting themselves another dynode and release a 
multiple of other electrons and so on. An initial ion is triggering an amplifying cascade of 
secondary electrons leading to an electric current that represents the measurement 
intensity (Figure 1.5). 
 
Figure 1.5: The secondary electron multiplier is a high sensitive ion detector. An ion causes an amplifying 
cascade of electrons which can be measures as an electric current. The disadvantage of multipliers is the 
decomposition of the dynodes. This has to be compensated by a frequent calibration, i.e. determination and 
application of an increased acceleration voltage. Nevertheless, they have to be replaced annually which makes 
them a major part in the running costs of the instrument. 
 
Beside their respective operation modes, the mass analyzers described here differ in 
principle in scanning speed (Multipoles > LIT > orbitrap), upper mass limits (Quadrupole: 
4000 Th, LIT: 6000 Th, Orbitrap: 50000 Th), resolutions (Quadrupole: 2000, LIT: 4000, 
Orbitrap: 100000) and accuracies (Quadrupole: 100 ppm, LIT: 100 ppm, Orbitrap: <5 ppm). 
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1.3.6 LTQ Orbitrap XL mass spectrometer. In the LTQ Orbitrap XL system (Thermo Fisher 
Scientific, Germany), a linear ion trap (LTQ) is coupled to an orbitrap. This creates a flexible 
system allowing for different fragmentation technics, namely CID and PQD and as an ETD 
(fluoranthene radical ion) source and a HCD cell is added as well, ETD and HCD. This is 
combined with the opportunity to acquire high resolution spectra in parallel. It is this, the 
high resolution, high flexibility and high scanning rate which accounts for the impact of this 
instrument to the –omics labs. We found CID superior in terms of protein and proteome 
coverage and used this fragmentation method throughout the experiments presented in 
this thesis. However, it is also possible to use a conditional selection procedure (decision 
tree) of fragmentation methods based on the masses and charges of the precursor ions 
(Figure 1.6). 
 
Figure 1.6: The LTQ Orbitrap XL ETD System as it is used in our lab. Other than the shown atmospheric pressure 
ionization source, for the measurement of peptides we use a nano-electrospray ionization source (nanoESI) 
(source: www.thermofisher.com). 
 
1.3.7 TopN-approach. In shotgun proteomics, the standard operation procedure for the LTQ 
orbitrap system is the TopN-approach. A MS1 spectrum is acquired with high resolution in 
the orbitrap. Right after beginning this process the system is using the preliminary data to 
automatically select precursors for parallel fragmentation and detection in the linear ion 
trap. While the MS1 spectrum is still measured, a number of MS2 spectra are acquired. The 
number of MS2 spectra should be programmed in a way that when the acquisition of the 
MS1 spectrum is finished, the acquisition of MS2 spectra is also finished and the cycle can be 
repeated again. The duration of the MS1 spectrum acquisition is depending on the 
resolution that should be achieved. For a resolution of 60000, the cycle time is appr. 2.8 s 
allowing to acquire 8 MS2 spectra. The criterion for the precursor selection is intensity. 
When the 8 most intense peptides are selected for fragmentation in that way, the method is 
called Top8-method (Figure 1.7). When a complex proteome is measured, peptide 
separation is imperfect and a lot of peptides co-elute from the reversed phase column and 
enter the mass spectrometer. The TopN method could lead to miss a lot of peptides that are 
never among the top eight, while on the other hand many fragmentation spectra are 
acquired for the same peptides. To adjust for this, the operation program contains a 
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dynamic exclusion option. A peptide can be excluded thus from being fragmented again for 
a certain time (e.g. 15 s), if it has already been fragmented a couple of times (e.g. 2 times) 
within a given period (e.g. 5 s). The transient exclusion list can hold up to 500 peptides 
allowing a much deeper coverage of the peptidome and hence number of proteins 
identified. Resolution, cycle time, number of MS2 spectra triggered and the settings for 
dynamic exclusion are parameters that can highly influence protein identification and label-
free quantification such as spectral count. The influence of dynamic exclusion settings on 
spectral counting has been studied by Zhang et al. (Zhang, 2009). They found an ideal 
duration time of 100 s. However, as they also showed that this is a matter of the 
chromatographic parameters, like gradient time (132 min) and peak capacity, we found a 
duration time of 15 s with a repeat count of 2 within 5 s ideal for our assembly (gradient 
time 60 min, peak capacity around 1000). We didn’t optimize the size of the exclusion list 
but set it to the maximum of 500 peptides instead. Kim et al. (Kim, 2010) analyzed the 
influence of different resolution settings, cycle times and if high resolution MS2 spectra 
subsequent MS1 in the orbitrap are superior to a shorter cycle time when MS2 spectra are 
acquired in parallel in the LTQ. They found that parallel acquisition is clearly superior with 
slight advantages for shorter cycle times, i.e. lower MS1 resolution. Their ideal resolution of 
30000 is close to our experience (60000).    
 
Figure 1.7: Top8 operation method for the LTQ Orbitrap XL. A - Low resolution MS
2
 spectra are acquired in 
parallel to a high resolution MS
1 
spectrum allowing higher duty cycles. B - MS
1
 spectrum with labeled selected 
precursors. Not all of the 8 precursors are among the 8 most prominent MS
1
 peaks. This is because dynamic 
exclusion was allowed that is aimed to prevent repetitive selection of the same precursors more than twice 
within 5 cycles and hence enhance the chance of co-eluting peptides to get fragmented as well. C - MS
2
 
spectra of the selected precursors. 
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1.4 Protein identification 
1.4.1 Collision induced fragmentation of peptides leads to a rupture of the peptides at the 
amide bond of the peptide backbone. Other types of ruptures also occur but less likely, 
expressed in less intense MS2 peaks. However, this is not true for phosphoserine 
or -threonine containing peptides as the collision energy is consumed here by the loss of 
phosphate. Fragmentation is a stochastic process, insofar as the amide bond that is 
ruptured is not the same one for every peptide molecule. This results in a ladder of peptide 
fragments with mass differences according to the amino acids between them. The situation 
is a bit complicated by the fact that the peptide charges can be transferred after cleavage to 
the carboxy- (y-ions) or amino-terminal (b-ions) part (only charged fragments can be 
observed in the mass spectrometer). Due to the basic residue at the carboxy-terminal part 
the acceptance of protons is more likely and thus the y-ions are more intense and dominate 
the MS2 spectra. Figure 1.8 gives an example for the manual interpretation of such a 
spectrum. However, spectra of such quality are rare and as in LC-MS, within a two hour 
measurement ten thousands of spectra are generated, manual interpretation is not possible 
and algorithms have to be used. 
 
 
Figure 1.8: Example of a manual interpretation of a MS
2
 spectrum performed on a MALDI-TOFTOF mass 
spectrometer (z=+1). The whole sequence had been deducible from this good quality spectrum. Unfortunately, 
this is not typical and only partial sequences can usually be elucidated. In addition, MS² spectra are commonly 
affected by imperfect precursor isolation in the LTQ and hence polluted by interfering fragment peaks. 
 
1.4.2 Error control. Protein identification is a multi-stage process. This starts basically with 
the selection of precursors by the operating program for the mass spectrometer. The next 
step is the assignment of MS2 spectra to peptides. This does not lead to a single peptide 
identification, but to a list of peptides of the same precursor mass that can represent the 
spectrum with a certain score. The score is a rating by the algorithm reflecting the grade of 
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matching, but it is not a probability. Characteristics that influence the score are the number 
of peaks matching to theoretical y- and b-ions and the number of remaining unmatched 
peaks. Every spectrum contains noise peaks, mainly from improper precursor isolation and 
side peaks, for instance from side chain fragmentations. This blurs the matching process and 
hence also a peptide of a lower score can in fact be the true origin of a certain fragment ion 
spectrum. The next step is the assignment of identified peptides to proteins. This is also a 
probabilistic step and the algorithms used assign scores to the matchings as well. Often a 
matching is not unique and leads to a group of proteins rather than to a single protein 
(Nesvizhskii, 2005). If probabilistic steps are consecutively applied and highly parallelized, 
errors will potentize and thus need to be controlled. This error control is performed by fixing 
the false discovery rate (Figure 1.9).  
 
Figure 1.9:  Error control demonstrated on peptide identification. The plot is a histogram reflecting the 
frequency at which peptides at specific scores (score ranges) occur. The unbroken line is what is commonly 
observed (observed peptide spectrum matches - PSM). This function is obviously a sum of two underlying 
Gaussian distributions. Nearly all assigned PSMs are falsely assigned (incorrect PSMs) while a small proportion 
with a higher mean score is correct. Unfortunately there is an overlap between both subdistributions. The 
distribution of incorrect PSMs can be experimentally assessed. All MS
2
 spectra are probed hereby for matching 
to a nonsense (decoy) database which can be generated by reversing the real protein database before in-silico 
generation of theoretical tryptic peptides. This leads to a distribution simulating the incorrect PSM 
distribution, while omitting the fraction of correct PSMs. The question is now, how to set a score threshold for 
the acceptance of identified peptides. If the threshold is been set too high, while decreasing the false positives, 
the false negatives are increased finally resulting in a shortened list of identified proteins. If the threshold is 
too low, then the number of false positives is too high, leading to many false protein entries. From the 
distributions, one can calculate the false discovery rate which is defined as the fraction of false positives 
among all proteins passing the threshold. The score threshold is set allowing a certain false discovery rate 
(usually 1%) (adopted from Brosch, 2010). 
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1.5 Quantitative mass spectrometric approaches 
Mass spectrometry has for long been considered as being inapplicable for quantitative 
proteomics, because of two major drawbacks. On the one hand, identifications and 
estimated quantities of proteins differ from LC-MS run to run. Slight differences in the 
sample loading by the autosampler as well as in the formation of the LC-gradient occur. One 
sample is usually constituted of ten thousands of peptides which are only partially separated 
in the chromatography, with a common peak capacity of around thousand. Hence, different 
peptides co-elute and compete for protons (charges) during ionization leading to 
suppression ('ionic suppression') of the inferior peptide species. Run to run differences in 
the chromatographic elution entail run to run differences in the detection of peptides and 
therefore protein identification. On the other hand, even in a single LC-MS run, the same 
amounts of different peptides, like those generated by tryptic digestion of a certain protein 
differ in the mass spectrometric intensities they cause. Two different proteins of the same 
amount will result in different sum intensities of their tryptic peptides in that way. This is, 
because the peptide's primary sequences and hence physicochemical properties differ 
largely. Also, the number of tryptic peptides differ largely among different proteins. 
Although bigger proteins tend to cause larger numbers of tryptic peptides, this is not a 
strong correlation because of large variations in the occurrence of lysine and arginine after 
which trypsin cleaves. Those two amino acids and histidine are the only amino acids that are 
positively charged in the chromatographic separation prior to mass spectrometry at pH=3. 
On the other hand, a higher content of acidic amino acid residues reduces the chance of a 
tryptic peptide to successfully compete with co-eluting peptides for accepting charges 
during ionization in positive mode. Hydrophilicity and hydrophobicity are further primary 
sequence-depending values restricting identification success. Highly hydrophobic peptides 
are difficult to keep soluble or to remove from the reversed phase columns, whereas highly 
hydrophilic peptides could be lost because of improper binding and retaining in the 
chromatography. During sample handling and processing, peptides are exposed to many 
kinds of surfaces, different plastics, glass, metals and polymeric bead materials to which 
they could be differentially bound and diminished (Goebel-Stengel, 2011). These factors 
hinder direct inference of protein amounts from their tryptic peptide signal intensities. In 
addition, proteins can differ in the type and grade of post translational modifications on 
specific sites in between to experimental samples. Often there is no evidence of these and 
hence lead to false inference from peptide to protein amount changes.  
1.5.1 Labeling approaches. Several strategies have been developed to circumvent these 
problems. In the so-called labeling approaches, peptides from proteins of one sample are 
differentially labeled than proteins from another sample or control making it possible to 
compare pairs or even octaplets of the same peptides and deduce related protein changes 
in a single LC-MS run.  One of the first such approaches introduced isotope-coded affinity 
tags (ICAT) (Gygi, 1999). Those tags are heterobifunctional linkers exhibiting a thiol-reactive 
group for coupling to cysteines and a biotin-group for affinity isolation on the other side. 
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The middle region of the linker either contains eight deuteriums or not. While only slightly 
changing physicochemical properties, peptides originating from different samples can be 
distinguished by mass spectrometry and its intensities compared in the MS1–spectra of a 
single run. Some drawbacks of the method are the loss of all cysteine-free peptides and the 
limitation to duplex labels, both of which have been addressed by the use of isobaric tags 
for relative and absolute quantitation (iTRAQ) (Ross, 2004) and Tandem Mass Tags (TMT) 
(Dayon, 2008). These tags are amine-reactive and do not differ in their overall mass and 
therefore do not enhance complexity of MS-spectra which reduces the number of different 
peptides selected for MS2 and hence protein identification rates. The fragmentation process 
releases a set of chemical identical reporter groups comprising different combinations of 
light and heavy stable isotopes of carbon, nitrogen and oxygen. Up to eight reporter group 
peaks appear apart in the lysine containing peptide’s MS2 spectra enabling octaplex 
experiments. One disadvantage of chemical labels is the bias of chemical reactions to 
specific sites, imperfect labeling and side reactions. Amine-directed labeling depends on 
unmodified lysine residues and all arginine containing tryptic peptides are useless for 
quantification. Also, labels are introduced late in the sample processing workflow and hence 
samples can be combined tardily. Errors during sample processing can influence all samples 
unequally and lead to introduced variations. This chain of errors is smartly prevented by the 
popular method of stable isotope labeling of amino acids in cell culture (SILAC) (Ong, 2002). 
Cells in culture are fed herein with the isotope labeled essential amino acids arginine or 
lysine. This early labeling allows for combining of samples right after cell lysis. However, 
several constraints restrict the usage of SILAC. In the SILAC-approach, the complexity of MS-
spectra is multiplied and so is the shotgun proteomics immanent problem of stochastically 
undetected proteins. This necessitates more protein and peptide fractionation steps, more 
replicates and finally resulting in more LC-MS runs. SILAC relies on multipassage cell cultures 
to achieve an indispensable maximum labeling efficiency of 98%. If the labeling efficiency is 
even minimal reduced the calculated protein ratios will drastically underestimate huge 
actual ratios. The labeling efficiency of arginine-containing peptides can also be reduced, if 
the cell possesses an arginine-proline interconversion pathway (Park, 2009), while proline 
could be itself partially labeled in that way. All in all, SILAC is restricted to specific long term 
cultivated cell lines of specific organisms and cell types. This impedes its use in stem cell 
proteomics where cultivation time is known to affect the cell surface composition 
(Karbanová, 2010). 
1.5.2 Label-free approaches. In recent years, label-free methods became very popular, as 
they can be applied to any biological sample. Additional benefits are low costs, ease of 
implementation and a non increase of MS1 complexity. In former years, the higher number 
of LC-MS runs needed, as label-free mass spectrometry relies on parallel sampling, cleared 
some of the gains in costs. With the high sensitivity and high duty cycles of modern high 
resolution mass spectrometers, less prefractionation is needed which drastically reduces the 
numbers of LC-MS runs and enable the researcher to investigate more biological replicates. 
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Less steps in prefractionation diminishes also errors in the parallel treatment of samples. In 
label-free MS approaches, protein abundances and abundance changes could be elucidated 
from mass spectrometric data using either empirical indices based on sequence coverage, 
number of observed peptides or number of triggered MS2 , or inferred from measurement 
values like MS1-intensity or MS2-intensity and retention time.  
While the quantitative bases determine the dynamic ranges of label-free methods, their 
linear ranges and accuracies are enhanced by engineered normalization formulas (Figure 
1.10). In the cell surface proteome, we expect a distribution of protein abundances over 
several orders of magnitude. This necessitates a huge linear range of a quantitation method, 
particularly when a sample's protein composition should be assessed. Sample composition 
and the difference between two samples are two types of information desired to gain in a 
quantitative approach. The sample composition, an estimation of relative amounts of 
different proteins within a sample, enables definition of frequency classes and group 
identified proteins for their suitability to serve as cell surface markers. Furthermore, the 
sample composition provides information on the accumulation of specific gene ontologies 
or protein domains. This also enables to monitor the effectivity of dedicated enrichment 
procedures. Analysis of the proteomic difference between two or more samples elucidates 
changes upon perturbance, different donors, different time points during proliferation, 
different cultivation parameters, etc. Such changes are quantitatively expressed in ratios of 
estimated values and hence are sensitive for the accuracy of their estimation.  
 
Figure 1.10: Dynamic range (DR) and linear range (LR) of a MS value that is used to assess protein amount (or 
concentration, respectively). The dynamic range is the range of protein amounts over which the MS value 
changes. The linear range is the range of protein amounts were the MS value has a certain degree of linear 
correlation with the protein amount. 
 
In shotgun mass spectrometry early label-free indices used were sequence coverage and 
the number of different non overlapping peptides (PN) identified for a particular protein. 
 
1. INTRODUCTION|19 
Their usage was mainly restricted to reflect the reliability of identification. Both values 
depend on the protein size, as high sequence coverage of smaller proteins is easier to 
achieve whereas a tryptic digestion of larger proteins will more likely result in a higher 
number of observable peptides (PO).  An attempt to normalize PN was to simply divide by 
PO to yield the protein abundance index (PAI) (Rappsilber, 2002). Observation of a peptide 
can be restricted through mass ranges defined in the workflow (e.g. linear ion trap) and 
rated by its predicted chromatographic behavior. Further studies modified the PAI and 
defined an exponentially modified protein abundance index (emPAI) as 10PAI-1 (Ishihama, 
2005) and on the base of 6.5 (emPAI65) (Kudlicki, 2012). The concept of spectral counting 
(SC) was introduced by Liu et al. (Liu, 2004). In shotgun proteomics the mass spectrometer is 
programmed to run in acquisition cycles of MS1 and several intermediate MS2 spectra. From 
MS1 spectra a number of most intensive signals trigger the selection of corresponding 
peptide ions as precursors for fragmentation. An enrichment of a certain protein in a sample 
will result in more intensive MS1 signals of its tryptic peptides compared to a control and 
hence being more often selected for MS2. Therefore, the MS2 sampling rate, or the sum of 
peptide spectrum matches (PSM) assigned to a protein is an indirect quantitative value for a 
protein's abundance in one sample compared to another. In their work, Liu et al. 
demonstrated for six standard proteins mixed into a yeast proteome that spectral counts 
correlated well over the tested two orders of magnitude with the input amount. The value 
was clearly an improvement to the sequence coverage or number of identified tryptic 
peptides (PN). This work raised the task to test this value for its operating capacity over a 
broader dynamic range. A number of normalization procedures and derived values were 
subsequently developed. One of those is the normalized spectral abundance factor (NSAF) 
which normalizes spectral counts twofold. Firstly, all spectral counts of a specific protein are 
normalized by the protein’s length (L). Secondly, the resulting SC/L ratio is divided by the 
sum of all such ratios for all proteins in a sample (Zybailov, 2006). Griffin et al. developed 
the normalized spectral index of an individual protein (SIN) that combines spectral counts 
with unique peptide numbers and MS2 intensities (Griffin, 2010). They demonstrated that 
the index correlates well over three orders of magnitude with input amounts of standard 
proteins. It was further shown that SIN suits better on replicate measurements than PN, SC, 
NSAF and ratios of spectral counts (RSC ) computed as proposed by Old et al. (Old, 2005). 
However, as all of the normalized indices rely also on the estimation of spectral counts, the 
availability of spectral count values determines also the dynamic range of all the indices. 
Intensity based methods have been widely used to assess analyte amounts as in the 
analysis of small molecules. Chelius et al. (Chelius, 2002) prepared a concentration series of 
a tryptic digest of myoglobin from 10 to 105 fmol. They demonstrated that the sum area 
under the curve (AUC) of five peptide's MS1-intensities in the chromatogram correlated well 
(r=0.995) with the amount of the protein over the five orders of magnitude tested. In 
addition, they still could quantify two different amounts of horse myoglobin (250 and 500 
fmol) spiked into a digest of human serum proteins. We wanted to extend this analysis for a 
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broader range in a complex proteomic background. We did so using digests of bovine serum 
albumin and beta casein as standard proteins and further tested the accuracy of 
normalization methods that should obliterate physicochemical differences of the proteins 
on a mixture of 49 proteins spreading over a range of 0.5 to 50000 fmol. An intrinsic 
problem in the endeavor to create an intensity-protein amount correlation independently  
on the proteins’ primary sequences are the different numbers of observable tryptic peptides 
that can be generated from them. Those numbers correlate not simply with the protein size, 
but moreover with the distribution of lysine and arginine residues. Too small and too large 
peptides are not observed in the mass spectrometer because of a maximum operation m/z-
range of the mass analyzers (e.g. quadrupoles, linear ion traps).  Also different 
physicochemical properties of the peptides could hinder them on binding to or eluting of 
the chromatographic column, or discriminate them in the ionization process. One approach 
is to reckon only the three most intensive peptides of a protein and constructing the protein 
intensity either by summing up (Ning, 2012), or averaging (Ishihama, 2008) those peptide 
intensities. The latter method is named extracted ion intensity-based protein abundance 
index (xPAI). This necessitates on the other hand the availability of at least three tryptic 
peptides and hence restricting the dynamic range on the bottom. On the other hand, a 
restriction to three tryptic peptides increases the susceptibility to appearing post 
translational modifications, if two experimental states are compared. Another approach is 
intensity normalization by division through the number of calculated observable tryptic 
peptides. This approach was introduced using a spiked-in universal proteomic standard and 
hence allowing even an intensity-based absolute quantification (iBAQ) (Schwanhäusser, 
2011). The observability defined in that method was a sequence length restriction from 6 to 
35 amino acids. When proteins across two or more samples ought to be compared, 
normalization should adjust for loading discrepancies. An approach realizing this is 
implemented in MaxQuant resulting in the label free quantification intensity (LFQ) values 
(Hubner, 2010). We compared ordinary MaxQuant intensities (MQ) (Cox, 2008), which 
represent the sum of intensity peak areas of extracted ion chromatograms (XIC) for all a 
protein’s tryptic peptides, LFQ and xPAI for their dynamic and linear ranges and accuracies 
in the estimation of protein abundance. 
Sample comparison approaches also generate the issue of an appropriate test statistic in 
which false discovery rates can be controlled. Roxas et al. (Roxas, 2008) adopted a method 
which has been developed for analyses of microarray experiments, the significance analysis 
of microarrays (SAM) (Tusher, 2001). This method is available through MaxQuant’s Perseus 
package (www.maxquant.org) (Hubner, 2010). We prepared yeast ‘background’ proteomes 
with different spiked-in amounts of universal proteomic standard 1 (UPS1) proteins and 
used MaxQuant LFQ values to assess this method’s capability to detect defined protein 
ratios. 
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1.6 Application I – Analysis of plasma membrane proteins 
38% of all proteins encoded by the mammalian genome are classified as membrane 
proteins and they represent more than one-third of the current list of biomarker candidates 
and two-thirds of the existing drug’s targets (Rusevic, 2011). Cell surface proteins arrange 
cell adhesion and thus determine cell localization and constitute an interface for 
communication to the cell’s environment. Both adds to the cell’s function, state and hence 
identity. The analysis of membrane proteins is still a challenge, as they are usually under-
represented in proteomic studies (Mindaye, 2012). Low detection rates are thought to be 
reasoned by low abundance and experimentally by their poor solubility (Vuckovic, 2012). 
Many of the technical advances in plasma membrane proteomics have been made so far 
using cancer cell lines and a further development to the direct analysis of clinically relevant 
patient samples was demanded to finally identify biomarkers that improve early disease 
detection and allow prognosis and prediction of treatment response (Leth-Larsen, 2010). A 
major focus with this respect is the identification and treatment of cancer though, but 
beside the analysis of pathogenic cells knowing the cell surface proteome of stem cells will 
aid in their isolation. In fact, there are crucial experimental differences to cancer biopsies, 
like a small number of isolatable cells, small rate of cell division and alterations in the cell 
surface proteome during cultivation.  We did a detailed identification of the cell surface 
proteome of mesenchymal stem cells at first (Niehage, 2010), which is still the most 
thorough study on this type of cells promising for their potentially therapeutic relevance. 
Upon implementation of more sophisticated and quantitative mass spectrometric 
workflows, we wanted to apply these to a related type of stem cells, the dental pulp stem 
cells (DPSC). The dental pulp has been demonstrated as an easy accessible source of somatic 
stem cells (Karbanová, 2011). Karbanová et al. also showed that cell surface proteomes 
develop differences in dependency on the culture media used, but did not identify those 
differences in an extensive untargeted approach. We wanted to fill the gap, as the 
mentioned experimental obstacles upon stem cells define this as a challenging approach to 
benchmark our procedures. 
A common assumption of membrane proteomics is that membrane proteins need to be 
enriched prior analysis (Sprenger, 2010). A multiplicity of enrichment procedures for plasma 
membrane proteins have been developed among which the most important are density 
centrifugation, lysine-directed biotinylation (Zhang, 2003a) and hydrazide capturing of 
reduced N-glycosidic carbohydrate side chains (Zhang, 2003b). Density centrifugation is 
highly affected by contaminant proteins, since the densities of plasma membranes, 
endoplasmic reticulum and mitochondria overlap (Zhang, 2003a). The hydrazide capturing 
technic can be considered to deliver the least contaminants as captured proteins are 
temporarily covalently coupled to a solid matrix allowing intense washing. The hydrazide 
capturing technic on the other hand, select only proteins that are glycosylated and are 
expected to introduce the hugest bias though. Because of this, we chose lysine-directed 
biotinylation to enrich for cell surface proteins and compare this with two types of controls. 
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This is at first, a similar experiment with non biotinylated samples to elucidate proteins that 
bind to the bead material and constitute the proteomic background and at second, a total 
proteome sample to elucidate possible biases by comparing intensity distributions of all 
plasma membrane proteins that occur in both samples. 
 
1.7 Application II – Analysis of membrane-associated protein networks 
1.7.1 Vesicular trafficking. The plasma membrane proteome is very dynamic. 
Transmembrane proteins are transported in the secretory and endocytic pathways by 
vesicular trafficking. After synthesis, transmembrane proteins are transported from the 
endoplasmic reticulum (ER) to the cis-Golgi and further trough the Golgi to the trans-Golgi 
by COPI and COPII coated vesicles (see chapter 1.7.4). The trans-Golgi network (TGN) 
represents a sorting hub were different proteins are directed to different trafficking ways 
(Figure 1.11). The following chapters on trafficking complexes provide a more detailed view 
on the respective trafficking mechanisms. 
 
Figure 1.11: Some post-Golgi trafficking routes of transmembrane proteins in epithelial cells. Proteins exit the 
trans-Golgi network on unknown mechanisms to the apical plasma membrane (1) or basolateral, supposedly 
via AP-1A (2b) or AP-4 (2a) adapter complexes (AP). Other routes lead either to late endosomes, via AP-1A or 
GGAs (Golgi-localized,  γ -ear-containing, Arf-binding protein) (3c), or to common recycling endosomes (CRE), 
supposedly via AP-3 (3a) or AP-4 (3b) adapter complexes. Proteins could leave the CRE either basolateral via 
the adapter complex AP-1B (5) or via apical recycling endosomes (ARE) (4) to the apical plasma membrane. 
Endocytosis directs transmembrane proteins from the plasma membrane without or with involvement of AP-2 
(6 and 7) back to the endosomal system. From the endosomes, proteins can also traffic back to the Golgi via 
the retromer complex (not shown), directed to the lysosomes, or incorporated to multivesicular bodies via 
ESCRT-complexes (not shown) and even integrated into exosomes hereafter. (Figure: Rodriguez-Boulan, 2005) 
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The vesicles generate from a donor membrane where transmembrane proteins need to be 
transported. At the beginning, trafficking complexes recognize and gather protein cargos. 
Vesicles are formed hereupon that are cutted off the donor membrane (Vesicle scission or 
budding), moved to the acceptor membrane (Vesicle motility or movement) to which they 
attach (Vesicle tethering) and fuse (Vesicle fusion) (Figure 1.12). These steps are regulated 
by peripheral membrane proteins, as for instance distinct families of GTPases (Arfs regulate 
formation, dynamins regulate scission, and Rabs and Rhos tethering and fusion) (Segev, 
2011; Behnia, 2005).  
 
 
 
Figure 1.12: Steps of vesicular trafficking (Behnia, 2005). 
 
The attachment of peripheral membrane proteins during vesicle formation premises the 
recognition of the type of membrane that represents the respective organelle. Also, the 
tethering of vesicles necessitates the recognition of the target membrane by the trafficking 
components involved. This implicates that organelle membranes differ in lipid composition, 
as shown by van Meer et al. (Figure 1.13) (van Meer, 2008). Although quantitative lipid 
analysis is hampered by inadequate isolation procedures that allow only insufficient 
separation of the different types of cellular membranes, it is known that the diverse types of 
lipids distribute heterogeneously across them. Despite of this lipid-content heterogeneities, 
phosphoinositides are thought to basically represent the identity of a membrane though. 
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Figure 1.13: Lipid composition of cell membranes. Blue bars - mammals; Light blue bars - yeast (van Meer, 
2008) 
 
1.7.2 Cargo sorting motifs. The transmembrane protein cargo, with its embedded 
sorting motifs, is the nucleation core of trafficking complexes. The individual sorting of 
intrinsic membrane proteins requires sequence information in the cytosolic domains of the 
cargo that can be accessed by cytosolic components of the trafficking complexes. One of 
this sequence classes causes its ubiquitination, while others are directly recognized by the 
trafficking complexes. Table 1.1 lists some known sorting motifs. Embedded thyrosines, 
serines and threonines are often phosphorylated and thus allow controlling trafficking by 
intervening of signaling processes. Just a minor part of the actual cargos of known trafficking 
complexes can be assumed to be known. Thus, table 1.1 can be assumed to be incomplete 
as well. Trafficking complexes are also believed to bind cargo motifs with a moderate affinity 
only. In the coincidence detection model, the affinity is dramatically increased by the 
presence of specific phosphoinositides and small GTPases.  
A former colleague in our group, Thorsten Baust, used a part of the cytosolic domain of 
varicella zoster virus glycoprotein E (gE, formerly gpI), covalently coupled to artificial 
liposomes to mimic trafficking complex formation in vitro (Baust, 2006). Figure 1.14B shows 
that the wildtype gE heavily recruits γ-adaptin (AP1G) along with the clathrin coat and the 
small GTPase Arf1, but as it seems, low amounts of members of the adapter complexes 2 (α-
adaptin), 3 ( σ3-subunit) or COP complexes (β-COP). Wild type and truncated or mutated gE 
variants (Figure 1.14A) were used to demonstrate the importance of the sorting motif in the 
recruitment of γ-adaptin and Arf1 (Figure 1.14C). 
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Table 1.1: Endosomal/lysosomal sorting motifs (adopted: Bonifacino, 2003; Burgos, 2010). 
 
Motif Proposed recognition protein or domain  Functions 
 
NPXY  Clathrin terminal domain,µ2 subunit of AP-2, PTB domain of Dab2 Internalization 
YXXØ µ subunits of AP complexes Internalization, lysosomal targeting, 
  Basolateral targeting 
(Y)KFFE AP-4 TGN-to-endosome sorting 
[DE]XXXL[LI] µand/or β subunits of AP complexes Internalization, lysosomal targeting,  
  Basolateral targeting 
DXXLL  VHS domain of the GGAs  TGN-to-endosomes sorting 
Acidic cluster  PACS-1  Endosomes-to-TGN sorting 
FW- or P-rich  TIP47  Endosomes-to-TGN sorting 
NPFX(1,2)D  SHD1 domain of Saccharomyces cerevisiae S1a1p Internalization 
Ubiquitin  UIM, UBA, and UBC domains, ESCRT complexes  Internalization, lysosomal/vacuolar targeting 
 
X - any amino acid; Ø - amino acid residue with a bulky hydrophobic side chain 
 
 
 
Figure 1.14: Recruitment experiments with gE coupled to artificial liposomes. A – sequences of wildtype and 
truncated or mutated variants of gE used. B – Western blots showing temperature and GTP-γS dependent 
recruitment of Arf1, γ-adaptin (AP1G) and clathrin. There is also indication of recruitment of some AP-2 and 
AP-3 (α-adaptin, σ3-subunit), whereas β-COP doesn’t seem to be recruited. C – Sorting motif dependent 
recruitment of γ-adaptin and Arf1. –cd – control experiment without cytosolic domain of gE. (Baust, 2006). 
 
1.7.3 Phosphoinositides. Along with the sorting motif, membranes are also recognized by 
the trafficking complexes. Often this is achieved through protein domains recognizing 
phosphoinositides. Phoshoinositides, or phosphatidylinositol phosphates (PIP) are 
derivatives of phosphatidylinositol (PI), were the inositol ring is decorated with organic 
phosphate in a combinatory manner on the 3, 4 and 5-positions (Figure 1.14). The different 
phosphoinositides are converted into another by specific kinases and phosphatases that act 
on specific membranes. Hence phosphoinositides are heterogeneously distributed among 
the membrane types. The exocytotic pathway is governed by PI4P that is predominantly 
occurring in the Golgi membrane but also found in the plasma membrane. The endocytic 
pathway on the other hand, is governed by PI3P in the early endosomes that is converted 
into PI35P2 which represents the late endosome or lysosomal membrane. PI4P in the 
plasma membrane is converted to PI45P2, the predominant phosphoinositide of the plasma 
membrane. Two phosphoinositides are generated in response to external signals, PI34P2 
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and PI345P3. PI345P3 is described to occur in specific regions of the plasma membrane (van 
Meer, 2008) or phagosomes (Byekova, 2010), PI34P2 at the plasma membrane (van Meer, 
2008) (Figures 1.13 & 1.17). The subcellular localization and cellular function of PI5P remains 
elusive. As PI5P is produced via PI3P and PI35P2 by phosphoinositide 5-kinase PIKfyve and 
the phosphoinositide 3-phosphatase MTMR3 (Oppelt, 2013), it might be embedded into a 
PI35P2-containing organelle, its maturation products or derivated vesicles. 
Phosphoinositides work together with small GTPases as sign posts of membrane recognition 
by trafficking complexes (Behnia, 2005). Phosphoinositides aid to acquire the specific 
GTPases when they are activated by guanine nucleotide exchange factors (GEFs). Trafficking 
complex constituents concertedly recognize both then, the phosphoinositide and the 
GTPase (Figure 1.16) (Di Paolo, 2006). 
 
 
 
Figure 1.15: Phosphoinositides (PIPs), their kinases and phosphatases and protein domains that bind PIPs 
(altered from: DeMatteis, 2005), along with exemplary proteins (taken from DiPaolo, 2006). 
 
1.7.4 Small GTPases. The identity of organelle membranes is also defined by small GTPases. 
The main classes of small GTPases contributing to this are Rab and Arf families (Behnia, 
2005). GTPases switch between the inactive state when GDP is bound and the active state 
with a bound GTP (Figure 1.16-A). In the inactive state, those GTPases are mostly cytosolic 
but can also bind to membranes transiently. Membrane binding is enabled by a myristoyl 
group (Arfs) or palmitoyl groups (Rabs). The Rab GTPases are associated in the inactive state 
with a GDP-dissociation inhibitor (GDI) that needs to be released by an intrinsic membrane 
protein, the GDI-displacement factor (GDF). The interconversion from active to inactive 
EpsinRFAPP1/2TAPP1/2 Dynamin Class II PI3K AP180CISKGRP1 
Ent5p SNX2,3 EEA1 SNX13 
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states is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating 
proteins (GAP). Specific GEFs recognize and convert inactive GTPases by recognizing both, 
the specific GTPase and the phosphoinositide that represents membrane identity. GAPs are 
likewise detecting the phosphoinositide and GTPase coincidently. This coincident detection 
is a general principle that allows triggering effector affinity due to cooperative binding 
(Figure 1.16-C). Coincidence detection also occurs when trafficking complexes bind to 
phosphoinositides and cargo (membrane receptor to be trafficked) sequences. Interestingly, 
the phosphoinositide converting enzymes like kinases (Figure 1.16-B) also detect and 
convert its substrate when they are bound to activated small GTPases in parallel. 
 
 
Figure 1.16 Interplay of phosphoinositides and small GTPases (Di Paolo, 2006). Purple - GTPases; Red – GDP; 
Yellow – GTP.  
 
These processes can occur simultaneously forming a negative feedback loop. The conversion 
of phosphoinositides changes the membrane identity and can prepare suborganelle 
membrane domains or trafficking vesicles for fusion with the target membrane. Figure 1.16  
shows the subcellular distribution of phosphoinositides and their metabolizing enzymes. 
Due to their phosphoinositide affiliation, Rab and Arf GTPases are heterogeneously 
distributed in the cell. Just a subset of them is constitutively expressed, while the expression 
of others depend on the cell type or cell state (reviewed in Stenmark, 2009; Donaldson, 
2011) (Figure 1.17). Two of the Arf GTPases, Arf1 and Arf6 have been studied particularly in 
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the context of coat formation. Arf1 localize at the Golgi, whereas Arf6 is predominantly 
found at the plasma membrane, but also occur in the endosomal system. Arf1 is required 
for the recruitment of the trafficking complex AP-1 (Stamness, 1993; Crottet, 2002) and Arf6 
was shown to recruit AP-2 (Paleotti, 2005).  
 
 
Figure 1.17: Subcellular distribution of phosphoinositides and their metabolizing enzymes (taken from 
Vivinanza, 2008). Blue names - phosphoinositide kinases; Green names - phosphoinositide phosphatases; 
PM - plasma membrane; EE - early endosome; SE - sorting endosomes; RE - recycling endosome; LY - lysosome; 
MVB/LE - multivesicular body/late endosome; PAS - pre-autophagosomal structure; PH - phagosome; 
TGN - trans-Golgi network; GC - Golgi complex; ER - endoplasmic reticulum; N - nucleus. 
 
 
1.7.5 COPI, COPII complexes. Basic trafficking ways have been discovered that are 
hallmarked by the trafficking coat complexes involved. After synthesis and membrane-
insertion in the rough endoplasmic reticulum, transmembrane proteins are trafficked to the 
cis-Golgi by vesicles coated with COPII. COPI coated vesicles are trafficking cargo either 
inside the Golgi or back to the endoplasmic reticulum. Post-Golgi trafficking vesicles are not 
coated with COPI/II but can be coated with clathrin instead.  
 
1.7.6 Adapter complexes. At least six adapter complexes, AP-1A, AP-1B, AP-2, AP-3, AP-4 
and AP-5, have been identified that serve on different post-Golgi trafficking routes. Adapter 
complex 1 or 2 link the clathrin coat to the vesicle. Several other trafficking complexes like 
AP-3 to 5, the retromer complex and a sequence of ESCRT-complexes ESCRT-0 to 3 do not 
seem to be coated. Clathrin has been implicated in retromer-mediated trafficking, but is 
shown to be not required for SNX-BAR-retromer-mediated carrier formation (McGough, 
2013). Adapter complexes are  heterotetramers, comprising of two large subunits ( β 1–5, 
and either α , γ , δ , ε or ζ ; ∼ 100 kDa), one medium ( μ 1–5; ∼ 50 kDa) and one small ( σ 1–
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5; ∼ 20 kDa) subunit (Figure 1.17). Isoforms of subunits of the adapter complexes 1 to 3 
have also been identified. The adapter complex 1 has two possible μ subunits, μ1 and μ2 
and the resulting complexes are indexed as AP-1A and AP-1B. In epithelial cells, both 
complexes traffic cargo on different routes. AP-1A mediates bi-directional transport 
between the trans-Golgi network and the endosomes, while AP-1B conducts basolateral 
trafficking. AP-2 provokes clathrin-mediated endocytosis from the plasma membrane and 
AP-3 is thought to function in the endosome to lysosome or Golgi to lysosome transport. 
AP-4 may play a role in trafﬁcking of proteins from the TGN to endosomes either directly or 
via the plasma membrane (Hirst, 2013). The trafficking routes and cargo of AP-5 that is 
believed to localize on late endosomal or lysosomal membranes remains elusive (Figure 
1.18). 
 
 
Figure 1.18: Trafficking by adapter complexes. A – Subunit structure of the adapter complexes 1-4 (taken from 
Robinson, 2001). B - Trafficking ways of the five adapter complexes. Red circles - AP-1; Green circles - AP-2; 
Blue circles - AP-3; Yellow circles - AP-4; Pink circles - AP-5; PM - Plasma membrane; E - Endosomes; 
L - Lysosomes; TGN - Trans Golgi network. C – Expression of the five adapter complexes in HeLa (B,C taken 
from Hirst, 2013). 
 
1.7.7 Retromer complex. Retromer directs cargo from the endosomes to the Golgi, enabling 
recycling of receptors back to the plasma membrane. The retromer complex consists of two 
subcomplexes. It is at first, the cargo-selective core complex with VPS35, VPS29 and either 
VPS26A or B. Secondly, this core complex binds to sorting nexin subcomplexes that 
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recognize membranes by phosphoinositide-binding domains, like SNX1,2,5,6 (Figure 1.19). 
The involvement of clathrin in the retromer complex has been supposed (Popoff, 2007; 
McGough, 2013). 
 
 
Figure 1.19: The retromer complex. The cargo-recognizing core of the retromer complex associates with 
sorting nexin subcomplexes that provide membrane-specificity (Cullen, 2011). 
 
1.7.8 GGAs. Golgi-localized, γ-ear-containing, Arf-binding family proteins (GGA) are believed 
to be involved in the trafficking of mannose 6-phosphate receptors including their cargos, 
from the trans-Golgi network to early or late endosome. However, the fact that substantial 
amounts of GGAs localize with peripherally distributed structures can be explained by 
vesicular trafficking of GGAs to that sites (endosomes?) or GGA-mediated trafficking from 
 
 
Figure 1.20: GGA coats. A - Domain organization of GGA1. B - Assembly of GGA-containing coats (Bonifacino, 
2004). 
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that sites (Bonifacino, 2004). GGAs bind clathrin and they bind to the DXXLL sorting motifs of 
CI-MPR, CD-MPR, Sortilin, SorLA, LRP3, β-secretase and to other GGAs 1 or 3. They do also 
directly bind to Arf1, clathrin and accessory proteins, like rafaptin-5 (Figure 1.20). 
 
Many more proteins that are capable of binding clathrin are recognizing membranes by 
phosphoinositides or Arfs, cargo sequences or ubiquitin were identified. Those proteins can 
have a similar central or an accessory role in a diversity of trafficking coats. Such proteins 
that localize at the plasma membrane are epsin-1, autosomal recessive form of 
hypercholesterolemia (ARH), huntingtin-interacting protein 1 (HIP1), disabled-2 (Dab2) and 
numb as well as hepatocyte-growth-factor-receptor substrate (Hrs) and signal-transducing 
adaptor molecule (Stam) on endosomes (Bonifacino, 2004). 
  
1.7.9 ESCRT complexes. Parts of the plasma membrane along with membrane-
associated cargo is internalized via endosomes and further internalized into the endosomes 
forming multivesicular bodies (MVB). These enclosed vesicles can subsequently be directed 
to the lysosomes or when MVBs fuse with the plasma membrane, be released from the cell 
as exosomes. Exosomal membrane proteomes differ in their composition from plasma 
membrane proteomes meaning that mechanisms exist that recognize cytosolic parts of 
membrane proteins and sort proteins for this route. The first step of these processes is the 
labeling of those membrane proteins with ubiquitin. Components of four ESCRT complexes 
(endosomal sorting complexes required for transport) (Table 1.2) recognize and cluster this 
cargo at the plasma membrane, provoke deubiquitination, sequestration and sorting 
(Figure 1.21).  
 
Table 1.2: ESCRT complex components (Phyllis, 2009). 
 
Complex Yeast  Metazoan 
 
ESCRT-0  Vps27   VPS27 (Hrs) 
 Hse1   STAM1, 2 (HSE1, 2) 
ESCRT-I  Vps23   VPS23 (Tsg101) 
 Vps28   VPS28 
 Vps37   VPS37A, B, C, D 
 Mvb12   MVB12A, B 
ESCRT-II  Vps22   VPS22 (EAP30) 
 Vps25   VPS25 (EAP20) 
 Vps36   VPS36 (EAP45) 
ESCRT-III  Vps2   VPS2-1, 2 (CHMP2A, B) 
 Vps24   VPS24 (CHMP3) 
 Vps20   VPS20 (CHMP6) 
 Vps32 (Snf7)   SNF7-1, 2, 3 (CHMP4A,B, C) 
 Vps60 (Mos1)  VPS60 (CHMP5) 
 Vps46 (Did2)   DID2-1, 2 (CHMP1A, B) 
 -  CHMP7 
Others  Vps4   VPS4A, B (SKD1) 
 Vta1   LIP5 (VTA1) 
 Ist1   IST1 
 Vps31 (Bro1)   ALIX (AIP1) 
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Figure 1.21: Sequential operation of ESCRT complexes (Henne, 2011). 
 
 
1.8 Aim of the thesis 
We want to establish label-free procedures that should enable us to answer the 
fundamental questions in proteomics: what is a sample’s composition, is a group of proteins 
enriched that is defined by the sharing of specific properties and what are the differences 
between two (or more) samples. To do so, we will systematically compare primary label-free 
parameters and associated normalization methods for their dynamic and linear ranges and 
their accuracies to reflect protein amounts. For the enrichment analysis we will develop a 
mathematical model and for all the elucidated procedures we will implement bioinformatic 
workflows. To demonstrate the convenience of the workflows, we will apply this to two 
challenging types of biological models. It is at first, the comparative analysis of stem cell 
plasma membrane proteomes where we expect low sample amounts, small proteomic 
differences and arduous to analyze proteins in a complex chemical and proteomic 
background. At second, we want to study early trafficking events by the realization of 
proteo-liposome recruitment experiments. Hereby, membrane-associated protein networks 
of strong interaction partners as well as fragile protein complexes will be generated. For this 
purpose, we will develop a new recruitment assay approach enabling to couple bacterial 
expressed proteins to synthetic liposomes. These constructs will represent cytosolic parts of 
type-I and –II membrane proteins containing partially known trafficking motives. Those 
motives, presented in a lipid environment and exposed to a complex cytosolic proteome, 
will mimic early trafficking events by recruitment of proteins and protein networks. We 
expect a huge proteomic background of proteins binding to the liposomes irrespective of 
the receptor or simply co-isolated proteins and a relatively small amount and number of 
receptor-specific binders. 
 
 
 2. RESULTS 
 
  
2.1 Label-free mass spectrometric parameters 
2.1.1 Dynamic ranges. We were interested in establishing label-free mass spectrometric 
workflows, to estimate sample composition as well as the proteomic difference between 
two samples. At first, the dynamic and linear ranges of the basic mass spectrometric 
parameters spectrum count (SC) and intensity (MQ) were analyzed. As for the extracted ion 
intensity-based protein abundance index (xPAI) three different peptides are needed, this 
parameter was also included into the analysis. A dilution series of a mixture of albumin and 
beta casein was therefore analyzed (Figure 2.1) and the MaxQuant-Intensity (MQ) was 
found to provide superior dynamic and linear range over six orders of magnitude when 
compared to the mass input (Figure 2.2). The dynamic range of the spectrum count method 
was clearly inferior, with 5 orders of magnitude for albumin and 4 orders of magnitude for 
beta casein. For all three parameters, the curves converge and even superpose (for MQ) if 
they are compared to mass inputs instead of molar inputs. This suggests a general 
requirement of normalization for protein size. The measurements were repeated in 
presence of a yeast background proteome which affected the three parameters unequally. 
While in the spectral count method the detection of albumin seems unaffected, the 
detection of the smaller protein beta casein was reduced to the higher amounts where a 
dynamic dependency can even barely be visualized. This might be, because the upper limit 
of the SC method seems to be already achieved when first detecting casein. In the xPAI 
method, the detection of albumin still span over 6 orders of magnitude but having the 
detection of casein restricted to higher amounts. Clearly the outperforming parameter is 
MQ, with a linear range over five orders of magnitude for both proteins, while having both 
curves nearly superposed (Figure 2.3). 
2.1.2 Accuracies. Secondly, the accuracies of normalized parameters in the estimation of 
protein abundances were observed on a broader spectrum of standard proteins. A tryptic 
digest of 49 proteins, presented in a range 0.5 to 50000 fmol (Universal proteomic standard 
UPS2) (Figure 2.5) was used therefore and the peptide numbers (PN), exponentially 
modified protein abundance indices (emPAI), spectral counts (SC), normalized spectral 
abundance factors (NSAF), MaxQuant-intensities (MQ) , label-free quantification intensities 
(LFQ), extracted ion intensity-based protein abundance indices (xPAI) and intensity-based 
absolute quantification values (iBAQ) were calculated. Both, emPAI and iBAQ require the 
number of observable tryptic peptides for normalization. Observability is defined by the size 
of the peptide, because the linear ion trap has to be operated in a certain mass range, it is 
defined by the capability to accept protons and to hold an overall charge of +2 or more, 
because of similar operative restrictions, and it is defined by a grade of hydrophilicity that 
allows binding to the reversed phase chromatography as well as its elution within the 
applied gradient. A total yeast proteome was analyzed and a python program was used, to 
compare experimental with theoretical retention times, and to spot retention time limits. 
Another python program was used then, to estimate numbers of observable tryptic peptides 
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from those limits, and a fasta-format data base of the respective organism, to carry out an 
in-silico digestion with trypsin. Other parameters were the charge (+2 or +3), number of 
amino acids (6 to 60) and the type of gradient (reversed phase, pH=3, with peptides eluting 
in between 5 and 35% acetonitrile) (Figure 2.4).  
 
 
Figure 2.1: Assessment of the dynamic range in protein quantification. A & B – Left panels: base peak 
chromatograms for different amounts of a mixture of tryptic peptides of albumin and beta casein; A - Right 
panel: base peak chromatogram and extracted ion chromatograms of tryptic peptides from a mixture of 500 
fmol tryptic peptides of albumin and beta casein; B – Right panel: extraced ion chromatograms for an albumin 
peptide across all dilution steps. This peak can be identified in the extracted ion chormatograms, even in 
experiments were there is no clear peak pattern in the base peak chromatograms.  
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Figure 2.2: Dynamic range of quantitative values. Two-component mixtures of different amounts of albumin 
(dotted) and beta casein (dashed) were trypsin-digested and analyzed via LC-MS. Highest dynamic range over 
five orders of magnitude, along with a strong linearity, was achieved by the use of MaxQuant intensity values 
(MQ), and similar good by using the extracted ion chromatogram-based protein abundance index (xPAI). The 
spectral count index (SC) was restricted to a dynamic range over three orders of magnitude, in case of the 
smaller beta casein. Using mass amounts on the abscissa, normalizes the data for protein length and converges 
both proteins’ curves. 
 
 
 
Figure 2.3: Dynamic range in a complex proteomic background. Albumin (dotted) and beta casein (dashed) 
were spiked in different amounts into a total yeast proteome, trypsin-digested and analyzed via LC-MS.  
Sample complexity slightly reduced the dynamic range of all values. The MaxQuant intensity performed best, 
in terms of dynamic range and linearity over four orders of magnitude. 
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Figure 2.4:  A - LC-gradient and base peak chromatogram (BP) as used in all experiments. The majority of 
peptides elute within 40 minutes of the gradient (RT = 20…60 min).  B - Estimation of RT-limit presets. The 
calculation of theoretical observable peptides is a prerequisite for the calculation of emPAI and iBAQ. All 
peptides of a tryptic in-silico digest are filtered first for those observable in the operation mass over charge 
range of 200 to 2000 amu with allowed charges of 2+ and 3+. Extremely hydrophilic (at pH=3) or hydrophobic 
peptides can also not be observed because they either not bind to the LC-columns or could not be recovered 
from the bead or other surface materials. To elucidate those the method of Zubarev (Gorshkov, 2006) is used 
to calculate theoretical retention times and a filtering window is constructed by comparison of those 
theoretical with practical retention times within the gradient of a pre-experiment. Grey circles – all redundant 
peptides measured. Black dots - highest scoring peptide identification. Whereas most of the peptides elute in 
between 20 and 60 minutes, above 60 min grey horizontal lines indicate an increasing repetitive 
measurement. This corresponds to the lack of peaks in the base peak diagram. Hence, there is some 
optimization potential in altering the classical linear 5 to 45 percent acetonitrile gradient to a sophisticated 
non-linear concave gradient. 
 
 
The quantitative indices in Figure 2.5 differ not only in the overall correlation (correlation 
coefficients), but also in the magnitude of single outliers which would lead to extremely 
false estimations of single protein abundances. This is particularly the case for emPAI and 
PN, but can also be seen for LFQ were a single protein is underestimated by two orders of 
magnitude. PN and emPAI proved to correlate absolutely poor when no manual data 
deselection is allowed. All other parameters seem to be generally suitable for assessing 
proteome compositions. Interestingly, the magnitude of single outliers is diminished when 
the parameters are compared to the mass inputs, rather than to the common molecular 
inputs, enlighten another level of normalization. Also, the overall correlation is enhanced in 
that way. The two predominating indices are LFQ and iBAQ. The latter appear as an almost 
ideal index for protein abundance in a sample, with low standard deviations of repeated 
measurements, a high correlation coefficient over a huge dynamic range and outliers below 
one order of magnitude. LFQ on the other hand, demonstrated to be reliable as well and as 
it is constructed as normalization between samples, these LFQ values were subsequently 
assessed for its use in the comparison of different samples. 
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Figure 2.5:  Accuracy of protein amount estimations. Different normalized parameters were compared for their 
linearity to a broad range of spike-in amounts of Universal proteomic standard 2 (UPS2) proteins. PN and its 
normalized derivative emPAI are highly affected by large outliers. SC, its normalized derivative NSAF and all 
intensity based parameters are generally suited for quantitative analyses. All parameters show slightly better 
Pearson correlation coefficients when been opposed to the mass inputs suggesting another level of 
normalization. Some proteins deviate largely from the regression lines, hampering confident estimation of 
single protein amounts whereas assumptions over group contingents, like proteins sharing a certain gene 
ontology, seem to be justified. This was not the case for iBAQ values, which suited best also in overall 
correlation. Deviations of single values were here less than one order of magnitude from the regression line. 
LFQ intensities were only slightly less accurate and as they are constructed for normalization between 
samples, were thus further used for differential proteome analyses. 
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2.2 Differential proteome analysis 
2.2.1 Imputation. We assume that for proteins, which were not detected in all the 
triplicates of at least one sample group (i.e. experimental state), there is no significant proof 
of their principal presence and hence they were removed from the data. In all other cases, 
we imputed missing values under the assumption that they were present below the 
detection limit. However, this assumption is not obvious for proteins with a low number of 
observable tryptic peptides where ion suppression could have led to missing identifications. 
To keep the overall standard deviation for protein intensities from the low intensity region 
of the data, we refrained from imputation using a constant. Instead, intensity values for 
imputation were randomly drawn from a Gaussian distribution around the detection limit, 
with a standard deviation estimated from the low intensity region of the data (Figure 2.6). 
 
 
Figure 2.6: A - Standard deviation (SD) in units of log2(LFQ-Intensity), versus LFQ-Intensity classes in a boxplot 
analysis. Low intensities are generally poorer estimated than higher intensities, as demonstrated by their 
higher standard deviations. One major reason for this might be an enhanced risk for ionic suppression. (Data 
were taken from an APP-recruitment experiment in a PI345P3 membrane context). B – Original (light bars) and 
imputed (grey bars) LFQ-values in a histogram plot. Imputation values were randomly drawn from a Gaussian 
distribution around the detection limit, with a standard deviation estimated from the low intensity region of 
the data (same data set as in Figure 2.5). 
 
2.2.2 Accuracy of protein change detection. Next, the universal proteomic standard 1 
(UPS1) consisting of of 49 equimolar proteins was spiked into a yeast background proteome 
in a series of different amounts (Figure 2.7 and 2.8). Four technical replicates of all such 
samples were analyzed via LC-MS and protein identification was accomplished using 
MaxQuant. LFQ values were log2-transformed, and proteins were eliminated if not at least 3 
values out of four replicates were achieved. Missing values were imputed with a normal 
distribution around the detection limit. A permutation based modified t-test, similar to a 
significance analysis of microarray experiments (SAM) (Tusher, 2001), was conducted using 
the MaxQuant Perseus software, with a threshold value of 0.01 and a slope value of 1.0.  No 
protein was found to be significantly different when 0.74 versus 0.24 fmol UPS1 proteins 
were compared.  This is, because with an input of 0.24 fmol, it was impossible to yield three 
LFQ values for anyone protein. As expected, the number of quantifiable proteins increases 
with the amounts spiked in, but also the accuracy of ratio estimation increases with the 
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actual ratio, but not with increasing input amounts. No saturation of this increase was 
reached within the experiments. The method elucidates even small changes in a complex 
background proteome. High accuracy is reached for high input ratios, in contrast to SILAC 
where the impossibility of a 100% labeling efficiency leads to great underestimation of high 
ratios. 
 
 
 
Figure 2.7: Volcano plots for differential proteome analysis. Different amounts of UPS1 standard proteins 
(black dots) were spiked into a total yeast proteome (grey dots). To assess the models response to protein 
abundance changes, four replicates of two of these samples were compared in each volcano plot. The dashed 
lines represent significance thresholds (TV=0.01 and s0  = 1.0).  Numbers inside the plot indicate spike-in 
amounts of UPS1 that are compared. H, L – High and low amounts of spiked-in UPS1 standard proteins.  
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Normal distributed data are preferred, and sometimes are even a prerequisite for 
statistical models of distributions. The general notion is that log-transformed abundances 
are approximately normal (Podwojski, 2010). To check if this is also the case for the 
normalized intensities that due to the preceding experiments reflect protein abundances, 
LFQ and iBAQ intensities from the yeast background proteome were compared to a normal 
distribution in a quantile-quantile (Q-Q) plot (Figure 2.9). iBAQ intensities prove to be 
perfectly normal distributed and the LFQ value can be represented by a normal distribution 
as well, although there is a certain deviation from the intersecting line for extreme values. 
 
Figure 2.8: Boxplots of ratios of UPS1 proteins, normalized by the actual input ratios. The experiment labels 
refer to Figure 2.7. Numbers inside the plot assign the number of proteins passing the significance thresholds. 
The accuracy increases with higher input ratios, but not with increasing input amounts. Even small changes in a 
complex background proteome are elucidated.  
 
 
 
Figure 2.9: A trypsin-digestion of a total yeast proteome was used to mine MaxQuant label-free quantification 
intensity values (LFQ) for a comparison to theoretical quantiles in a Q-Q plot. Log-transformed LFQ-intensities 
proved to be normal distributed in a complex sample, and so were the protein amounts due to their 
demonstrated strict linear correlation to MQ/LFQ values.  
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2.2.3 Receiver Operating Characteristic. The choice of a threshold value and the slope 
parameter which has a minor influence on the curve is not obvious. The SAM approach was 
initially developed to resolve the issue of multiple testing (Roxas, 2008) and the threshold 
was designed to reflect the false discovery rate (FDR) (Hubner, 2010). However, we 
recognized that this doesn’t hold true for proteomics data. To test the robustness of 
 
Table 2.1: ROC-Analyses of the modified t-test (SAM), as implemented in PERSEUS. 
A - Experiment D (20 fmol versus 6.7 fmol UPS1 in a yeast background proteome); 
B - Experiment B (2.2 vs. 0.74 fmol UPS1) 
 A TV T P D+ D- TP FP TPR FPR 
 
 0.001 477 45 11 466 11 0 0.244 0.000 
 0.01 477 45 25 452 25 0 0.556 0.000 
 0.02 477 45 34 443 34 0 0.756 0.000 
 0.03 477 45 38 439 38 0 0.844 0.000 
 0.04 477 45 42 435 41 1 0.911 0.002 
 0.05 477 45 42 435 41 1 0.911 0.002 
 0.06 477 45 42 435 41 1 0.911 0.002 
 0.07 477 45 42 435 41 1 0.911 0.002 
 0.08 477 45 42 435 41 1 0.911 0.002 
 0.09 477 45 43 434 42 1 0.933 0.002 
 0.10 477 45 43 434 42 1 0.933 0.002 
 0.15 477 45 44 433 42 2 0.933 0.005 
 0.20 477 45 44 433 42 2 0.933 0.005 
 0.25 477 45 44 433 42 2 0.933 0.005 
 0.30 477 45 45 432 42 3 0.933 0.007 
 0.40 477 45 52 425 43 9 0.956 0.020 
 0.50 477 45 53 424 43 10 0.956 0.023 
 0.60 477 45 55 422 44 11 0.978 0.025 
 0.70 477 45 137 340 44 93 0.978 0.177 
   
 B TV T P D+ D- TP FP TPR FPR 
 
 0.001 477 45 15 462 15 0 0.333 0.000 
 0.01 477 45 23 454 23 0 0.511 0.000 
 0.02 477 45 23 454 23 0 0.511 0.000 
 0.03 477 45 23 454 23 0 0.511 0.000 
 0.04 477 45 24 453 24 0 0.533 0.000 
 0.05 477 45 24 453 24 0 0.533 0.000 
 0.06 477 45 24 453 24 0 0.533 0.000 
 0.07 477 45 24 453 24 0 0.533 0.000 
 0.08 477 45 24 453 24 0 0.533 0.000 
 0.09 477 45 24 453 24 0 0.533 0.000 
 0.10 477 45 26 451 25 1 0.556 0.002 
 0.15 477 45 32 445 30 2 0.667 0.004 
 0.20 477 45 32 445 30 2 0.667 0.004 
 0.25 477 45 33 444 30 3 0.667 0.007 
 0.30 477 45 37 440 31 6 0.689 0.014 
 0.40 477 45 43 434 31 12 0.689 0.027 
 0.50 477 45 55 422 32 23 0.711 0.051 
 0.60 477 45 165 312 32 142 0.711 0.247 
 0.70 477 45 251 226 38 213 0.844 0.330 
 
TV – Threshold value of the SAM-threshold function (s0 = 0.5); T - True positives, the number of identified 
proteins (Yeast and UPS1); P - Positives, all identified among the 48 UPS1 proteins; D
+
 - The number of proteins 
that are positively tested; D
-
 - The number of proteins below the threshold; TP - True positives, the number of  
UPS1 proteins among the proteins that passed the threshold; FP - False positives, the number of UPS1 proteins 
that were identified, but below the threshold; TPR - True positive rate, the number of true positives with 
respect to all positives (all identified UPS1); FPR - False positive rate, the number of false positives with respect 
to all negatives, which is the sum of true negatives and false positives. 
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Figure 2.10: ROC-Analysis of experiments D and B (Indices correspond to Figure 2.7). Threshold values (TV) 
were varied from 0.001 to 0.7, with a constant slope value s0 = 0.5. By increasing TV, the true positive rate 
(TPR) drastically increases with nearly no false positives (FPR - False positive rate) up to a TV of 0.25 (arrow) 
where FPR < 0.01. By further increasing the TV, only the FPR is increased. AUC - Area under the curve; 
Stars - Approximated points. 
 
the assay for different threshold settings and the accuracy of the method, ROC-analysis 
(Receiver Operating Characteristic) was performed on two of the experiments, with UPS1-
ratios of 3 (Table 2.1, Figure 2.10). The true positive rate (TPR) was calculated with respect 
to the 45 of the 48 UPS1 proteins which were identified in the overall analysis. The 
difference between both experiments was that although in both cases UPS1 ratios of three 
were analyzed, in experiment D both samples had 9-fold bigger UPS1 amounts as the 
respective samples in experiment B. In the ROC-analysis, the TRR is compared to the false 
positive rate (FPR) reflecting yeast proteins that wrongly passed the threshold. If pairs of 
yeast and UPS1 proteins (i.e. non differentially and differentially abundant proteins) are 
randomly drawn and analyzed, the area under the curve (AUC) in a ROC-analysis represents 
the percentage of pairs were the method correctly classifies  the proteins. The AUCs in 
Figure 2.10 denote an excellent accuracy of experiment D and a good accuracy of 
experiment B (0.9-1: excellent; 0.8-0.9: good; 0.7-0.8:fair; 0.6-0.7: poor; 0.5-0.6: fail). This is, 
because the true positive rate in experiment B was also estimated with respect to the 45 
UPS1 proteins identified across all experiments. One characteristic of the workflow is that 
MaxQuant interpolates peptide fragment information and hence protein identifications to 
samples processed in parallel were fragmentation was not triggered. Although 45 proteins 
were identified in such way, not all of them were in the dynamic range window and hence 
the TPR-maximum in experiment B is below 1.0. Beside the high accuracies to detect 
differentially abundant proteins, the curves reveal a high robustness with respect to the 
threshold values. In both cases the threshold values can be set as high as 0.25 before the 
false positive rate exceeds 1%. However, these analyses were performed in an ideal 
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situation with a very low variability in protein amounts of both, standards and background. 
Depending on the type of biological experiment, different grades of variability in levels of 
proteins were achieved within the replicates. Manual inspection of the proteins surpassing 
the threshold, let us choose threshold values far below 0.25 thus, i.e. 0.001 to 0.05. If 
doubts persisted that some proteins passing the threshold were representing true positives, 
the number of replicates was increased. 
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2.3 Application I – Analysis of plasma membrane proteins 
Compositional proteomic analysis, enrichment analysis and differential proteomic analysis 
of membrane proteins before and upon biochemical enrichment 
Stem cells possess unique proliferation and differentiation capabilities. They 
demonstrate prolonged self-renewal power, in contrast to mature (specialized) cells that 
have a more limited capability of dividing. All cells of the body can be generated from stem 
cells and the differentiation potential of a particular linage is classified into either 
totipotent, pluripotent or multipotent stem cells. Totipotent stem cells deriving from 
fertilized eggs can differentiate into a placenta and an embryo. Pluripotent stem cells can 
differentiate into any cells derived from three embryonic layers: mesoderm, endoderm and 
ectoderm, whereas multipotent stem cells are progenitors of a closely related lineage of 
cells (Lin, 2008). With the immanent ethic controversy in the use of embryonic stem cells, 
adult stem cells are a promising alternative source of stem cells for research and therapeutic 
applications. Two types of stem cells can be isolated from bone marrow, hematopoietic and 
mesenchymal stem cells. An additional multipotent mesenchymal stem cell population has 
been isolated from the dental pulp and termed dental pulp stem cells (DPSC) (Gronthos, 
2000). These cells are capable of differentiation into chondrogenic, endothelial, osteogenic, 
neuronal and smooth muscle linages. Traditional isolation procedures for dental pulp stem 
cells do not appear much sophisticated and hence indeed lead to heterogeneous 
subpopulations. It is at first, a procedure based on their high proliferation capacity, in which 
single cells are separated and the clones with the highest growth rate are selected 
(Kawashima, 2012). A second approach uses the plastic adhesion characteristic of DPSC cells 
to isolate those. A more advanced approach is based on the presence (or absence) of 
specific cell surface markers used for fluorescence-activated cell sorting. Once DPS cells are 
isolated, they need to be cultivated. Karbanová et al. (Karbanová, 2010) showed that the 
chosen cultivation medium has an influence on the cell surface proteome. The work 
presented here is a continuation of the work of Dr. Jana Karbanová in collaboration with her 
in the group of Dr. Denis Corbeil (Biotec, Dresden). The depicted workflow is aimed to 
elucidate appropriate markers for a clear definition of a DPSC population and its isolation by 
FACS. The described cell surface proteome differences, caused by the cultivation media, 
should be analyzed on a molecular level. 
Dental pulp stem cells were isolated and cultivated either in 10% fetal calf serum (FCS) 
‘standard medium’ (as described in Karbanová, 2010) or in ‘basic expansion medium’, 
containing 2% FCS and epidermal growth factor (EGF) as well as platelet-derived growth 
factor BB (PDGF-BB) as supplements (Karbanová, 2010). Figure 2.11 illustrates the sample 
types that were generated for LC-MS analyses. Proteome compositions and the proteome 
differences, caused by the cultivation media, were investigated by the newly implemented 
proteomic workflows. 
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Figure 2.11: Experimental workflow. Dental pulp stem cells were cultivated either in 2% fetal calf serum, with 
PDGF-BB and EGF additives, or in 10% fetal calf serum (indices 2 or 10). A - Total proteome (samples T2 and 
T10). B - Control samples without labeling, but with affinity purification (samples C2 and C10). C - Cell surface 
proteome-enrichment with biotinylation and affinity purification (samples B2 and B10). Gel lanes from the 
total proteome samples were indistinguishable by their band patterns. Gel lanes of the controls exhibit small 
differences. Some obvious differences in the gel band patterns of cell surface proteome-enriched samples are 
indicated by arrows. 
 
2.3.1 Enrichment analysis. The cell surface proteome-enriched samples were compared to 
the total proteome samples to assess the effectivity of the lysine-directed biotinylation and 
affinity chromatography enrichment procedure, which is one of three major CSP enrichment 
methods. The two other methods are density centrifugation, where we expect largest 
numbers of contaminant proteins due to the similar densities of plasma membranes, 
endoplasmic reticulum and mitochondria, and hydrazide capturing of reduced N-glycosidic 
carbohydrate side chains, which is claimed to be nearly free of false positives. Within the 
presented mass spectrometric workflow, we take advantage of the presence of a certain 
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degree of proteomic background, as this is used for the calculation of deviations and 
normalization. This is why the lysine-biotinylation method had been chosen. 
We were comparing different methods to access and plot enrichment efficiency. Pie-
charts are widely used to give an overview about sample composition by partitioning the 
samples according to the gene ontology classifications (GO) (http://www.geneontology.org). 
The total proteome, cell surface proteome and control samples are nearly indistinguishable 
in pie-charts (Figure 2.12). Several problems are associated with this representation. Gene 
 
 
Figure 2.12: Pie-diagrams showing the grade of gene ontology assignments within the samples. Samples are 
partioned by the grade of gene ontology assignments. 
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ontologies are not exclusive, i.e. proteins can be part of more than one of the gene 
ontologies used in the diagram. This necessitates a selection of gene ontologies ensuring a 
minimum of such overlaps. Pie-chart representations do not utilize intensity values of 
proteins, and hence ignore protein abundances. The diagram resembles a percental 
representation making it difficult to compare samples of unequal sizes. 
Venn-diagrams as in Figure 2.13 are popular to compare samples in a certain aspect, 
such as gene ontology. This diagram type circumvents the problems with different sample 
sizes and gene ontology overlap. As in the pie-charts the biotinylated samples as well as the 
total proteome samples show 27-30% cytosol annotation, comparing the numbers of 
proteins by Venn-diagrams elucidates a larger difference: 10% of all proteins were identified 
in the cell surface proteome only, whereas 43% were exclusively identified in the total 
proteome. The overall overlap is 40% and slightly more proteins (34%) were solely identified 
in the total proteome samples than were solely identified in the cell surface proteome 
sample (26%). About three times more proteins are assigned to the plasma membrane 
solely in the cell surface proteome sample than in the total proteome. Also for organelle 
membrane proteins, there are roughly one third more proteins unique in the cell surface 
proteome samples than in the total proteome samples. The question remains which of 
these differences are obvious, and also protein abundances are not utilized in Venn-
diagrams as well. In high sensitivity and high accuracy mass spectrometry, huge numbers of 
proteins are identified and enrichment is less effecting the identification of proteins as their 
intensities.  
 
 
Figure 2.13: Venn-diagrams of cell surface proteome-enriched (B) and total proteome (T) samples. Around 40% 
of the 2867 identified proteins were found in both types of samples. The cell surface proteome-enriched 
sample exhibit an appr. three fold higher number of proteins with a gene ontology assignment to plasma 
membrane localization (GO:0005886), whereas the total proteome sample contain a more than four fold 
number of cytosol localizing proteins (GO:0005829). Proteins assigned to organelle membranes (GO:0031090) 
are not preferentially enriched in either sample. 
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Histogram diagrams as shown in Figure 2.14 can be used to embed intensity values in 
enrichment analysis by plotting the number of proteins in small intensity regions (‘bins’). If 
the mean of a subpopulation of proteins sharing a certain gene ontology is greater than the 
overall mean, those proteins are stated to be enriched by Pan et al. (Pan, 2009). However, 
when proteins are enriched compared to a total proteome, those means not necessarily 
differ in the final sample. What can differ in addition, is also the area under the curve 
fraction of the subpopulation meaning that the Pan and Cox (Cox, 2012) methods ignore a 
relative increase in the number of different proteins assigned to a specific gene ontology. 
 
 
Figure 2.14: Histogram plots reflecting the number of proteins in small intensity-ranges. Distributions of 
protein subpopulations defined by gene ontology assignments barely differ in their means from the overall 
mean. 
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Figure 2.14 demonstrates that the means of all subpopulations, i.e. proteins with gene 
ontology assignments to plasma membrane, organelle membrane or cytosol, do not clearly 
differ from the overall means in any of the samples. What can be seen are slight 
redistributions in the intensity bins. As an example, a loss of proteins can be seen in the B2 
bins 227-231  when compared to the respective T2 bins, whereas plasma membrane proteins 
were added (arrows). 
In our method, proteins are ranked by intensity before binning and the number of 
proteins classified to a specific gene ontology in a bin is then compared to a random draw by 
a hypergeometric distribution model. The resulting p-values reflect the possibility of 
receiving that number of specific proteins by chance. The negative decadic logarithm of the 
p-value is used to express enrichment thus and can be seen as a rescaling of the number of 
positive draws. This rescaling is a normalization of the respective gene ontology for its 
sparsity. The total number of proteins in a bin is always the same here (100), in contrast to 
the histogram plots. Figure 2.15 shows the application of the model to the experimental 
data.  In the cell surface proteome samples, plasma membrane proteins accumulate in the 
first (high intensity) bins, whereas organelle membrane and cytosolic proteins are equally 
distributed over all intensities. In the total proteome samples, cytosolic proteins dominate 
in the higher intensity bins on the contrary and plasma membrane proteins and organelle 
membrane proteins are equally distributed. In the controls, proteins of all gene ontologies 
are equally distributed on a lower level. All three sample types clearly differ in this analysis. 
Enrichment of cell surface proteins seem to be effected by an increase of the number of 
plasma membrane proteins in high intensity bins and a simultaneous decrease of cytosolic 
proteins in those.  
In the plots of Figure 2.15, redistributions could be overseen if they occur less drastic so 
that there is a smaller shift in intensity of the respective proteins. This would reposition the 
bars only slightly in proximity. As the scaling on the x-axes are always the same (bins of 100 
intensity-ranked proteins), two plots can be combined into one comparing the p-values of 
the corresponding bins. This plot type, which is hereby named P-P plot, is applied in 
Figure 2.16 to the data of both cultivation media. Significance regions can be defined where 
high differences of enriched and total proteome samples get revealed by high differences in 
the p-values of the respective bins and gene ontologies. For the cell surface proteome 
enriched samples, those districts contain only data points representing plasma membrane 
protein enrichment, as on the other hand for total proteome samples, only cytosolic 
proteins appear to be enriched. The P-P plot illustrates all information to judge success of an 
enrichment procedure in a single mathematical analysis, numbers of proteins that are 
shifted into or out of the observation window as well as proteins that are decreased or 
increased in numbers but were always observed. Gene ontologies are normalized herein to 
insure their explanatory power.  
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Figure 2.15: Enrichment analysis based on hypergeometric distribution. Proteins were ranked and binned by 
intensity. In each bin, the number of proteins with a gene ontology-assignment to cytosol, plasma membrane 
or organelle membrane is estimated. The possibility (p-value) of observing such a number with respect to the 
bin size, the number of proteins in the UniProt data bank in total and assigned to that gene ontology is 
calculated with a hypergeometric distribution model. As the significance of accumulation is increasing with 
decreasing p-values, a taller bar in the plot represents a more significant accumulation. Proteins in high 
intensity bins were partially identified in the controls as well, but were enriched in amount. 
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Figure 2.16: P-P plot of cell surface proteome enriched versus total proteome samples (B2,T2 or B10,T10). 
Regions of low p-values (p-value
-10..25
) can be encircled where emerging labels spot respective enrichments. 
 
2.3.2 Compositional analysis. The detailed compositional proteome analysis is based on the 
LFQ intensity values, because these values are normalized between samples and thus allow 
averaging. The log2-transformed LFQ intensities were simplified by dividing into five 
abundance classes, below 18 and between 18 to 23, 23 to 28, 28 to 33 and above 33 
(Labeled as: -, +, ++, +++, ++++ in table S.1). Figure 2.17 shows a comparison of LFQ 
intensities for the T10 and T2 samples. 
 
 
Figure 2.17: Compositional analysis of the total proteomic samples. Averages of LFQ-intensities of cells growing 
in BE-medium (T2) and S-medium (T10) were compared. Open grey circles – Non CSP proteins; grey circles – 
CSP-proteins; black circles – CD-marker proteins; triangles – selected CD-marker proteins for FACS validation; 
open black circles – CSP-proteins, found to significantly differ in t-tests between B10 and B2. 
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Common mesenchymal stem cell markers are those proteins that enable prolonged self-
renewal - the stemness factors (Nanog, Oct-3/4, Sox-2) - and cell surface markers. Table 2.2 
compares the respective cell surface markers to our findings. Stro-1 is omitted, because the 
nature and identity of the associated antigen is unclear. We found 7 of 8 proposed 
mesenchymal markers in high or highest intensities in the cell surface proteome enriched 
samples (B) and 5 of this as well in the total proteome sample (T). CD271 was identified in 
neither of the samples. It remains to be observed, if the absence of CD271 is a result of the 
isolation or cultivation methods used. None of the hematopoietic stem cell surface markers 
were identified indicating the purity of the stem cell isolation. Maybe of similar importance 
are not identified cell surface markers. As they proof to be present on co-occurring cells of 
the same niche, those markers can be used as negative selection markers in FACS. We did 
not identify 285 protein markers of the CD system in the total proteome or cell surface 
proteome enriched samples. This forms a sound base for further work where the cell 
surface proteome of co-occurring cell types will be elucidated. In addition to the expected 
mesenchymal stem cell surface markers, we identified 31 CD-marker in the total proteome 
samples (one was found exclusively here) and 73 CD-marker in the cell surface proteome 
enriched samples. Beside the CD-classified proteins for which commercial antibodies for 
FACS analysis are generally available, we identified 79 intense or high intense potential cell 
surface protein markers in the total proteome samples and 180 in the cell surface proteome 
enriched samples. This is the so far most comprehensive and rigorous quantitative 
compositional analysis of a mammalian cell surface proteome. 
 
Table 2.2:  Stem cell surface markers (Kawashima, 2012; Karbanová, 2010). 
Marker AccNo  B T Name 
 
Mesenchymal stem cell markers 
CD29 P05556 ++++ ++++ Integrin beta-1 
CD44 P16070 ++++ ++++ CD44 antigen 
CD73 P21589 ++++ ++++ 5-nucleotidase 
CD90 P04216 ++++ +++ Thy-1 membrane glycoprotein 
CD105 P17813 ++++ - Endoglin 
CD146 P43121 +++ - Cell surface glycoprotein MUC18 
CD166 Q13740 ++++ ++++ CD166 antigen 
CD271 P08138 - - Tumor necrosis factor receptor superfamily member 16 
Hematopoietic stem cell markers 
CD34 P28906 - - Hematopoietic progenitor cell antigen CD34 
CD45 P08575 - - Receptor-type tyrosine-protein phosphatase C 
CD117 P10721 - - Mast/stem cell growth factor receptor Kit 
CD133 O43490 - - Prominin-1 
 
B,T - average of LFQ intensities of all cell surface proteome enriched (B) or total proteome (T) samples.  
 
 
The results are in good agreement with the previous FACS results of Karbanová et al. 
(Karbanová, 2010) (Figure 2.18).  All hematopoietic markers negatively tested in FACS were 
also not identifiable in MS. Five mesenchymal stem cell markers positively tested in FACS 
were intense even in the total proteome. Only a small number of cells were positively tested 
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for CD146 in FACS, not identified though in the total proteome, and of high but not highest 
intensity after cell surface protein enrichment. The latter is an example for the bias of the 
enrichment procedure which is also reflected by a low Spearman's rank correlation 
coefficient (0.183). An identified cell surface marker should be present on every cell for its 
suitability, so one might prefer not to identify such an ambivalent protein. On the other 
hand, the cell surface protein enrichment procedure elucidated, in conjunction with the 
total proteome, this ambivalence and hence the protein from the negative marker 
 
 
 
Figure 2.18: FACS analyses and immunofluorescence microscopic images of DPS cells cultivated in BE (B2) 
medium (from Karbanova2010, PMID 21071916). Unfilled area under the curve – antigen expressing cells. Grey 
area – appropriate isotype-matching controls. 
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candidate list. The total proteome sample’s LFQ intensity values are yet reflecting the actual 
relative abundance of the cell surface markers, with the higher risk of false negative 
identifications. 
To further validate the quantitative compositional analysis, six CD-marker proteins of 
different intensity classes (Table 2.3) were selected for FACS and immunostaining analyses 
(Figure 2.19). All four markers, high intense or intense in mass spectrometric 
measurements, show homogeneous occurrence among all cells. The two marker proteins 
that were only identified upon CSP enrichment appeared only sporadic. No differences were 
observed between samples of the two media.  
 
Table 2.3:  6 CD-marker proteins, two of which showed high intensity in the total proteome, 
2 intense and 2 were only detected after enrichment of cell surface proteins. 
CD AccNo  B T Name 
 
CD44 P16070 ++++ ++++ CD44 antigen 
CD166 Q13740 ++++ ++++ CD166 antigen 
CD9 P21926 ++++ +++ CD9 antigen 
CD151 P48509 ++++ +++ CD151 antigen 
CD39 P49961 ++ - Ectonucleoside triphosphate diphosphohydrolase 1 
CD106 P19320 ++ - Vascular cell adhesion protein 1 
 
B,T - average of LFQ intensities of all cell surface proteome enriched (B) or total proteome (T) samples.  
 
 
 
 
Figure 2.19: FACS analyses and immunofluorescence microscopic images of DPS cells cultivated in BE (B2) 
medium (Left images) or S (B10) medium (Right images). Unfilled area under the curve – antigen expressing 
cells. Grey area – appropriate isotype-matching controls. 
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2.3.3 Differential proteome analysis. Next, we were interested in elucidating differences in 
the cell surface proteomes of DPSC cultivated in the two different media. Such a procedure 
should be based on a statistical model. Most proteins in Figure 2.17 are close to the 
bisecting line, but some proteins deviate by up to 24.  However, these are only mean values 
and standard deviations of both LFQ intensities have to be taken into account. Such a plot, 
with standard deviations in both directions, would be unreadable and the estimation of 
standard deviations of triplicate samples is vague. Therefore, plots that compare intensity 
means, like figure 2.17 are not suited for such analyses. To integrate a statistical assessment 
of the values, a modified t-test is used to calculate p-values and to define a significance 
threshold line. The negative decadic logarithm of those p-values is plotted over the 
logarithm of the mean LFQ intensity ratios in a volcano plot (Figure 2.18). Cell surface 
proteins that pass the threshold and thus represent significant differences between the 
samples are labeled in figures 2.18 and 2.17. Selected CD-marker proteins which were used 
for validation experiments, such as fluorescence-activated cell sorting (FACS), are also 
labeled in Figure 2.17. CD44 and CD166 belong to the most abundant cell surface proteins, 
CD9 and CD151 are of medium abundance and CD39 and CD106 were not detected in the 
total proteomic samples, but in the cell surface proteome enriched samples. 
 
 
Figure 2.18: Differential proteome analysis. Cells were isolated by cell surface biotin labeling after cultivation, 
either in BE-medium (B2) or S-medium (B10). 9 proteins are passing a conservative threshold of 0.001 on the 
B10 side and 6 show preferential abundance in the B2 samples. Black labels – significant hits, assigned to the 
CSP by the Boolean algorithm. Grey labels – significant non CSP proteins. 
 
The differential proteome analysis (Figure 2.18) unbosomed the mentioned influence of 
cultivation media on the cell surface proteome. Quantitative PCR and Western blotting 
(where antibodies were available) were used in subsequent experiments to validate those 
findings for a broader number of donors (Figure 2.19). Table 2.4 summarizes the results. 
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Figure 2.19: Validation experiments of the differential proteome analysis of DPS cells cultivated in two 
different media. Left - qPCR results. Right – Western blot results. BE – Basic expansion medium (B2), 
S - Standard medium (B10). Samples from donors 1 and 7 were also used for differential proteome analysis as 
shown in figure 2.18. 
 
 
Table 2.4:  Summary of the validation of the differential proteome analysis of DPS cells, 
cultivated in two different media by qPCR and Western blotting of total proteomic samples. 
Protein AccNo  CSP WB qPCR Name 
 
Differential MS-analysis: B2>B10 
UPAR Q03405 +  0 Urokinase plasminogen activator surface receptor 
ITA10 O75578 + a a Integrin alpha-10 
CBPM P14384 +   Carboxypeptidase M 
CADH2 P19022 + h 0,h Cadherin-2 
SYTC P26639 -   Threonine--tRNA ligase, cytoplasmic 
SLIK2 Q9H156 +  a SLIT and NTRK-like protein 2 
Differential MS-analysis: B10>B2 
1A24 P05534 +   HLA class I histocompatibility antigen, A-24 alpha chain 
ITA8 P53708 + a,h a Integrin alpha-8 
CADH6 P55285 +   Cadherin-6 
NCAM2 O15394 +  h Neural cell adhesion molecule 2 
EGFR P00533 + a,h 0 Epidermal growth factor receptor 
MFGM Q08431 + a,h 0 Lactadherin 
LSAMP Q13449 +   Limbic system-associated membrane protein 
GPNMB Q14956 +   Transmembrane glycoprotein NMB 
LRC15 Q8TF66 +  a,h Leucine-rich repeat-containing protein 15 
 
CSP – Cell surface protein, B2 (BE – Basic expansion medium), B10 (S – Standard medium), WB – Western 
blotting, qPCR – quantitative polymerase chain reaction, a – affirmed difference, h – heterogeneous between 
donors, 0 – no difference detected, c – conflictive difference (none)  
. 
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The validation discloses differences that occur due to donor-dependent deviations, but also 
cogent distinctions. The most conclusive distinctions are the integrins 10 and 8. In similar 
cultivation experiments, a significant increase in integrins ITB1 (CD29) and ITA6 (CD49f), 
upon cultivation in serum-free media, has been previously reported (Lorenz, 2009). The EGF 
receptor seems to be comparably expressed in B2 medium, but internalized and degraded, 
taken by its lower detection in mass spectrometry and Western blotting. As EGF was 
provided as a supplement in the B2 medium, internalization and degradation of the receptor 
are part of the normal EGF uptake mechanism (Kirisitis, 2007). The diminished cell surface 
localization of the receptor could demonstrate a mechanism of counter-regulation to the 
constant triggering of the EGF-signaling pathway. The threonine-tRNA ligase SYTC is believed 
to be a false positive finding. Although the t-test threshold was set very strictly, so that the 
false discovery rate can be assumed far below 1%, false positives can never be completely 
excluded. No conflictive results were yielded from the validation experiments. For a 
generalization of the findings, a huger number of donors should be used, preferably for 
FACS or Western blot analyses. Whilst the findings of Lorenz et al. were yielded by flow 
cytometry and immunofluorescence, those experiments were hypothesis-driven. The major 
advantage of the shotgun mass spectrometric approach is the unbiased, discovery-driven 
way to yield proteomic differences.  
 
One of the purposes of this project was the selection of cell surface markers that can be 
used in fluorescence-activated cell sorting (FACS) to isolate and quantitate cells like stem 
cells or cancer cells. The supplemental table S.1 lists the identified CD-markers and intensity 
grades in the cell surface and total proteome samples. A comprehensive list of all other cell 
surface proteins is given in the supplemental table S.2. 
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2.4 Application II – Analysis of membrane-associated protein networks 
Introducing a new coupling chemistry and differential proteomics into recruitment assays 
to study post-Golgi trafficking of a multitude of transmembrane proteins 
 
2.4.1 Recruitment assay development. Synthetic liposomes allow in-vitro studies of 
membrane-binding processes and enable to elucidate the influence of distinct lipid 
compositions on this. After recruitment, liposomes can be separated from the cytosol by 
discontinuous density centrifugation. Catimel et al. (Catimel, 2008) used synthetic liposomes 
with embedded PI35P2 or PI45P2 (5 mol-%) to study phosphoinositide- dependent and 
independent recruitment of cytosolic proteins from a LIM1215 colonic carcinoma cell line. 
They used a somewhat differential proteomic approach by the use of a control sample 
lacking phosphoinositides. Proteins that were identified with this control were subtracted 
from the identification lists of the two phosphoinositide containing samples, irrespective of 
protein abundance changes. Also, because no replicates where measured, their results 
suffer from a huge false positive content. In shotgun proteomics, identification of proteins is 
a stochastic procedure meaning that single measurements are tend to lack to identify a 
minor number of proteins. Biological replicates not only overcome variability of the assay, 
but also fill-in the gaps in the identification list. If no replicates are done in a differential 
proteomic assay, many estimated differences can be just accidental. This can be seen in the 
work of Catimel et al. by many proteins that were classified as been recruited, although they 
are intrinsic membrane proteins and hence belong to the co-purified proteins that form part 
of the background. Moreover, these stochastic lacks of identification is likewise leading to a 
huge false negative rate. In addition, false negatives are also immanent to this approach, 
because many proteins bind to membrane surfaces unspecific, i.e. with low affinity. When 
additional factors, like the ‘correct’ phosphoinositide are presented, the affinity is increased 
leading to an increased abundance and mass spectrometric intensity-sum for this protein. 
As in both cases, i.e. in the sample and control, the protein may have been identified, this 
would lead to an elimination of the protein from the list of recruited proteins and thus a 
false negative. To complement this project, they repeated the analysis with PI345P3 
(Catimel, 2009). Many membrane-associated processes are triggered by proteins that bind 
to more than a phosphoinositide in a cooperative kinetic. This so-called coincidence 
detection occurs for instance when adapter complexes like AP-2 assemble and bind in the 
initial steps of vesicle formation. AP-2 recognizes PI45P2 by two binding sites, at the 
N-terminus of the AP-2α subunit and within the cargo-recognizing AP-2µ subunit (Krauss, 
2007). The binding affinity therefor depends on the endocytic sorting motif of the cargo 
protein presented in the context of a PI45P2 containing (plasma) membrane. In the 
liposome-experiments of Catimel et al., AP-2α2 was consequently the only part of adapter 
complexes found and could moreover indicate that AP-2 complexes itself form on top of 
membranes - as distinguished from Figure 2.20. However, it could also indicate that just a 
certain amount of AP-2α is monomeric in the cytosol. 
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Figure 2.20: Coincidence detection when AP-2 recognizes sorting motifs in the context of a PI45P2-containg 
membrane (Di Paolo, 2006). 
 
Proteo-liposomes present coupled proteins or parts of proteins in a membrane 
(phosphoinositide) context. Zhu et al. used liposomes with myristoylated Arf1-GTPγS to 
successfully recruit AP-1 complexes, even without integral membrane proteins (Zhu, 1999). 
Crottet et al. extended the approach with a coupled synthetic peptide carrying Lamp1A or 
TGN38A-derived sorting motifs (Crottet, 2002). Unfortunately, they neglected the 
opportunity to perform a thorough mass spectrometric analysis of their recruitment 
samples. Wenk et al. coupled recombinant synaptotagmin to liposomes (Wenk, 2003). Their 
protocols relied on an amino-terminal gluthathione tag, fused to the protein of interest. 
They also omitted an extended proteomic analysis. This was subsequently done by Baust et 
al. (Baust, 2006) in our group (Prof. Dr. Hoflack), who changed the coupling principle into 
hydrazone bonds, introducing a highly selective and efficient chemistry (Bourel-Bonnet, 
2005).  
However, this chemistry is also a crux as it relies on synthetic peptides which restrict the 
application to cargo with short cytosolic domains. Also, this type of modification (amino-
terminal hydrazino acetyl) is not offered by commercial peptide synthesis services. 
Moreover, peptide synthesis is expensive conflicting its use in screening approaches. We 
therefor changed the coupling chemistry to a thiol-directed maleimide-anchor lipid allowing 
to couple peptides, either recombinant or synthesized, equipped with a free (nearly 
terminal) cystein. Baust et al. performed a single proteomic analysis without controls. The 
classification of recruited proteins into background and recruited proteins relied on manual 
selection and made unbiased findings impossible. In fact, we expected that, as it was shown 
by Catimel et al., the majority of proteins both in number and abundance bind unspecific or 
are co-purified, while a minority represents the truly recruited proteins. Such recruitment 
assays thus represented an appropriate task for sophisticated differential proteomic 
analyses with promising possibilities (Figure 2.21).  
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Figure 2.21: Recruitment assay with differential proteomic analysis. A - Preparation of liposomes for control 
and with receptor sequence. B - Recruitment with cytosol and drugs with triplicates of each. C - Separation of 
cytosol and liposomes by a sucrose density gradient centrifugation. D - Harvest and wash of the liposomes. 
E - Fractionation and in-gel digestion. F - High resolution mass spectrometry. G - Label-free quantitative 
analysis. 
 
In the previous recruitment experiments of Dr. Thorsten Baust in our group (Baust, 
2006; Baust, 2008), the adapter complexes AP-1 and AP-3 have been shown to be recruited 
to the liposomes. Along with that, accessory proteins were found that provided new insights 
into the mechanisms of trafficking. This motivated us to proceed with in-vitro recruitment 
assay experiments. The preparation of the liposomes basically followed an established 
protocol of Baust et al. (Baust, 2006), with the buffer composition adopted with respect to 
the altered coupling chemistry. The extrusion through a filter membrane was omitted, 
because the maleimide group of the anchor lipid is sensitive to hydrolysis and extrusion 
would have extended the exposure of the reactive group to water. Also, we did not want to 
produce unisize, unilamellar liposomes but a distribution of liposome sizes instead. We 
suspected that a size selection introduces unwanted biases for proteins sensitive for 
membrane curvature and we were, in contrast to Baust et al., not aimed to idealize for 
mimicking clathrin-coated vesicles in particular. The coupling efficiency was monitored by 
individual controls of the purified construct, Tev-secession of the His-MBP-tag, the 
supernatant of the liposome wash after coupling and the pelleted liposomes with coupled 
receptor domains. Tev-digestion and coupling was always successful and coupling of the full 
construct never observed. The elimination of the tag was not completely accurate, but 
remaining traces of the tag were incapable of coupling due to the total absence of cysteine. 
As to the subsequent exposure to cytosolic proteins, the presence of a minor fraction of tag-
protein was tolerated. We were confident thus that we had the proper complex baits at 
hand for recruitment screening experiments. 
The biochemical workflow is depicted in Figure 2.22. The recruitment time, the 
concentration of the cytosol, and the concentration of GTP-γS were optimized on PI4P-
containing liposomes with coupled Varicella zoster virus glycoprotein E (gE) using Western 
blot analyses of clathrin heavy chain (CHC) and adapter protein 1 gamma (AP1G) 
(Figure 2.23). Optimal differences between gE-samples and Cys-controls were achieved by a 
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cytosolic protein concentration of 4 mg/ml, a GTP-γS concentration of 1.5 µM, and a 
recruitment time between 8 and 16 minutes. 
  
Figure 2.22: Development of an improved recruitment assay. Cytosolic domains of membrane receptors are 
coupled via an introduced cysteine to a maleimido-functionalized lipid anchor. As a control, a similar liposome 
preparation is saturated with free cysteine instead. Recruitment reactions are performed for receptor 
containing and control liposomes in parallel. For screening of receptor baits and their addiction to specific 
trafficking adapters, spectral counts of unique samples are compared. Triplicates of such pairs of samples and 
controls enable application of statistically validated mass spectrometric label-free relative quantification of 
recruited proteomes. 
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Figure 2.23: Optimization of recruitment parameters. Recruitment experiments were performed using 
Varicella zoster virus glycoprotein E (gE) on PI4P-containg liposomes with varying recruitment times (A), 
cytosolic protein concentrations (B), and GTP-γS concentrations. Clathrin heavy chain (CHC) and AP1G were 
detected by Western blotting.  
 
 
2.4.2 Recruitment screen. The purpose of the screening experiment was to assess the 
recruitment assay with an array of different membrane proteins for which different sorting 
motifs and hence interacting proteins were expected. As in the previous studies, we used 
the varicella-zoster virus envelope glycoprotein E (gE), as it is a known cargo of the adapter 
complex 1 (AP-1). We used the vesicular stomatitis virus glycoprotein G (VSVG), as it is 
known for clathrin-dependent endocytosis to the endosomes. We included the beta amyloid 
precursor protein (APP), for which trafficking and localization is partially known, to further 
extend the validation of our approach and to enable unbiased investigation of this key 
player in Alzheimer’s disease. The localization and trafficking of sortilin (SORT) have been 
studied in depth before and we included it into the screening because of its three different 
types of known trafficking motifs (Table 2.5). We used the transferrin receptor (TFR) as an 
example of a type-II membrane protein, neuroligin 1 (NLG1), because we were interested in 
the cytosolic interaction partners beyond trafficking and crumbs 2 (CRB) to elucidate 
trafficking of this cell polarity determinant. The cytosolic sequences of this membrane 
proteins and the supposed trafficking motifs therein are listed in table 2.5. We used 
different types of phosphoinositides (either PI3P, PI4P, PI45P2 or PI345P3), as 
phosphoinositides represent membrane labels for complexes, like trafficking complexes, 
that need to recognize and form on top of specific organelles. 
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Table 2.5:  Cargos and sorting motifs. 
Name Motif   Sequence after cleavage by Tev 
APP YXXØ,NPXY, GSCGKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN 
 YXXØ, (Y)KFFE 
CRB  GSCGRKRRQSEGTYSPSQQEVAGARLEMDSVLKVPPEERLI 
gE YXXØ, GSIEGRCTKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYTVYIDKTR 
 acidic cluster 
NLG P-rich GSCGYYKKDKRRHDVHRRCSPQRTTTNDLTHAPEEEIMSLQMKHTDLDHECESIHPHEVVLRTACPPDYTLAMRRSPDDIP 
  LMTPNTITMIPNTIPGIQPLHTFNTFTGGQNNTLPHPHPHPHSHSTTRV 
 
SORT  [WF]L[MV]*, GSCGKKYVCGGRFLVHRYSVLQQHAEANGVDGVDALDTASHTNKSGYHDDSDEDLLE 
 YXXØ ,DXXLL 
TFR YXXØ GSMMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVTKPKRCSGSIC 
VSVG YXXØ, YXXØ GSCGYLYIKLKHTKKRQIYTDIEMNRLGR 
The varicella zoster virus envelope protein gE was not part of the screen. *retromer binding motif according to 
Seaman 2007 [Seaman2007, PMID17606993]. Ø - bulky hydrophobic residue. 
 
 
The gel band patterns among experiments with the same phosphoinositide are related, 
but not identical suggesting a broad background of proteins binding to the liposomes 
irrespective of the receptor, but affected by the phosphoinositides used. Many of the 
trafficking complex proteins were identified in the majority of samples. Hence, the spectral 
count values were extracted from the data to enable a simple quantitative examination 
(Figure 2.25). All member of the AP-1 complex, except for AP1M2, were found in the 
controls, highly in the APP, sortilin and TfR samples, some in NLG and minor counts were 
received for crumbs and VSVG. A tendency for a preference of PI4P containing liposomes or 
others is not apparent. All members of the AP-2 complex were also widely identified across 
the samples, with minor counts in the controls, crumbs and VSVG and high counts for the 
PI345P3 containing liposomes decorated with the cytosolic domains of APP, NLG, sortilin or 
TfR. Members of the AP-3 complex were found only sporadic and in low amounts. The full 
complex was found in the controls, with higher counts for MBP and in the PI345P3-TfR 
experiment. Members of the AP-4 complex were only identified in the APP-samples with an 
unclear preference for the phosphoinositides. The AP-5 complex members were not 
identified. Members of the cargo-selective retromer core complex were found in smallest 
amounts in the controls, minor amounts in the crumbs and sortilin samples and high 
amounts in the TfR, APP, NLG and VSVG samples. A general preference for a specific 
phosphoinositide is not visible. Clathrin heavy chain was found with all receptors and 
controls, highest in sortilin for which also highest counts for AP-1 and AP-2 members were 
achieved. A preference for PI345P3 containing samples can be spotted in which partially 
also clathrin light chain proteins were identified. The clathrin coat assembly protein AP180 
was found across all samples but doesn’t seem to correlate with the clathrin proteins.  
 
64|2. RESULTS 
 
 
Figure 2.24: Recruitment screening. Recruitment experiments were performed with a library of cytosolic 
receptor domains and liposomes that differ in the phosphoinositides used. A – PI3P containing liposomes, B –
 PI4P, C – PI45P2, D - PI345P3, E – PI3P and PI45P2 as labeled. For all gels, 50% of the final samples were 
loaded. MW-Molecular weight marker, CYS – Cystein and MBP were used as a control, APP – beta amyloid 
precursor protein, CRB – Crumbs 2, NLG – Neuroligin 1, SORT – Sortilin, TFR – Transferrin receptor, VSVG – 
Vesicular stomatitis virus glycoprotein G.  
 
When having a closer look on the retromer complex members, one can identify clear 
recruitment of the complex members in the APP, NLG, TfR and VSVG experiments with 
respect to the controls, but only relatively small increased counts in the crumbs-PI3P 
sample. It’s not obvious how a significance threshold for a spectral-count ratio (crumbs vs. 
respective control) can be set. A better alternative is the use of a G-test analysis where the 
sum of all spectral counts of a sample is used for normalization and the test statistic can be 
approximated by a chi-square distribution. The model allows to classify quantitative 
comparative protein data into strongly significantly recruited, significantly recruited and not 
significantly recruited, and hence allows to compare different proteins, with different 
absolute values, to be compared. This is specifically of interest for complexes, like the 
adapter complexes, where proteins of fairly different sizes, and thus spectral count levels, 
occur.  
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Figure 2.25: Spectral count analysis of trafficking complex members. A - AP-1 complex, B - AP-2 complex, 
C - AP-3, complex, D -  AP-4 complex, E -  Retromer complex, F -  Clathrins and clathrin associated proteins. 
Labels: 3,4,45,345 refers to the respective phosphoinositeds in the liposomes, i.e. PI3P, PI4p, PI45P2 and 
PI345P3 (Other labels as in Figure 2.19). 
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Table 2.6:  G-test applied to spectral count results of the recruitment screen. Spectral counts that were 
significantly enhanced in the receptor domain containing sample versus the respective control are labeled with 
+ when passing a confidence threshold of p=0.01 or with (+) for p=0.05. 
 
 
 APP CRB NLG SOR TFR VSVG 
    3 345 4 45  3 345 45  345 3 45  3 345 4 45  3 345 4 45  3 4 45 
 AP1B1 +  + +          (+) + +           
 AP1G1 +  + +          (+)  +           
 AP1M1   +           (+)  +           
 AP1M2                           
 AP1S1                           
 AP1S2                           
 
 
 APP CRB NLG SOR TFR VSVG 
    3 345 4 45  3 345 45  345 3 45  3 345 4 45  3 345 4 45  3 4 45 
 AP2A1 + + + +      +    + + + +   +  +      
 AP2A2 + +  +      +    + +     +        
 AP2B1 + + + +      +    + + + (+)   +        
 AP2M1 + + + +      +    + + (+) +   + (+) +      
 AP2S1   +             +     (+)        
 
 
 APP CRB NLG SOR TFR VSVG 
   3 345 4 45  3 345 45  345 3 45  3 345 4 45  3 345 4 45  3 4 45  
 AP3B1                         
 AP3B2                         
 AP3D1                          
 AP3M1                          
 AP3M2                          
 AP3S1                          
 
 
 APP CRB NLG SOR TFR VSVG 
   3 345 4 45  3 345 45  345 3 45  3 345 4 45  3 345 4 45  3 4 45  
 AP4B1 (+)   +                      
 AP4E1                         
 AP4M1                          
 
 
 APP CRB NLG SOR TFR VSVG 
   3 345 4 45  3 345 45  345 3 45  3 345 4 45  3 345 4 45  3 4 45  
 AP180                    (+) +       
 CLCA                           
 CLCB                           
 CLH1    +   +  +       +            
 CLH2                          
 
 
 APP CRB NLG SOR TFR VSVG 
   3 345 4 45  3 345 45  345 3 45  3 345 4 45  3 345 4 45  3 4 45  
 VP26A   +       + +         (+)    +   
 VP26B   +       + +             +   
 VPS29           +              +    
 VPS35  + + + +  (+)    + +         + +   +    
 
In table 2.6, the G-test is applied to the spectral count data for p-values of 0.01 and 0.05. 
This cleaned the data from dubious values and enhanced the explanatory power of the 
spectral counts. Herewith, AP-1 recruitment is achieved presumably with PI4P-liposomes 
and attached APP or sortilin. AP-2 recruitment seem to be slightly better with liposomes 
containing PI345P3 and no significant recruitment of AP-3 complex members can be 
observed, while there is still evidence of AP4B1 recruitment on APP-liposomes. While APP 
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still proves to recruit retromer, only VPS35 was significantly passing the test for crumbs with 
a relaxed p-value of 0.05 leaving an ambiguous statement about retromer complex 
recruitment under this conditions. 
2.4.3 gE coupled to PI4P-liposomes. The varicella zoster virus (VZV), or human herpes virus 
3 (HHV-3) is a member of the alphaherpesvirinae subfamily of the herpesviridae. VZV 
encodes eight membrane glycoproteins, gB, gC, gE, gH, gI, gK, gL and gM (Govero, 2007). 
One basic question in virology is how and thus where inside the cell a virus is assembled. 
This virus assembly requires the cell surface proteins being accumulated and in case of 
viruses like the VZV, that are surrounded by a lipid envelope, this means that accumulation 
has to take place in a membrane domain of a certain organelle. Hence VZV envelope 
proteins were objects of extended trafficking studies. On the surface of VZV-infected cells, 
gE is the most abundant VZV glycoprotein (Mo, 2003). On the contrary, most of the gE 
localizes not on the plasma membrane, but on the trans Golgi network. After their synthesis, 
transmembrane proteins are transported to and through the Golgi. It was shown that gE 
does not reside in the TGN, but is cycled between the plasma membrane and the TGN via an 
early endosomal compartment and it is in fact a steady-state distribution instead that 
localizes the majority of gE to the TGN (Alconada, 1996). As a hypothesis, the steady-state 
distribution offers a real time control of the amount of gE localized at the TGN in parallel to 
the assembly of the virus. The gE protein must contain trafficking signals for this routes. The 
sequence comprises two motifs that are presumably having such a function (Table 2.5). It is 
at first, an YXXØ motif. Such motifs are present in many cellular transmembrane proteins 
and in an extremely high number of herpes virus membrane proteins (Favoreel, 2006). 
Functions that have been presumed for such tyrosine-based motifs of alphaherpesvirus 
envelope proteins are the AP-2-mediated endocytosis, COP-II-mediated ER to Golgi 
transport, AP-1B-mediated basolateral sorting, AP-3-mediated sorting to axons and the 
target for signaling by phosphorylation through tyrosine kinases like Src (Favoreel, 2006) 
(Figure 2.26). The second trafficking motif present in gE is an acidic cluster with embedded 
potential serine and threonine phosphorylation sites. The calcium-independent mannose 
6-phosphate receptor is a cellular protein with an acidic cluster motif and it was shown that 
this motif is critical for receptor sorting at early stages of intracellular transport following 
endocytosis (Totorella, 2007). PACS-1 is a known effector of acidic clusters controlling the 
correct subcellular localization of integral membrane proteins. It associates with both AP-1 
and AP-3, but not AP-2, and forms a ternary complex with its cargo (Crump, 2001). Other 
parts of the gE-sequence underlie the evolutional pressure of economy and their thus 
obligatory functions remain to be discovered. 
We used the cytosolic domain of gE in recruitment experiments to assess the assay for its 
ability to reflect accepted trafficking events. Figure 2.27A shows the results of the coupling. 
After cleavage with the protease Tev, the construct is split into an appr. 40 kDa cystein-free 
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Figure 2.26: Trafficking ways operated by the YXXØ motif in herpes virus envelope proteins (Favoreel, 2006). 
 
His-MBP tag and an appr. 10 kDa peptide representing the cytosolic domain of the type I 
membrane receptor with an amino-terminal introduced cystein for coupling. A small 
increase of roughly 1.5 kDa according to the gel’s molecular weight marker demonstrates 
coupling to the anchor lipid, which was functionalized with a maleimide head group. The 
remaining uncoupled peptide indicates saturation of the anchor. After washing of the 
liposomes, the liposome-free supernatant lacks the gel-band of the coupled gE, as expected. 
The comparison of gel bands of a cystein-control and a gE-sample after recruitment show 
related, but not identical patterns (Figure 2.27B) pointing out a broad background 
proteome. Also, in addition to the debut of gel bands in gE with respect to the control, 
prominent bands resign suggesting a displacement of pure membrane binders, when 
protein networks are formed. 
 
Figure 2.27: Recruitment experiment with the cytosolic domain of gE coupled to PI4P-liposomes. A - Coupling 
controls: a-full construct, b-construct cleaved by Tev, c-gE-peptide after coupling to the liposomes, d-
supernatant after first washing of the liposomes, e-supernatant after second wash; B - Comparison of 
recruitment sample (gE) and control (Cys). 
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 Differential proteomic analysis on recruited protein networks was performed then to 
introduce firmer statistic models and hence yield more rigorous lists of recruited proteins. 
The main experimental difference to the screening experiments is - beside the complex 
bioinformatic data processing - that controls and replicates (at least triplicates) are generally 
required. Also, mouse cytosol instead of pig was used, because of the greater data base 
(UniProt) annotation and hence identification probability of tryptic peptides and proteins. 
However, for a screening experiment the use of pig brain cytosol is justified, because the 
proteome is largely similar to human or mouse, but much easier to prepare in huger 
amounts. 
We expected to recruit AP-2 and AP-1 along with clathrin because of the YXXØ motif and 
PACS as an indicator for trafficking caused by its acidic cluster. We had no evidence to 
expect other adapter complexes, retromer or ESCRT complexes to be recruited.  
All members of the heterotetrameric complexes AP-1 and AP-2, including two isoforms 
of AP-1S (S1 and S2) and AP-2A (A1 and A2), were identified (Figure 2.28). The AP-2 complex 
was even recruited on PI4P-containing liposomes. It remains elusive if the reason for the 
seeming unspecificity of AP-2 with respect to the phosphoinositide was caused by the 
design of the experiment, with a large amount of concentrated cargo and too less PI4P, or if 
a loss or conversion of PI4P occurred. Interestingly, all complex members were found in 
tight ratio ranges, which could be due to equal affinities to the pure liposome membrane 
and a stoichiometric recruitment with the receptor. The complete AP-3 complex was also 
present, irrespective of the presence of the receptor and thus not recruited specific. AP-4 
and AP-5 complex members were not identified. The retromer complex was not recruited, 
as VPS35 and VPS26B were present independent of gE. Clathrin heavy chain (CHC) and the 
clathrin coat assembly proteins AP180 AND PICA (Phosphatidylinositol-binding clathrin 
assembly protein) were recruited. CHC was hereby recruited in a similar ratio as for instance 
the AP-2 members. The supplemental table S.3 lists all proteins that passed the t-test 
threshold. There is no evidence that clathrin light chain was also recruited. The absence of 
the small (25 kDa) clathrin light chain is most probably founded by a lack of identification in 
the probabilistic fragmentation procedure of shotgun mass spectrometric methods. This 
could be overcome in a mass spectrometric experiment by adding more replicates or by the 
addition of another dimension of peptide fractionation prior mass spectrometry. However, 
it should be mentioned that this would highly increase measurement time and costs. 
Western blotting can often be used alternatively to answer such targeted questions in 
recruitment studies. The experiment further elucidated the recruitment of PACS2. As it is 
closely related to PACS1 (500 identical amino acids on the respective positions of the 961 
and 862 amino acids of PACS1 and PACS2) and AP-3 was not recruited, PACS2 presumably 
aids in the AP-1 mediated trafficking of gE. On the contrary, PACS1 together with 
PLIN3/TIP47 was also found to be involved in retromer-mediated trafficking, which is clearly 
not related to gE according to our data (Seaman, 2005; Bonifacino, 2006).  
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Figure 2.28: Post-golgi trafficking complexes identified in the differential proteomics analysis. A - AP-1 
complex, in mouse composed of AP1G1/2 (either G1 or G2), AP1B1, AP1M1/2, AP1S1/2/3; B - AP-2, composed 
of AP2A1/2, AP2B1, AP2M1, AP2S1; C - AP-3, composed of AP3D1, AP3B1/2, AP3M1/2, AP3S1/2; D – Retromer 
cargo recognition subcomplex composed of VPS26A/B, VPS29, VPS35; E - Clathrin and clathrin assembly 
proteins, CHC1, CLCA/B, AP180, PICA; Members of the AP-4 (composed of AP4E1, AP4B1, AP4M1, AP4S1, 
AP4AT) , AP-5 (composed of AP5Z1, AP5B1, AP5M1, AP5S1), or ESCRT-0 (STAM1/2, HGS), ESCRT-1 (TS101, 
VPS28, VP37A/B/C/D, MB12A/B), ESCRT-2 (VPS25, VPS36,SNF8), ESCRT-3 complexes were not identified. 
 
 
The achieved results were in very good agreement with the known mechanisms in the 
trafficking of gE. This encouraged us to use the workflow for the analysis of unknown 
trafficking routes and interactors of other membrane proteins.  
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2.4.4 Crumbs2 coupled to PI3P-liposomes. Crumbs is an evolutionary conserved apical 
determinant. It is essential for many epithelial tissues for maintaining apicobasal polarity 
and integrity (Pocha, 2011). As a part of a group of apical polarity regulators it is functional 
related to a serine/threonine kinase (aPKC), a lipid phosphatase (PTEN), a small GTPase 
(Cdc42), FERM domain proteins (Moesin, Yurt), and several adaptor or scaffolding proteins 
(Bazooka/Par3, Par6, Stardust, Patj) (Tepass, 2012). Par3, Par6 have been implicated in 
endocytosis and recycling. Moreover, Cdc42 and aPKC have been shown to regulate 
trafficking mechanisms and crumbs was presumed to be the primary target of endocytic 
regulation by Cdc42, its downstream acting aPKC and the Par proteins (Tepass, 2012). 
The cytosolic domains of all crumbs proteins are highly conserved suggesting that their 
trafﬁcking mechanisms may also be conserved (Pocha, 2011). We chose crumbs2, because it 
is the predominant crumbs gene expressed in the vertebrate brain, which allowed us to 
perform recruitment experiments with the respective brain cytosol. Crumbs lacks all known 
trafficking motifs leaving its trafficking routes so far elusive (Table 2.5).  
The G-test in table 2.6 unbosomed no recruitment of any of the AP-1 to AP-5 complex 
members in experiments with the crumbs-like protein 2 (crumbs, Crb). But nevertheless, 
clathrin heavy chain was recruited. The involvement of retromer in the trafficking of crumbs 
was indicated through recruitment of VPS35, but premised to accept a p-value of 0.05. 
These results inspired us to a more detailed analysis for two reasons. At first, it was so far 
unknown that crumbs is trafficked by the retromer complex. Secondly, the smallest 
indication of the recruitment of a complex is a demanding approach to benchmark the 
sophisticated differential proteomic workflow. Therefore, triplicate recruitment 
experiments were performed on PI3P-liposomes that were either decorated with crumbs or 
not (Figure 2.29). As an additional control, PI4P-liposomes were used without crumbs. 
A String-analysis (www.string-db.org) of CRUM2_MOUSE results in potential interactors 
that were previously experimentally identified. Of this, MPP5 and MPDZ were recruited in 
the recruitment experiments (Figure 2.30), hereby validating the approach. We aimed to 
observe, if the implementation of a sophisticated differential proteomics approach delivers 
clearer indication of retromer recruitment. This implies at first, a positive result with a lower 
rate of false positives allowed and at second, evidence of recruitment of other retromer 
core complex members. We fully succeeded with this approach and yielded VPS35, VPS29 
and VPS26A/B clearly recruited, along with clathrin heavy and light chains (Figure 2.31-A) 
(Niehage, 2013, in press). The four sorting nexins (SNX1/2/5/6) were also recruited, but as a 
comparison of the cargo-free liposomes containing PI3P or PI4P showed, predominantly 
because of the PI3P-content (Figure 2.31-B). However, the small abundance-increase of this 
sorting nexins in presence of the crumbs-cargo and the retromer core complex can be 
interpreted as a coincidence detection mechanism. 
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Figure 2.29: A - Coupling controls of crumbs and the cysteine-free His-MBP tag. a: Purified expressed protein 
construct. b: Construct after Tev-cleavage. c: Supernatant on top of pelleted liposomes after coupling. d: 
Liposome-pellet. Arrows: a small offset between the gel bands indicates success of coupling. B - Comparison of 
gel lanes from recruitment experiments without (Cys) and in presence of crumbs (Crbs). Each lane was 
fractionated into 10 slices for separate mass spectrometric analysis. 
 
 
Figure 2.30:  Volcano plot of CRB vs. Cys PI3P. All two identified known direct crumbs 2-interactors emerge on 
the upper right side, representing significantly recruited proteins.  
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Figure 2.31: A: Volcano plot of CRB vs. Cys (PI3P). The cargo-recognizing components of the retromer complex 
VPS26A, VPS26B, VPS29, VPS35 are recruited due to the presence of the cytosolic domain of crumbs 2. 
B: Volcano plot of Cys3 vs. Cys4. The phosphoinositide-recognizing components of the retromer complex SNX1, 
SNX2, SNX5, SNX6 are recruited due to the presence of PI3P. Recruitment of those sorting nexins is further 
enhanced by the presence of the tail indicating coincidence detection of PI3P and VPS-proteins. 
 
 
We validated the recruitment of VPS35 by western blotting before phenotypes were 
studied on Drosophila larvae (Figure 2.32) (Pocha, 2011). 
 
 
Figure 2.32: Duplicate recruitment experiment with PI3P-liposomes with crumbs2 or without (controls). The 
western blot was probed with an anti-VPS35 antibody. VPS35 was highly abundant in the cytosol (input) and 
recruited in the presence of crumbs, while not detectable on control liposomes. 
 
With this study at hand we had clear evidence that crumbs is trafficked by the retromer 
complex. 
The data bare many more interesting proteins that have been recruited in that context, 
like members of the WASH complex, which is known to associate with retromer and others 
with less obvious functional relations, like ELAV3, a factor in neuronal differentiation and 
maintenance. All proteins found to be significantly recruited by crumbs are listed in the 
supplemental table S.4. Supplemental table S.5 denotes sorting nexins found to be recruited 
by bare PI3P liposomes with respect to PI4P liposomes. 
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2.4.5 APP coupled to various phosphoinositide-containing liposomes. The function of the 
amyloid precursor protein (APP) is still a matter of discussion. It is ubiquitously expressed 
and has been implicated to diverse processes like the import of copper (Treiber, 2009) or 
synapse maintenance (Priller, 2006). The major focus on APP research, however, is its role in 
the formation of amyloid plaques in brains of patients with Alzheimer's disease. APP is a 
member of the small, extremely well-conserved APP family of type-I membrane proteins, 
consisting of APP, APLP1 and APLP2 (Suzuki, 2000). APP is the only protein among this 
paralogues that is causing the amyloidogenic Aβ peptide. It is ubiquitously-expressed with 
various isoforms, with the APP695-isoform as the predominant expressed in the brain 
(Figure 2.33-A). Various post-translational modifications are executed on APP. The most 
profoundly are proteolytic cleavages in the transmembrane region. Two cleavages, caused 
by α-secretase or β-secretase occur alternatively before a γ-secretase-cleavage. The 
amyloidogenic Aβ peptide is the result of the combined β- and γ-secretase cleavage (Figure 
2.33-B) and an overproduction of the Aβ peptide is thought to be a major factor in the 
development of Alzheimer (Burgos, 2010). Various functions have been elucidated for the 
cleavage products, such as the targeting of the intracellular domain (AICD) to the nucleus 
and its involvement in gene regulation due to the binding of a diversity of factors.  
 
 
Figure 2.33: A – APP-family, consisting of APP and APP-like proteins 1 (APLP1) and 2 (APLP2). 3 isoforms of APP 
occur: APP770, APP751, APP695. APP695 is the major isoform in the brain. B – Proteolytic processing of 
APP695 (Nalivaeva, 2013). 
 
APP co-localizes predominantly with EEA1 although there is also a population co-
localizing with TGN46 (Burgos, 2010). This distribution of APP is not static, but a steady-state 
distribution as a result of APP-trafficking (Figure 2.36) (Caporaso, 1994; Haass, 1992). The 
two primary secretases are believed to act on different membranes, the plasma membrane 
(α-secretase) and the endosomal system (β-secretase) (Rajendran, 2012). Proteomic studies 
of Alzheimer patient’s brains revealed also a deficiency in the retromer sorting pathway 
(Fjorback, 2012). The elucidation of trafficking mechanisms involved in Alzheimer’s disease, 
as the trafficking of APP or the different secretases, is crucial though to understand the 
disease itself. 
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The G-test in table 2.6 indicates AP-4 mediated trafficking of APP. When we did this 
experiment, this was unknown and we chose to study APP in different membrane contexts. 
Expression, purification and coupling of APP were successful (Figure 2.34).  
 
Figure 2.34: Coupling controls of APP. a: Purified expressed protein construct. b: Construct after Tev-cleavage. 
c: Final liposome pellet used for recruitment. d: Supernatant on top of pelleted liposomes after coupling. 
e: Supernatant after wash. 
 
Recruitment experiments were performed with liposomes containing either PI3P, PI4P, 
PI35P2, PI45P2 or PI345P3 (Figure 2.35). 
 
Figure 2.35: Comparison of recruitment samples. While triplicates were indistinguishable (not shown), gel 
lanes of samples and respective controls vary in several bands. Gel lanes of different phosphoinositide-
experiments differ also to some degree. 
 
Differential proteomic analyses were conducted, comparing samples of the APP-
containing liposomes with the respective controls. All results are listed in the supplementary 
table S.6. Figures 2.38 to 2.47 show selected proteins that are associated with certain 
processes or complexes.  
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We observed our results at first for known general interactors of the APP-intracellular 
domain (AICD). The amyloid precursor protein possesses the most intricate combination of 
putative trafficking signals among the transmembrane proteins tested. The AICD 
incorporates three sites that are known to interact with other proteins, an YTSI site 
representing a binding YXXØ motif of trafficking-adapter complexes, a NPTY site following  
 
 
Figure 2.36: Membrane trafﬁcking pathways in APP processing as summarized by Rajendran et al. (Rajendran, 
2012). 
 
the NPXY recognition motif of AP-2µ and Dab2 and overlapping with the latter, an (Y)KFFE 
binding site for AP-4µ (Table 2.5) (Burgos, 2010).  The NPXY-motif is also part of the YENPTY 
motif, the binding site for APBA1 (X11), APBB1 (Fe65) and JIP1. This is remarkably due to 
their phosphotyrosine binding domain (PTB) (King, 2004), although the Y687-residue 
(numbering according to the major APP695-isoform of the brain) inside the YENPTY motif is 
not phosphorylated in the brain (Suzuki, 2008).  
We found APBA1, APBA2 and APBB1 clearly recruited in a phosphoinositide-
independent manner, but we did not identify JIP1 though (Figure 2.37). This is most 
probably, because of an unmodified tyrosine on the -14 position upstream of the YKFFE 
motif, that has been shown to be necessarily phosphorylated for binding of JIP1 (Muresan, 
2005). It was further shown that a phosphorylation of this specific threonine (T668) 
diminishes the interaction with APBB1 (Fe65) by a conformational change in the AICD, while 
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Figure 2.37: Known interactors of AICD. A - Distribution of LFQ Intensities. B - volcano plot of the t-test of 
PI45P2-liposomes with and without APP.  
 
it had no influence on the binding of X11 (Ando, 2001). It remains to be investigated, which 
parameters could be altered to enable in vitro phosphorylation of the T668-residue during 
recruitment experiments. The interaction data base of the european bioinformatics institute 
(EMBL-EBI, www.ebi.ac.uk/intact) lists 85 direct or indirect interactors, or co-localizing 
proteins of APP. As the AICD can be targeted to the nucleus, interactions of the AICD can 
occur with proteins from the cytoplasm or nucleus. Filtering of this interactor list for such 
proteins results in a list of 57 putative interactors. Another popular resource for interaction 
information is the STRING-data base (http://www.string-db.org). 4 of the 57 in the EBI-list 
are also annotated in STRING as ‘experimental evident’. Another 2 are missing in the EBI-list. 
A comparison with our experimental data showed that 8 proteins of this 59 proteins in total 
were recruited with APP (APBA1, APBB1, CALR, EXOC6, GSK3A, NF1, NSF, TBB5), while one 
(TPD54) yielded ambiguous results (recruited on PI3P-APP, diminished on PI35P2-APP 
liposomes). Recently, Chakrabarti et al. used in vitro pull-down experiments, followed by 
2D-gel electrophoresis and MALDI-MS to identify interactors of the AICD (Chakrabarti, 
2012). The experiment was constructed as a differential proteome analysis, comparing AICD 
pull-down samples with those obtained from control pull-down experiments with bare bead 
material. None of the accepted interactors as APBB1 (Fe65), APBB3, the Mint proteins 
APBA1/2/3 (X11α/β/γ), or AP-4 complex members (particularly AP-4 µ) were identified 
herewith suggesting a severe false negative rate. In addition, many likely false positive hits 
appeared among the mere 20 identified proteins, like secreted proteins. Notably, none of 
the potential AICD-interactors stated in Chakrabarti et al. was found to be recruited in our 
experiments, except for a vague recruitment of DYHC2/Dynein. Some proteins like APOA4 
that showed binding to bare liposomes were even highly diminished in presence of APP. This 
demonstrates the benefit of both improved in vitro experiments as well as sophisticated 
mass spectrometry and post-acquisition workflows. 
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In addition to APBA1 and APBA2, we found also a considerable recruitment of CASK 
(CSKP) and LIN7B. CASK is present at low levels in all cells, but expressed primarily in the 
brain (Hata, 1993) where it localizes in presynaptic and postsynaptic densities (Hsueh, 
1998). CASK (CSKP), Velis (LIN7A, LIN7B or LIN7C), and Mint 1 (APBA1) form a tripartite 
complex (Tabuchi, 2002) which is therefor a synapse-specific heterotrimeric complex. This 
specificity is ensured through a binding of CASK to the cytoplasmic tails of several cell-
surface proteins, like neurexins (Figure 2.38) (Tabuchi, 2002). A direct binding to APP is so 
far not reported.  An alternative for APBA1 in the complex is Caskin-1, which we did not 
identify (Tabuchi, 2002). If APBA2 could compete with APBA1 is not known, but both 
proteins share huge sequence similarities, mainly in the carboxy-terminal halves. An 
evolving model is that of APBA1 and APBA2 binding to the NPXY-motif of APP, with which 
CASK and LIN7B is forming a subcomplex that is linked in the pre- and post-synaptic regions 
of nerve cells via CASK to neurexins and other transmembrane proteins. This network could 
be further stabilized, by the binding of neurexins to APBA1 (Rogelj, 2006). 
 
Figure 2.38: Heterotrimeric complex of Mint 1 (APBA1), CASK (CSKP) and Velis (LIN7A, LIN7B or LIN7C) bound 
to transmembrane receptors, like neurexins (Tabuchi, 2002). 
 
The experiments with APP also revealed vast recruitment of NUMB and NUMBL 
(Figure 2.39). Both are known interactors of APP (Roncarati, 2002) and impart clathrin-
dependent and -independent endocytosis by binding of AP-2α and various proteins of the 
epsin15 homology domain family (Gulino, 2010). Clathrin heavy and light chains (CLH,CLCB) 
as well as clathrin-associated proteins were allways present, but not recruited by APP. 
We exploited our results further for post-Golgi trafficking complex members. We 
received ambiguous results from the screening experiment and the sophisticated 
recruitment experiment for the recruitment of AP-1 and AP-2 (Figures 2.40 and 2.41). The 
major differences between both types of experiments - except for the mass spectrometry 
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Figure 2.39: Known interactors of APP (NUMB, NUMBL) and other proteins functioning in endocytosis. A - 
Distribution of LFQ Intensities. B - volcano plot of the t-test of PI45P2-liposomes with and without APP.  
 
and post-acquisition workflows - was the use of pig brain cytosol in the sreen and mouse 
brain cytosol in the sophisticated approach, a recruitment time of 1 hour versus 20 minutes, 
150 µM versus 1.5 µM GTP-µS and the addition of latrunculin B in the sophisticated 
approach to prevent actin polymerization which hampers isolation of the liposomes from 
the cytosol. While we achieved recruitment of AP-2 (and AP-1) in the screen, this was only 
slightly, but not significantly the case in the sophisticated experiment. However, the 
desribed experimental differences did not interfere with the capability of gE to 
 
 
Figure 2.40: Proteins of the AP-1 trafficking complex. A - Distribution of LFQ Intensities. B - volcano plot of the 
t-test of PI4P-liposomes with and without APP.  
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Figure 2.41: Proteins of the AP-2 trafficking complex. A - Distribution of LFQ Intensities. B - volcano plot of the 
t-test of PI45P2-liposomes with and without APP. 
 
recruit AP-1 and AP-2. The much higher concentration of GTP-µS in the recruitment screen 
on the other hand could have added up with a weak capability of APP to recruit AP-1 and 
AP-2. Members of the AP-3 complex were not recruited (Figure 2.42). In the recruitment 
screening experiment, we found indication of AP-4 recruitment with the identification of 
AP4B1, AP4E1 and AP4M1 with one of these (AP4B1) significantly recruited (Figure 2.43). 
When we did this study, no AP-4 cargo was identified so far. A short time later, a publication 
of Burgos et al. (Burgos, 2010) demonstrated that APP is trafficked by AP-4, providing us 
with the biological validation experiments. The improved recruitment assays elucidate 
 
 
Figure 2.42: Proteins of the AP-3 trafficking complex. A - Distribution of LFQ Intensities. B - volcano plot of the 
t-test of PI3P-liposomes with and without APP. 
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Figure 2.43: Proteins of the AP-4 trafficking complex. The former UniProt-Trembl entry B0V3P2 is meanwhile 
annotated as AP4B1. A - Distribution of LFQ Intensities. B - volcano plot of the t-test of PI35P2-liposomes with 
and without APP. 
 
clear recruitment of the whole AP-4 complex with no predilection for a specific 
phosphoinositide. AP-4 localization is known to be largely restricted to the trans-Golgi 
network, whereas under normal conditions APP localizes predominantly to endosomes. 
Upon disruption of the APP-AP-4 binding, APP is redistributed to the TGN, suggesting a TGN 
to endosome AP-4 mediated trafficking route of APP (Burgos, 2010). Burgos et al. discovered 
the AP-4  involvement in the trafficking of AP-4 in a hypothesis-driven discovery approach 
when they used yeast-two-hybrid assays to prove for interaction. The strength of the 
recruitment assay is that it is discovery-driven and unbiased, except for the selection of the 
receptor and cytosol. A fifth adapter complex (AP-5) was recently found in a genetic screen 
(Hirst, 2011). No cargo has been identified so far, but lately two additional members of the 
AP-5 complex, SPG11 (SPTCS) and SPG15 (ZFY26), were discovered (Hirst, 2013). We found 
YK046 (AP5B1) together with SPTCS and ZFY26 recruited with APP (Figure 2.44). None of the 
other three expected AP-5 complex members were identified (AP5Z1, AP5M1, AP5S1). This 
could indicate, that the three complex members found represent a cargo-binding core 
complex and that experimental factors (maybe PI5P ?) are missing which would allow to 
assemble the holo-complex. If AP-5-mediated trafficking of APP could be confirmed by 
additional experiments, this would thus not only add to the understanding of APP-trafficking 
but also represent the first AP-5-cargo identified and open new possibilities to study this 
adapter complex. We also found all members of the retromer complex recruited with APP 
(VPS26A/B, VPS29, VPS35, SNX1/2/5/6) (Figure 2.45). Here, the phosphoinositides show 
great influence. The sorting nexins seem not to be recruited when PI3P was used, but this is 
clearly due to the enhanced binding to the control liposomes (Figure 2.45-A). Recruitment 
was lowest when PI4P was used. Involvement of the retromer complex is known for long, 
though the underlying mechanism remains a matter of discussion. Recently, Fjorback et al.  
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Figure 2.44: Proteins of the AP-5 trafficking complex. The former UniProt-Trembl entries are meanwhile 
exchanges by AP5B1 (YK046), AP5S1 (CT029), AP5M1 (MUDEN) and AP5Z1 (ZFY26). Former synonyms for 
SPTCS and ZFY26 were SPG11 and SPG15. A - Distribution of LFQ Intensities. B - volcano plot of the t-test of 
PI35P2-liposomes with and without APP. 
 
proposed SorLA, a type-I transmembrane protein as a molecular link for retromer-
dependent sorting of APP (Fjorback, 2012). The absence of other transmembrane proteins in 
the recruitment confutes the necessity for such a mechanism. Retromer is believed to 
traffick APP from the endosomes to the trans-Golgi network in a long-range axonal 
transport and a VPS35-deficiency was associated with  Aβ-increase (Bhalla, 2012) 
underlining the importance of retromer-mediated APP trafficking. Sorting nexin 17 (SNX17) 
has also been shown to associate with AICD, Fe65 and X11 (Lee, 2008). In addition, Lee at al. 
identified Dab2 to bind to the same YXNPXY-motif of APP and they proposed that both 
proteins regulate APP endocytic trafficking.  SNX17 possesses a PX domain that imparts 
binding to PI3P. We found SNX17, but not Dab2, recruited with APP, particularly on PI45P2, 
PI345P3 and PI3P-liposomes that represent the early stages of endocytosis. 
In vesicular trafficking, also membranes are transported and fuse with the target 
membrane. Embedded phosphoinositides that represent the identity of the membrane need 
to be converted thus. We found the PIKfyve complex (FYV1, FIG4, VAC14), that facilitates 
the interconversion of PI3P and PI35P2, recruited on APP-liposomes (Jin, 2008) (Figure 2.46). 
We propose that APP in turn regulates the PIKFyve complex through this recruitment and 
thus regulates the endosomal phosphoinositide metabolism (Balklava, 2013a, submitted). 
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Figure 2.45: Proteins of the retromer complex. A - Distribution of LFQ Intensities. B,C,D - volcano plots of the 
t-tests of PI3P, PI4P and PI345P3-liposomes with and without APP. 
 
 
Vesicular trafficking and signaling pathways are often intertwined (Clague, 2001;  Shilo, 
2011). We found the mTOR complex 1 (MTOR, LST8, RPTOR) recruited on APP-liposomes 
(Balklava, 2013b, submitted) (Figure 2.47). Interestingly, localization of the mTOR complex 
to endomembranes has been proposed as a prerequisite for Rheb-association and activation 
of downstream targets (Buerger, 2006). No direct liaison between APP and the mTOR 
complexes 1 or 2 have been hypothesized so far, although functional bonds between Aβ 
overproduction in Alzheimer’s disease and mTOR-signaling have been described (Caccamo, 
2010). 
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Figure 2.46: Proteins of the PIKfyve complex. A - Distribution of LFQ Intensities. B,C - volcano plots of the 
t-tests of PI3P and PI45P2-liposomes with and without APP. 
 
 
 
 
 
 
Figure 2.47: Proteins of the mTOR1/2 complexes. A - Distribution of LFQ Intensities. B - volcano plot of the 
t-test of PI345P3-liposomes with and without APP. 
 
 3. DISCUSSION 
  
3.1 Sample composition 
3.1.1 Label-free mass spectrometric parameters. Proteomics is the science and associated 
technics of analyzing the proteome, the entity of all proteins present in a given cell type or 
sample. The matter of proteomic analyses are essentially protein identifications and 
quantifications, but can also be post-translational modifications or protein-protein 
interactions. Probably the most important high throughput technique in proteomics is mass 
spectrometry as it allows for unbiased identification and quantification of a few thousand 
proteins in parallel. With the instrumental developments of the last 10 years or so, the 
achievable resolution was increased and so was throughput and reliability of protein 
identification. However, protein quantification was hampered by physico-chemical effects 
that distorted direct derivation of protein abundance from corresponding tryptic peptide 
measurements. A successful strategy to overcome these obstacles is the chemical labeling 
of proteins and since its introduction in 2002 notably the metabolic labeling by SILAC (Ong, 
2002). On the other hand, labeling approaches are expensive and often impede mass 
spectrometric analyses or screening experiments. They introduce biases due to imperfect 
labeling and are sometimes not applicable.  A multiplicity of label-free approaches was 
additionally developed. Those approaches are based on intensity values or indirect 
parameters which are subsequently normalized in different aspects and thus represent 
engineered ‘rule of thumb’-parameters. To implement a label-free mass spectrometry 
platform, we saw the need for a systematic comparison of label-free mass spectrometric 
parameters. We found that the intensity (MQ) as it is estimated by MaxQuant performed 
best in terms of dynamic range and linearity over four orders of magnitude, even in 
presence of a complex proteomic background. When we assayed the accuracy with which 
amounts of standard proteins have been estimated, the MaxQuant-intensity and its 
normalized values, the label-free quantification intensity (LFQ) and the intensity-based 
absolute quantification values (iBAQ) were clearly superior to the purely engineered values 
peptide number (PN), spectrum counts (SC), exponentially-modified protein abundance 
index (emPAI) and normalized spectral abundance  factor (NSAF). These experiments also 
showed that the accuracy was even better when the values were compared to mass 
amounts instead of molar amounts, suggesting another level of normalization. Moreover, 
outliers were minimized allowing even a reliable absolute quantification of all proteins 
tested. In a detailed view, iBAQ values slightly outperformed LFQ values here and both were 
clearly dominating before pure MQ values. However there is a basic difference between 
iBAQ and LFQ values. LFQ-values are normalized in a way that reduces sample-to-sample 
variations, allowing the comparison of different samples. To achieve this with iBAQ values, 
they must be further normalized with spiked-in UPS standards as was demonstrated in the 
initial publication of Schwanhäusser et al. (Schwanhäusser, 2011). The costs of these spike-
in standards are comparable to SILAC experiments. Therefore, we use LFQ values to 
estimate protein abundance for both, compositional analyses of single samples and 
differential proteome analyses of two or more samples. While we cannot completely 
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exclude single principle outliers through atypic physico-chemical effects when different 
proteins are compared within a sample, comparing different groups of proteins seems 
justifiable. This is for instance the case when the success of a certain biochemical 
enrichment procedure has to be demonstrated. 
 
3.1.2 Enrichment analysis. In mass spectrometry based proteomics, sample composition 
can be studied by either targeted approaches, where only predefined proteins are 
monitored by the mass spectrometer, or shotgun approaches where as many proteins as 
possible are traced. Targeted approaches allow label-free absolute quantification of 
proteins with high sensitivity even in complex proteomes. It is the method of choice when 
specific questions are addressed like in doping analysis. The approach is technically 
restricted to the parallel monitoring of up to 100 proteins per LC-MS run. For each protein 
of interest a method has to be established were a set of tryptic peptides that are unique for 
this protein isoform have to be selected and their retention time and mass spectrometric 
detection and fragmentation behavior have to be studied on synthetic analogs. When 
constructing a method for the parallel monitoring of different proteins those peptide probes 
should also differ in retention time and mass, as low resolution mass spectrometers are 
used, like triple quadrupole instruments. Such a method development is time and cost 
intensive although major progress took place in the last years (Picotti, 2012). Shotgun 
approaches are commonly appointed unbiased, meaning that phenotypes can be studied – 
in theory – on the whole proteome.  In a shotgun experiment up to 4000 proteins are 
identified from a complex proteomic sample (Nagaraj, 2012) leaving the majority of 
expressed proteins unidentified. The typical shotgun approach uses a TopN-program that 
conducts the mass spectrometer to automatically select the N most intensive peptides in 
the MS1 spectrum to be fragmented for MS2. As the most abundant proteins are more likely 
generating higher intense MS1 peaks they are more likely being identified. This results in a 
bias of identified proteins for the more abundant proteins in a proteomic sample. Not all of 
the proteins that are identified can be quantified. The reasons for this are manifold and 
differ in the quantitative methods. In shotgun experiments, low intense proteins are often 
not identified in replicates and hence are deselected because statistical tests are 
mandatory. This results in a further bias in the selection of the more abundant of the 
identified proteins for being quantified as well (Figure 3.1-A). If specific questions are 
addressed to an experiment like the presence or absence of specific marker proteins, a 
chemical enrichment procedure can be used to increase the abundances of those proteins 
within the proteomic sample and either elevate those proteins into the observation window 
or increase their intensity within all the hitherto identified proteins (Figure 3.1-B). A 
question that arises is how to define and detect enrichment success. Pie charts are broadly 
used to demonstrate sample composition reflecting the relative numbers of proteins 
assigned to certain gene ontologies. All parts of this pie should add up to 100%. 
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Figure 3.1: Histograms to access protein enrichment. The proteins are grouped for their abundances and the 
relative frequency at which different proteins in the abundancy bins occur is plotted. A - Bias of detection. In 
shotgun proteomic experiments not all proteins present can be detected. The subpopulation of identified 
proteins is composed of more abundant proteins than the average of all proteins present. Likewise, the 
subpopulation of quantified proteins is biased to the more abundant proteins among the identified. The 
reason for this prevalence to identify more abundant proteins is that more abundant proteins are more likely 
yielding more intense peptide precursors and are hence more likely selected for fragmentation. Likewise, more 
abundant proteins are more likely generating more and higher scoring peptide identifications, explaining the 
bias (modified from: Bantscheff, 2007). B - Observation of enrichment. Upon enrichment proteins can be 
shifted either within the observation window (A) or into (B). Moreover, proteins which are not promoted by 
the enrichment procedure can be decreased in intensity and even leave the observation window. 
C - Enrichment analysis by comparing the mean intensity of a subpopulation of identified proteins with the 
overall mean (Pan, 2009; Cox, 2012). This leads to information about the sample composition but as a chemical 
enrichment procedure does not necessarily lead to such an intrasample shift of the intensity distribution the 
method’s axiom seems improper. As an example, if an absolute enrichment would have been achieved leading 
to identify proteins from a specific gene ontology only, this method would yield no enrichment at all. 
D -  Schematic representation of all 20256 proteins annotated in UniProt/Sprot and the 22.4% of this which are 
assigned as plasma membrane proteins (PM). As there is no prior information about abundances in the data 
bank, p-value-based enrichment calculations assume uniform distribution which is very unlikely to reflect the 
real situation. The strategy presented here is to calculate p-values for cell surface proteome enriched samples 
as well as for total proteome samples and compare p-values of respective intensity bins. 
 
 
However, as proteins are assigned to many different gene ontologies there are 
redundant occurrences of proteins in different groups. Also, there is no information if a size 
of a group reflects enrichment or just a probabilistic sampling. When samples before and 
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after enrichment are compared, only those proteins that were unobserved in either sample 
effect the size of a sample group while proteins that are altered in abundance but were 
always observed do not. The latter is also the case for Venn diagrams which are commonly 
used to compare the number of proteins assigned to a specific group between two samples. 
The more sensitive the mass spectrometer and the more broadly a proteome is covered in 
the identification pipeline, the more indistinguishable two samples are in a Venn diagram. 
Cox et al. (Cox, 2012) uses a ranking of proteins by intensity in a histogram plot and defines 
enrichment as a subpopulation of proteins sharing a specific gene ontology with a mean 
value deviating from the mean of all other proteins. This is similar to Pan et al. (Pan, 2009) 
were the subpopulation mean is compared to the mean of all proteins identified (Figure 
3.1-C). This approach has its weakness when proteins of a specific GO-assignment enter the 
observation window in a number that could not have happened by chance, but do not 
deviate in their distribution mean from the overall. For instance, if an absolute enrichment 
would have been prepared leading to identify proteins from a specific gene ontology only, 
this method would yield no enrichment at all. Cox et al. expanded their approach to a two 
dimensional form which allowed comparisons of different samples and even from different 
types of experiments. They converted the distance from the mean into a ranking value and 
prepared multivariate analysis of variance (MANOVA). In that way the approach still relies 
on intrasample distributions and does not implicate comparisons with the ‘gene universe’ 
(Falcon, 2007),  i.e. the entry of proteins into the observation window.  
Our approach is based on intensity-ranked even-sized contingents of proteins (‘bins’), 
were accumulation of certain gene ontologies is tested for their likelihood to occur by 
chance. We define enrichment as the negative decadic logarithm of the resulting p-value 
and replace the simple number of proteins in histogram plots herewith. This enables 
different gene ontologies to be compared as GO categories are weighted for their 
explanatory power. A problem that arises with such an approach is that we do not know the 
actual intensity distribution of a certain gene ontology within all proteins. If for instance, a 
gene ontology for the glycolytic pathway is studied, the assumption can be made that 
involved proteins generally occur in high copy numbers. But without prior information about 
all the protein abundancies we have to assume a uniform distribution for the calculation of 
the p-values (Figure 3.1-D). The problem is circumvented in an extended two dimensional 
form of the approach by comparing ranked intensity bins of samples after chemical 
enrichment and total proteomic samples. The approach comprises both, proteins that were 
entering the identification window and that once intensified inside due to an intrinsic 
ranking comparison. 
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3.2 Differential proteome analysis  
3.2.1 Imputation. Missing values in shotgun proteomic data are very common and limit the 
reproducibility of protein identifications. The reasons for missing values are multifaceted 
[Karpievitch2012]: a protein is not present in an experimental state, a protein is not 
detected, although present in a detectable amount, or a protein is present in an amount 
below the detection limit. There are several ways to handle missing values: related protein 
hits could be deleted, which could enhance the false negative rate. On the other hand, if a 
protein is deteced in only a small number of samples this protein could be coincidental 
present through variabilities in the biological experiment, sample preparation or 
representing a contaminant, e.g. from previous runs on the LC-MS system. In this case it 
would be advisable removing the protein from the list to avoid a false positive hit. Missing 
values could also be ignored, but this causes a diversity of possible errors. Ignoring could 
exclude proteins from t-testing leading to false negatives. It could lead to overestimation of 
the relative presence in one state compared to another, or it could lead to underestimate 
standard deviations and hence overestimate the significance in a t-test. The latter would 
cause false positive interpretations. If a fixed value would be used for imputation, this could 
as well lead to an underestimation of standard deviations and likewise cause false positives. 
Thus, a sophisticated imputation algorithm should be used. We estimated the distributions 
of standard deviations for different intensity classes to create a Gaussian distribution 
around the detection limit with a standard deviation estimated from the low intensity 
region to impute missing values from random draws. 
 
3.2.2 Two-sample comparison. The simple analysis of a biological sample in a single 
condition doesn’t offer much detailed information. It is hence more frequently of interest to 
compare the effects of one condition with another, like for instance when cells treated with 
a certain drug are compared with untreated control cells. A common problem in 
experiments that do not require a differential analysis on the first view, such as pull-down 
experiments, that are aimed to identify protein interaction partners, is the co-occurrence of 
unspecific background proteins. This is, because such experiments include the use of solid 
matrices to which many proteins bind and often represent the huge majority of identified 
proteins. A differential proteome analysis of pull-down samples in presence and absence of 
the bait is the most effective way to define true interaction partners then. 
When recruitment experiments were previously performed (Crottet, 2002; Baust, 2006), 
supposed ‘true’ interaction partners were manually selected from a background proteome. 
We started our recruitment experiment project with a screening of different receptors in 
different conditions and used blank liposomes without receptor peptides as controls. We 
used spectral counting to compare protein levels in samples and controls, as spectrum 
counts are simple to acquire. We found that a definition of thresholds for minimal required 
spectrum counts and spectrum count ratios was not obvious and we thus implemented a 
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G-test-based approach to put this on a statistical base. It was previously shown that a 
sampling statistic based on the G-test is a robust approach to detect differential levels of 
proteins between two samples (Zhang, 2006). The method first normalizes the spectrum 
counts within sample and control and allows a Chi-square distribution to access p-values. 
The method is fairly good working, an improvement of the spectral counting-based 
differential proteome analyses and the method of choice for screening experiments. 
Nevertheless, we found that the sensitivity was low and suspected a severe false negative 
rate as many known multicomponent protein complexes appeared only partially. One 
reason for this might be the random sampling effect, meaning that peptides identified in 
one mass spectrometric run could be missed by another run, although present. This can 
happen for instance when co-eluting peptides suppress others during ionization, or during 
precursor-selection. The omitting of single or view peptides reduces the spectrum counts 
and thus reported quantitative level of the corresponding protein. The random sampling 
effect can be minimized by performing replicate runs and the use of statistical tests that can 
benefit from replicates, such as t-tests (Liu, 2009). As we favored MaxQuant’s LFQ-intensity 
values for assessing protein levels, we evaluated the label-free differential proteomics 
workflow that is implemented in MaxQuant’s accompanied statistical data evaluation 
package ‘Perseus’. 
The test statistic used in Perseus is a modified t-test. It is reported to be based on the 
significance analysis of microarrays (SAM) (Tusher, 2001). A constant (s0) is added to the 
denominator of the t-test function that prevents indefinite high values when the standard 
deviation tends to values close to zero, as can coincidentally happen with small numbers of 
replicates: 
() = 	 ̅	() −	 ̅()() +	  () - t-test value of protein i ; ̅	(), ̅() - means of expression values of protein i in states S (sample) or C 
(control) ;  - fuse constant of SAM ; () - pooled standard deviation of intensity values of protein i, 
calculated as:  
 
() =  1n +	 1nn + n − 2 ∙ ,(i) − ̅	()

 ! +,"(i) − ̅()
#
" ! $	 
%		, %  - number of replicates in states S or C, with & = 	n + n − 2 degrees of freedom; S,j(i), C,k(i) - j-th 
or k-th intensity value of protein i in states S or C 
 
In the SAM-procedure the test statistic is calculated for every protein first. In a second step, 
the grouping of values to state S (sample) or C (control) is changed in a random and 
nonsense way. The test statistic is calculated again. This is repeated for all possible 
permutations of data-group associations. A significant changed protein should exhibit a 
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much higher test-value as the average of all nonsense test-values. Such occurrences are 
elucidated by a comparison of the test-value distributions in a Q-Q plot (Figure 3.2).  
 
 
Figure 3.2: SAM-method to identify significant changing proteins. The distribution of the modified t-test values 
( d(i) ) is compared to the distribution of corresponding median t-test values from all nonsense permutations 
( dE(i) ) of data-group associations in a Q-Q plot. Symmetric threshold lines in parallel to the bisecting line 
define significant changing proteins with real t-test values that largely differ from the random counterparts 
[Tusher2001, 11309499]. 
 
Threshold lines in parallel to the bisecting line are chosen to define significant changing 
proteins. These thresholds can be set in a way that a certain maximum FDR is not exceeded. 
The FDR is estimated from the permutations by counting the number of proteins classified 
as significant from all nonsense permutations that thus present false positives, calculating 
the median across all permutations and divide this by the number of all proteins in the 
original data (Draghici, 2013). 
The precision of the permutation-based estimation of the FDR depends on the number 
of permutations, which is in turn depending on the number of replicates and can be 
calculated as follows: 
 The intensity values are written as a table header, e.g.:  
1.4E11 2.1E11 9.2E10 2.4E10 8.3E09 1.8E10 
 The group-classifiers, S or C are written into the table and are permuted from line to 
line. 
1.4E11 2.1E11 9.2E10 2.4E10 8.3E09 1.8E10 
 S S S C C C 
 S S C C C S 
 S C S C C S 
 … … … … … … 
  
 This represents a permutation of  6 elements with two times three equal elements 
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+,, -, . =	 %!%	! ∙ %! 							⇒ 					+1,2,2 =	 6!3! ∙ 3! = 	20 
Thus, 3 replicates of controls and samples allow for 20 permutations only and a low 
precision of the estimated FDR, accordingly. Much more confident FDRs can be yielded with 
5 replicates each (252 permutations), but on the costs of a nearly doubled measurement 
time and sample consumption.  
Moreover, a fixed FDR is just another representation of a constant p-value threshold, 
which would appear in a volcano plot as a constant horizontal threshold line. Non-changing 
proteins with low ratios might pass this threshold as well and it is hence required to add 
additional vertical thresholds for minimal accepted ratios. An intuitive way to unify these 
orthogonal threshold lines are hyperbolic curves. This is basically what the modified t-test in 
Perseus does (Figure 3.3). The exact algorithm of Perseus’ modified t-test is not published 
and a systematic assessment of this quantitative method is also not available. We used the 
universal proteomic standard 1 (UPS1) consisting of 49 equimolar proteins and spiked it into 
a total yeast proteome in a series of different amounts. An array of pairwise comparisons 
with the Perseus’ modified t-test was performed to assess the test’s accuracy when 
different ratios and overall amount of standard is varied. These experiments revealed a very 
good accuracy even for low standard amounts. The quantitative accuracy of the method was 
good for all ratios tested from 3x to 81x, although fewer proteins passed the significance 
thresholds for lower amounts or ratios.  
 
Figure 3.3: Threshold lines from Perseus’ modified t-test in a volcano plot. The hyperbolic threshold lines (red) 
combine a horizontal p-value threshold (blue) with vertical ratio thresholds (green). Significant changing 
proteins are labeled in red or black (Retromer complex components and clathrin), while the majority of 
proteins that represent the background proteome is labeled in grey.  
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As shown in the results part, the standard deviations of LFQ intensities differ for 
different intensity regions and is largest for smaller values below 2
24
. This raises the 
questions, if the reliability of the differential proteomic workflow to detect significantly 
changing proteins can be further enhanced by taking the absolute intensities into account. 
In his doctoral thesis, Christian A. Luber (LMU Munich, 2009) performed an experiment with 
lysates of HeLa cells and E. coli, where the E. coli lysates were used in an one to three ratio, 
while HeLa protein levels kept constant. He analyzed the overlap of ratio-distributions for 
the top-75% most intensive proteins (that represent the top-66% of decades of the dynamic 
range), the top-50% and the top-25% (representing nearly half of the dynamic range) and 
calculated the 3-σ deviations for this quantiles as 2.16-fold, 2.01 and 1.64. Thus a nearly 
complete separation of 3-fold ratio E. coli proteins and the unchanged HeLa proteins was 
only successful for the top-25% most intensive proteins, the upper half of the dynamic range 
(Figure 3.4). This experiment assessed the accuracy of the quantitative values, i.e. the LFQ-
intensities, but not the accuracy of the Perseus’ modified t-test. This means that only mean 
LFQ-values were used and standard deviations of individual proteins in the ground or lifted 
state were neglected. The Perseus’ modified t-test on the other hand exploits this protein- 
and sample-specific scattering through its permutation-based estimation of p-values, thus 
leading to lower p-values for lower intense proteins that show greater variability in absolute 
LFQ-intensity values. A lower p-value could hinder these proteins from passing the threshold 
and could hence lower the true positive rate. 
 
 
Figure 3.4:  Accuracy of protein ratios estimated by LFQ-intensities and its dependency of the height of the 
sum intensity. Red – proteins from Hela cells in a 1:1 ratio, green – proteins from E. coli in a 1:3 ratio. 
[Dissertation Christian A. Luber, Ludwig-Maximilians-Universität München, 2009] 
 
Another question to address was the influence of the test’s parameters, the s0-value and 
the TV (threshold value). The t-test and its derivatives, like the Welch’-modified t-test or 
SAM, are binary classifier systems and their performance can be studied in a receiver 
operating characteristic (ROC) analysis where the discrimination threshold is varied. A 
prerequisite to ROC-analysis is to exactly know which proteins are actually changing and 
which are actually not changing. This is the case in our experiments on the accuracy of 
Perseus’ modified t-test where all positives are proteins of the universal proteome standard 
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(UPS1) whereas all yeast proteins are negatives. There are certain forms of ROC-analysis 
according to which parameters are compared. Probably the most common one is the 
comparison of the true positive rate to the false negative rate. The true positive rate is the 
fraction of true positives among all that are actually positives. In other words it’s the 
fraction of all UPS-proteins that the test classified as changing among all UPS proteins 
identified. The true positive rate is sometimes also called sensitivity or recall. The true 
negative rate is the fraction of false positives among all that are actually negative. In our 
experiment, it is the fraction of yeast proteins that the test classified as changing among all 
yeast proteins identified. Sometimes, the sensitivity is compared to the specificity, which is 
equivalent to 1-FPR and represents the fraction of total negatives among all actual 
negatives. Other studies compare recall with precision. That is the fraction of true positives 
among all classified positives. Another term used is accuracy, which in this context is defined 
as the sum of true positives and true negatives divided by the number of all proteins 
identified. 
We found that the s0-value has a minor influence on the threshold curve and hence 
modified the TV for a receiver operating characteristic (ROC) analysis. Surprisingly, the assay 
exhibits an excellent characteristic, meaning that the TV can be selected in a great range 
before false positives increase. It should be adjusted not to conservative on the other hand, 
to allow as many true positives as possible. However, within ‘real’ biochemical experiments, 
as for instance the recruitment assays, broader background variability is common and the 
TV was found to be best selected between 0.001 and 0.05. 
As a summary, the modified t-test implemented in Perseus was proven to be reliable in 
the detection even of subtle proteomic changes with excellent accuracy over a broad 
dynamic range. The ROC analysis with a varying threshold value showed that no thorough 
experiment-specific adaptation of test parameters is required and thus proved the methods 
usability for sophisticated screening experiments. 
The gold standard of quantitative mass spectrometric approaches so far is SILAC. This is 
because label-free methods were thought to be generally impractical due to the different 
responses of the mass spectrometer for different peptides. Among the labeling approaches, 
SILAC is the most accurate one, because samples and controls are mixed early in the sample 
processing workflow and no chemistry is involved that introduces biases in the efficiency to 
label different peptides. But there is still a labeling efficiency below 100%. 100% pure 
labeled arginine or lysine is not available and in many cases costs hinder multiple passages 
of cultured cells in the labeled media. Impurities are introduced by fetal calf serum and 
arginine to proline (and back) interconversion occurs widely. The labeling efficiency has a 
huge impact on the quantitative accuracy. A labeling efficiency of 98% does not mean that 
the final ratio is underestimated by just 2%, as is demonstrated in the following calculation: 
 We assume, that a SILAC-experiment had been performed where cells of the control 
are not labeled, whereas cells that were perturbed are labeled with (
13
C6, 
15
N2)-Lys. 
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HE and LE are the estimated peak heights of the heavy and light monoisotopic peaks. 
The theoretical height of the heavy peak HT is underestimated due to imperfect 
labeling. On the other hand, the theoretical height of the light peak LT is 
overestimated, because some molecules that were not labeled in the perturbed 
sample, appear in the light peak (Figure 3.5). 
 
 
 
 
 
 
 
 
Figure 3.5: SILAC-Pair of heavy and light monoisotopic peaks. The estimated peak heights of the heavy and 
lights peaks under- and overestimate the theoretical peak heights because of a not achievable 100% labeling 
efficiency. 
 
 We like to find a relation, where the estimated ratio is a function of the theoretical 
ratio and the labeling efficiency E [in %]. 
 
(1)      
6787 = 9:;(6<8< 	 , =) 
 The estimated peak height is the theoretical peak height, reduced by the labeling 
efficiency. 
(2)  >? =		>@ 	 ∙ 		 ?!% 
 The peptides that are not labeled due to the imperfect labeling appear in the light 
peak. 
(3)  B? −	B@ =	>@ −	>? ⇔		B? =	>@ −	>? +	B@ 
 Equation (2) and (3) combined: 
(4)  
()&	(2)EFFFFG		B? =	>@ 	H1 − ?!%I + B@ 
 The relation in (1) is yielded by dividing the equations (2) and (4): 
LE 
LT 
Light 
HT 
HE 
Heavy 
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 (5)   
()&	(J)EFFFFG			 6787 =	 6<∙	 7KLL%6<	H!M	 7KLL%IN8< =	 7KLL%!	M	 7KLL%	N	O<P< =	 !O<P<QK7KLL% 	M	!
			R. T. . 
 
 This equation allows for a graphical analysis of the behavior of the estimated ratio, 
when different theoretical ratios are analyzed with a theoretical 100%, a maximal 
98% and an often accomplished 93% labeling efficiency (Figure 3.6). 
 
Figure 3.6: The accuracy of SILAC largely depends on the achieved labeling efficiency. A - Comparison of the 
estimated and theoretical SILAC ratios. B - Estimated SILAC ratios as  a function of the labeling efficiency. 
 
 
This problematic behavior of the SILAC method (and other methods based on stable 
isotopes), caused by imperfect labeling efficiencies is so far not a matter of discussion in the 
literature, but indirectly mentioned as in Altelaar et al. (Altelaar, 2012). The authors refer to 
Ong et al. (Ong, 2005) while stating : "...exact levels mostly depend on the purity of the 
amino acids". In the context of e.g. a 98% labeling efficiency and a huge, 100-fold actual 
ratio, this appears to be rather an understatement as the estimated fold-change is only one 
third here. Altelaar et al. performed experiments to assess the accuracy of SILAC to reflect 
actual ratios of 2- and 10-fold, resulting in 2.8- and 3.7-fold estimated ratios and hence 
overestimated (!) the actual ratios by 40% and 30% in the small ratio range (standard 
deviations were 0.35 and 0.68). Unfortunately, the reasons for these inaccuracies remained 
undiscussed there. Our assumption is that, the large underestimation of huge actual ratios 
has a great impact of the dynamic range of the SILAC method even for the best possible 
labeling efficiency of 98%. Quantitative analyses are thus restricted to small proteomic 
differences. The label-free approach on the contrary delivered reliable ratios in the dynamic 
range tested from 3x to 81x. Another flaw immanent in the SILAC method is the multiplying 
of MS
1
 features. This reduces the identification of peptides in a shotgun proteomic approach 
and hence also reduces the number of proteins identified and quantified.  
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3.3 Application I – Analysis of plasma membrane proteins 
Since we published the cell surface proteome of mesenchymal stem cells (Niehage, 
2011), such cell surface proteome studies have been often requested by other groups. Their 
projects were either addressed to stem cells or cancer cells. In any case this is, because the 
mass spectrometric approach elucidates cell surface markers extensively and untargeted. 
These markers can be used within antibody-based technics, like fluorescence-activated cell 
sorting (FACS) or enzyme-linked immunosorbent assay (ELISA) that are commonly utilized in 
hospital labs. This opens new prospects in cancer diagnosis and pioneers regenerative 
medicine.  
From a mass spectrometrist’s point of view, such samples are challenging, as the 
hydrophobic membrane proteins are imbedded in a complex environment of lipids and a 
huge proteomic background. Moreover, sample amounts are very low and the degree of 
variation between replicates is high. In our initial project, we used spectral counting to 
register frequent cell surface proteins of mesenchymal stem cells. The suitability of 
identified proteins serving as stem cell markers was studied in broad FACS analyses 
hereafter. In a subsequent collaborative project, we studied the extracellular matrix 
generated by mesenchymal stem cells (Prewitz, 2013). Here, we were confronted with the 
necessity to elucidate the sample composition meaning the relative levels of different 
proteins. Moreover, we wanted to demonstrate the accumulation of proteins sharing 
certain characteristics, like their known affiliation to the extracellular matrix as judged by 
their annotations of respective gene ontologies. We used label-free quantification intensity 
values (LFQ) for the comparison of protein levels, but were not satisfied with the common 
representation of sample composition based on pie-diagrams. This was basically for three 
reasons. First, gene ontologies are not exclusive meaning that proteins can be associated to 
more than one gene ontology which cannot be reflected by pie-diagrams. Second, the levels 
of individual proteins are neglected. If 5% of the proteins would be annotated as 
extracellular matrix (ECM) and would represent 99% of the molecules in the sample, a pie-
diagram would describe a 5% ECM content and thus wrongly present a non ECM sample. 
Third, the frequency of gene ontology annotations within all proteins in the UniProt data 
base is largely diverse. As an example, 1/8 of all 20272 human proteins annotated is 
assigned to the cytosol (2545 proteins, GO:0005829), but only 1/50 of the proteins is 
assigned to the extracellular matrix (395 proteins, GO:0031012). If 100 proteins were 
identified in a sample and 13 of which are assigned to the cytosol, 13 to the ECM, the 
probabilities of such identifications being coincidental findings differ largely: 49% for 
cytosolic proteins, but 0.0000074% for ECM proteins (estimated from a hypergeometric 
distribution). Such different explanatory powers of different gene ontologies are not 
accessed with pie-diagrams. We developed a two-dimensional mathematical model (see 
chapter 3.1.2) that is based on a hypergeometric distribution and implies individual protein 
abundances by their LFQ-values to assess accumulation of gene ontologies. As p-values are 
compared, the model allows comparing different gene ontologies and different sample 
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sizes.  In a collaborative project with Dr. Jana Karbanová (group of Dr. Denis Corbeil, Biotec 
TU Dresden), we applied the compositional proteome analysis, enrichment analysis and 
differential proteome analysis to samples from a CSP-enrichment of dental pulp stem cells 
(CPS cells). The partners previously noted that such cells exhibit differences in the cell 
surface proteome when cultivated in different media. We elucidated and validated these 
differences. This study is the most thorough study on a cell surface proteome so far (two 
publications in preparation). A current project is extending this approaches to elucidate 
potential differences in the cell surface proteomes of leukemic cells of patients with chronic 
lymphocytic leukemia, before transplantation of hematopoietic cells and after relapse (in 
collaboration with Dr. Falk Heidenreich, group of PD Dr. Johannes Schetelig, Uniklinikum 
Carl Gustav Carus, TU Dresden). 
 
3.4 Application II – Analysis of membrane-associated protein networks 
  
As membrane proteins are challenging to analyze, transient protein networks that form 
on top of membranes in the early steps of trafficking are even more demanding. These 
proteins are masked by an overwhelming amount of proteins binding to the membrane 
irrespective of the presence or absence of a short, moderately conserved sorting sequence. 
We assume a high variability between replicates in both, proteomic background and specific 
transient binders. To enable us to use a variety of type-I and –II membrane proteins, we 
changed the coupling chemistry to a cysteine-targeted maleimido-functionalized lipid head 
group. The coupling was always successful. The introduction of label-free differential mass 
spectrometric approaches also succeeded and replaced the manual classification of 
identified proteins to specific binders or background proteome. It is this, what enabled 
unbiased findings while keeping false positives low. 
However, we did not always observe a selective effect of the phosphoinositides used on 
the formation of recruitment complexes. In recruitment experiments with gE on PI4P 
containing liposomes, the AP-2 complex was recruited beside AP-1. One would expect to 
recruit AP-2 in presence of PI45P2 or PI345P3 rather than PI4P. This could be because of 
very high affinities of the sorting signals to components of various coats. It remains elusive 
thus, if the reason for the seeming unspecificity of AP-2 with respect to the 
phosphoinositide was caused by the design of the experiment with the sorting motifs 
analyzes, with a large amount of concentrated cargo and too less PI4P, or if a loss or 
conversion of PI4P occurred. It would be a further improvement to accompany lipidomic 
studies to recruitment experiments to explore this. The synthesis and use of 
phosphoinositide derivatives containing phosphothioesters instead of phosphoesters and 
thiols or hydrogen instead of alcoholic groups that might be still recognized by 
phosphoinositide-binding proteins, but kept unaltered, could be also a step forward to 
ensure phosphoinositide-specificity and to dissect steps of trafficking events. Also, we probe 
recruitment only with different phosphoinositides, but other lipids can also influence 
 
3.DISCUSSION|99 
trafficking. Even close lipid deviates can cause tremendous discrepancies in trafficking, for 
instance by altering membrane curvature or aggregating a subset of lipids into membrane 
microdomains. Potentially rapid conversion of phosphoinositides has to be considered. It 
might be circumvented by optimizing recruitment times as well as the concentration of 
GTP-γS for every type of recruitment route and mechanism separately. Another inexactness 
which could lead to improper conclusion about trafficking mechanisms is the use of 
heterologous expressed proteins. Inaccurate protein conformations or missing  post 
translational modifications can occur and impact trafficking mechanisms. The absence of 
transmembrane domains, of non-cytosolic domains or co-trafficking membrane proteins, as 
are proposed for SorLa or sortilin and APP (Yang, 2013; Gustafsen, 2013), can also puzzle the 
identification of trafficking routes and mechansims. 
Despite that, we were able to selectively recruit, detect and statistically validate 
AP-1, AP-2, AP-4, AP-5, retromer and ESCRT complexes in nearly stoichiometric amounts, 
thus mimicking respective trafficking ways. Moreover, we found interconnection to a 
diversity of signaling processes and links to structural determinants as the presynaptic 
complex. The concurrent discovery of AP-4 mediated trafficking of APP by Burgos et al. 
(Burgos, 2010) was based on a hypothesis driven study. The discovery of AP-4 and AP-5, 
demonstrated that unbiased, discovery driven recruitment experiments yield strikingly more 
information in shorter time. We are currently using recruitment experiments to mimic 
trafficking of other receptors, like integrin beta 1 (CD29), which was identified in exosomes, 
thus serving as a model for ESCRT-mediated, exosome-directed sorting (Hakulinen, 2008). 
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3.5 Epilogue 
A systematic assessment of mass spectrometric parameters and quantification methods 
allowed us to establish workflows for a sound and serious quantitative compositional 
proteomic analysis, to substantiate enrichment success and to define proteomic differences 
between samples on an accurate statistical foundation. The in-depth analysis of cell surface 
proteome-enriched samples further validated the workflows and demonstrated their 
usefulness and general suitability. A notably demanding application is the analysis of 
recruitment experiments, where proteomic differences between samples are negligible with 
respect to the huge proteomic background and variabilities of the replicates. Nonetheless, 
the procedures succeeded to unravel interacting proteins and protein complexes even in 
near stoichiometric ratios. Such improved recruitment assays yield global and reliable 
information about trafficking routes, signaling pathway interrelations and more. 
The achievements gained through the development of quantitative mass spectrometric 
parameters, of statistical methods and error models showed that a mass spectrometry lab 
has to be constant innovative. This is also true for the installed instrumentation. As the 
newest orbitrap system, Thermo Scientific’s Orbitrap Fusion Tribrid, offers resolutions of 
450,000 (m/z=200), new parameters and models will take advantage of this making 
accessible lower intense signals. This gain in resolution is accompanied by increase in 
accuracy, sensitivity and reliability and hence in the dynamic range and it widens the 
quantification window. Faster scanning is another attribute of new instruments, which will 
allow accessing more proteins for identification and quantification. The next milestone in 
proteomics will be the identification and quantitative description of a complete mammalian 
proteome in a single sample. Lately, the yeast proteome was analyzed that way (Nagaraj, 
2012) with an estimated number of approximately 4000 proteins expressed. An important 
aspect that often repels the use of mass spectrometry in research projects is the costs of the 
approach. With the ability to analyze more complex samples fractionation steps can be 
reduced and so are the number of samples to be analyzed. The introduction of reliable 
label-free methods is yet another step that reduces costs twice. It is firstly the waiving of 
expensive labels and secondly the omitting of tedious adaptation processes. The work 
presented here, demonstrates that label-free approaches can be universally used.  
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‘Label-free mass spectrometric analysis of in vitro constituted trafficking processes’ 
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Cellular Functions of Lipid/Protein Assemblies’, Dresden 
 
Sept. 2013, Invited talk 
‘Label-free mass spectrometric approaches in proteomics’ 
Novo Nordisk Foundation Center for Biosustainability (Technical University of Denmark) 
 4. MATERIALS AND METHODS 
 
  
4.1 General methods 
 
4.1.1 SDS-PAGE  
SDS-PAGEs were performed with a separation lane length of app. 4 cm using a Protean 2 
system (BIO-RAD, CA USA) according to Sambrook et al. 2001.  Replicates of different types 
of samples which were dedicated for quantitative comparison were allways separated on 
different gels and kept in different staining containers to avoid cross contamination by 
diffusion (Knaust, 2012).  
 
4.1.2 Gel-staining/destaining 
Gels were stained with 40% MeOH / 10% acetic acid / 0.25% (w/v) coomassie brilliant blue 
G-250  for 1h at room temperature and destained twice with 40% methanol / 10% acetic 
acid for 15 minutes and over night hereafter. The gels were transferred into 10% acetic acid 
(without methanol) and were allowed to destain further and swell for at least 4 hours. 
 
4.1.3 Western Blotting 
Unstained gels were electro-blotted in a Mini Trans-Blot Cell tank blot system (BIO-RAD, CA 
USA) assembled according to the manufacturer's protocol. The transfer buffer used was a 
4:6 mixture of methanol and 25 mM Tris base / 190 mM glycine / 0.1%(w/v) SDS with an 
intrinsic pH of 8.3. Proteins were blotted onto a nitrocellulose membrane with a constant 
electric current of 250 mA at 4°C within 90 minutes. First antibodies used were anti clathrin 
heavy chain antibody (BD Biosciences, CA USA) and anti AP-1 gamma antibody (in-house 
preparation) in a dilution of 1:500 and 1:2000 for 1 hour at room temperature and detected 
with an 1:5000 dilution of an anti rabbit second antibody conjugated to a horse radish 
peroxidase. The light emitting conversion of a Luminate Forte Western HRP Substrate 
(Merck Millipore, Germany) was observed with a LAS-3000 (Raytest, Germany) imaging 
system. Tiff-format images were uploaded into the free GelAnalyzer-Software 
(www.GelAnalyzer.com) and gel band intensities were quantified by integration of 
illumination intensities over gel band areas.  
 
4.1.4 Protein concentration assay 
Protein concentrations were estimated using an RC/DC-Assay (BIO-RAD, CA USA), according 
to the manufacturer's protocol, skipping the pre-pecipitation (RC) step if applicable. 
 
4.1.5 In-gel digestion after SDS-PAGE 
Gel-separated protein samples were trypsin-digested in a modified procedure from 
Shevchenko et al., 2006. The coomassie-stained gel lanes were cut into 10 slices, each slice 
was further cut into cubes of app. 1 mm and all cubes of a slice transferred into an 0.5 ml 
Eppendorf tube. 400 µl H2O was added, incubated for 10 minutes, vortexed, spun down and 
removed. This step was repeated first with 150 µl 25 mM ammonium bicarbonate in 
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acetonitrile and hereafter with 150 µL acetonitrile. The samples were reduced 150 µl 10 mM 
dithiothreitol / 100 mM ammonium bicarbonate was added, incubated for 45 minutes at 
56°C, vortexed, spun down and removed. Cysteins were alkylaled by the addition of 150 µl 
55 mM iodoacetamide / 100 mM ammonium bicarbonate and incubation for 20 minutes in 
the dark. The gel pieces were vortexed, spun down and solution was removed. 150 µl 
25 mM ammonium bicarbonate in acetonitrile was added, incubated for 5 minutes, 
vortexed, spun down and removed. This step was repeated with 150 µl. Remaining 
acetonitrile was evaporated in a speed-vacuum system (Eppendorf, Germany) for 15 
minutes. Trypsin-digestion was performed by the addition of 30 µl (0.15 µg) of trypsin 
(Trypsin Gold, Promega, WI USA) in 5 mM ammonium bicarbonate to the gel pieces, 
incubation for 5 minutes, addition of 30 µl 5 mM ammonium bicarbonate and storage of the 
closed tubes for 16h at 37°C. To stop digestion 60 µl of 0.5% trifluoroacetic acid in 
acetonitrile was added and tubes were sonicated in an ultrasonic bath for 10 minutes and 
spun down. The peptide eluates were transferred into empty LC-vials. 60 µl acetonitrile was 
added to the gel pieces and tubes are sonicated in an ultrasonic bath for 10 minutes and 
spun down. The eluates were added to the previous ones. Peptides were dried in a speed-
vacuum system. 20 µl of LC-buffer A ( 0.1% formic acid ) was added. The glass vials were 
closed and sonicated for 10 minutes in an ultrasonic bath and spun down. 
 
4.1.6 In-solution digestion 
Filter-aided sample preparation (FASP) was adapted from the Prince-Lab 
(http://openwetware.org/wiki/Prince:FASP). Dry proteins or protein pellets after 
recruitment assays were resuspended in 30 µl of 4%(w/v) SDS / 0.1 M DTT / 0.1 M TrisHCl, 
pH 7.6 and sonicated in an ultrasonic bath for 10 minutes at 65°C. The suspension was 
allowed to cool down to 20°C, mixed with 200 µl 8 M urea / 0.1 M TrisHCl, pH 8.5 and 
transferred to a 30K filter insert (Vivacon500 V01H22, Sartorius, Germany) placed in a 2 ml 
Eppendorf tube. The solution was concentrated for 15 minutes in a table-top centrifuge 
(Eppendorf, Germany) at 14000xg, 20°C. Twice, 100 µl of 8 M urea / 0.1 M TrisHCl, pH 8.5 
was added and centrifugated for 15 minutes at 14000xg, 20°C. 100 µl 55 mM iodoacetamide 
in 8 M urea / 0.1 M TrisHCl, pH 8.5 was added and alkylation was performed for 20 minutes 
at room temperature in the dark. The reagent was eliminated by centrifugation for 15 
minutes at 14000xg, two washes of 100 µL 8 M urea / 0.1 M TrisHCl, pH 8.5 followed by two 
washes of 100 µl 50 mM ammonium bicarbonate. Digestion was performed by addition of 
50 µL trypsin in a ratio of 1:40(w/w) to the overall protein amount in 50 mM ammonium 
bicarbonate. The filters were vortexed and pulse-centrifugated to 2000xg, tubes closed and 
incubated for 4h to 18h at 37°C. The filter units were transferred into new collection tubes 
and centrifugated for 15 minutes at 14000xg. The filters were washed once with 40 µL 
50 mM ammonium bicarbonate and the eluates acidified to 1% formic acid. Peptides were 
desalted using C18-SepPak cartridges (WAT023590, Waters, Great Britain). The cartridges 
were washed by one column volume (CV = 200 µl) of methanol, 1 CV of 80% acetonitrile / 
0.1% trifluoro acetic acid and 3 CV of 0.1% trifluoro acetic acid. Peptides were loaded on top 
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of the column material and slowly passed three times through it. The column was washed 
with 3 CV of 0.1% trifluoro acetic acid and eluted into a LC-vial with 1 CV of 80% acetonitrile 
/ 0.1% trifluoro acetic acid. Peptides were dried in a speed-vacuum system and resuspended 
in 0.1% formic acid for 10 minutes in an ultrasonic bath. 
 
4.2 Assessment of mass spectrometric quantification methods 
 
4.2.1 Preparation of a yeast background proteome 
1 g of a backer's yeast cube was dissolved in 10 mL 4% SDS / 0.1 M DTT / 0.1 M TrisHCl, 
pH 7.6 . 250 U benzonase (Merck, Germany) was added. Yeast cells were disrupted by 3 
rounds of homogenization in an EmulsiFlex-C5 Homogenizer (Avestin, Canada) and cell 
debris was pelleted by centrifugation for 30 minutes, 10000xg at 4°C. The supernatant was 
filtered (0.45 µm) and kept on ice while the concentration of proteins was estimated. 
Aliquots of 80 µg total protein were used for in-solution trypsin digestion.  
 
4.2.2 Preparation of dynamic range standards 
Tryptic digests of 500 pmol bovine serum albumin (#217498, Bruker, Germany) and 
500 pmol ß-casein (#217507, Bruker, Germany) were each dissolved in 50 µl 0.1% formic 
acid by 15 minutes of sonication in an ultrasonic bath and combined. A dilution series of 
500 amol and 5, 50 and 500 fmol and 5, 50 and 500 pmol digested proteins each in 90 µl 
0.1% formic acid was prepared and replicates of 9 µl were measured in the LC-MS system. A 
similar dilution series was prepared with additional 600 ng of yeast peptides in each vial as a 
complex proteomic background and replicates of 9 µl were measured in the LC-MS system. 
 
4.2.3 Preparation of accuracy standards 
1 vial universal proteomics standard 2 (UPS2, Sigma-Aldrich, Germany) consisting of 48 
proteins in different molar amounts as listed in Table 4.1 (10.6 µg total protein) was 
reduced, alkylated and digested in-solution with 0.2 µg of trypsin. One tenth of the total 
sample was used for each of four replicate LC-MS runs.  
 
4.2.4 Preparation of differential proteome standards 
1 vial of universal proteomics standard 1 (UPS1, Sigma-Aldrich, Germany) consisting of 48 
proteins in an amount of 5 pmol (6 µg total protein) was reduced, alkylated and digested in-
solution with 0.1 µg of trypsin. This stem solution and a preparation of a yeast background 
proteome was used to construct a series of samples as follows (actual protein amounts 
injected into the LC-MS system, each sample contained 60 ng yeast): 20 fmol, 6.7 fmol, 
2.2 fmol, 0.74 fmol, 0.24 fmol UPS1. All samples were measured in quadruplets. 
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 Table 4.1:  Universal Proteomic Standards (Sigma-Aldrich) 
 
 UNIPROT UPS1 UPS2 Name MW 
 AccNo [fmol] [fmol]  [kDa] 
 
 P00915 5 50000 Carbonic anhydrase 1  28.738 
 P00918  5 50000 Carbonic anhydrase 2  29.095 
 P01031  5 50000 Complement C5  8.266 
 P69905  5 50000 Hemoglobin alpha chain  15.127 
 P68871  5 50000 Hemoglobin beta chain  15.867 
 P41159  5 50000 Leptin  16.024 
 P02768  5 50000 Serum Albumin  66.393 
 P62988  5 50000 Ubiquitin  9.387 
 P04040  5 5000 Catalase  59.583 
 P00167  5 5000 Cytochrome b5  16.021 
 P01133  5 5000 Epidermal Growth Factor  6.211 
 P02144  5 5000 Myoglobin C  17.051 
 P15559  5 5000 NAD(P)H dehydrogenase 30.984 
 P62937  5 5000 Peptidyl-prolyl cis-trans isomerase A   17.947 
 Q06830  5 5000 Peroxiredoxin 1  22.106 
 P63165  5 5000 Small ubiquitin-related modifier 1   37.42 
 P00709  5 500 Alpha-lactalbumin  14.07 
 P06732  5 500 Creatine kinase M-type 43.07 
 P12081  5 500 Histidyl-tRNA synthetase  58.223 
 P61626  5 500 Lysozyme C  14.692 
 Q15843  5 500 Neddylin [Nedd8]  9.071 
 P02753  5 500 Retinol-binding protein  21.065 
 P16083  5 500 Ribosyldihydronicotinamide dehydrogenase  25.817 
 P63279  5 500 Ubiquitin-conjugating enzyme E2 I  22.907 
 P01008  5 50 Antithrombin-III  49.033 
 P61769  5 50 Beta-2-microglobulin  11.729 
 P55957  5 50 BH3 Interacting domain death agonist  21.978 
 P07339  5 50 Cathepsin D  26.624 
 P08263  5 50 Glutathione S-transferase A1 25.482 
 P01344  5 50 Insulin-like growth factor II  7.464 
 P01127  5 50 Platelet-derived growth factor B chain  12.286 
 P10599  5 50 Thioredoxin  12.424 
 P08311  5 5 Cathepsin G  26.751 
 P99999  5 5 Cytochrome c  11.608 
 P06396  5 5 Gelsolin  82.954 
 P09211  5 5 Glutathione S-transferase P  23.22 
 P01112  5 5 GTPase HRas  21.292 
 P02787  5 5 Serotransferrin  75.143 
 O00762  5 5 Ubiquitin-conjugating enzyme E2 C  20.473 
 P51965  5 5 Ubiquitin-conjugating enzyme E2 E1  22.222 
 P08758  5 0.5 Annexin A 5  35.782 
 P02741  5 0.5 C-reactive protein  23.03 
 P05413  5 0.5 Fatty acid-binding protein  14.716 
 P10145  5 0.5 Interleukin-8  8.381 
 P02788  5 0.5 Lactotransferrin  78.289 
 P10636  5 0.5 Microtubule-associated protein tau  46.81 
 P00441  5 0.5 Superoxide dismutase 15.8 
 P01343  5 0.5 Insulin-like growth factor IA  7.643 
 P01375  5 0.5 Tumor necrosis factor 17.35 
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4.3 Analysis of plasma membrane proteins 
 
4.3.1 Cell surface protein enrichment 
All steps were carried out at 4°C. Dental pulp stem cells were isolated and prepared by a 
project partner (Jana Karbanova, Corbeil-Lab, TU Dresden). 6 petri dishes (diameter: 15 cm) 
corresponding to app. 2.5 107 cells were washed three times with Ca/Mg-PBS (phosphate-
buffered saline containing 1 mM CaCl2, 0.5 mM MgCl2). Cells were incubated with 2 mL 
0.2 mM Sulfo-NHS-SS-Biotin (Pierce, IL USA) in Ca/Mg-PBS for 1h on a rocking platform. 
After three rounds of washing with Ca/Mg-PBS residual N-hydroxysuccinimide is quenched 
in a 10 minutes incubation with 20 mM glycine followed by three more rounds of washing 
with Ca/Mg-PBS. Cells were scraped in 4 mL of Ca/Mg-PBS and transferred ito a 15 ml falcon 
tube. After centrifugation for 5 minutes at 500xg, the supernatant was removed and cells 
were lysed by addition of 250 µl ice-cold solubilization buffer (1% Triton-X-100, 0.1% SDS, 
Complete Protease Inhibor Cocktail (Sigma, Germany) in PBS). The extract was diluted 
fourfold with Ca/Mg-PBS. 20 µl of streptavidin beads (GE Healthcare....) were washed three 
times with 1 ml of the same buffer and added to the cell extract. Binding of the biotinylated 
cell-surface proteins to the streptavidin beads were allowed to occur during 2h at 4°C while 
rotating the tubes. The beads were washed ten times with 0.1% Triton-X-100 in Ca/Mg-PBS. 
Hereafter, proteins were released from the beads by reduction of the crosslinker with 100 µl 
of 50 mM 2-mercaptoethane sufonate in 0.1% Triton-X-100 / Ca/Mg-PBS. Solution and 
slurry were deposited into an Ultrafree-MC spin filter (0.45 µm, Milipore, Germany) and 
spun down. An acetone precipitation was performed on the flow through: the fourfold 
volume of ice-cold acetone was added and incubated for 15 minutes on ice. After 
centrifugation for 10 minutes at 14000xg, the supernatant was discarded and the 
precipitation repeated once. Residual acetone was removed in a speed-vacuum system. 
20 µl of twofold Laemmli sample buffer was added to the pellet and dissolvation was aided 
by 10 minutes of sonication in an ultrasonic bath at 65°C. Proteins were seperated on a 10% 
SDS-PAGE before staining/destaining and in-gel digestion. 
 
4.4 Analysis of membrane-associated protein networks 
 
4.4.1 Preparation of mouse brain cytosol  
For mass spectrometric approaches using a mouse proteome is effective as mouse is the 
best anotated organism in the non redundant UniprotKB beside human. Brain cytosol is easy 
to prepare and trafficking complex proteins in neurons are well expressed. However, for the 
study of more special trafficking ways like basolateral trafficking via AP-1 beta (AP1M2) 
(Gonzalez and Rodriguez-Boulan, 2009) other cell types may be prefered. 30 mice (CD1, 
female ,12-14 weeks old) were decapitated and the brains were dissected. The brains were 
homogenized with a 7 ml - Dounce homogenizer (Gerresheimer,  Germany) in 4 ml of 
recruitment buffer (20 mM HepesKOH pH 7.2, 125 mM K-acetate, 2.5 mM Mg-acetate) 
      
4. MATERIALS AND METHODS |107 
 
supplied with complete protease inhibitor cocktail  (Roche, Germany). The homogenate was 
cleared from cell debris by centrifugation for 60 minutes, 370000xg at 4°C and another 
centrifugation of the supernatant for 60 minutes, 170000xg at 4°C. The supernatant was 
collected and immediately used for recruitment assays. An aliquot was removed for 
estimating the protein concentration. 
  
4.4.2 Expression and purification of 6xHis-MBP-Tev-Cys-tagged proteins 
The pET28-derived expression plasmid was transormed into an E. coli expression strain 
(BL21). The cytosolic domains of type I membrane receptors were amino-terminal flanked 
by a 6xHis-MBP dual tag and an interjacent TEV protease cleavage site followed by a 
cysteine. This allowed to remove the double tag with a high sequence-specific, high activity  
protease and to receive a cysteine for coupling to the maleimide lipid anchor. In case of 
type II membrane receptors this cysteine was placed at the carboxy-terminal site of the 
peptide. The 6xHis-tag allowed easy purification of the construct whereas a MBP-tag was 
introduced for enhancing solubility. A 5 ml over night culture was prepared from the 
respective expression strain in LB-medium with the requisite antibiotic 30 mg/l kanamycin 
at 37°C. It was transferred into a 2.5 l flask containing 500 ml LB medium plus kanamycin 
and cultivated at 37°C until the relative optical density to uninfected medium at 600 nm 
reached 0.6 (1 cm optical path). The culture is cooled to 15°C and the construct expression 
was induced with 0.1 mM IPTG. The expression was performed over night at 15°C. Bacteria 
were harvested by centrifugation at 2500xg for 20 minutes at 4°C. The pellets were 
resuspended in 15 ml cell disruption buffer (50 mM TrisHCl, 100 mM NaCl, protein inhibitor 
mix M (Serva, Germany) without EDTA, 20 mM imidazole, pH 7.4) on ice. 250 U benzonase 
(Merck, Germany) was added. The bacteria were disrupted by 3 rounds of homogenization 
in an EmulsiFlex-C5 Homogenizer (Avestin, Canada). Cell debris was pelleted by 
centrifugation for 30 minutes, 10000xg at 4°C. The supernatant was filtered (0.45 µm) and 
kept on ice. An empty 10 ml Poly-Prep column (BIO-RAD, CA USA) was filled with 1 ml IMAC 
sepharose (GE Healthcare, Sweden). The sepharose was washed 3 times with 10 ml H2O. 
Metal was loaded with 10 ml NiCl and the sepharose was washed 3 times with 10 ml H2O. 
The sepharose was washed once with cell disruption buffer. The supernatant was loaded 
onto the column, flow through was kept on ice. The column was washed 3 times with 10 ml 
cell disruption buffer. All flow throughs were kept separately on ice. The first elution step 
was performed by 3 washes with 1.8 ml cell disruption buffer containing 250 mM imidazole, 
all flow throughs were kept separately on ice. The second elution step was performed by 
3 washes with 1.8 ml cell disruption buffer containing 500 mM imidazole, all flow throughs 
were kept separately on ice. An SDS-PAGE was performed from aliquots of all steps and 
checked for the elution peak of the construct (usually the first elution step with 250 mM 
imidazole). The respective sample was dialyzed over night vs. coupling buffer (20 mM 
HepesKOH pH 7.2, 125 mM K-acetate, 1 mM EDTA, no protease inhibitors). The sample was 
harvested, protein concentration estimated and adjusted to 10 mg/ml. Aliquots of 50 µl 
were stored at -80°C. 
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4.4.3 Preparation of liposomes 
Liposomes were prepared in following molar ratio of lipids: 42% PC, 11% PS, 33% PE, 11% C, 
1% PI, 2% anchor (PE) (see Table 4.2).  The use of  an extruder is optional. Extrusion causes 
monolaminar vesicles with a restricted size distribution. To keep size heterogeneity and to 
minimize hydrolysis of the maleimido anchor extrusion was omitted. For a full differential 
proteomic approach - 3 recruitments plus 3 controls - two of the following preparations 
were performed.  For three different samples lipids were mixed as follows: 18.0 μl PC, 
33.2 μl PE, 12.1 μl, 5.75 μl C, 32 μl of the respective phosphoinositide and 6.6 μl PE-MCC in a 
siliconized 1.5 ml Eppendorf tube. The mixture was thoroughly vortexed and dried down 
under a stream of nitrogen to yield a thin and homogeneous film of lipids. Lipids were 
resuspended in 330 μl coupling buffer (20 mM HepesKOH pH 7.2, 125 mM K-acetate, 1 mM 
EDTA). Six cycles of 4 minutes freezing in liquid nitrogen and 4 minutes of thawing in a 
thermoshaker at 25°C  with thorough vortexing were applied. After 6 cycles (when the 
suspension appeared homogenous) 3 aliqouts of the liposome suspension were prepared in 
new siliconized Eppendorf tubes (100 μl/sample) and kept on room temperature to avoid 
phase transitions for immediate coupling of peptides. Optional extrusion step before 
aliquoting: A LipoFast handheld extruder (Avestin, Canada) was assembled according to the 
manufacturers manual with a polycarbonate membrane of a pore diameter of 400 nm. The 
liposome preparation was passed 21 times through the filter and harvested on the opposite 
syringe.  
 
Table 4.2:  Lipids used to prepare liposomes. 
  
Lipid Name  Vendor(#Order) Stem solution 
PI3P 1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-inositol-3'-phosphate) Avanti  (850150) 0.2 mg/ml in CHCl3/MEOH/H2O  
    (65:35:8) 
PI4P L-α-phosphatidylinositol-4-phosphate Avanti (840045) 0.2 mg/ml in CHCl3/MEOH/H2O  
    (65:35:8) 
PC 1,2-dioleoyl-sn-glycero-3-phosphocholine Avanti  (850375) 25 mg/ml in CHCl3 
PS L-α-phosphatidylserine Avanti  (840032) 10 mg/ml in CHCl3 
PE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine Avanti  (850725) 10 mg/ml in CHCl3 
C cholesterol Avanti  (700000) 25 mg/ml in CHCl3 
PE-MCC 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N Avanti  (780201) 0.5 mg/ml in CHCl3 
 -[4-(p-maleimidomethyl)cyclohexane-carboxamide] 
PE-CHO Di-O-hexadecyl-rac-glyceraldehyde was synthesized as described  (*) 10.0 mg/ml in CHCl3 
 
* (Bourel-Bonnet et al., 2005) 
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4.4.4 Coupling of peptides to liposomes via cysteine 
Three aliquots of chosen His-MBP-TEV-receptor tail (50 μl in 20 mM HepesKOH pH 7.2, 
125 mM K-Acetate, 2.5 mM Mg-Acetate) were defrosted. Details about the receptor 
domains used for recruitment assays are listed in Table 4.3. For a coupling control gel, an 
aliquot of 2.5 μl was removed and 2.5 μl 2x-Laemmli sample buffer was added. 2.5 μl 
dialyzed TEV-protease (1 mg/ml in 50 mM TrisCl pH 7.0, 150 mM NaCl, 20% glycerol, 1 mM 
TCEP) was added to the remaining 47.5 μl receptor tail. TCEP was adjusted to a final 
concentration of 1 mM. Tev-digestion was allowed to take place over night at 25°C. An 
aliquot of 2.5 μl was removed and 2.5 μl 2x-Laemmli sample buffer was added. Remaining 
47.5 μl were kept on ice, until the liposome preparation was ready. Three Cys-controls were 
prepared as follows: 47.5 µl of cysteine (1 mg /ml) in coupling buffer and 1 mM TCEP was 
filled in each of three new 1.5 ml siliconized Eppendorf tubes. The 47.5 μl digested protein 
or 47.5 µl cysteine was added to each 100 µl-liposome suspension (6 samples : 3x Crb or 
other receptor and 3x Cys). Proteins were allowed to couple to liposomes for 60 min at 
room temperature. To saturate remaining maleimido groups, beta-mercaptoethanol was 
added to a final concentration of 1 mM to the liposome suspension, and incubated at RT for 
15 min. Liposomes were pelleted in an Eppendorf table-top centrifuge (RT, 5 min, 20000xg). 
The supernatant (appr. 150 μl) was removed and an aliquot of 7.5 μl was kept and 7.5 μl 2x-
Laemmli sample buffer was added. The pellet was washed once with 150 µl recruitment 
buffer (20 mM HepesKOH pH 7.2, 125 mM K-Acetate, 2.5 mM Mg-Acetate) and 
centrifugation (RT, 5 min, 20000xg). The liposome-pellet was resuspended in 200 μl 
recruitment buffer. An aliquot of 10 μl was removed and 10 μl 2x-Laemmli sample buffer 
was added. A SDS-PAGE was performed with collected samples ( 2.5 µl pre-TEV digest, 2.5 µl 
post-TEV digest, 7.5 µl post-coupling supernatant and 10 µl resuspended pellet) and stained 
with coomassie to assess the success of Tev-digestion and coupling reaction. 
 
4.4.5 Recruitment of cytosolic proteins 
The in vitro recruitment approach offers multiple parameters to assess like the 
concentration of cytosolic proteins, of anchor,  phosphoinositide, recruitment time, addition 
of ATP, an ATP-regenerative system, of GTP, GTPγS (guanosine 5'-O-[gamma-
thio]triphosphate) or the addition of drugs like latrunculin B. 500 μl of mouse brain cytosol 
(protein conc. 4.2 mg/ml) was supplemented with latrunculin B to yield a concentration of 
28 µM. GTPγS was added to a concentration of 0.21 mM. The recruitment was started by 
addition of 200 µl liposome suspension (final protein concentration of  3 mg/ml) and 
incubation for 20 minutes at 37°C. 
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Table 4.3:  Peptide constructs used for recruitment assays. 
  
Name UNIPROT    Sequence after cleavage by Tev 
APP A4_HUMAN GSCGKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN 
CRB CRUM2_HUMAN GSCGRKRRQSEGTYSPSQQEVAGARLEMDSVLKVPPEERLI 
gE GE_VZVO GSIEGRCTKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYTVYIDKTR 
NLG NLGN1_MOUSE GSCGYYKKDKRRHDVHRRCSPQRTTTNDLTHAPEEEIMSLQMKHTDLDHECESIHPHEVVLRTACPPDYTLAMRRSPDDIP 
  LMTPNTITMIPNTIPGIQPLHTFNTFTGGQNNTLPHPHPHPHSHSTTRV 
 
SORT SORT_HUMAN GSCGKKYVCGGRFLVHRYSVLQQHAEANGVDGVDALDTASHTNKSGYHDDSDEDLLE 
TFR TFR1_HUMAN GSMMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVTKPKRCSGSIC 
VSVG VGLG_VSIVG GSCGYLYIKLKHTKKRQIYTDIEMNRLGR 
 
His-MBP-Tag MGSSHHHHHHSSGLVPRGSHMASGKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDG 
  PDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELK 
  AKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKG 
  ETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGA 
  VALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITKGENLYFQ 
 
 
4.4.6 Postrecruitment purification of liposomes 
The recruitment reaction was stopped by mixing with 1.4 ml of ice-cold 60% sucrose in 
recruitment buffer in a 13 ml ultracentrifugation tube. It was overlaid with 30% sucrose in 
recruitment buffer to 1 cm below tube’s top. This was overlaid with recruitment buffer to 
2 mm below tube’s top. Opposite centrifuge tube were balanced with recruitment buffer if 
necessary. The sucrose step gradients were centrifugated for 14h, 200.000xg at 4°C. The 
liposome fraction on top of the gradient was transferred into a 4.5 ml ultracentrifugation 
tube, diluted with recruitment buffer and filled up to to 2 mm below tube’s top. Opposite 
centrifuge tube were balanced with recruitment buffer if necessary. Liposomes were 
pelleted by centrifugation for 1h, 370.000xg at 4°C. The supernatant was completely 
removed and tube walls were dried with a dust-free wipe avoiding touching the pellet. 30 µl  
of 2x Laemmli sample buffer was added and the pellet was scratched with the pipette’s tip. 
The tubes were placed into an ultrasonic bath and sonicated for 10 minutes at 65°C. The 
samples were transferred into 0.5 ml Eppendorf tubes and spun down. The sample volumes 
was adjusted to 30 µl with 2x Laemmli sample buffer and SDS-PAGEs followed by in-gel 
digestion was performed. 
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4.5 LC-MS and bioinformatic postacquisition workflows 
 
4.5.1 LC-MS acquisition 
Liquid chromatography of peptides before mass spectrometry was performed on an 
UltiMate 3000 HPLC-System (Thermo Fisher Scientific, MA USA) equipped with a 15 cm 
analytical reversed-phase C18-column, inner diameter 75 mm ; particle size 2 mm, 100 Å 
(Dionex, CA USA). The gradient was 5% B to 45% B linear in 80 minutes (A, 0.1% formic acid; 
B, acetonitrile, 0.1% formic acid). The detailed operation method is shown in listing I. 
Mass spectrometry was performed on a LTQ-Orbitrap XL system (Thermo Fisher Scientific, 
MA USA) in a Top8-procedure. MS1 was hereby accomplished in the orbitrap with a 
resolution of 60000 (at 400 Th) triggering parallel LTQ acquisition (resolution of 30000) of 
MS2 of the 8 most intensive MS1 features. Dynamic exclusion was enabled with a repeat 
count of 2, a repeat duration of 5 seconds, an exclusion duration of 15 seconds with an 
exclusion list size of 500. Lock mass was optionally set to a polysiloxane adduct of 445.12 
(Keller et al., 2008). Collision activated dissociation was executed with an activation-Q of 
0.25  and a normalized collision energy of 35 for 30 milliseconds. Details of the operation 
method are shown in listings II and III. 
4.5.2 Processing of mass spectrometric spectra by MaxQuant 
 All .raw-files from XCalibur were loaded into MaxQuant (V1.2.2.5) (Cox and Mann, 2008) 
and an experimental table was created in a way that all slices of one lane were assigned to 
the same experiment (listing VIII). Carbamidomethylation of cysteine was considered as a 
fixed modification and oxidation of methionine, acetylation of the N-terminus, and 
deamidation of asparagine or glutamine as variable modifications. Other parameters are 
multiplicity of 1, trypsin as enzyme, maximum number of modifications per peptide of 3, 
maximal missed cleavages of 2, maximum charge of 4 with individual peptide mass 
tolerances allowed. A suitable FASTA data base was assigned (UNIPROT-TrEMBL 2012-01). 
Parameters in the protein identification tab were as follows: peptide and site FDR of 0.01, 
maximum peptide posterior error probability of 1, all minimum peptides of 1, filter labeled 
amino acids disabled, second peptides, re-quantify, label-free quantification and match 
between runs ( 2 minutes) enabled. Details of chosen MaxQuant parameters are shown in 
listing XI. 
 
4.5.3 Parameters of label-free mass spectrometry  
Quantification using peptide numbers, exponentialy modified protein abundance index,  
spectral counts,  normalized spectral abundance factors MaxQuant-Intensities, Label-free 
quantification intensities, extraced ion intensity protein abundance index and intensity-
based absolute quantification values are collected or calculated as follows and 
demonstrated on the prepared and measured accuracy standards (UPS2). 
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Peptide numbers (PN) were extracted from the respective columns of the MaxQuant 
proteinGroupfile output. 
Exponentialy modified protein abundance indices (emPAI) were calculated for each protein 
(p) from the peptide numbers (PN) and the number of observable peptides (PO, see below: 
iBAQ) as follows: 
 
 = 10


 
 
Spectral counts (SC) were extracted from the MS/MS-count columns of the MaxQuant 
proteinGroupfile output.  
Normalized spectral abundance factors (NSAF) of single proteins (p) were calculated from 
the spectral counts (SC), the length of the respective protein (L) and the number (n) of 
proteins in the data base as follows: 
 =	

 
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MaxQuant intensities (MQ) were extracted from the repective columns in the 
proteinGroups.txt  file. 
Label-free quantification intensities (LFQ) were extracted from the respective columns of 
the MaxQuant proteinGroupfile output. 
Extracted peptide abundance intensities (xPAI) were calculated using the ‘Precursor Ions 
Area Detector’ module of the Proteome Discoverer 1.2 Software (Thermo Fisher Scientific, 
MA USA) with a mass range window of 2 ppm. 
Intensity-based absolute quantification intensities (iBAQ) were calculated from the MQ-
intensities in the proteinGroups.txt file by division through the number of observable 
peptides and logarithmizing. Numbers of theoretically observable peptides (PO) were 
calculated using a self-made python script (Listing 4.5) after retention time limits have been 
estimated by a yeast proteome analysis and the use of another python script (Listing 4.4 and 
4.6).  Parameters that restrict observability are extreme hydrophobicity or hydrophilicity, 
charge states and too low or high number of amino acids and can be passed to the python 
programs via a setting.ini – file (Listing 4.7). Since implementation into MaxQuant (Version 
1.2.2.5) iBAQ values were extracted from the respective columns in the proteinGroups.txt 
file. This streamlined the workflow, but restricted the so far adjustable parameters to the 
preset values of 6 to 35 amino acids in peptide length. 
All values were paired in a SQL-database and further analyzed in R. 
 
4.5.4 Differential proteomics: G-tests on spectral counts 
Spectral counts were used as a simple and easy accessible read-out value for the screening 
experiments. G-tests were used to judge for confidence in protein abundance changes as 
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follows. The sum of spectral counts of all proteins in a sample was calculated and likewise 
the sum of spectral counts of the respective control sample. Both were added to yield the 
grand total and the ratio of the sum of spectral counts of the sample and the grand total 
yielded the fraction of these on the grand total. Likewise, the fraction of the sum of spectral 
counts of the control was calculated. The sum of spectral counts of a specific protein in both 
the sample and control was calculated and multiplication with the sample's sum spectral 
count fraction yielded the expected number of spectral counts in the sample under the null 
hypothesis that there was no difference of abundance for that protein in the sample and 
control and that the difference in spectral counts reflected just the difference in the overall 
sum spectral counts of the sample and the control. Likewise, the expected spectral counts of 
that protein in the control was calculated. The G-value for that protein was calculated using 
the actual (a) and expected (e) spectral counts of sample (s) and control (c) as follows: 
 
 = 2	 
 ln   	+ 		$ ln
$
$ 	 
 
G-value thresholds for p=0.01 (G=6.64) and p=0.05 (G=3.84) were estimated by 
approximation of this test statistics with a chi-square function (degree of freedom = 1).  All 
calculations were done using R. 
 
4.5.5 Differential proteomics: Permutation-based t-tests on LFQ intensities 
The proteinGroups.txt-file was loaded into Perseus (Hubner et al., 2010) with all LFQ-
intensities as ‘expression’. All proteins matching any of the three categorical annotations 
were deleted, LFQ-intensities were logarithmized, experiments were grouped to sample or 
control and proteins that were not detected in all three replicates of at least one group 
were deleted. Missing values were imputed by normal distribution with parameters that 
were adapted using histogram plots. A two sided t-test was performed with a false 
discovery rate in between 0.1 and 1%, and a slope value of 0.2 to 1, the control was hereby 
assigned to ‘group 2’. The protein table and the threshold curve table were exported for 
further analysis in R (a brief example is given in listing 4.11). 
 
4.5.6 Gene ontology assignment and enrichment analysis 
Proteins in the proteinGroupfile.txt-output of MaxQuant were sorted for their sum 
intensities in a decreasing order and bins of 50 proteins were created. Uniprot identifiers 
were pasted into the gene products-field of the term enrichment tool of AmiGO 
(http://amigo.geneontology.org/cgi-bin/amigo/term_enrichment). Like for microarray 
analysis, no background set was selected. The database filter was set to UniProt KB and 
electronically inferred (IEA) annotations were allowed. The Bonferroni-corrected p-value 
threshold was set to 0.05 and the minimal number of gene products to 2. This procedure 
was applied for all intensity bins, the tables of GO terms and associated p-values were 
exported, unified in a SQL database and further analyzed in R (Listing 4.12). 
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Listing 4.1 : Operating method for the Dionex Ultimate 3000 system 
 
20120529_BSAbCAS_500fmol_#3 
Dionex Chromatography MS Link 
Program for Dionex Chromatography MS Link 
Sampler.TempCtrl = On 
Sampler.Temperature.Nominal = 8.0 [°C] 
Sampler.Temperature.LowerLimit =4.0 [°C] 
Sampler.Temperature.UpperLimit =45.0 [°C] 
Sampler.ReadyTempDelta = None 
ColumnOven.TempCtrl = On 
ColumnOven.Temperature.Nominal =40.0 [°C] 
ColumnOven.Temperature.LowerLimit =20.0 [°C] 
ColumnOven.Temperature.UpperLimit =50.0 [°C] 
EquilibrationTime = 0.0 [min] 
ColumnOven.ReadyTempDelta = 5.0 [°C] 
LoadingPump.Pressure.LowerLimit =0 [bar] 
LoadingPump.Pressure.UpperLimit =500 [bar] 
LoadingPump.MaximumFlowRampDown =14 [µl/min²] 
LoadingPump.MaximumFlowRampUp =14 [µl/min²] 
LoadingPump.%A.Equate = "%A" 
LoadingPump.%B.Equate = "%B" 
%C.Equate = "%C" 
NC_Pump.Pressure.LowerLimit = 0 [bar] 
NC_Pump.Pressure.UpperLimit = 800 [bar] 
NC_Pump.MaximumFlowRampDown = 0.199 [µl/min²] 
NC_Pump.MaximumFlowRampUp = 0.199 [µl/min²] 
NC_Pump.%A.Equate = "%A" 
NC_Pump.%B.Equate = "%B" 
DrawSpeed = 200 [nl/s] 
DrawDelay = 5000 [ms] 
DispSpeed = 2000 [nl/s] 
DispenseDelay = 2000 [ms] 
WasteSpeed = 4000 [nl/s] 
WashSpeed = 4000 [nl/s] 
LoopWashFactor = 2.000 
SampleHeight = 1.500 [mm] 
PunctureDepth = 7.000 [mm] 
WashVolume = 500.000 [µl] 
RinseBetweenReinjections = Yes 
LowDispersionMode = Off 
InjectMode = ulPickUp 
FirstTransportVial = G1 
LastTransportVial = G1 
TransportVialCapacity = 99999 
TransLiquidHeight = 5.000 [mm] 
TransVialPunctureDepth = 8.000 [mm] 
FlushVolume = 7.000 [µl] 
LoadingPump_Pressure.Step = 0.01 [s] 
LoadingPump_Pressure.Average =Off 
NC_Pump_Pressure.Step = 0.01 [s] 
NC_Pump_Pressure.Average = Off 
ValveRight = 1_2 
0.000 Wait UV.Ready and LoadingPump.Ready and 
NC_Pump.Ready and ColumnOven.Ready and Sampler.Ready and PumpModule.Ready 
;Chromeleon sets this property to signal to Xcalibur that it is ready to 
start a run. 
ReadyToRun = 1 
;Xcalibur sets this property to start the run or injection. 
Wait StartRun 
LoadingPump.Flow = 6.000 [µl/min] 
LoadingPump.%B = 0.0 [%] 
%C = 0.0 [%] 
NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 5.0 [%] 
Wait UV.Ready and LoadingPump.Ready and 
NC_Pump.Ready and ColumnOven.Ready and Sampler.Ready and PumpModule.Ready 
Inject 
LoadingPump_Pressure.AcqOn 
NC_Pump_Pressure.AcqOn 
;Chromeleon sets this property to signal the injection to Xcalibur. 
InjectResponse = 1 
 
continued on next page 
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Listing 4.1 - continued: Operating method for the Dionex Ultimate 3000 system 
 
;Depending on your system configuration it might be necessary to manually 
insert 
;a "Relay" command below in order to send the start signal to the MS. 
;Typical syntaxes: 
;Pump_Relay_1.Closed Duration =2.00 
;UM3PUMP_Relay1.On Duration = 2.00 
;Pump_Relay_1.Closed Duration =2.00 
;UM3PUMP_Relay1.On Duration = 2.00 
LoadingPump.Flow = 6.000 [µl/min] 
ValveRight = 1_2 
LoadingPump.%B = 0.0 [%] 
%C = 0.0 [%] 
NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 5.0 [%] 
0.200 Relay_1_MS_Start.Duration = 5.00 
10.000 NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 5.0 [%] 
ValveRight = 10_1 
12.000 LoadingPump.Flow = 6.000 [µl/min] 
LoadingPump.%B = 0.0 [%] 
%C = 0.0 [%] 
15.000 LoadingPump.Flow = 30.000 [µl/min] 
LoadingPump.%B = 0.0 [%] 
%C = 0.0 [%] 
90.000 NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 45.0 [%] 
95.000 NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 45.0 [%] 
96.000 NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 95.0 [%] 
100.000 LoadingPump.Flow = 30.000 [µl/min] 
LoadingPump.%B = 0.0 [%] 
%C = 0.0 [%] 
103.000 LoadingPump.Flow = 6.000 [µl/min] 
LoadingPump.%B = 0.0 [%] 
%C = 0.0 [%] 
106.000 NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 95.0 [%] 
107.000 NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 5.0 [%] 
110.000 ValveRight = 1_2 
130.000 LoadingPump_Pressure.AcqOff 
NC_Pump_Pressure.AcqOff 
LoadingPump.Flow = 6.000 [µl/min] 
LoadingPump.%B = 0.0 [%] 
%C = 0.0 [%] 
NC_Pump.Flow = 0.200 [µl/min] 
NC_Pump.%B = 5.0 [%] 
InjectResponse = 0 
End
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Listing 4.2 : Abstract of the LTQ Orbitrap XL tuning method 
20120529_BSAbCAS_500fmol_#3 
Segment: 1 
Tune File Values 
Source Type: NSI 
Capillary Temp (C): 200.00 
APCI Vaporizer Temp (C): 0.00 
Sheath Gas Flow (): 0.00 
Aux Gas Flow (): 0.00 
Sweep Gas Flow (): 0.00 
Injection Waveforms: Off 
Ion Trap Zoom AGC Target: 3000.00 
Ion Trap Full AGC Target: 30000.00 
Ion Trap SIM AGC Target: 10000.00 
Ion Trap MSn AGC Target: 10000.00 
FTMS Injection Waveforms: On 
FTMS Full AGC Target: 500000.00 
FTMS SIM AGC Target: 50000.00 
FTMS MSn AGC Target: 200000.00 
Reagent Ion Source Polarity: Negative 
Reagent Ion Source Temp (C): 160.00 
Reagent Ion Source Emission 
Current (uA): 
50.00 
Reagent Ion Source Electron 
Energy (V): 
-70.00 
Reagent Ion Source CI Pressure 
(psi): 
11.00 
Reagent Vial 1 Ion Time: 100.00 
Reagent Vial 1 AGC Target: 100000.00 
Reagent Vial 2 Ion Time: 50.00 
Reagent Vial 2 AGC Target: 100000.00 
Supplemental Activation Energy: 15.00 
POSITIVE POLARITY 
Source Voltage (kV): 2.10 
Source Current (uA): 100.00 
Capillary Voltage (V): 6.00 
Tube Lens (V): 80.00 
Skimmer Offset (V): 0.00 
Multipole RF Amplifier (Vp-p): 400.00 
Multipole 00 Offset (V): -4.00 
Lens 0 Voltage (V): -4.50 
Multipole 0 Offset (V): -5.75 
Lens 1 Voltage (V): -10.00 
Gate Lens Offset (V): -54.00 
Multipole 1 Offset (V): -6.50 
Front Lens (V): -6.75 
Ion Trap Zoom Micro Scans: 1 
Ion Trap Zoom Max Ion Time (ms): 50.00 
Ion Trap Full Micro Scans: 1 
Ion Trap Full Max Ion Time (ms): 25.00 
Ion Trap SIM Micro Scans: 1 
Ion Trap SIM Max Ion Time (ms): 50.00 
Ion Trap MSn Micro Scans: 1 
Ion Trap MSn Max Ion Time (ms): 100.00 
FTMS Full Micro Scans: 1 
FTMS Full Max Ion Time (ms): 500.00 
FTMS SIM Micro Scans: 1 
FTMS SIM Max Ion Time (ms): 50.00 
FTMS MSn Micro Scans: 1 
FTMS MSn Max Ion Time (ms): 100.00 
Reagent Ion Lens 1 (V): -20.00 
Reagent Ion Gate Lens (V): -120.00 
Reagent Ion Lens 2 (V): -15.00 
Segment: 1 
Reagent Ion Lens 3 (V): -15.00 
Reagent Ion Back Lens Offset (V): -6.50 
Reagent Ion Back Multipole Offset 
(V): 
-7.00 
 
continued on next page 
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Listing 4.2 - continued: Abstract of the LTQ Orbitrap XL tuning method 
 
 
NEGATIVE POLARITY 
Source Voltage (kV): 1.50 
Source Current (uA): 100.00 
Capillary Voltage (V): -35.00 
Tube Lens (V): -100.00 
Skimmer Offset (V): 0.00 
Multipole RF Amplifier (Vp-p): 400.00 
Multipole 00 Offset (V): 4.00 
Lens 0 Voltage (V): 4.20 
Multipole 0 Offset (V): 4.50 
Lens 1 Voltage (V): 15.00 
Gate Lens Offset (V): 35.00 
Multipole 1 Offset (V): 8.00 
Front Lens (V): 5.25 
Ion Trap Zoom Micro Scans: 1 
Ion Trap Zoom Max Ion Time (ms): 50.00 
Ion Trap Full Micro Scans: 1 
Ion Trap Full Max Ion Time (ms): 25.00 
Ion Trap SIM Micro Scans: 1 
Ion Trap SIM Max Ion Time (ms): 50.00 
Ion Trap MSn Micro Scans: 1 
Ion Trap MSn Max Ion Time (ms): 50.00 
FTMS Full Micro Scans: 1 
FTMS Full Max Ion Time (ms): 500.00 
FTMS SIM Micro Scans: 1 
FTMS SIM Max Ion Time (ms): 50.00 
FTMS MSn Micro Scans: 1 
FTMS MSn Max Ion Time (ms): 100.00 
Reagent Ion Lens 1 (V): 140.00 
Reagent Ion Gate Lens (V): 21.75 
Reagent Ion Lens 2 (V): 88.25 
Reagent Ion Lens 3 (V): 31.75 
Reagent Ion Back Lens Offset (V): 5.40 
Reagent Ion Back Multipole Offset 
(V): 
19.00 
Additional FT Tune File Values 
FT Tune Item 1: 0.000000 
FT Tune Item 2: 0.000000 
FT Tune Item 3: 0.000000 
FT Tune Item 4: 0.000000 
FT Tune Item 5: 0.000000 
FT Tune Item 6: 0.000000 
FT Tune Item 7: 0.000000 
FT Tune Item 8: 0.000000 
FT Tune Item 9: 0.000000 
FT Tune Item 10: 0.000000 
Calibration File Values 
Multiple RF Frequency: 2545.400000 
Main RF Frequency: 1190.000000 
QMSlope0: 32.633474 
QMSlope1: 32.653024 
QMSlope2: 32.375685 
QMSlope3: 0.000000 
QMSlope4: 0.000000 
QMInt0: -28.495468 
QMInt1: 0.000000 
QMInt2: -25.488200 
QMInt3: 0.000000 
QMInt4: 0.000000 
End Section Slope: 0.000000 
End Section Int: 12.000000 
PQD CE Factor: 11.033762 
IsoW Slope: 0.000010 
IsoW Int: 0.310542 
Reagent MP Slope: 6.014851 
Reagent MP Int: -4.431932 
Tickle Amp. Slope0: 0.000058 
Tickle Amp. Int0: 0.003728 
 
continued on next page 
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Listing 4.2 - continued: Abstract of the LTQ Orbitrap XL tuning method 
 
 
Tickle Amp. Slope1: 0.002000 
Tickle Amp. Int1: 0.400000 
Tickle Amp. Slope2: 0.002000 
Tickle Amp. Int2: 0.400000 
Tickle Amp. Slope3: 0.002000 
Tickle Amp. Int3: 0.400000 
Multiplier 1 Normal Gain (pos): -1160.000000 
Multiplier 1 High Gain (pos): -1315.000000 
Multiplier 2 Normal Gain (pos): -1175.000000 
Multiplier 2 High Gain (pos): -1335.000000 
Multiplier 1 Normal Gain (neg): -1310.000000 
Multiplier 1 High Gain (neg): -1485.000000 
Multiplier 2 Normal Gain (neg): -1295.000000 
Multiplier 2 High Gain (neg): -1470.000000 
Normal Res. Eject Slope: 0.013551 
Normal Res. Eject Intercept: 4.064961 
Zoom Res. Eject Slope: 0.004181 
Zoom Res. Eject Intercept: 2.089748 
Turbo Res. Eject Slope: 0.069200 
Turbo Res. Eject Intercept: 35.000000 
AGC Res. Eject Slope: 0.069200 
AGC Res. Eject Intercept: 17.300000 
UltraZoom Res. Eject Slope: 0.001276 
UltraZoom Res. Eject Intercept: 0.323719 
Normal Mass Slope: 28.609101 
Normal Mass Intercept: -6.297141 
Zoom Mass Slope: 27.043745 
Zoom Mass Intercept: -38.640341 
Turbo Mass Slope: 28.282197 
Turbo Mass Intercept: 128.677267 
AGC Mass Slope: 28.282197 
AGC Mass Intercept: 128.677267 
UltraZoom Mass Slope: 27.080305 
UltraZoom Mass Intercept: -29.121168 
Vernier Fine Mass Slope: 428.431667 
Vernier Fine Mass Intercept: 0.000000 
Vernier Coarse Mass Slope: 0.000000 
Vernier Coarse Mass Intercept: 0.000000 
Cap. Device Min (V): -139.476020 
Cap. Device Max (V): 139.129266 
Tube Lens Device Min (V): 260.533478 
Tube Lens Device Max (V): -259.376421 
Skimmer Device Min (V): -139.832412 
Skimmer Device Max (V): 139.770320 
Multipole 00 Device Min (V): -139.168632 
Multipole 00 Device Max (V): 139.095879 
Lens 0 Device Min (V): -140.040678 
Lens 0 Device Max (V): 139.381980 
Gate Lens Device Min (V): -136.299647 
Gate Lens Device Max (V): 135.915741 
Split Gate Device Min (V): 0.197153 
Split Gate Device Max (V): 0.147953 
Multipole 0 Device Min (V): -139.391930 
Multipole 0 Device Max (V): 139.222408 
Lens 1 Device Min (V): -139.472669 
Lens 1 Device Max (V): 139.354340 
Multipole 1 Device Min (V): -138.695366 
Multipole 1 Device Max (V): 138.496867 
Front Lens Device Min (V): -139.762120 
Front Lens Device Max (V): 139.666672 
Front Section Device Min (V): -142.297965 
Front Section Device Max (V): 141.819813 
Center Section Device Min (V): -141.865740 
Center Section Device Max (V): 141.573812 
Back Section Device Min (V): -142.760199 
Back Section Device Max (V): 142.557238 
Back Lens Device Min (V): -142.688682 
Back Lens Device Max (V): 142.365528 
Reagent Lens 1 Device Min (V): -143.565954 
 
continued on next page 
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Listing 4.2 - continued: Abstract of the LTQ Orbitrap XL tuning method 
 
 
Reagent Lens 1 Device Max (V): 143.427374 
Reagent Gate Lens Min (V): -132.970381 
Reagent Gate Lens Max (V): 132.933349 
Reagent Lens 2 Device Min (V): -142.554596 
Reagent Lens 2 Device Max (V): 142.067153 
Reagent Lens 3 Device Min (V): -143.410874 
Reagent Lens 3 Device Max (V): 142.707489 
Reagent Electron Lens Device Min 
(V): 
-0.190768 
Reagent Electron Lens Device Max 
(V): 
149.758668 
 
 
Listing 4.3 : Operating method for the LTQ Orbitrap XL 
 
Creator: LTQ Orbitrap XL 
Last modified: 5/31/2011 by LTQ Orbitrap XL 
MS Run Time (min): 130.00 
Sequence override of method parameters not enabled. 
Divert Valve: not used during run 
Contact Closure: not used during run 
Syringe Pump: not used during run 
MS Detector Settings: 
Real-time modifications to method enabled 
Stepped collision energy not enabled 
Additional Microscans: 
MS2 0 0 
MS3 0 0 
MS4 0 0 
MS5 0 0 
MS6 0 0 
MS7 0 0 
MS8 0 0 
MS9 0 0 
MS10 0 0 
Segment 1 Information 
Duration (min): 130.00 
Number of Scan Events: 9 
Tune Method: 110120_nanoESI 
Scan Event Details: 
1: FTMS + p norm !corona !pi res=60000 o(200.0-2000.0) 
CV = 0.0V 
2: ITMS + c norm !corona !pi Dep MS/MS Most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
3: ITMS + c norm !corona !pi Dep MS/MS 2nd most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
 
continued on next page 
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Listing 4.3 - continued: Operating method for the LTQ Orbitrap XL 
 
4: ITMS + c norm !corona !pi Dep MS/MS 3rd most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
5: ITMS + c norm !corona !pi Dep MS/MS 4th most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
6: ITMS + c norm !corona !pi Dep MS/MS 5th most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
7: ITMS + c norm !corona !pi Dep MS/MS 6th most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
8: ITMS + c norm !corona !pi Dep MS/MS 7th most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
9: ITMS + c norm !corona !pi Dep MS/MS 8th most intense ion from (1) 
Activation Type: CID 
Min. Signal Required: 500.0 
Isolation Width: 3.00 
Normalized Coll. Energy: 35.0 
Default Charge State: 2 
Activation Q: 0.250 
Activation Time: 30.000 
CV = 0.0V 
Lock Masses: 
Pos List Name: 445 
Source: API Source 
Mass List: 445.120030 
Neg List Name: N/A 
Source: API Source 
Mass List: (none) 
Data Dependent Settings: 
Use separate polarity settings disabled 
Parent Mass List: (none) 
Reject Mass List: (none) 
Neutral Loss Mass List: (none) 
Product Mass List: (none) 
Neutral loss in top: 3 
Product in top: 3 
Most intense if no parent masses found not enabled 
 
continued on next page 
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Listing 4.3 - continued: Operating method for the LTQ Orbitrap XL 
 
Add/subtract mass not enabled 
FT master scan preview mode enabled 
Charge state screening enabled 
Charge state dependent ETD time enabled 
Monoisotopic precursor selection enabled 
Non-peptide monoisotopic recognition not enabled 
Charge state rejection enabled 
Unassigned charge states : rejected 
Charge state 1 : rejected 
Charge state 2 : not rejected 
Charge state 3 : not rejected 
Charge states 4+ : not rejected 
Chromatography mode is disabled 
Global Data Dependent Settings: 
Use global parent and reject mass lists not enabled 
Exclude parent mass from data dependent selection not enabled 
Exclusion mass width relative to mass 
Exclusion mass width relative to low (ppm): 10.000 
Exclusion mass width relative to high (ppm): 10.000 
Parent mass width by mass 
Parent mass width low: 0.50000 
Parent mass width high: 0.50000 
Reject mass width relative to mass 
Reject mass width relative to low (ppm): 10.000 
Reject mass width relative to high (ppm): 10.000 
Zoom/UltraZoom scan mass width by mass 
Zoom/UltraZoom scan mass width low: 5.00 
Zoom/UltraZoom scan mass width high: 5.00 
FT SIM scan mass width low: 5.00 
FT SIM scan mass width high: 5.00 
Neutral Loss candidates processed by decreasing intensity 
Neutral Loss mass width by mass 
Neutral Loss mass width low: 0.50000 
Neutral Loss mass width high: 0.50000 
Product candidates processed by decreasing intensity 
Product mass width by mass 
Product mass width low: 0.50000 
Product mass width high: 0.50000 
MS mass range: 0.00-1000000.00 
MSn mass range by mass 
MSn mass range: 0.00-1000000.00 
Use m/z values as masses not enabled 
Analog UV data dep. not enabled 
Dynamic exclusion enabled 
Repeat Count: 2 
Repeat Duration: 5.00 
Exclusion List Size: 500 
Exclusion Duration: 15.00 
Exclusion mass width relative to mass 
Exclusion mass width relative to low (ppm): 10.000 
Exclusion mass width relative to high (ppm): 10.000 
Expiration: disabled 
Isotopic data dependence not enabled 
Mass Tags data dependence not enabled 
Custom Data Dependent Settings: 
Not enabled 
 
122|4. MATERIALS AND METHODS 
 
Listing 4.4 : Python-script to facilitate ascertaining of retention time limits. 
import csv 
from pyteomics import fasta, parser, mass, achrom, electrochem, auxiliary 
 
def run(): 
 ini = iniFile("RCLimits.ini") 
 writer=csv.writer(open(ini.getSetting('OutPut','RCLimits.csv'), 'wb'), delimiter='\t',  
 quotechar='|', quoting=csv.QUOTE_MINIMAL) 
 reader=csv.reader(open(ini.getSetting('FileName','peptides.csv'), 'rb'), delimiter='\t',  
 quotechar='|') 
 firstRow = True 
 seqColumn = 0 
 for row in reader: 
  if firstRow: 
   firstRow = False 
   header = [] 
   for entryNum in range(len(row)): 
    header.append(row[entryNum]) 
    if row[entryNum]=='Sequence': 
     seqColumn = entryNum 
     header.append('RT_RP') 
     header.append('RT_normal') 
   writer.writerow(header) 
  else: 
   try: 
    rowToWrite = [] 
    for j in range(seqColumn+1): 
     rowToWrite.append(row[j]) 
    parsed = parser.parse( row[seqColumn], show_unmodified_termini=True) 
    RT_RP = achrom.calculate_RT(parsed, achrom.RCs_zubarev) 
    RT_normal = achrom.calculate_RT(parsed, achrom.RCs_yoshida_lc) 
    rowToWrite.append(str(RT_RP)) 
    rowToWrite.append(str(RT_normal)) 
    for i in range(len(row)-1-seqColumn): 
     rowToWrite.append(row[seqColumn+1+i]) 
    writer.writerow(rowToWrite) 
   except Exception: 
    print "Errored Sequence" 
class iniFile(object): 
 def __init__(self, fname): 
  self.fname = fname 
  self.settings = {} 
  self.read() 
 def printOut(self): 
  for setting in self.settings: 
   print setting + " : " + self.settings[setting] 
 def read(self): 
  try: 
   reader = csv.reader(open(self.fname, 'rb'), delimiter='=', quotechar='|') 
   for row in reader: 
    self.settings[row[0]]=row[1] 
  except Exception: 
   print "An error occured while reading "+self.fname 
 def getSetting(self, setting, default=""): 
  try: 
   return self.settings[setting] 
  except Exception: 
   return default 
 def getSettingInt(self, setting, default=0): 
  try: 
   return int(self.settings[setting]) 
  except Exception: 
   return default 
 def getSettingFloat(self, setting, default=0.0): 
  try: 
   return float(self.settings[setting]) 
  except Exception: 
   return default 
 def __del__(self): 
  del self.fname 
  del self.settings 
if (__name__=="__main__"): 
 run() 
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Listing 4.5: Python-script to estimate numbers of observable tryptic peptides. 
import csv 
 
from pyteomics import fasta, parser, mass, achrom, electrochem, auxiliary 
 
import re 
from collections import deque 
from itertools import chain, product 
 
def run(): 
 ini = iniFile('settings.ini') 
  
 debug = True 
  
 writeName = ini.getSetting('OutputPeptidesFileName', 'peptides.csv') 
 writeNameProt = ini.getSetting('OutputProteinsFileName', 'proteins.csv') 
  
 writingPeptides = True 
 if writeName == "false": 
  writingPeptides = False 
  
 writingProteins = True 
 if writeNameProt == "false": 
  writingProteins = False 
  
 errorWriter = csv.writer(open(ini.getSetting('ErrorLog','error.csv'), 'wb'),  
 delimiter='\t', quotechar='|', quoting=csv.QUOTE_MINIMAL) 
  
 csv.field_size_limit(1000000000) 
  
 if writingPeptides: 
  writer = csv.writer(open(writeName, 'wb'), delimiter='\t', quotechar='|',  
  quoting=csv.QUOTE_MINIMAL) 
 if writingProteins: 
  protWriter = csv.writer(open(writeNameProt, 'wb'), delimiter='\t', quotechar='|',  
  quoting=csv.QUOTE_MINIMAL) 
  
 if writingPeptides: 
  writer.writerow(['AccNo', 'PeptideSeq', 'RCrp', 'RCnorm', 'm', 'z', 'mz']) 
 if writingProteins: 
  protWriter.writerow(['AccNo', 'AccStr', 'GN', 'AA', 'm', 'NoP']) 
  
 try: 
  AAFilter = False 
  if(ini.getSetting('AA', 'false')=="true"): 
   print "AA-Filter enabled" 
   AAFilter = True 
  else: 
   print "AA-Filter disabled" 
   
  RTFilter = False 
  if(ini.getSetting('RT_RP', 'false')=="true"): 
   print "RT_RP-Filter enabled" 
   RTFilter = True 
  else: 
   print "RT_RP-Filter disabled" 
   
  RTNormFilter = False 
  if(ini.getSetting('RT_Norm', 'false')=="true"): 
   print "RT_normal-Filter enabled" 
   RTNormFilter = True 
  else: 
   print "RT_normal-Filter disabled" 
   
  ZFilter = False 
  if(ini.getSetting('Z', 'false')=="true"): 
   print "Z-Filter enabled" 
   ZFilter = True 
  else: 
   print "Z-Filter disabled" 
    
     
   
continued on next page 
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Listing 4.5 – continued : Python-script to estimate numbers of observable tryptic peptides. 
  pHValue = ini.getSettingFloat('pH') 
   
  proteinCount = 0 
  erroredPeptideCount = 0 
    
  for description, sequence in fasta.read(ini.getSetting('FileName', 'example.fasta')): 
   proteinCount += 1 
   new_peptides = cleave(sequence, parser.expasy_rules['trypsin']) 
   valid_peptides = [] 
    
   AccNo = re.split('\|', description)[1] 
   AccStr = re.split('_', re.split('\|', description)[2])[0] 
    
   GN="" 
   if 'GN=' in re.split('\|', description)[2]: 
    for arg in re.split(' ', re.split('\|', description)[2]): 
     if arg.startswith('GN='): 
      GN=arg[3:] 
    
   ProtMass = "" 
   NoP = 0 
   erroredPeptideCountProt = 0 
    
   for p in new_peptides: 
    validPeptide = True 
    if AAFilter: 
     if len(str(p)) < ini.getSettingInt('AA-min'): 
      validPeptide = False 
     elif len(str(p)) > ini.getSettingInt('AA-max'): 
      validPeptide = False 
     
    if validPeptide: 
     valid_peptides.append(p) 
    
   new_peptides_length = len(new_peptides) 
   del new_peptides 
    
   peptides = [{'sequence':i} for i in valid_peptides] 
    
   del valid_peptides 
    
   for peptide in peptides: 
    try: 
     peptide['parsed_sequence'] = parser.parse( peptide['sequence'],  
     show_unmodified_termini=True) 
     peptide['valid'] = True 
    except Exception: 
     errorWriter.writerow([AccNo, peptide['sequence']]) 
     peptide['valid'] = False 
     
    if peptide['valid']: 
     peptide['length'] = parser.length(peptide['parsed_sequence']) 
    
   for peptide in peptides: 
    if peptide['valid']: 
     peptide['charge'] = int(round(electrochem.charge( 
     peptide['parsed_sequence'], pH=pHValue))) 
     peptide['mass'] = mass.calculate_mass(peptide['parsed_sequence']) 
     peptide['m/z'] = mass.calculate_mass( 
     peptide['parsed_sequence'], charge=peptide['charge']) 
    
   for peptide in peptides: 
    if peptide['valid']: 
     peptide['RT_RP'] = achrom.calculate_RT(peptide['parsed_sequence'],  
     achrom.RCs_zubarev) 
     peptide['RT_normal'] = achrom.calculate_RT(peptide['parsed_sequence'],  
     achrom.RCs_yoshida_lc) 
    
   counter = 0 
 
     
   
continued on next page 
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 Listing 4.5 – continued : Python-script to estimate numbers of observable tryptic peptides. 
 
   while counter < len(peptides): 
    peptide = peptides[counter] 
    removed = False 
 
    if peptide['valid']: 
      
     if RTFilter: 
      if peptide['RT_RP'] < ini.getSettingInt('RT_RP-min'): 
       peptides.remove(peptide) 
       removed = True 
      elif peptide['RT_RP'] > ini.getSettingInt('RT_RP-max'): 
       peptides.remove(peptide) 
       removed = True 
      
     if RTNormFilter and not removed: 
      if peptide['RT_normal'] < ini.getSettingInt('RT_Norm-min'): 
       peptides.remove(peptide) 
       removed = True 
      elif peptide['RT_normal'] > ini.getSettingInt('RT_Norm-max'): 
       peptides.remove(peptide) 
       removed = True 
      
     if ZFilter and not removed: 
      if peptide['charge'] < ini.getSettingInt('Z-min'): 
       peptides.remove(peptide) 
       removed = True 
      elif peptide['charge'] > ini.getSettingInt('Z-max'): 
       peptides.remove(peptide) 
       removed = True 
     
    if not removed: 
     counter += 1 
    
   for peptide in peptides: 
    try: 
     rp = peptide['RT_RP'] 
     if writingPeptides: 
      writer.writerow([AccNo, peptide['sequence'], peptide['RT_RP'],  
      peptide['RT_normal'], peptide['mass'], peptide['charge'],  
      peptide['m/z']]) 
    except Exception: 
     erroredPeptideCount += 1 
     erroredPeptideCountProt += 1 
    
   NoP = len(peptides)-erroredPeptideCountProt 
    
   try: 
    parsedProtein = parser.parse( sequence, show_unmodified_termini=True) 
    ProtMass = str(mass.calculate_mass(parsedProtein)) 
   except Exception: 
    ProtMass = "" 
    
   if writingProteins: 
    protWriter.writerow([AccNo, AccStr, GN, str(len(sequence)), ProtMass,  
    str(NoP)]) 
    
   print str(proteinCount) + " proteins parsed "  
   del peptides 
   del AccNo 
 except Exception: 
  print "An error occured while reading "+ini.getSetting('FileName', 'example.fasta') 
  
 del errorWriter 
 if writingPeptides: 
  del writer 
 if writingProteins: 
  del protWriter 
  
 print 'Done! '+str(erroredPeptideCount)+' peptides have failed to parse' 
  
 
continued on next page 
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 Listing 4.5 – continued : Python-script to estimate numbers of observable tryptic peptides. 
 
raw_input('') 
  
 del ini 
 
def cleave(sequence, rule, missed_cleavages=0): 
    peptides = [] 
    cleavage_sites = deque([0], maxlen=missed_cleavages+2) 
    for i in chain(map(lambda x: x.end(), re.finditer(rule, sequence)), 
                   [None]): 
        cleavage_sites.append(i) 
        for j in range(0, len(cleavage_sites)-1): 
            peptides.append(sequence[cleavage_sites[j]:cleavage_sites[-1]]) 
    if '' in peptides: 
        peptides.remove('') 
    return peptides 
 
class iniFile(object): 
 def __init__(self, fname): 
  self.fname = fname 
  self.settings = {} 
   
  self.read() 
  
 def printOut(self): 
  for setting in self.settings: 
   print setting + " : " + self.settings[setting] 
  
 def read(self): 
   
  try: 
   reader = csv.reader(open(self.fname, 'rb'), delimiter='=', quotechar='|') 
    
   for row in reader: 
    self.settings[row[0]]=row[1] 
   
  except Exception: 
   print "An error occured while reading "+self.fname 
  
 def getSetting(self, setting, default=""): 
  try: 
   return self.settings[setting] 
  except Exception: 
   return default 
  
 def getSettingInt(self, setting, default=0): 
  try: 
   return int(self.settings[setting]) 
  except Exception: 
   return default 
  
 def getSettingFloat(self, setting, default=0.0): 
  try: 
   return float(self.settings[setting]) 
  except Exception: 
   return default 
  
 def __del__(self): 
  del self.fname 
  del self.settings 
  
if(__name__=="__main__"): 
 run() 
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Listing 4.6 : Parameter-file for listing 4.4 (RCLimits.ini). 
 
FileName=evidence.txt 
OutPut=evidence_out.txt  
 
 
Listing 4.7 : Parameter-file for listing 4.5 (Settings.ini). 
 
AA=true 
AA-min=6 
AA-max=60 
RT_RP=false 
RT_RP-min=5 
RT_RP-max=35 
Z=true 
Z-min=2 
Z-max=3 
RT_Norm=false 
RT_Norm-min=0 
RT_Norm-max=0 
Gradient_Length=40 
pH=3.0 
FileName=human.fasta 
OutputPeptidesFileName=peptides.csv 
OutputProteinsFileName=proteins.csv 
Path=C:\Users\Admin\Python 
ErrorLog=error.csv 
 
 
 
 
Listing 4.8 : Abstract of an experimental design-file for MaxQuant (experimentalDesign.txt). 
Name Fraction Experiment 
3APP1-01 3APP1 
3APP1-02 3APP1 
...  ... 
3APP1-18 3APP1 
3APP2-01 3APP2 
3APP2-02 3APP2 
...  ... 
3APP2-18 3APP2 
3APP3-01 3APP3 
3APP3-02 3APP3 
...  ... 
3APP3-18 3APP3 
3Cys1-01 3Cys1 
3Cys1-02 3Cys1 
...  ... 
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Listing 4.9 : MaxQuant (Version 1.2.2.5) parameter settings 
NumberOfThreads = 11  # For an Intel 6-core processor and Hyperthreading activated 
VariableModifications = Oxidation (M) ; Deamidation (NQ) 
Multiplicity = 1 # No variable modifications through introduced labels 
Enzym = Trypsin # No Lys-C pre-digestion 
FirstSearch = 20 ppm 
MainSearch = 6 ppm 
MaxNumberOfModificationsPerPeptide = 3 
MaxMissedCleavages = 2 
MaxCharge = 4 
IndividualPeptideMassTolerances = TRUE 
Type = Standard # Normal precursor selection 
FTMS MS/MS-tolerance = 20 ppm 
FTMS TopPeaksPer100Da = 10 
FTMS De-isotoping = TRUE 
FTMS HigherChargeStates = TRUE 
FTMS WaterLoss = TRUE 
FTMS AmmoniaLoss = TRUE 
FTMS DependendIons = TRUE 
ITMS MS/MS-tolerance = 0.5 Da 
ITMS TopPeaksPer100Da = 10 
ITMS De-isotoping = FALSE 
ITMS HigherChargeStates = TRUE 
ITMS WaterLoss = TRUE 
ITMS AmmoniaLoss = TRUE 
ITMS DependendIons = TRUE 
FASTA-files = uniprot_sprot_2011_02_HUMAN.fasta # or 2012_01_MOUSE.fasta 
IncludeContaminants = TRUE 
I=L = TRUE 
FixedModifications = Carbamidomethyl (C) 
PeptideFDR = 0.01 
SiteFDR = 0.01 
MaxPeptidePEP = 1 
MinPeptides = 1 
MinRazorPlusUniquePeptides = 0 
MinUniquePeptides = 0 
ProteinFDR = 0.01 
ApplySiteFDRSeparately = TRUE 
MinPeptideLength = 6 
MinScore = 0 
FilterLabeledAminoAcids = FALSE 
SecondPeptides = TRUE 
ExperimentalDesignFile = …\experimentalDesign.txt 
UseOnlyUnmodifiedPeptides = FALSE 
UseRazorAndUniquePeptides = TRUE 
DiscardUnmodifiedCounterpartPeptides = FALSE 
MinRatioCount = 2 
SiteQuantificationMode = UseLeastModifiedPeptides 
SiteQuantificationUseForOccupancies = NormalizedRatios 
Re-quantify = TRUE 
MatchBetweenRuns = TRUE 
TimeWindow = 2 min 
Label-freeQuantification = TRUE 
LFQMinRatioCount = 2 
iBAQ = TRUE 
LogFit = TRUE 
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Listing 4.10 : Perseus workflow 
Generic upload{}() => {matrix1} 
Filter category{matrix1}(Column=Only identified by site, Find=+, Mode=Remove matching rows) => 
{matrix2} 
Filter category{matrix2}(Column=Reverse, Find=+, Mode=Remove matching rows) => {matrix3} 
Filter category{matrix3}(Column=Contaminant, Find=+, Mode=Remove matching rows) => {matrix4} 
Log{matrix4}(Base=2, Columns=LFQ Intensity 345APP1; LFQ Intensity 345APP2; LFQ Intensity 
345APP3; LFQ Intensity 345Cys1; LFQ Intensity 345Cys2; LFQ Intensity 345Cys3; LFQ Intensity 
35APP1; LFQ Intensity 35APP2; LFQ Intensity 35APP3; LFQ Intensity 35Cys1; LFQ Intensity 
35Cys2; LFQ Intensity 35Cys3; LFQ Intensity 3APP1; LFQ Intensity 3APP2; LFQ Intensity 3APP3; 
LFQ Intensity 3Cys1; LFQ Intensity 3Cys2; LFQ Intensity 3Cys3; LFQ Intensity 45APP1; LFQ 
Intensity 45APP2; LFQ Intensity 45APP3; LFQ Intensity 45Cys1; LFQ Intensity 45Cys2; LFQ 
Intensity 45Cys3; LFQ Intensity 4APP1; LFQ Intensity 4APP2; LFQ Intensity 4APP3; LFQ Intensity 
4Cys1; LFQ Intensity 4Cys2; LFQ Intensity 4Cys3) => {matrix5} 
Create groups{matrix5}(LFQ Intensity 345APP1=345APP, LFQ Intensity 345APP2=345APP, LFQ 
Intensity 345APP3=345APP, LFQ Intensity 345Cys1=345Cys, LFQ Intensity 345Cys2=345Cys, LFQ 
Intensity 345Cys3=345Cys, LFQ Intensity 35APP1=35APP, LFQ Intensity 35APP2=35APP, LFQ 
Intensity 35APP3=35APP, LFQ Intensity 35Cys1=35Cys, LFQ Intensity 35Cys2=35Cys, LFQ Intensity 
35Cys3=35Cys, LFQ Intensity 3APP1=3APP, LFQ Intensity 3APP2=3APP, LFQ Intensity 3APP3=3APP, 
LFQ Intensity 3Cys1=3Cys, LFQ Intensity 3Cys2=3Cys, LFQ Intensity 3Cys3=3Cys, LFQ Intensity 
45APP1=45APP, LFQ Intensity 45APP2=45APP, LFQ Intensity 45APP3=45APP, LFQ Intensity 
45Cys1=45Cys, LFQ Intensity 45Cys2=45Cys, LFQ Intensity 45Cys3=45Cys, LFQ Intensity 
4APP1=4APP, LFQ Intensity 4APP2=4APP, LFQ Intensity 4APP3=4APP, LFQ Intensity 4Cys1=4Cys, LFQ 
Intensity 4Cys2=4Cys, LFQ Intensity 4Cys3=4Cys) => {matrix6} 
Filter valid values{matrix6}(Matrix access=Rows, Min. number of valid values=3, Mode=In at 
least one group) => {matrix7} 
Replace missing values by normal distribution{matrix7}(Width=0.3, Down shift=1.8) => {matrix8} 
Two samples{matrix8}(Group 1=4APP, Group 2=3APP, Test=T-test, Side=both, Use for 
truncation=Permutation-based FDR, Threshold value=0.05, S0=1, -Log10=True, Number of 
randomizations=250) => {matrix9} 
Scatterplot{matrix9}()
 
130|4. MATERIALS AND METHODS 
 
Listing 4.11 : R-script to generate a volcano-plot. 
 
setwd("K:\\LABOR\\20120509 CrbsvsCys PI3P") 
 
ExperimentTable <- 'PI3P_CrbsvsCys-postE.txt' 
ThresholdTable <- 'PI3P_CrbsvsCys-thresholds.txt' 
TitleText <- 'Crb2 vs. Cys (PI3P)' 
FDR <- 0.01 
So <- 0.2 
 
Experiment <- read.table(ExperimentTable, quote = "\"", header = TRUE,  
            sep = "\t", stringsAsFactors = FALSE, comment.char = "") 
 
 
Threshold <- read.table(ThresholdTable, quote = "\"", header = TRUE,  
            sep = "\t", stringsAsFactors = FALSE, comment.char = "") 
           
xx <- (Experiment$tdiff)     # t-test difference  
     
yy <- (Experiment$pval)     # t-test -log10(p-value) 
   
 
par(oma=c(0,0,0,0), mgp = c(3.5,1,0), mar = c(5, 4, 4, 2), mai = c(1.5,1.75,1,1)) 
 
plot( xx,yy,         
main= TitleText,      
 xlab = expression(log[2](Crb2/Cys)),     
 ylab = expression(-log[10](p-value)),       
 xlim = c(-max(abs(xx))*1.2,max(abs(xx)*1.2)), 
 ylim = c(0,max(abs(yy)*1.2)), 
     pch = 20,col='lightgrey',cex.axis = 1.5, cex.lab=2)     
   
 
abline(v=0, col='black', lty=1, lwd=2) 
 
text( x=par()[['usr']][1], 
 y=par()[['usr']][3] + (par()[['usr']][4] - par()[['usr']][3])/20, 
 labels=c(paste("FDR = ", FDR, "\nSO = ", So)), 
 pos=4)  
 
signSignificant <- Experiment$tsign == "+"    # t-test significant 
 
points(xx[signSignificant], yy[signSignificant],col="lightgrey",bg="lightgrey",pch=16) 
 
lines(x=Threshold$diff, y=Threshold$pval, col='black', lwd=2, lty=2) 
 
signAP <- Experiment$AdapterComplex != "" 
 
points(xx[signAP], yy[signAP],col="black",bg="black",pch=16) 
 
text( xx[signAP],        
 yy[signAP],        
 labels=Experiment$AccStr[signAP],   
 pos=2,cex=0.8) 
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Listing 4.12 : R-script for GO-enrichment analysis by hypergeometric distribution. 
 
# for improved regular expression operations, here: strapply() 
library(gsubfn)  
 
# Set Working Directory 
setwd("K:\\My Paper\\2013 - MCP")  
 
# Parse MaxQuant-Table 
Experiment<- read.table( "proteinGroups - CORRECTED.txt", quote = "\"", header = TRUE,  
 sep ="\t", stringsAsFactors = FALSE, comment.char = "") 
 
# Filter for 'only identified by site','reverse','contaminant' 
Experiment<-Experiment[Experiment$Reverse != "+",] 
Experiment<-Experiment[Experiment$Only.identified.by.site != "+",] 
Experiment<-Experiment[Experiment$Contaminant != "+",] 
exclude.columns<-c("Only.identified.by.site", "Reverse","Contaminant") 
'%!in%' <- function(x,y)!('%in%'(x,y)) # Create a not-in Operator 
Experiment<-Experiment[,colnames(Experiment)%!in%exclude.columns] 
 
# Filter for columns needed 
include.columns<-c("Only.identified.by.site", 
                   "Reverse", 
                   "Contaminant",  
                   "Gene.Names", 
                   "Protein.Names", 
                   "Protein.Descriptions", 
                   "LFQ.Intensity.B10D", 
                   "LFQ.Intensity.B10H", 
                   "LFQ.Intensity.B10L", 
                   "LFQ.Intensity.B2C", 
                   "LFQ.Intensity.B2G", 
                   "LFQ.Intensity.B2K", 
                   "LFQ.Intensity.C10B", 
                   "LFQ.Intensity.C10F", 
                   "LFQ.Intensity.C10J", 
                   "LFQ.Intensity.C2A", 
                   "LFQ.Intensity.C2E", 
                   "LFQ.Intensity.C2I", 
                   "LFQ.Intensity.T10F", 
                   "LFQ.Intensity.T10G", 
                   "LFQ.Intensity.T10H", 
                   "LFQ.Intensity.T10I", 
                   "LFQ.Intensity.T10J", 
                   "LFQ.Intensity.T2A", 
                   "LFQ.Intensity.T2B", 
                   "LFQ.Intensity.T2C", 
                   "LFQ.Intensity.T2D", 
                   "LFQ.Intensity.T2E") 
Experiment<-Experiment[,colnames(Experiment)%in%include.columns] 
 
# log2-transformation of LFQ-values 
expression.values<-c( 
  "LFQ.Intensity.B10D", 
  "LFQ.Intensity.B10H", 
  "LFQ.Intensity.B10L", 
  "LFQ.Intensity.B2C", 
  "LFQ.Intensity.B2G", 
  "LFQ.Intensity.B2K", 
  "LFQ.Intensity.C10B", 
  "LFQ.Intensity.C10F", 
  "LFQ.Intensity.C10J", 
  "LFQ.Intensity.C2A", 
  "LFQ.Intensity.C2E", 
  "LFQ.Intensity.C2I", 
  "LFQ.Intensity.T10F", 
  "LFQ.Intensity.T10G", 
  "LFQ.Intensity.T10H", 
  "LFQ.Intensity.T10I", 
  "LFQ.Intensity.T10J", 
  "LFQ.Intensity.T2A", 
 
 
continued on next page 
 
132|4. MATERIALS AND METHODS 
 
 Listing 4.12 - continued : R-script for GO-enrichment analysis. 
 
  "LFQ.Intensity.T2B", 
  "LFQ.Intensity.T2C", 
  "LFQ.Intensity.T2D", 
  "LFQ.Intensity.T2E") 
expression.groups<-c("B10", 
                     "B2", 
                     "C10", 
                     "C2", 
                     "T10", 
                     "T2") 
expression.columns<-paste("log2.",expression.values,sep = "") 
Exp.log2<-sapply(Experiment[,colnames(Experiment)%in%expression.values],log2) 
colnames(Exp.log2)=expression.columns<-paste("log2.",expression.values,sep = "") 
 
# Convert -Inv into NA 
index<-Exp.log2[,]<1 
Exp.log2[index] <- NA 
 
# Create Mean-LFQ columns 
Exp.log2<-data.frame(Exp.log2, 
                     B10=rowMeans(Exp.log2[,1:3],na.rm = TRUE), 
                     B2=rowMeans(Exp.log2[,4:6],na.rm = TRUE), 
                     C10=rowMeans(Exp.log2[,7:9],na.rm = TRUE), 
                     C2=rowMeans(Exp.log2[,10:12],na.rm = TRUE), 
                     T10=rowMeans(Exp.log2[,13:17],na.rm = TRUE), 
                     T2=rowMeans(Exp.log2[,18:22],na.rm = TRUE))                 
Experiment<-cbind(Experiment,Exp.log2) 
 
# Create AccStr column 
fun.AccStr<-function(x) 
  { 
    SProt<-unlist(strapply(x,"sp\\|.{6,9}\\|(.{2,6})_")) 
    Trembl<-unlist(strapply(x,"\\A>(tr\\|.{6,9}\\|)")) 
    if(is.null(SProt)){return(Trembl)}else{return(SProt[1])} 
  } 
Experiment$AccStr<-(lapply(Experiment$Protein.Descriptions,FUN=fun.AccStr)) 
 
# Create AccNo column 
fun.AccNo<-function(x) 
{ 
  SProt<-unlist(strapply(x,"sp\\|(.{6,9})\\|")) 
  Trembl<-unlist(strapply(x,"\\A>tr\\|(.{6,9})\\|")) 
  if(is.null(SProt)){return(Trembl)}else{return(SProt[1])} 
} 
Experiment$AccNo<-(lapply(Experiment$Protein.Descriptions,FUN=fun.AccNo)) 
 
# Map specific gene ontology entries from Uniprot by AccNo   
Cytosol<- read.delim("GO0005829.tab",stringsAsFactors = FALSE) # cytosol (CC) 
PM<- read.delim("GO0005886.tab",stringsAsFactors = FALSE)      # plasma membrane (CC) 
OM<- read.delim("GO0031090.tab",stringsAsFactors = FALSE)      # organelle membrane (CC) 
Experiment$Cytosol<-Experiment$AccNo%in%Cytosol$Entry 
Experiment$PM<-Experiment$AccNo%in%PM$Entry 
Experiment$OM<-Experiment$AccNo%in%OM$Entry 
 
# Create & Sort single Mean-LFQ-AccStr-AccNo-GO subtables 
B10<-Experiment[!is.na(Experiment$B10),colnames(Experiment)%in%c("B10","Cytosol","PM","OM")] 
B10<-B10[order(B10$B10,decreasing=TRUE),] 
B2<-Experiment[!is.na(Experiment$B2),colnames(Experiment)%in%c("B2","Cytosol","PM","OM")] 
B2<-B2[order(B2$B2,decreasing=TRUE),] 
C10<-Experiment[!is.na(Experiment$C10),colnames(Experiment)%in%c("C10","Cytosol","PM","OM")] 
C10<-C10[order(C10$C10,decreasing=TRUE),] 
C2<-Experiment[!is.na(Experiment$C2),colnames(Experiment)%in%c("C2","Cytosol","PM","OM")] 
C2<-C2[order(C2$C2,decreasing=TRUE),] 
T10<-Experiment[!is.na(Experiment$T10),colnames(Experiment)%in%c("T10","Cytosol","PM","OM")] 
T10<-T10[order(T10$T10,decreasing=TRUE),] 
T2<-Experiment[!is.na(Experiment$T2),colnames(Experiment)%in%c("T2","Cytosol","PM","OM")] 
T2<-T2[order(T2$T2,decreasing=TRUE),] 
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 Listing 4.12 - continued : R-script for GO-enrichment analysis. 
# Create bin tables with numbers of GO-assignments 
binsize<-100 
B10.bins<-data.frame()  
DF<-B10 
L<-length(DF[,1])%/%binsize 
 
for(i in c(1:L)){ 
  B10.bins[i,1]<-sum(DF[((i*binsize)-binsize):(i*binsize),2]) 
  B10.bins[i,2]<-sum(DF[((i*binsize)-binsize):(i*binsize),3]) 
  B10.bins[i,3]<-sum(DF[((i*binsize)-binsize):(i*binsize),4]) 
} 
B2.bins<-data.frame() 
DF<-B2 
L<-length(DF[,1])%/%binsize 
for(i in c(1:L)){ 
  B2.bins[i,1]<-sum(DF[((i*binsize)-binsize):(i*binsize),2]) 
  B2.bins[i,2]<-sum(DF[((i*binsize)-binsize):(i*binsize),3]) 
  B2.bins[i,3]<-sum(DF[((i*binsize)-binsize):(i*binsize),4]) 
} 
C10.bins<-data.frame() 
DF<-C10 
L<-length(DF[,1])%/%binsize 
for(i in c(1:L)){ 
  C10.bins[i,1]<-sum(DF[((i*binsize)-binsize):(i*binsize),2]) 
  C10.bins[i,2]<-sum(DF[((i*binsize)-binsize):(i*binsize),3]) 
  C10.bins[i,3]<-sum(DF[((i*binsize)-binsize):(i*binsize),4]) 
} 
C2.bins<-data.frame() 
DF<-C2 
L<-length(DF[,1])%/%binsize 
for(i in c(1:L)){ 
  C2.bins[i,1]<-sum(DF[((i*binsize)-binsize):(i*binsize),2]) 
  C2.bins[i,2]<-sum(DF[((i*binsize)-binsize):(i*binsize),3]) 
  C2.bins[i,3]<-sum(DF[((i*binsize)-binsize):(i*binsize),4]) 
} 
T10.bins<-data.frame() 
DF<-T10 
L<-length(DF[,1])%/%binsize 
for(i in c(1:L)){ 
  T10.bins[i,1]<-sum(DF[((i*binsize)-binsize):(i*binsize),2]) 
  T10.bins[i,2]<-sum(DF[((i*binsize)-binsize):(i*binsize),3]) 
  T10.bins[i,3]<-sum(DF[((i*binsize)-binsize):(i*binsize),4]) 
} 
T2.bins<-data.frame() 
DF<-T2 
L<-length(DF[,1])%/%binsize 
for(i in c(1:L)){ 
  T2.bins[i,1]<-sum(DF[((i*binsize)-binsize):(i*binsize),2]) 
  T2.bins[i,2]<-sum(DF[((i*binsize)-binsize):(i*binsize),3]) 
  T2.bins[i,3]<-sum(DF[((i*binsize)-binsize):(i*binsize),4]) 
} 
 
# calculate p-values from Hpergeometric Distribution 
total.HUMAN <- 20253 # Uniprot> organism:homo sapiens AND reviewed:yes 
total.Cytosol <- length(Cytosol$Entry) 
total.PM <- length(PM$Entry) 
total.OM <- length(OM$Entry) 
fun.hyper<-function(x,binsize,GO,human){ 
  (dhyper(x,GO,human-GO,binsize))} 
fun.invers<-function(x){(-1)*x} 
# B10 
B10.bins$V4<-(lapply(B10.bins[,1],FUN=fun.hyper,binsize,total.Cytosol,total.HUMAN)) 
B10.bins$V5<-(lapply(B10.bins[,2],FUN=fun.hyper,binsize,total.PM,total.HUMAN)) 
B10.bins$V6<-(lapply(B10.bins[,3],FUN=fun.hyper,binsize,total.OM,total.HUMAN)) 
# convert p-values to: -1 * log(p-values) 
B10.bins$V4<-(lapply(B10.bins[,4],FUN=log10)) 
B10.bins$V5<-(lapply(B10.bins[,5],FUN=log10)) 
B10.bins$V6<-(lapply(B10.bins[,6],FUN=log10)) 
B10.bins[,4]<-as.matrix(sapply(B10.bins[,4],fun.invers)) 
B10.bins[,5]<-as.matrix(sapply(B10.bins[,5],fun.invers)) 
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 Listing 4.12 - continued : R-script for GO-enrichment analysis. 
 
B10.bins[,6]<-as.matrix(sapply(B10.bins[,6],fun.invers)) 
# provide meaningful column names 
colnames(B10.bins)<-c("NoCytosol","NoPM","NoOM","Cytosol","PM","OM") 
# B2 
B2.bins$V4<-(lapply(B2.bins[,1],FUN=fun.hyper,binsize,total.Cytosol,total.HUMAN)) 
B2.bins$V5<-(lapply(B2.bins[,2],FUN=fun.hyper,binsize,total.PM,total.HUMAN)) 
B2.bins$V6<-(lapply(B2.bins[,3],FUN=fun.hyper,binsize,total.OM,total.HUMAN)) 
 
# convert p-values to: -1 * log(p-values) 
B2.bins$V4<-(lapply(B2.bins[,4],FUN=log10)) 
B2.bins$V5<-(lapply(B2.bins[,5],FUN=log10)) 
B2.bins$V6<-(lapply(B2.bins[,6],FUN=log10)) 
B2.bins[,4]<-as.matrix(sapply(B2.bins[,4],fun.invers)) 
B2.bins[,5]<-as.matrix(sapply(B2.bins[,5],fun.invers)) 
B2.bins[,6]<-as.matrix(sapply(B2.bins[,6],fun.invers)) 
# provide meaningful column names 
colnames(B2.bins)<-c("NoCytosol","NoPM","NoOM","Cytosol","PM","OM") 
# C10 
C10.bins$V4<-(lapply(C10.bins[,1],FUN=fun.hyper,binsize,total.Cytosol,total.HUMAN)) 
C10.bins$V5<-(lapply(C10.bins[,2],FUN=fun.hyper,binsize,total.PM,total.HUMAN)) 
C10.bins$V6<-(lapply(C10.bins[,3],FUN=fun.hyper,binsize,total.OM,total.HUMAN)) 
# convert p-values to: -1 * log(p-values) 
C10.bins$V4<-(lapply(C10.bins[,4],FUN=log10)) 
C10.bins$V5<-(lapply(C10.bins[,5],FUN=log10)) 
C10.bins$V6<-(lapply(C10.bins[,6],FUN=log10)) 
C10.bins[,4]<-as.matrix(sapply(C10.bins[,4],fun.invers)) 
C10.bins[,5]<-as.matrix(sapply(C10.bins[,5],fun.invers)) 
C10.bins[,6]<-as.matrix(sapply(C10.bins[,6],fun.invers)) 
# provide meaningful column names 
colnames(C10.bins)<-c("NoCytosol","NoPM","NoOM","Cytosol","PM","OM") 
# C2 
C2.bins$V4<-(lapply(C2.bins[,1],FUN=fun.hyper,binsize,total.Cytosol,total.HUMAN)) 
C2.bins$V5<-(lapply(C2.bins[,2],FUN=fun.hyper,binsize,total.PM,total.HUMAN)) 
C2.bins$V6<-(lapply(C2.bins[,3],FUN=fun.hyper,binsize,total.OM,total.HUMAN)) 
# convert p-values to: -1 * log(p-values) 
C2.bins$V4<-(lapply(C2.bins[,4],FUN=log10)) 
C2.bins$V5<-(lapply(C2.bins[,5],FUN=log10)) 
C2.bins$V6<-(lapply(C2.bins[,6],FUN=log10)) 
C2.bins[,4]<-as.matrix(sapply(C2.bins[,4],fun.invers)) 
C2.bins[,5]<-as.matrix(sapply(C2.bins[,5],fun.invers)) 
C2.bins[,6]<-as.matrix(sapply(C2.bins[,6],fun.invers)) 
# provide meaningful column names 
colnames(C2.bins)<-c("NoCytosol","NoPM","NoOM","Cytosol","PM","OM") 
# T10 
T10.bins$V4<-(lapply(T10.bins[,1],FUN=fun.hyper,binsize,total.Cytosol,total.HUMAN)) 
T10.bins$V5<-(lapply(T10.bins[,2],FUN=fun.hyper,binsize,total.PM,total.HUMAN)) 
T10.bins$V6<-(lapply(T10.bins[,3],FUN=fun.hyper,binsize,total.OM,total.HUMAN)) 
# convert p-values to: -1 * log(p-values) 
T10.bins$V4<-(lapply(T10.bins[,4],FUN=log10)) 
T10.bins$V5<-(lapply(T10.bins[,5],FUN=log10)) 
T10.bins$V6<-(lapply(T10.bins[,6],FUN=log10)) 
T10.bins[,4]<-as.matrix(sapply(T10.bins[,4],fun.invers)) 
T10.bins[,5]<-as.matrix(sapply(T10.bins[,5],fun.invers)) 
T10.bins[,6]<-as.matrix(sapply(T10.bins[,6],fun.invers)) 
# provide meaningful column names 
colnames(T10.bins)<-c("NoCytosol","NoPM","NoOM","Cytosol","PM","OM") 
# T2 
T2.bins$V4<-(lapply(T2.bins[,1],FUN=fun.hyper,binsize,total.Cytosol,total.HUMAN)) 
T2.bins$V5<-(lapply(T2.bins[,2],FUN=fun.hyper,binsize,total.PM,total.HUMAN)) 
T2.bins$V6<-(lapply(T2.bins[,3],FUN=fun.hyper,binsize,total.OM,total.HUMAN)) 
# convert p-values to: -1 * log(p-values) 
T2.bins$V4<-(lapply(T2.bins[,4],FUN=log10)) 
T2.bins$V5<-(lapply(T2.bins[,5],FUN=log10)) 
T2.bins$V6<-(lapply(T2.bins[,6],FUN=log10)) 
T2.bins[,4]<-as.matrix(sapply(T2.bins[,4],fun.invers)) 
T2.bins[,5]<-as.matrix(sapply(T2.bins[,5],fun.invers)) 
T2.bins[,6]<-as.matrix(sapply(T2.bins[,6],fun.invers)) 
# provide meaningful column names 
colnames(T2.bins)<-c("NoCytosol","NoPM","NoOM","Cytosol","PM","OM") 
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 Listing 4.12 - continued : R-script for GO-enrichment analysis. 
 
# Define Plotframe 
nf <- layout(matrix(c(1),1,1, byrow=TRUE), respect=TRUE) 
 
# Define Histogramplot-Function 
fun.plot<-function(DF,SAMPLE){ 
  par(oma=c(0,0,0,0), mgp = c(3.5,1,0), mar = c(5, 4, 4, 2), mai = c(1,1.5,0.5,0.25)) 
  mp <- barplot(DF, 
        beside = TRUE, 
        axisnames = FALSE, 
        ylim=c(0,25), 
        axes=FALSE, 
        legend=c("Plasma membrane","Organelle membrane","Cytosol"), 
        args.legend=list(x=1.4*length(DF),y=23,box.lwd = 0,box.col = "white",bg = "white"), 
        col=c(grey(0.25),grey(0.60),grey(1)) 
  ) 
  # create a baseline for column groups of three (in case a bar is zero) 
  minmp <- mp[2,]-1.5 
  maxmp <- mp[2,]+1.5 
  segments(minmp,0,maxmp,0) 
  # Add axes texts and y-axis 
  mtext(paste("Bins of intensity-ranked proteins (",SAMPLE,")",sep=""),side=1,cex=1.5,padj=2) 
  mtext("p-value",side=2,cex=1.5,padj=-4) 
  axis( 
    2, 
    at=c(0,5,10,15,20,25), 
    labels=c(expression(-10^0), 
expression(-10^5), 
expression(-10^10), 
expression(-10^15), 
expression(-10^20), 
expression(-10^25)), 
    tick=TRUE, 
    lty="solid",  
    lwd=2,  
    lwd.ticks=2, 
    col=NULL,  
    col.ticks=NULL, 
    cex.axis=1.0, 
    las=1) 
} 
 
# arrange data for barplots 
B10.plot<-as.vector(t(as.matrix(B10.bins[,c(5,6,4)]))) 
B2.plot<-as.vector(t(as.matrix(B2.bins[,c(5,6,4)]))) 
C10.plot<-as.vector(t(as.matrix(C10.bins[,c(5,6,4)]))) 
C2.plot<-as.vector(t(as.matrix(C2.bins[,c(5,6,4)]))) 
T10.plot<-as.vector(t(as.matrix(T10.bins[,c(5,6,4)]))) 
T2.plot<-as.vector(t(as.matrix(T2.bins[,c(5,6,4)]))) 
 
# Do the plots 
fun.plot(B10.plot,"B10") 
fun.plot(B2.plot,"B2") 
fun.plot(T10.plot,"T10") 
fun.plot(T2.plot,"T2") 
fun.plot(C10.plot,"C10") 
fun.plot(C2.plot,"C2") 
 
# Two dimensional plot (pp-plot) 
 
# B10 vs T10 
min.length<-min(length(T10.plot),length(B10.plot)) 
length(T10.plot)<-min.length 
length(B10.plot)<-min.length 
B10T10.plot<-cbind(T10.plot,B10.plot) 
# B2 vs T2 
min.length<-min(length(T2.plot),length(B2.plot)) 
length(T2.plot)<-min.length 
length(B2.plot)<-min.length 
B2T2.plot<-cbind(T2.plot,B2.plot) 
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 Listing 4.12 - continued : R-script for GO-enrichment analysis. 
 
# Define pp-plot-function 
fun.pp<-function(DF,x,y){ 
  par(oma=c(0,0,0,0), mgp = c(3.5,1,0), mar = c(5, 4, 4, 2), mai = c(1.5,1.5,0.5,0.25)) 
  plot(DF, 
       xlab="", 
       ylab="", 
       xlim=c(0,25), 
       ylim=c(0,25), 
       type="p", 
       pch=22, 
       bg=c(grey(0.25),grey(0.60),grey(1)), 
       cex=2, 
       axes=FALSE 
       ) 
  segments(0,0,25.5,0,lty = 2) 
  segments(0,0,0,25.5,lty = 2) 
  segments(25.5,0,25.5,12.5,lty = 2) 
  segments(12.5,12.5,25.5,12.5,lty = 2) 
  segments(12.5,12.5,12.5,25.5,lty = 2) 
  segments(0,25.5,12.5,25.5,lty = 2) 
  segments(0,10,10,10,lty = 2) 
  segments(10,0,10,10,lty = 2) 
  segments(10,10,12.5,12.5,lty = 2) 
  mtext(expression(-log[10](p-value)),side=1,cex=2,padj=2.0,adj=0.5) 
  mtext(x,side=1,cex=2,padj=2.7,adj=1) 
  mtext(expression(-log[10](p-value)),side=2,cex=2,padj=-1.5,adj=0.5) 
  mtext(y,side=2,cex=2,padj=-2.5,adj=1) 
  legend(13,25, 
         ncol=1, 
         x.intersp=0.6, 
         y.intersp=0.4, 
         cex=1.5, 
         pt.cex=2, 
         pch = 22, 
         pt.bg=c(grey(0.25),grey(0.60),grey(1)), 
         c("Plasma membrane","Organelle membrane","Cytosol"), 
         box.lwd = 0,box.col = "white",bg = "white") 
  axis( 
    2, 
    at=c(0,5,10,15,20,25), 
    labels=c(0,5,10,15,20,25), 
    tick=TRUE, 
    lty="solid",  
    lwd=2,  
    lwd.ticks=2, 
    col=NULL,  
    col.ticks=NULL, 
    cex.axis=1.5, 
    #yaxp = c(20,40,4), 
    las=1) 
  axis( 
    1, 
    at=c(0,5,10,15,20,25), 
    labels=c(0,5,10,15,20,25), 
    tick=TRUE, 
    lty="solid",  
    lwd=2,  
    lwd.ticks=2, 
    col=NULL,  
    col.ticks=NULL, 
    cex.axis=1.5, 
    padj=0, 
    pos=-1, 
    #yaxp = c(20,40,4), 
    las=1) 
} 
 
# Do the plots 
fun.pp(B10T10.plot,"T10","B10") 
fun.pp(B2T2.plot,"T2","B2") 
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 6. SUPPLEMENT 
 
Table S.1:  CD-marker proteins identified. 
CD AccNo  B T Name 
 
CD9 P21926 ++++ +++ CD9 antigen 
CD10 P08473 ++++ +++ Neprilysin 
CD13 P15144 ++++ ++++ Aminopeptidase N 
CD14 P08571 ++ - Monocyte differentiation antigen CD14 
CD29 P05556 ++++ ++++ Integrin beta-1 
CD39 P49961 ++ - Ectonucleoside triphosphate diphosphohydrolase 1 
CD40 P25942 +++ - Tumor necrosis factor receptor superfamily member 5 
CD44 P16070 ++++ ++++ CD44 antigen 
CD46 P15529 +++ - Membrane cofactor protein 
CD47 Q08722 ++++ ++ Leukocyte surface antigen CD47 
CD49a P56199 ++++ - Integrin alpha-1 
CD49b P17301 ++++ ++++ Integrin alpha-2 
CD49c P26006 ++++ +++ Integrin alpha-3 
CD49d P13612 ++++ - Integrin alpha-4 
CD49e P08648 ++++ +++ Integrin alpha-5 
CD49f P23229 +++ - Integrin alpha-6 
CD51 P06756 ++++ +++ Integrin alpha-V 
CD54 P05362 ++ - Intercellular adhesion molecule 1 
CD55 P08174 +++ - Complement decay-accelerating factor 
CD56 P13591 ++ - Neural cell adhesion molecule 1 
CD58 P19256 ++ - Lymphocyte function-associated antigen 3 
CD59 P13987 ++++ +++ CD59 glycoprotein 
CD61 P05106 +++ - Integrin beta-3 
CD63 P08962 +++ ++++ CD63 antigen 
CD68 P34810 ++ - Macrosialin 
CD71 P02786 ++++ ++++ Transferrin receptor protein 1 
CD73 P21589 ++++ ++++ 5-nucleotidase 
CD81 P60033 ++++ +++ CD81 antigen 
CD82 P27701 ++ - CD82 antigen 
CD87 Q03405 ++ - Urokinase plasminogen activator surface receptor 
CD88 P21730 ++ - C5a anaphylatoxin chemotactic receptor 
CD90 P04216 ++++ +++ Thy-1 membrane glycoprotein 
CD91 Q07954 ++++ ++++ Prolow-density lipoprotein receptor-related protein 1 
CD92 Q8WWI5 ++++ ++ Choline transporter-like protein 1 
CD95 P25445 +++ - Tumor necrosis factor receptor superfamily member 6 
CD97 P48960 ++++ - CD97 antigen 
CD98 P08195 ++++ +++ 4F2 cell-surface antigen heavy chain 
CD99 P14209 +++ - CD99 antigen 
CD105 P17813 ++++ - Endoglin 
CD106 P19320 ++ - Vascular cell adhesion protein 1 
CD107a P11279 +++ ++++ Lysosome-associated membrane glycoprotein 1 
CD107b P13473 - +++ Lysosome-associated membrane glycoprotein 2 
CD108 O75326 ++ ++ Semaphorin-7A 
CD109 Q6YHK3 ++++ ++++ CD109 antigen 
CD112 Q92692 ++++ - Poliovirus receptor-related protein 2 
CD113 Q9NQS3 ++++ - Poliovirus receptor-related protein 3 
CD119 P15260 ++ - Interferon gamma receptor 1 
CD120a P19438 ++ - Tumor necrosis factor receptor superfamily member 1A 
CD121a P14778 ++ - Interleukin-1 receptor type 1 
CD130 P40189 +++ - Interleukin-6 receptor subunit beta 
CD140a P16234 ++++ ++ Alpha-type platelet-derived growth factor receptor 
CD140b P09619 ++++ +++ Beta-type platelet-derived growth factor receptor 
CD141 P07204 ++ - Thrombomodulin 
CD142 P13726 ++ - Tissue factor 
CD143 P12821 ++++ - Angiotensin-converting enzyme 
CD146 P43121 +++ - Cell surface glycoprotein MUC18 
CD147 P35613 ++++ +++ Basigin 
CD148 Q12913 ++++ - Receptor-type tyrosine-protein phosphatase eta 
CD151 P48509 ++++ +++ CD151 antigen 
CD155 P15151 ++++ - Poliovirus receptor 
CD156b P78536 +++ - Disintegrin and metalloproteinase domain-containing protein 17 
CD156c O14672 ++++ ++ Disintegrin and metalloproteinase domain-containing protein 10 
CD157 Q10588 ++ - ADP-ribosyl cyclase 2 
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CD166 Q13740 ++++ ++++ CD166 antigen 
CD167b Q16832 ++++ ++ Discoidin domain-containing receptor 2 
CD172a P78324 +++ - Tyrosine-protein phosphatase non-receptor type substrate 1 
CD201 Q9UNN8 ++++ - Endothelial protein C receptor 
CD203a P22413 ++++ - Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 
CD213a1 P78552 + - Interleukin-13 receptor subunit alpha-1 
CD217 Q96F46 +++ - Interleukin-17 receptor A 
CD221 P08069 +++ - Insulin-like growth factor 1 receptor 
CD222 P11717 ++++ +++ Cation-independent mannose-6-phosphate receptor 
CD224 P19440 ++ - Gamma-glutamyltranspeptidase 1 
CD230 P04156 ++ - Major prion protein 
CD232 O60486 ++ - Plexin-C1 
CD236 P04921 +++ - Glycophorin-C 
CD239 P50895 +++ - Basal cell adhesion molecule 
CD248 Q9HCU0 ++++ +++ Endosialin 
CD261 O00220 ++ - Tumor necrosis factor receptor superfamily member 10A 
CD262 O14763 +++ - Tumor necrosis factor receptor superfamily member 10B 
CD264 Q9UBN6 ++ - Tumor necrosis factor receptor superfamily member 10D 
CD266 Q9NP84 ++ - Tumor necrosis factor receptor superfamily member 12A 
CD273 Q9BQ51 +++ - Programmed cell death 1 ligand 2 
CD274 Q9NZQ7 ++ - Programmed cell death 1 ligand 1 
CD276 Q5ZPR3 ++++ ++ CD276 antigen 
CD277 O00481 ++ - Butyrophilin subfamily 3 member A1 
CD280 Q9UBG0 ++++ +++ C-type mannose receptor 2 
CD282 O60603 + - Toll-like receptor 2 
CD292 P36894 ++ - Bone morphogenetic protein receptor type-1A 
CD295 P48357 +++ - Leptin receptor 
CD298 P54709 ++++ +++ Sodium/potassium-transporting ATPase subunit beta-3 
CD302 Q8IX05 ++ - CD302 antigen 
CD304 O14786 ++++ +++ Neuropilin-1 
CD316 Q969P0 ++++ - Immunoglobulin superfamily member 8 
CD318 Q9H5V8 +++ - CUB domain-containing protein 1 
CD325 P19022 +++ - Cadherin-2 
CD331 P11362 +++ - Basic fibroblast growth factor receptor 1 
CD339 P78504 ++ - Protein jagged-1 
CD340 P04626 +++ - Receptor tyrosine-protein kinase erbB-2 
CD362 P34741 ++ - Syndecan-2 
CDw210b Q08334 ++ - Interleukin-10 receptor subunit beta 
 
 
Not identified CD-marker proteins: CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8a, CD8b, CD11a, 
CD11b, CD11c, CD11d, CD16a, CD16b, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD30, CD31, CD32, CD33, 
CD34, CD35, CD36, CD37, CD38, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD45, CD48, CD50, CD52, CD53, CD62E, CD62L, CD62P, CD64, 
CD66a, CD66b, CD66c, CD66d, CD66e, CD66f, CD69, CD70, CD72, CD74, CD79a, CD79b, CD80, CD83, CD84, CD85a, CD85c, CD85d, CD85e, 
CD85f, CD85g, CD85h, CD85i, CD85j, CD85k, CD86, CD89, CD93, CD94, CD96, CD100, CD101, CD102, CD103, CD104, CD110, CD111, CD114, 
CD115, CD116, CD117, CD118, CD120b, CD121b, CD122, CD123, CD124, CD125, CD126, CD127, CD129, CD131, CD132, CD133, CD134, 
CD135, CD136, CD137, CD138, CD144, CD150, CD152, CD153, CD154, CD156a, CD158a, CD158b1, CD158b2, CD158c, CD158d, CD158e, 
CD158f1, CD158f2, CD158g, CD158h, CD158i, CD158j, CD158k, CD158z, CD159a, CD159c, CD160, CD161, CD162, CD163, CD163b, CD164, 
CD167a, CD168, CD169, CD170, CD171, CD172b, CD172g, CD177, CD178, CD179a, CD179b, CD180, CD181, CD182, CD183, CD184, CD185, 
CD186, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CDw198, CDw199, CD200, CD202b, CD203c, CD204, CD205, CD206, CD207, 
CD208, CD209, CD210, CD212, CD213a2, CD215, CD218a, CD218b, CD220, CD223, CD225, CD226, CD227, CD228, CD229, CD231, CD233, 
CD234, CD235a, CD235b, CD238, CD240CE, CD240D, CD241, CD242, CD243, CD244, CD246, CD247, CD249, CD252, CD253, CD254, CD256, 
CD257, CD258, CD263, CD265, CD267, CD268, CD269, CD270, CD271, CD272, CD275, CD278, CD279, CD281, CD283, CD284, CD286, CD288, 
CD289, CD290, CDw293, CD294, CD296, CD297, CD299, CD300a, CD300b, CD300c, CD300d, CD300e, CD300f, CD300g, CD301, CD303, 
CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD309, CD312, CD314, CD315, CD317, CD319, CD320, CD321, CD322, CD324, 
CD326, CD327, CD328, CD329, CD332, CD333, CD334, CD335, CD336, CD337, CD338, CD344, CD349, CD350, CD351, CD352, CD353, CD354, 
CD355, CD357, CD358, CD360, CD361, CD363 
 
149|6.SUPPLEMENT 
Table S.2 :  non CD-marker cell surface proteins identified. 
SP TM GA PM ECS ECR ECM AccNo B T Name 
 
 +  +    Q15125 ++ - 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase 
+    + + + P08253 ++ - 72 kDa type IV collagenase 
+ +  +    Q04771 +++ - Activin receptor type-1 
 +  +    P51828 ++ - Adenylate cyclase type 7 
 +  +    O60503 +++ - Adenylate cyclase type 9 
+ +  +    Q9H6B4 ++++ - Adipocyte adhesion molecule 
+    + +  Q8IUX7 ++ - Adipocyte enhancer-binding protein 1 
 +  +    P12235 + - ADP/ATP translocase 1 
 +  +    P05141 +++ +++ ADP/ATP translocase 2 
+     +  Q9BRR6 ++ ++ ADP-dependent glucokinase 
+    + +  P43652 ++ - Afamin 
+  + + + +  P05186 ++ - Alkaline phosphatase, tissue-nonspecific isozyme 
+     +  P04217 ++ - Alpha-1B-glycoprotein 
+    + + + P02765 ++ - Alpha-2-HS-glycoprotein 
+   +  +  P30533 +++ - Alpha-2-macroglobulin receptor-associated protein 
+ +  +    Q86SJ2 ++ - Amphoterin-induced protein 2 
+    + +  Q9UKU9 ++ - Angiopoietin-related protein 2 
 +  +    P04920 ++ - Anion exchange protein 2 
 +  +    Q9NW15 - +++ Anoctamin-10 
 +  +    Q4KMQ2 ++++ - Anoctamin-6 
+ +  +    Q9H6X2 +++ - Anthrax toxin receptor 1 
+ +  +  +  P58335 +++ - Anthrax toxin receptor 2 
 +  +    Q03518 ++ - Antigen peptide transporter 1 
 +  +    Q03519 ++ - Antigen peptide transporter 2 
+   + + +  P04114 ++ - Apolipoprotein B-100 
 +  +    Q12797 +++ ++++ Aspartyl/asparaginyl beta-hydroxylase 
 +  +    O95477 +++ - ATP-binding cassette sub-family A member 1 
 +  +    O94911 ++ - ATP-binding cassette sub-family A member 8 
+ +  +    P20594 +++ - Atrial natriuretic peptide receptor 2 
+ +  +    P17342 ++ - Atrial natriuretic peptide receptor 3 
 +  +  +  Q9Y5Q5 ++ - Atrial natriuretic peptide-converting enzyme 
+ +  + + +  O75882 +++ - Attractin 
 +  +    P30411 +++ - B2 bradykinin receptor 
+   + + + + P98160 - +++ Basement membrane-specific heparan sulfate proteoglycan core protein 
 +  +    P51572 ++ +++ B-cell receptor-associated protein 31 
 +  +    P07550 ++ - Beta-2 adrenergic receptor 
+   + + +  P61769 +++ - Beta-2-microglobulin 
 +  +    Q16585 +++ - Beta-sarcoglycan 
+ +  +    Q13873 +++ - Bone morphogenetic protein receptor type-2 
+ +  +    Q7KYR7 +++ - Butyrophilin subfamily 2 member A1 
 +  +    Q9P296 ++ - C5a anaphylatoxin chemotactic receptor C5L2 
+ +  +    P55287 ++++ - Cadherin-11 
+  + + + +  P55290 ++ - Cadherin-13 
+ +  +    P55283 ++ - Cadherin-4 
+ +  +    P55285 ++ ++ Cadherin-6 
 +  +    Q96D31 ++ - Calcium release-activated calcium channel protein 1 
 +  +    Q12791 +++ - Calcium-activated potassium channel subunit alpha-1 
 +  +    Q9UJS0 - +++ Calcium-binding mitochondrial carrier protein Aralar2 
+   + + + + P27797 +++ ++++ Calreticulin 
+     +  O43852 +++ ++++ Calumenin 
 +  +    O15438 ++ - Canalicular multispecific organic anion transporter 2 
+ +  +    O43570 ++ - Carbonic anhydrase 12 
+  + +    P14384 +++ - Carboxypeptidase M 
+     + + O75718 - +++ Cartilage-associated protein 
 +  +    P21964 +++ +++ Catechol O-methyltransferase 
+   + + +  P07858 ++ +++ Cathepsin B 
+    + +  P07339 ++ +++ Cathepsin D 
+    + +  P43235 ++ - Cathepsin K 
+    + +  Q9UBR2 - +++ Cathepsin Z 
+ +  +    P20645 +++ - Cation-dependent mannose-6-phosphate receptor 
+ +  +    Q8TCZ2 +++ - CD99 antigen-like protein 2 
 +  +    O14735 ++ + CDP-diacylglycerol--inositol 3-phosphatidyltransferase 
+ +  +    Q9BY67 ++ - Cell adhesion molecule 1 
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 +  +    Q99788 ++ - Chemokine-like receptor 1 
 +  +    O00299 ++ ++++ Chloride intracellular channel protein 1 
 +  +    Q9Y696 ++ ++++ Chloride intracellular channel protein 4 
 +  +    Q8IWA5 ++++ ++ Choline transporter-like protein 2 
+ +  +  +  Q6UVK1 ++++ ++++ Chondroitin sulfate proteoglycan 4 
 +  +    Q9NY35 +++ - Claudin domain-containing protein 1 
 +  +    O96005 - +++ Cleft lip and palate transmembrane protein 1 
+    + + + P02452 +++ ++++ Collagen alpha-1(I) chain 
+     + + P20908 ++ ++ Collagen alpha-1(V) chain 
+   +  + + P12109 ++ ++++ Collagen alpha-1(VI) chain 
+     + + Q02388 - ++ Collagen alpha-1(VII) chain 
+    + + + Q99715 - ++ Collagen alpha-1(XII) chain 
+    + + + P39060 ++ ++ Collagen alpha-1(XVIII) chain 
+    + + + P08123 ++ +++ Collagen alpha-2(I) chain 
+    + + + P12110 ++ ++++ Collagen alpha-2(VI) chain 
+   + + + + P12111 ++++ ++++ Collagen alpha-3(VI) chain 
+     + + A6NMZ7 ++ - Collagen alpha-6(VI) chain 
+    + + + Q96CG8 ++ ++ Collagen triple helix repeat-containing protein 1 
+ +  +    P78357 ++ - Contactin-associated protein 1 
 +  +    Q9UPY5 ++ - Cystine/glutamate transporter 
 +  +    Q07065 +++ ++++ Cytoskeleton-associated protein 4 
 +  +    Q92629 ++++ - Delta-sarcoglycan 
+     +  P81605 ++ ++ Dermcidin 
+ +  +    Q02413 ++ - Desmoglein-1 
+ +  +    Q96PD2 +++ - Discoidin, CUB and LCCL domain-containing protein 2 
+ +  + + +  Q13443 ++++ ++ Disintegrin and metalloproteinase domain-containing protein 9 
+     +  Q8IXB1 ++ ++ DnaJ homolog subfamily C member 10 
+ +  + + + + Q14118 ++++ - Dystroglycan 
+     +  O43854 ++ - EGF-like repeat and discoidin I-like domain-containing protein 3 
 +  +    Q9Y6R1 +++ - Electrogenic sodium bicarbonate cotransporter 1 
+     + + Q9Y6C2 + +++ EMILIN-1 
+     +  O94919 ++ - Endonuclease domain-containing 1 protein 
 +  +    P42892 +++ - Endothelin-converting enzyme 1 
+ +  +    P29317 ++++ +++ Ephrin type-A receptor 2 
+ +  +    P54764 +++ - Ephrin type-A receptor 4 
+ +  +    P54756 ++ - Ephrin type-A receptor 5 
+ +  +    P29323 +++ - Ephrin type-B receptor 2 
+ +  +    P54753 ++ - Ephrin type-B receptor 3 
+ +  +    P54760 ++++ - Ephrin type-B receptor 4 
+ +  +  +  O15197 +++ - Ephrin type-B receptor 6 
+  + +    P52803 ++ - Ephrin-A5 
+ +  +    P98172 +++ - Ephrin-B1 
+ +  +    P52799 ++ - Ephrin-B2 
+ +  + + +  P00533 ++++ +++ Epidermal growth factor receptor 
 +  +    O43556 +++ - Epsilon-sarcoglycan 
 +  +    Q99808 ++ - Equilibrative nucleoside transporter 1 
 +  +    O94905 +++ +++ Erlin-2 
+     +  Q8NBQ5 ++ ++ Estradiol 17-beta-dehydrogenase 11 
 +  +    P43005 ++ - Excitatory amino acid transporter 3 
 +  +    A0FGR8 +++ +++ Extended synaptotagmin-2 
 +  +    O95864 +++ +++ Fatty acid desaturase 2 
 +  +    Q9UPI3 ++ - Feline leukemia virus subgroup C receptor-related protein 2 
+    + + + P02751 +++ ++++ Fibronectin 
+    + + + P23142 ++ - Fibulin-1 
 +  +    P41440 ++ - Folate transporter 1 
+ +  +    Q9UP38 ++ - Frizzled-1 
+ +  +    Q14332 +++ - Frizzled-2 
+ +  +    O75084 +++ - Frizzled-7 
+    + + + Q08380 ++ - Galectin-3-binding protein 
+    + +  Q92820 ++ ++ Gamma-glutamyl hydrolase 
 +  +    P36269 ++ - Gamma-glutamyltransferase 5 
 +  +    P17302 ++++ +++ Gap junction alpha-1 protein 
+  + +    P56159 ++ - GDNF family receptor alpha-1 
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+    + +  P06396 - ++++ Gelsolin 
+   + + + + P07093 + - Glia-derived nexin 
+ +  +  +  P48060 +++ - Glioma pathogenesis-related protein 1 
+     +  Q96SL4 ++ - Glutathione peroxidase 7 
+  + + + + + P35052 ++++ +++ Glypican-1 
+  + + + + + Q9Y625 ++ - Glypican-6 
+ +     + Q92896 ++++ +++ Golgi apparatus protein 1 
+ +  +    Q96PE1 +++ - G-protein coupled receptor 124 
+    + +  O60565 ++ +++ Gremlin-1 
+  + +    P54826 ++ - Growth arrest-specific protein 1 
+    + +  Q14393 +++ - Growth arrest-specific protein 6 
+    + +  P00738 ++ - Haptoglobin 
+    + +  P02790 ++ - Hemopexin 
+ +  +    Q30201 ++ - Hereditary hemochromatosis protein 
 +  +    P30825 +++ - High affinity cationic amino acid transporter 1 
+ +  +    P30443 ++++ - HLA class I histocompatibility antigen, A-1 alpha chain 
+ +  +    P01892 ++++ - HLA class I histocompatibility antigen, A-2 alpha chain 
+ +  +    P05534 ++ - HLA class I histocompatibility antigen, A-24 alpha chain 
+ +  +    P04439 - +++ HLA class I histocompatibility antigen, A-3 alpha chain 
+ +  +    P30481 ++ - HLA class I histocompatibility antigen, B-44 alpha chain 
+ +  +    P30460 ++++ - HLA class I histocompatibility antigen, B-8 alpha chain 
+ +  +    P30504 +++ - HLA class I histocompatibility antigen, Cw-4 alpha chain 
+ +  +    P10321 +++ - HLA class I histocompatibility antigen, Cw-7 alpha chain 
+  + +    Q12891 ++ - Hyaluronidase-2 
+ +  +    P55899 +++ - IgG receptor FcRn large subunit p51 
+ +  +    Q8TDY8 +++ - Immunoglobulin superfamily DCC subclass member 4 
 +  +    Q14573 ++ - Inositol 1,4,5-trisphosphate receptor type 3 
 +  +    Q9NQX7 ++ - Integral membrane protein 2C 
+ +  +    O75578 +++ ++ Integrin alpha-10 
+ +  +    Q13683 +++ - Integrin alpha-7 
+ +  +    P53708 +++ +++ Integrin alpha-8 
+ +  +    P18084 ++++ - Integrin beta-5 
+ +  +    Q9UMF0 + - Intercellular adhesion molecule 5 
 +  +    Q01628 +++ - Interferon-induced transmembrane protein 3 
+ +  +  +  Q9NPH3 ++ - Interleukin-1 receptor accessory protein 
+ +  + + +  Q9BX67 +++ - Junctional adhesion molecule C 
+ +  +    Q96J84 +++ - Kin of IRRE-like protein 1 
 +  +    Q86UP2 ++ +++ Kinectin 
+   + + +  Q08431 +++ ++ Lactadherin 
+    + + + P07942 - +++ Laminin subunit beta-1 
+     + + P55268 - ++ Laminin subunit beta-2 
+    + + + P11047 - +++ Laminin subunit gamma-1 
 +  +    Q01650 ++++ - Large neutral amino acids transporter small subunit 1 
+ +  +    O95490 +++ - Latrophilin-2 
+ +  +  + + O43155 ++ - Leucine-rich repeat transmembrane protein FLRT2 
+ +  +  + + Q9NZU0 +++ - Leucine-rich repeat transmembrane protein FLRT3 
 +  +  +  Q9UIQ6 +++ ++ Leucyl-cystinyl aminopeptidase 
+  + +    Q13449 ++ - Limbic system-associated membrane protein 
+ +  +    Q86UK5 ++ - Limbin 
 +  +    O14495 +++ ++ Lipid phosphate phosphohydrolase 3 
 +  +    P52569 ++ - Low affinity cationic amino acid transporter 2 
+ +  + + +  P01130 +++ ++ Low-density lipoprotein receptor 
+ +  +    O75581 ++ - Low-density lipoprotein receptor-related protein 6 
 +  +    Q92633 ++++ - Lysophosphatidic acid receptor 1 
 +  +    Q14108 ++ +++ Lysosome membrane protein 2 
+    + +  P61626 ++ - Lysozyme C 
+ +  + + +  P09603 ++ - Macrophage colony-stimulating factor 1 
+ +  +    Q9H0U3 ++ - Magnesium transporter protein 1 
+     +  Q9UM22 +++ - Mammalian ependymin-related protein 1 
 +  +    Q96AM1 +++ - Mas-related G-protein coupled receptor member F 
+ +  +   + P50281 ++++ +++ Matrix metalloproteinase-14 
+     +  Q9NR99 ++ ++ Matrix-remodeling-associated protein 5 
 +  +    Q5HYA8 ++ - Meckelin 
 
continued on next page 
 
152|6.SUPPLEMENT 
 Table S.2 - continued:  non CD-marker cell surface proteins identified. 
SP TM GA PM ECS ECR ECM AccNo B T Name 
 
+    + +  P55145 - ++ Mesencephalic astrocyte-derived neurotrophic factor 
 +  +    Q8NE01 ++ - Metal transporter CNNM3 
 +  +    Q6P4Q7 ++ - Metal transporter CNNM4 
+     + + P01033 ++ - Metalloproteinase inhibitor 1 
 +  +    Q9UHE8 +++ - Metalloreductase STEAP1 
 +  +    Q8NFT2 ++ - Metalloreductase STEAP2 
 +  +    Q658P3 +++ - Metalloreductase STEAP3 
+ +  + + +  Q29983 ++ - MHC class I polypeptide-related sequence A 
 +  +    Q8TCT9 +++ +++ Minor histocompatibility antigen H13 
 +  +    Q02978 +++ +++ Mitochondrial 2-oxoglutarate/malate carrier protein 
 +  +    Q8IXI2 ++ - Mitochondrial Rho GTPase 1 
 +  +    Q8IXI1 ++ - Mitochondrial Rho GTPase 2 
 +  +    P53985 ++++ ++ Monocarboxylate transporter 1 
 +  +    O60669 ++ - Monocarboxylate transporter 2 
 +  +    O15427 ++++ +++ Monocarboxylate transporter 4 
 +  +    O15374 ++ - Monocarboxylate transporter 5 
 +  +    P36021 +++ - Monocarboxylate transporter 8 
 +  +    P33527 ++++ - Multidrug resistance-associated protein 1 
 +  +    O15439 +++ - Multidrug resistance-associated protein 4 
+ +  +    O95297 ++++ - Myelin protein zero-like protein 1 
 +  +    Q9NZM1 ++++ ++++ Myoferlin 
+     +  Q96PD5 ++ - N-acetylmuramoyl-L-alanine amidase 
 +  +    Q9Y2A7 ++ +++ Nck-associated protein 1 
+ +  +    Q92859 ++++ ++ Neogenin 
+  + +    Q9Y2I2 ++ - Netrin-G1 
+ +  +    O15394 ++ - Neural cell adhesion molecule 2 
+ +  +  + + O00533 ++ - Neural cell adhesion molecule L1-like protein 
+ +  +    O94856 ++++ - Neurofascin 
+ +  +  +  P46531 ++ - Neurogenic locus notch homolog protein 1 
+ +  +  +  Q04721 ++++ ++ Neurogenic locus notch homolog protein 2 
+ +  +  +  Q9UM47 +++ - Neurogenic locus notch homolog protein 3 
+ +  +    Q8N2Q7 ++ - Neuroligin-1 
+ +  +    Q8NFZ4 ++ - Neuroligin-2 
+ +  +    Q92823 ++ - Neuronal cell adhesion molecule 
+  + +    Q7Z3B1 +++ - Neuronal growth regulator 1 
 +  +    Q13491 ++ - Neuronal membrane glycoprotein M6-b 
+ +  +    O60462 ++ - Neuropilin-2 
+ +  +    Q9Y639 ++++ +++ Neuroplastin 
+  + +    Q9P121 +++ - Neurotrimin 
 +  +    P43007 +++ - Neutral amino acid transporter A 
 +  +    Q15758 ++++ +++ Neutral amino acid transporter B(0) 
+    + +  P59665 + - Neutrophil defensin 1 
+ +  +    Q92542 ++++ +++ Nicastrin 
+     + + Q14112 ++ - Nidogen-2 
+  + +    Q9BZM4 ++ - NKG2D ligand 3 
+ +  +    Q99650 +++ - Oncostatin-M-specific receptor subunit beta 
 +  +    Q96RD7 +++ - Pannexin-1 
+     +  P26022 + - Pentraxin-related protein PTX3 
+    + + + Q92626 ++ +++ Peroxidasin homolog 
+    + +  Q13162 +++ +++ Peroxiredoxin-4 
 +  +    Q00325 ++++ ++++ Phosphate carrier protein, mitochondrial 
 +  +   + O15162 +++ - Phospholipid scramblase 1 
 +  +    Q9NRY6 - +++ Phospholipid scramblase 3 
 +  +    P20020 ++++ ++ Plasma membrane calcium-transporting ATPase 1 
 +  +    P20020 ++++ ++ Plasma membrane calcium-transporting ATPase 1 
 +  +    P23634 ++++ ++++ Plasma membrane calcium-transporting ATPase 4 
+   + + + + P05121 +++ +++ Plasminogen activator inhibitor 1 
+ +  +    Q5VY43 +++ - Platelet endothelial aggregation receptor 1 
+ +  +    Q9UIW2 ++++ - Plexin-A1 
+ +  +    O75051 +++ - Plexin-A2 
+ +  +    P51805 +++ - Plexin-A3 
+ +  +  +  O43157 ++ - Plexin-B1 
+ +  +    O15031 ++++ - Plexin-B2 
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+ +  +    Q9Y4D7 ++++ - Plexin-D1 
 +  +    Q13563 ++ - Polycystin-2 
+   + + +  Q9UHG3 ++ +++ Prenylcysteine oxidase 1 
 +  +    P49768 +++ - Presenilin-1 
+    + +  P07602 - +++ Proactivator polypeptide 
 +  +    Q14439 +++ - Probable G-protein coupled receptor 176 
 +  +    Q9C0B5 ++ - Probable palmitoyltransferase ZDHHC5 
 +  +    Q9Y2G3 +++ - Probable phospholipid-transporting ATPase IF 
 +  +    Q8NB49 ++++ - Probable phospholipid-transporting ATPase IG 
 +  +    P98196 ++ - Probable phospholipid-transporting ATPase IH 
 +  +    Q9P241 ++ - Probable phospholipid-transporting ATPase VD 
+    + +  Q15113 ++ - Procollagen C-endopeptidase enhancer 1 
 +  +    Q9HCJ1 ++ - Progressive ankylosis protein homolog 
+   +  +  P12273 ++ - Prolactin-inducible protein 
+     + + Q32P28 - +++ Prolyl 3-hydroxylase 1 
 +  +    P43116 ++ - Prostaglandin E2 receptor EP2 subtype 
 +  +    Q8TCG1 + - Protein CIP2A 
+     +  O00622 + +++ Protein CYR61 
+   +  +  P07237 +++ ++++ Protein disulfide-isomerase 
+     +  Q92520 ++ ++ Protein FAM3C 
+ +  +  +  Q9ULI3 ++ - Protein HEG homolog 1 
 +  +    Q86UE4 ++ +++ Protein LYRIC 
 +  +    Q92508 +++ ++ Protein PIEZO1 
 +  +    Q9C0H2 +++ ++ Protein tweety homolog 3 
+   + + + + P41221 ++ - Protein Wnt-5a 
+   + + + + Q9H1J7 ++ - Protein Wnt-5b 
+ +  +  +  P25116 +++ - Proteinase-activated receptor 1 
+    + + + P28300 ++ - Protein-lysine 6-oxidase 
 +  +    Q04941 +++ - Proteolipid protein 2 
+ +  +    Q6V0I7 +++ - Protocadherin Fat 4 
+ +  +    Q9Y5H3 ++ - Protocadherin gamma-A10 
+ +  +    Q9Y5G0 +++ - Protocadherin gamma-B5 
+ +  +    Q9Y5F8 ++ - Protocadherin gamma-B7 
+ +  +    Q9UN70 ++++ - Protocadherin gamma-C3 
+ +  +    Q96JQ0 ++ - Protocadherin-16 
+ +  +    Q9HCL0 +++ - Protocadherin-18 
+ +  +    Q9HC56 ++ - Protocadherin-9 
+ +  +    Q68D85 + - Putative Ig-like domain-containing protein  
 +  +    Q9BSK0 +++ - Putative MARVEL domain-containing protein 1 
+ +  +    P18433 +++ - Receptor-type tyrosine-protein phosphatase alpha 
+ +  +    P10586 +++ - Receptor-type tyrosine-protein phosphatase F 
+ +  +    P23470 ++++ - Receptor-type tyrosine-protein phosphatase gamma 
+ +  +    Q15262 +++ - Receptor-type tyrosine-protein phosphatase kappa 
+ +  +    P28827 +++ - Receptor-type tyrosine-protein phosphatase mu 
+ +  +    Q13332 +++ - Receptor-type tyrosine-protein phosphatase S 
+ +  +    Q8IUW5 +++ - RELT-like protein 1 
+ +  +    O75787 ++ - Renin receptor 
 +  +    Q9NQC3 ++++ ++++ Reticulon-4 
+  + +    O95980 +++ - Reversion-inducing cysteine-rich protein with Kazal motifs 
+  + +    Q6NW40 +++ - RGM domain family member B 
 +  +    Q9HAB3 +++ - Riboflavin transporter 3 
+ +  +    Q9Y6N7 ++++ - Roundabout homolog 1 
+ +  +    Q9HCK4 +++ - Roundabout homolog 2 
 +  +    P16615 ++++ ++++ Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
+ +  + + +  Q8WVN6 ++ - Secreted and transmembrane protein 1 
+   + + + + Q8N474 ++ ++ Secreted frizzled-related protein 1 
 +  + + +  Q12884 ++++ +++ Seprase 
 +  +    Q9NRX5 ++ - Serine incorporator 1 
+    + +  Q92743 - ++ Serine protease HTRA1 
+   +  +  Q15165 ++ - Serum paraoxonase/arylesterase 2 
 +  +    Q99720 +++ ++ Sigma non-opioid intracellular receptor 1 
+ +  +    Q8TCT8 +++ - Signal peptide peptidase-like 2A 
+ +  +    Q8TCT7 ++ - Signal peptide peptidase-like 2B 
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 Table S.2 - continued:  non CD-marker cell surface proteins identified. 
SP TM GA PM ECS ECR ECM AccNo B T Name 
 
 +  +    P31641 +++ - Sodium- and chloride-dependent taurine transporter 
 +  +    Q9Y6M7 ++ - Sodium bicarbonate cotransporter 3 
+ +  +    P32418 +++ - Sodium/calcium exchanger 1 
 +  +    P19634 +++ - Sodium/hydrogen exchanger 1 
 +  +    Q92581 ++ - Sodium/hydrogen exchanger 6 
 +  +    P53794 ++ - Sodium/myo-inositol cotransporter 
 +  +    P05023 ++++ ++++ Sodium/potassium-transporting ATPase subunit alpha-1 
 +  +    P05026 ++++ - Sodium/potassium-transporting ATPase subunit beta-1 
 +  +    Q96QD8 +++ +++ Sodium-coupled neutral amino acid transporter 2 
 +  +    Q8WUX1 ++ - Sodium-coupled neutral amino acid transporter 5 
 +  +    Q9Y289 +++ - Sodium-dependent multivitamin transporter 
 +  +    Q8WUM9 ++ - Sodium-dependent phosphate transporter 1 
 +  +    Q08357 ++ - Sodium-dependent phosphate transporter 2 
 +  +    P55011 + - Solute carrier family 12 member 2 
 +  +    Q9UP95 +++ - Solute carrier family 12 member 4 
 +  +    Q9UHW9 ++ - Solute carrier family 12 member 6 
 +  +    Q9BXP2 ++ - Solute carrier family 12 member 9 
 +  +    P11166 ++++ +++ Solute carrier family 2, facilitated glucose transporter member 1 
 +  +    O95528 ++ - Solute carrier family 2, facilitated glucose transporter member 10 
 +  +    Q96BI1 ++ - Solute carrier family 22 member 18 
+ +  +    Q99523 ++ - Sortilin 
+    + + + P09486 ++ - SPARC 
 +  +    O15121 +++ - Sphingolipid delta(4)-desaturase DES1 
 +  +    O95136 ++ - Sphingosine 1-phosphate receptor 2 
 +  +    Q99500 ++ - Sphingosine 1-phosphate receptor 3 
+   + + +  P48061 + - Stromal cell-derived factor 1 
 +  +    P50443 ++ - Sulfate transporter 
+ +   + +  O00391 ++ - Sulfhydryl oxidase 1 
+ +  +  +  Q6ZRP7 + - Sulfhydryl oxidase 2 
 +  +    O43760 ++ - Synaptogyrin-2 
 +  +    Q16563 ++++ - Synaptophysin-like protein 1 
+ +  +  +  P31431 +++ - Syndecan-4 
 +  +    Q12846 +++ - Syntaxin-4 
 +  +    Q9UNK0 ++ ++ Syntaxin-8 
+ +    +  Q8TB96 ++ - T-cell immunomodulatory protein 
+    + + + P24821 - +++ Tenascin 
+     +  Q9Y6I9 ++ - Testis-expressed sequence 264 protein 
 +  +    O14817 ++ - Tetraspanin-4 
 +  +    O75954 +++ - Tetraspanin-9 
+ +  +    P36897 ++ - TGF-beta receptor type-1 
+ +  +    P37173 +++ - TGF-beta receptor type-2 
 +  +    Q9UKU6 +++ - Thyrotropin-releasing hormone-degrading ectoenzyme 
+ +  + + + + Q03167 +++ - Transforming growth factor beta receptor type 3 
+   + + + + Q15582 ++ +++ Transforming growth factor-beta-induced protein ig-h3 
 +  +    Q8TD43 ++ - Transient receptor potential cation channel subfamily M member 4 
 +  +    Q9Y5S1 +++ ++ Transient receptor potential cation channel subfamily V member 2 
+ +  +    Q99805 - ++ Transmembrane 9 superfamily member 2 
+ +  +    P49755 +++ +++ Transmembrane emp24 domain-containing protein 10 
 +  +  +  O14668 ++ - Transmembrane gamma-carboxyglutamic acid protein 1 
+ +  +    Q14956 ++ - Transmembrane glycoprotein NMB 
 +  +    Q86WV6 ++ ++ Transmembrane protein 173 
 +  +    Q9BQJ4 ++ - Transmembrane protein 47 
 +  +    Q96GC9 ++ - Transmembrane protein 49 
+ +  +    Q13641 ++++ ++ Trophoblast glycoprotein 
+ +  + + +  P30530 +++ ++ Tyrosine-protein kinase receptor UFO 
+ +  +    Q01973 ++ - Tyrosine-protein kinase transmembrane receptor ROR1 
+ +  +    Q13308 ++++ +++ Tyrosine-protein kinase-like 7 
+     +  Q969H8 - +++ UPF0556 protein C19orf10 
+ +    +  Q6EMK4 ++++ +++ Vasorin 
 +  +    P63027 +++ - Vesicle-associated membrane protein 2 
 +  +    Q15836 - +++ Vesicle-associated membrane protein 3 
 +  +    O95183 ++ - Vesicle-associated membrane protein 5 
 +  +    Q9P0L0 +++ +++ Vesicle-associated membrane protein-associated protein A 
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Table S.2 - continued:  non CD-marker cell surface proteins identified. 
SP TM GA PM ECS ECR ECM AccNo B T Name 
 
 +  +    P21796 +++ ++++ Voltage-dependent anion-selective channel protein 1 
+ +  +    P54289 ++++ +++ Voltage-dependent calcium channel subunit alpha-2/delta-1 
 +  +    Q93050 ++ - V-type proton ATPase 116 kDa subunit a isoform 1 
 +  +    Q13488 ++ +++ V-type proton ATPase 116 kDa subunit a isoform 3 
 +  +    Q92536 +++ - Y+L amino acid transporter 2 
 +  +    Q9Y6M5 +++ - Zinc transporter 1 
+ +  +    Q15043 +++ - Zinc transporter ZIP14 
+ +  +    Q13433 ++ - Zinc transporter ZIP6 
+   +  +  P25311 + - Zinc-alpha-2-glycoprotein 
 
 
Identified proteins were accepted as cell surface proteins if they are GPI-anchored (GA) or transmembrane proteins (TM) assigned to the 
plasma membrane (PM) or signal peptide-containing proteins (SP) that are assigned to either the extracellular space (ECS), region (ECR) or 
matrix (ECM) see listing S.1. SLIK2 and LRC15 are missing because they are not assigned to either PM, ECS, ECR or ECM. 
 
 
Listing S.1 : Boolean expression to create a list of and to filter for cell surface proteins  
 
organism:homo sapiens AND reviewed:yes  AND (( GO:0005886 AND (keyword:GPI-anchor OR 
annotation:(type:transmem count:[1 TO *])) ) OR ((GO:0005615 OR GO:0005576 OR GO:0031012) AND 
annotation:(type:signal peptide))) 
 
4508 matches in Uniprot (Version 2011_01). GO:0005886 - plasma membrane – PM, GO:0005615 - extracellular space – ECS, GO:0005576 
- extracellular region – ECR, GO:0031012 - extracellular matrix  - ECM 
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Table S.3:  Proteins recruited with gE on PI4P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
P58871 TB182 +++ + +++ 182 kDa tankyrase-1-binding protein 
Q9Z1B3 PLCB1 +++ ++ ++++ 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-1 
P51432 PLCB3 ++ ++ ++++ 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-3 
P70290 EM55 ++ + ++++ 55 kDa erythrocyte membrane protein 
O54950 AAKG1 + ++ ++ 5-AMP-activated protein kinase subunit gamma-1 
P70265 F262 ++ + +++ 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 
P61211 ARL1 ++ + +++ ADP-ribosylation factor-like protein 1 
Q9WUL7 ARL3 ++ + ++ ADP-ribosylation factor-like protein 3 
O88848 ARL6 +++ + ++++ ADP-ribosylation factor-like protein 6 
Q80WT5 AFTIN ++ ++ ++ Aftiphilin 
Q8R5F3 CF130 ++ ++ ++ AI314976 protein 
Q8K341 ATAT ++ + +++ Alpha-tubulin N-acetyltransferase 
Q7TQF7 AMPH ++ + +++ Amphiphysin 
B2RW11 B2RW11 ++ + +++ Ankyrin repeat domain 34A 
Q8CC13 AP1B1 +++ ++ ++++ AP-1 complex subunit beta-1 
P22892 AP1G1 +++ + +++ AP-1 complex subunit gamma-1 
P35585 AP1M1 +++ + ++ AP-1 complex subunit mu-1 
P61967 AP1S1 ++ ++ +++ AP-1 complex subunit sigma-1A 
Q9DB50 AP1S2 ++ ++ +++ AP-1 complex subunit sigma-2 
P17426 AP2A1 +++ + +++ AP-2 complex subunit alpha-1 
P17427 AP2A2 +++ ++ ++++ AP-2 complex subunit alpha-2 
P84091 AP2M1 +++ ++ ++++ AP-2 complex subunit mu 
P62743 AP2S1 +++ ++ +++ AP-2 complex subunit sigma 
Q3UHJ0 AAK1 ++ ++ +++ AP2-associated protein kinase 1 
Q8VHH5 AGAP3 ++ + +++ Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3 
Q9Z2A5 ATE1 ++ ++ +++ Arginyl-tRNA--protein transferase 1 
Q9D7A8 ARMC1 ++ ++ +++ Armadillo repeat-containing protein 1 
Q6P542 ABCF1 ++ ++ +++ ATP-binding cassette sub-family F member 1 
Q91VR5 DDX1 +++ ++ +++ ATP-dependent RNA helicase DDX1 
Q62167 DDX3X ++ + ++ ATP-dependent RNA helicase DDX3X 
Q9Z2H5 E41L1 +++ + ++ Band 4.1-like protein 1 
P62204 CALM ++ ++ ++ Calmodulin 
Q3UHL1 CAMKV +++ + +++ CaM kinase-like vesicle-associated protein 
Q9Z0H8 CLIP2 ++ + +++ CAP-Gly domain-containing linker protein 2 
Q9DBC3 MTR1 ++ + +++ Cap-specific mRNA (nucleoside-2-O-)-methyltransferase 1 
Q8BK63 KC1A ++ ++ ++++ Casein kinase I isoform alpha 
Q9JMK2 KC1E ++ ++ ++ Casein kinase I isoform epsilon 
Q8BHE3 ATCAY +++ + ++++ Caytaxin 
Q5M8N0 CNRP1 ++ + +++ CB1 cannabinoid receptor-interacting protein 1 
Q8BI72 CARF ++ ++ +++ CDKN2A-interacting protein 
Q9JKY0 RCD1 ++ ++ ++++ Cell differentiation protein RCD1 homolog 
Q6A068 CDC5L ++ ++ +++ Cell division cycle 5-related protein 
Q6A065 CE170 ++ ++ +++ Centrosomal protein of 170 kDa 
Q8R1T1 CHMP7 + + ++ Charged multivesicular body protein 7 
Q61548 AP180 +++ ++ ++++ Clathrin coat assembly protein AP180 
Q68FD5 CLH +++ ++ ++++ Clathrin, heavy polypeptide (Hc) 
Q9CQF3 CPSF5 ++ ++ +++ Cleavage and polyadenylation specificity factor subunit 5 
Q8K1A6 C2D1A ++ + +++ Coiled-coil and C2 domain-containing protein 1A 
Q9EQG9 C43BP ++ ++ +++ Collagen type IV alpha-3-binding protein 
Q9WUM4 COR1C ++ ++ +++ Coronin-1C 
P45481 CBP ++ ++ +++ CREB-binding protein 
Q9D5V5 CUL5 + + ++ Cullin 5 
O35495 CDK14 + ++ ++ Cyclin-dependent kinase 14 
P97315 CSRP1 ++ ++ +++ Cysteine and glycine-rich protein 1 
P63254 CRIP1 ++ ++ ++ Cysteine-rich protein 1 
Q9DCT8 CRIP2 +++ ++ +++ Cysteine-rich protein 2 
P63034 CYH2 ++ + ++ Cytohesin-2 
Q8K4R4 PITC1 +++ ++ +++ Cytoplasmic phosphatidylinositol transfer protein 1 
A2AGT5 CKAP5 +++ ++ +++ Cytoskeleton-associated protein 5 
Q61656 DDX5 ++ ++ +++ DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
A2RSQ0 DEN5B ++ + +++ DENN domain-containing protein 5B 
Q9D9Z5 DDA1 ++ ++ +++ DET1- and DDB1-associated protein 1 
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Table S.3 - continued:  Proteins recruited with gE on PI4P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
P32233 DRG1 ++ ++ +++ Developmentally-regulated GTP-binding protein 1 
Q9QXB9 DRG2 ++ + +++ Developmentally-regulated GTP-binding protein 2 
Q6P5E8 DGKQ ++ +++ ++ Diacylglycerol kinase theta 
B7ZMZ7 B7ZMZ7 ++ + +++ Dip2c protein 
Q8BWT5 DIP2A +++ ++ ++++ Disco-interacting protein 2 homolog A 
Q3UH60 DIP2B +++ ++ +++ Disco-interacting protein 2 homolog B 
Q811D0 DLG1 ++ + ++ Disks large homolog 1 
P07903 ERCC1 + ++ ++ DNA excision repair protein ERCC-1 
P52431 DPOD1 + + ++ DNA polymerase delta catalytic subunit 
P28352 APEX1 ++ ++ +++ DNA-(apurinic or apyrimidinic site) lyase 
Q8C7M3 TRIM9 ++ + +++ E3 ubiquitin-protein ligase TRIM9 
Q80TA9 EPG5 ++ + ++ Ectopic P granules protein 5 homolog 
P62631 EF1A2 +++ + +++ Elongation factor 1-alpha 2 
P42567 EPS15 ++ ++ ++++ Epidermal growth factor receptor substrate 15 
Q60902 EP15R ++ ++ +++ Epidermal growth factor receptor substrate 15-like 1 
Q8C460 ERI3 ++ ++ ++ ERI1 exoribonuclease 3 
Q6ZWX6 IF2A ++ ++ +++ Eukaryotic translation initiation factor 2 subunit 1 
Q99L45 IF2B ++ ++ +++ Eukaryotic translation initiation factor 2 subunit 2 
Q9Z0N1 IF2G ++ ++ +++ Eukaryotic translation initiation factor 2 subunit 3, X-linked 
Q6NZJ6 IF4G1 ++ + +++ Eukaryotic translation initiation factor 4 gamma 1 
P59325 IF5 + + ++ Eukaryotic translation initiation factor 5 
Q61545 EWS ++ +++ +++ Ewing sarcoma breakpoint region 1 
Q8CIB5 FERM2 ++ ++ +++ Fermitin family homolog 2 
Q7TPM6 FSD1 ++ + ++ Fibronectin type III and SPRY domain-containing protein 1 
Q9ESZ8 GTF2I ++ + ++ General transcription factor II-I 
P48318 DCE1 ++ + ++ Glutamate decarboxylase 1 
P26443 DHE3 +++ ++ +++ Glutamate dehydrogenase 1, mitochondrial 
Q9WV60 GSK3B +++ + +++ Glycogen synthase kinase-3 beta 
Q8BS40 GLTD1 ++ ++ +++ Glycolipid transfer protein domain-containing protein 1 
Q8BW56 GTDC1 + ++ +++ Glycosyltransferase-like domain-containing protein 1 
O70311 NMT2 ++ + +++ Glycylpeptide N-tetradecanoyltransferase 2 
Q60780 GAS7 +++ +++ ++++ Growth arrest-specific protein 7 
Q9JLM9 GRB14 + ++ ++ Growth factor receptor-bound protein 14 
O08582 GTPB1 ++ ++ +++ GTP-binding protein 1 
P36916 GNL1 ++ + +++ Guanine nucleotide-binding protein-like 1 
Q8C547 HTR5B ++ + ++ HEAT repeat-containing protein 5B 
Q9R257 HEBP1 ++ ++ +++ Heme-binding protein 1 
Q921F4 HNRLL ++ ++ ++++ Heterogeneous nuclear ribonucleoprotein L-like 
Q8VEK3 HNRPU ++ + ++ Heterogeneous nuclear ribonucleoprotein U 
P63158 HMGB1 +++ +++ +++ High mobility group protein B1 
P70288 HDAC2 ++ + +++ Histone deacetylase 2 
Q6GSS7 H2A2A ++ ++ ++ Histone H2A type 2-A 
Q9Z0R4 ITSN1 +++ ++ +++ Intersectin-1 
Q9DBG3 AP2B1 +++ ++ +++ Isoform 2 of AP-2 complex subunit beta 
Q7TQH0 ATX2L + + +++ Isoform 2 of Ataxin-2-like protein 
Q8BKX1 BAIP2 +++ + +++ Isoform 2 of Brain-specific angiogenesis inhibitor 1-associated protein 2 
Q6ZQ08 CNOT1 ++ + +++ Isoform 2 of CCR4-NOT transcription complex subunit 1 
Q61211 EIF2D + ++ ++ Isoform 2 of Eukaryotic translation initiation factor 2D 
Q99M31 HSP7E + ++ ++ Isoform 2 of Heat shock 70 kDa protein 14 
Q8CGP2 H2B1P ++ ++ +++ Isoform 2 of Histone H2B type 1-P 
Q5DU31 ICEF1 ++ + ++ Isoform 2 of Interactor protein for cytohesin exchange factors 1 
Q3V3V9 LR16C ++ ++ ++++ Isoform 2 of Leucine-rich repeat-containing protein 16C 
Q5SUF2 LC7L3 ++ ++ ++ Isoform 2 of Luc7-like protein 3 
Q9DB27 MCTS1 ++ ++ +++ Isoform 2 of Malignant T cell-amplified sequence 1 
Q9D868 PPIH + ++ ++ Isoform 2 of Peptidyl-prolyl cis-trans isomerase H 
Q6ZWR4 2ABB + ++ +++ Isoform 2 of Serine/threonine-protein phosphatase 2A 55 kDa reg.… 
P53996 CNBP ++ ++ +++ Isoform 3 of Cellular nucleic acid-binding protein 
Q9JM52 MINK1 ++ ++ ++ Isoform 3 of Misshapen-like kinase 1 
Q80TZ3 AUXI ++ ++ +++ Isoform 3 of Putative tyrosine-protein phosphatase auxilin 
Q9JLB0 MPP6 ++ + +++ Isoform Alpha of MAGUK p55 subfamily member 6 
P10637 TAU +++ ++++ ++++ Isoform Tau-B of Microtubule-associated protein tau 
Q9CR30 JOS2 ++ ++ +++ Josephin-2 
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Table S.3 - continued:  Proteins recruited with gE on PI4P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
Q8K0T4 KATL1 ++ ++ +++ Katanin p60 ATPase-containing subunit A-like 1 
F7A5U9 F7A5U9 ++ ++ ++ Kelch-like protein 3 
Q60749 KHDR1 ++ ++ +++ KH domain-containing, RNA-binding, signal transduction-ass. protein 1 
Q9DBS5 KLC4 + ++ ++ Kinesin light chain 4 
Q9QXL2 KI21A +++ ++ +++ Kinesin-like protein KIF21A 
P28740 KIF2A +++ + +++ Kinesin-like protein KIF2A 
Q6TA13 Q6TA13 ++ ++ +++ Kinesin-related microtuble-based motor protein 
O89112 LANC1 ++ + ++ LanC-like protein 1 
Q505F5 LRC47 ++ ++ ++++ Leucine-rich repeat-containing protein 47 
Q61792 LASP1 ++ + +++ LIM and SH3 domain protein 1 
P32067 LA +++ ++ +++ Lupus La protein homolog 
Q3UYG8 MACD2 + ++ ++ MACRO domain-containing protein 2 
Q14BB9 MA6D1 +++ ++ +++ MAP6 domain-containing protein 1 
A2AJI0 MA7D1 +++ ++ +++ MAP7 domain-containing protein 1 
A2AG50 MA7D2 +++ ++ +++ MAP7 domain-containing protein 2 
O54879 HMGB3 ++ ++ +++ MCG114640 
Q9CR80 FA32A ++ ++ ++ MCG125076 
Q9D883 U2AF1 ++ ++ ++ MCG14259, isoform CRA_b 
Q80TK0 K1107 +++ +++ +++ MCG19133, isoform CRA_b 
G3X9K3 G3X9K3 +++ + ++ MCG8317 
Q8K4B0 MTA1 ++ ++ ++ Metastasis-associated protein MTA1 
Q9R190 MTA2 ++ + +++ Metastasis-associated protein MTA2 
Q9CQG2 MET16 ++ ++ ++ Methyltransferase 10 domain containing 
P10637 TAU +++ ++ ++++ Microtubule-associated protein 
E9PZ43 E9PZ43 ++ ++ ++++ Microtubule-associated protein 
G3UZJ2 G3UZJ2 ++ ++ +++ Microtubule-associated protein (Fragment) 
Q9QYR6 MAP1A +++ ++ +++ Microtubule-associated protein 1 A 
Q8C052 MAP1S ++ ++ +++ Microtubule-associated protein 1S 
P20357 MAP2 ++++ ++ +++ Microtubule-associated protein 2 
P27546 MAP4 +++ ++ ++++ Microtubule-associated protein 4 
Q7TSJ2 MAP6 ++++ ++ +++ Microtubule-associated protein 6 
O88735 MAP7 ++ ++ +++ Microtubule-associated protein 7, isoform CRA_b 
Q61166 MARE1 ++ + +++ Microtubule-associated protein RP/EB family member 1 
Q6PER3 MARE3 +++ + +++ Microtubule-associated protein RP/EB family member 3 
Q91VR7 MLP3A ++ ++ ++ Microtubule-associated proteins 1A/1B light chain 3A 
Q9CYG7 TOM34 +++ + +++ Mitochondrial import receptor subunit TOM34 
Q8BPM2 M4K5 ++ + ++ Mitogen-activated protein kinase kinase kinase kinase 5 
Q9WVA3 BUB3 ++ + +++ Mitotic checkpoint protein BUB3 
O08539 BIN1 +++ ++ +++ Myc box-dependent-interacting protein 1 
Q80TA6 MTMRC + ++ ++ Myotubularin-related protein 12 
Q99KK2 NEUA +++ ++ +++ N-acylneuraminate cytidylyltransferase 
Q8BG30 NELFA + ++ ++ Negative elongation factor A 
Q8C4Y3 NELFB + ++ +++ Negative elongation factor B 
Q6ZWR6 SYNE1 ++ ++ ++ Nesprin-1 
Q6ZWQ0 SYNE2 +++ ++++ +++ Nesprin-2 
Q8K4Q0 RPTOR ++ + +++ Novel protein containing six WD40 domains at C-terminus 
Q9JJR9 NRIP3 ++ ++ +++ Nrip3 protein 
P97863 NFIB ++ ++ ++ Nuclear factor 1 B-type 
O08919 NUMBL ++ + +++ Numb-like protein 
Q8CI95 OSB11 ++ + +++ Oxysterol binding protein-like 11 
Q3B7Z2 OSBP1 +++ ++ +++ Oxysterol-binding protein 
Q91XL9 OSBL1 +++ ++ +++ Oxysterol-binding protein-related protein 1 
Q8R326 PSPC1 ++ ++ +++ Paraspeckle component 1 
Q99JF8 PSIP1 ++ ++ +++ PC4 and SFRS1-interacting protein 
Q9JMD3 PCTL ++ +++ +++ PCTP-like protein 
Q9D0W5 PPIL1 + ++ ++ Peptidyl-prolyl cis-trans isomerase-like 1 
Q2PFD7 PSD3 +++ ++ +++ PH and SEC7 domain-containing protein 3 
P59644 PI5PA ++ + ++ Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A 
P53810 PIPNA ++ ++ +++ Phosphatidylinositol transfer protein alpha isoform 
Q7M6Y3 PICA ++ ++ +++ Phosphatidylinositol-binding clathrin assembly protein 
Q3V3Q7 PACS2 ++ + +++ Phosphofurin acidic cluster sorting protein 2 
P53811 PIPNB ++ ++ +++ Pitpnb protein 
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Table S.3 - continued:  Proteins recruited with gE on PI4P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
Q922V4 PLRG1 ++ ++ +++ Pleiotropic regulator 1 
P11103 PARP1 ++ ++ +++ Poly (ADP-ribose) polymerase family, member 1 
O54724 PTRF + ++ ++ Polymerase I and transcript release factor 
Q99KP6 PRP19 +++ ++ ++++ Pre-mRNA-processing factor 19 
Q9D287 SPF27 ++ ++ +++ Pre-mRNA-splicing factor SPF27 
Q3TSG4 ALKB5 ++ ++ ++ Probable alpha-ketoglutarate-dependent dioxygenase ABH5 
P54823 DDX6 +++ ++ +++ Probable ATP-dependent RNA helicase DDX6 
Q8BWU5 OSGEP ++ +++ ++ Probable tRNA threonylcarbamoyladenosine biosynthesis protein Osgep 
E9PV26 E9PV26 ++ +++ ++ Protein BC068157 
Q6PGH1 BUD31 + ++ ++ Protein BUD31 homolog 
Q924A2 CIC ++ ++ +++ Protein capicua homolog 
Q7TNV0 DEK ++ ++ +++ Protein DEK 
E9PUQ8 E9PUQ8 ++ + ++ Protein Dgkd  
D3YXJ0 D3YXJ0 ++ + +++ Protein Dgkh 
D3YWQ0 D3YWQ0 ++ + +++ Protein Dgki 
E9PV14 E9PV14 ++ + +++ Protein Epb4.1l1 
Q78T81 F102A ++ ++ +++ Protein FAM102A 
Q8BJH1 F164A +++ +++ ++++ Protein FAM164A 
Q8BHZ0 FA49A +++ + +++ Protein FAM49A 
Q80VD1 FA98B ++ ++ +++ Protein FAM98B 
E9PYD1 E9PYD1 ++ ++ +++ Protein Fam98c 
E9PVA8 E9PVA8 +++ + ++ Protein Gcn1l1 
P28867 KPCD ++ + ++++ Protein kinase C delta type 
Q9D0R8 LSM12 ++ ++ +++ Protein LSM12 homolog 
Q8K2F8 LS14A ++ ++ +++ Protein LSM14 homolog A 
Q8CGC4 LS14B ++ + ++ Protein LSM14 homolog B 
Q9QZS3 NUMB ++ + ++ Protein numb homolog 
Q60829 PPR1B ++ ++ ++ Protein phosphatase 1 regulatory subunit 1B 
Q7TSC1 PRC2A ++ ++ ++ Protein PRRC2A 
Q3TLH4 E9QKG5 ++ ++ +++ Protein PRRC2C 
E9PZZ8 E9PZZ8 +++ + +++ Protein Rap1gap 
Q8BK67 RCC2 ++ ++ ++++ Protein RCC2 
P31725 S10A9 ++ ++ ++ Protein S100-A9 
Q8BX57 PXK ++ ++ ++++ PX domain-containing protein kinase-like protein 
A2ALS7 A2ALS7 ++ + +++ Rap1 GTPase-activating protein (Fragment) 
Q5SVL6 RPGP2 ++ ++ +++ Rap1 GTPase-activating protein 2 
Q921Q7 RIN1 ++ + ++ Ras and Rab interactor 1 
Q60790 RASA3 ++ + +++ Ras GTPase-activating protein 3 
Q9JKF1 IQGA1 ++ ++ +++ Ras GTPase-activating-like protein IQGAP1 
Q9QUG9 GRP2 + + ++ RAS guanyl-releasing protein 2 
Q80U57 RIMS3 + ++ ++ Regulating synaptic membrane exocytosis protein 3 
Q9DC04 RGS3 ++ + ++ Regulator of G-protein signaling 3 
Q5SSM3 RHG44 +++ + ++++ Rho GTPase-activating protein 44 
P70335 ROCK1 ++ + +++ Rho-associated protein kinase 1 
P70336 ROCK2 +++ + +++ Rho-associated protein kinase 2 
Q14BI8 Q14BI8 ++ ++ +++ Rltpr protein 
Q6NZN0 RBM26 ++ ++ +++ RNA-binding protein 26 
P56959 FUS ++ ++ ++ RNA-binding protein FUS 
Q9JLC8 SACS ++ + ++ Sacsin 
Q9JHW4 SELB + ++ ++ Selenocysteine-specific elongation factor 
Q3UQA7 SELH ++ +++ ++ Selenoprotein H 
P29621 SPA3C ++ ++ ++ Serine protease inhibitor A3C 
P84104 SRSF3 ++ ++ +++ Serine/arginine-rich splicing factor 3 
Q8QZV4 ST32C ++ ++ +++ Serine/threonine-protein kinase 32C 
P28028 BRAF ++ + +++ Serine/threonine-protein kinase B-raf 
Q9JLM8 DCLK1 +++ ++ +++ Serine/threonine-protein kinase DCLK1 
Q9CZ91 SRFB1 + ++ +++ Serum response factor-binding protein 1 
Q6A026 PDS5A ++ ++ +++ Sister chromatid cohesion protein PDS5 homolog A 
Q4VA53 PDS5B ++ +++ +++ Sister chromatid cohesion protein PDS5 homolog B 
Q9CSN1 SNW1 ++ ++ +++ SNW domain-containing protein 1 
Q6NZD2 Q6NZD2 +++ ++ +++ Sorting nexin 1 
Q91ZR2 SNX18 ++ ++ +++ Sorting nexin 18 
 
continued on next page 
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Table S.3 - continued:  Proteins recruited with gE on PI4P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
Q9CWK8 SNX2 +++ +++ ++++ Sorting nexin-2 
Q3UHD6 SNX27 ++ + +++ Sorting nexin-27 
Q8CE50 SNX30 ++ ++ +++ Sorting nexin-30 
Q91YJ2 SNX4 +++ + +++ Sorting nexin-4 
Q9D8U8 SNX5 +++ +++ +++ Sorting nexin-5 
Q6P8X1 SNX6 +++ +++ +++ Sorting nexin-6 
Q9QYY8 SPAST ++ ++ +++ Spastin 
Q8VIJ6 SFPQ ++ ++ +++ Splicing factor, proline- and glutamine-rich 
Q91VZ6 SMAP1 ++ ++ +++ Stromal membrane-associated protein 1 
Q6P5D8 SMHD1 ++ ++ +++ Structural maintenance of chromosomes flexible hinge domain-con…. 
Q8BGT7 SPF30 + ++ ++ Survival of motor neuron-related-splicing factor 30 
Q6PDG5 SMRC2 + + +++ SWI/SNF complex subunit SMARCC2 
Q8BJL0 SMAL1 ++ + +++ SWI/SNF-related matrix-associated actin-dependent regulator of chroma…. 
O88935 SYN1 +++ ++ +++ Synapsin-1 
Q64332 SYN2 +++ + +++ Synapsin-2 
Q8JZP2 SYN3 ++ + +++ Synapsin-3 
Q80TB8 VAT1L +++ ++ ++++ Synaptic vesicle membrane protein VAT-1 homolog-like 
Q8CHC4 SYNJ1 +++ ++ ++++ Synaptojanin-1 
Q8R3T5 STXB6 ++ + +++ Syntaxin binding protein 6 (Amisyn) 
P62340 TBPL1 ++ +++ +++ TATA box-binding protein-like protein 1 
Q6PCN3 TTBK1 ++ ++ +++ Tau-tubulin kinase 1 
Q8BYJ6 TBCD4 ++ + +++ TBC1 domain family member 4 
Q5SSZ5 TENS3 ++ ++ ++++ Tensin-3 
Q8VD63 TSYL4 ++ ++ +++ Testis-specific Y-encoded-like protein 4 
Q8BYY4 TT39B ++ ++ ++ Tetratricopeptide repeat protein 39B 
P97770 THUM3 + ++ ++ THUMP domain-containing protein 3 
Q9ES56 TPPC4 ++ + ++ Trafficking protein particle complex subunit 4 
Q8CGF7 TCRG1 ++ + +++ Transcription elongation regulator 1 
Q9ESN6 TRIM2 ++ ++ +++ Tripartite motif-containing protein 2 
Q9R1R2 TRIM3 ++ ++ +++ Tripartite motif-containing protein 3 
Q99LF4 RTCB +++ ++ ++++ tRNA-splicing ligase RtcB homolog 
Q7TQD2 TPPP +++ +++ +++ Tubulin polymerization-promoting protein 
D3Z230 D3Z230 ++ + ++ Type I inositol 3,4-bisphosphate 4-phosphatase 
Q91WQ3 SYYC ++ ++ ++++ Tyrosyl-tRNA synthetase 
Q922U1 PRPF3 ++ ++ +++ U4/U6 small nuclear ribonucleoprotein Prp3 
Q8CCF0 PRP31 ++ ++ ++++ U4/U6 small nuclear ribonucleoprotein Prp31 
Q9DAW6 PRP4 ++ ++ +++ U4/U6 small nuclear ribonucleoprotein Prp4 
Q3TIX9 SNUT2 ++ +++ +++ U4/U6.U5 tri-snRNP-associated protein 2 
F8VPZ3 F8VPZ3 ++ ++ ++ Ubiquitin carboxyl-terminal hydrolase 
Q99PL6 UBXN6 ++ + +++ UBX domain-containing protein 6 
E9QB05 E9QB05 ++ ++ +++ Uncharacterized protein 
E9QMW6 E9QMW6 ++ ++ ++ Uncharacterized protein 
Q9D735 CS043 ++ ++ ++ Uncharacterized protein C19orf43 homolog 
Q9CQE8 CN166 ++ ++ ++ UPF0568 protein C14orf166 homolog 
Q9CWN7 CB029 + + ++ UPF0760 protein C2orf29 homolog 
A2AT37 A2AT37 ++ ++ +++ UPF2 regulator of nonsense transcripts homolog (Yeast) 
Q3ULL6 Q3ULL6 ++ ++ ++ UPF3 regulator of nonsense transcripts homolog B 
Q8VDJ3 VIGLN ++ ++ ++++ Vigilin 
Q3UMB9 WASH7 + ++ ++ WASH complex subunit 7 
Q8C2E7 STRUM + ++ ++ WASH complex subunit strumpellin 
Q8BH57 WDR48 ++ + ++ WD repeat-containing protein 48 
Q3TIV5 ZC3HF ++ ++ ++ Zinc finger CCCH domain-containing protein 15 
 
Abundance - averaged log2(LFQ)-values of the gE-triplicates, classified as below 18 and between 18 to 23, 23 to 
28, 28 to 33 and above 33; Ratio - log2-t-test differences, classified as below 1 and between 1 to 3, 3 to 6, 6 to 
9 and above 9; Significance – -log10(p-value),  classified as below 1 and between 1 to 2, 2 to 4, 4 to 6 and above 
6; all classes were accordingly labeled as: -, +, ++, +++, ++++. The t-test threshold value was hereby set to 1.2% 
and the slope value to 0.2. 
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Table S.4:  Proteins recruited with Crb on PI3P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
Q9Z1B3 PLCB1 +++ + ++ 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-1 
Q99J27 ACATN ++ + ++ Acetyl-coenzyme A transporter 1 
Q91VR5 DDX1 ++ + +++ ATP-dependent RNA helicase DDX1 
Q9WV92 E41L3 ++ - ++ Band 4.1-like protein 3 
Q8CCN5 BCAS3 +++ + +++ Breast carcinoma-amplified sequence 3 homolog 
Q9WTR5 CAD13 + + ++ Cadherin-13 
Q8BGD5 CPT1C ++ + ++ Carnitine O-palmitoyltransferase 1, brain isoform 
Q6IRU5 CLCB ++ ++ ++ Clathrin light chain B 
B1AWD9 B1AWD9 ++ ++ ++ Clathrin light polypeptide (Lca) 
Q68FD5 CLH +++ ++ +++ Clathrin, heavy polypeptide (Hc) 
Q8BXA5 CLP1L ++ + ++ Cleft lip and palate transmembrane protein 1-like protein 
O55029 COPB2 ++ + ++ Coatomer subunit beta 
Q9QZE5 COPG ++ + ++ Coatomer subunit gamma 
Q9QXK3 COPG2 + + ++ Coatomer subunit gamma-2 
Q9D024 CC47 + + ++ Coiled-coil domain-containing protein 47 
Q80YA8 CRUM2 ++++ +++ ++ Crumbs homolog 2 
Q811D0 DLG1 ++ + +++ Disks large homolog 1 
Q9DC23 DJC10 ++ + ++ DnaJ homolog subfamily C member 10 
Q3TDQ1 STT3B ++ + ++ Dolichyl-diphosphooligosaccharide—protein glycosyltransferase sub. STT3B 
Q8CCJ3 UFL1 ++ + ++ E3 UFM1-protein ligase 1 
Q8BL66 EEA1 +++ ++ +++ Early endosome antigen 1 
Q60900 ELAV3 +++ ++++ +++ ELAV-like protein 3 
Q8VHI3 OFUT2 + + ++ GDP-fucose protein O-fucosyltransferase 2 
O08795 GLU2B ++ + ++ Glucosidase 2 subunit beta (Isoform 2) 
Q99JX3 GORS2 ++ ++ +++ Golgi reassembly-stacking protein 2 
Q3UUQ7 PGAP1 ++ + ++ GPI inositol-deacylase 
P07901 HS90A ++ - ++ Heat shock protein HSP 90-alpha 
P11499 HS90B +++ - ++ Heat shock protein HSP 90-beta 
Q9QUJ7 ACSL4 ++ + ++ Long-chain-fatty-acid--CoA ligase 4 
Q99PU5 ACBG1 ++ + ++ Long-chain-fatty-acid--CoA ligase ACSBG1 
Q9JLB2 MPP5 ++ ++ ++ MAGUK p55 subfamily member 5 
Q80UM7 MOGS ++ + ++ Mannosyl-oligosaccharide glucosidase 
G3X922 G3X922 +++ + ++ MCG115602 
A2A8R0 A2A8R0 ++ + ++ MCG17975 
Q9QYR6 MAP1A ++ + ++ Microtubule-associated protein 1 A 
P35282 RAB21 +++ + ++ MKIAA0118 protein (Fragment) 
Q62074 KPCI ++ ++ ++ MKIAA4165 protein (Fragment) 
Q9Z2L6 MINP1 + + + Multiple inositol polyphosphate phosphatase 1 
Q8VBX6 MPDZ ++ ++ ++ Multiple PDZ domain protein 
Q6ZWR6 SYNE1 ++ +++ ++ Nesprin-1 
Q62443 NPTX1 + + ++ Neuronal pentraxin-1 
Q9DBG5 PLIN3 + + ++ Perilipin-3 
Q9Z2G6 SE1L1 ++ + ++ Protein sel-1 homolog 1 
P53994 RAB2A +++ + ++ Ras-related protein Rab-2A 
P35278 RAB5C +++ + ++ Ras-related protein Rab-5C 
E9Q401 E9Q401 +++ + ++ Ryanodine receptor 2 
Q3URD3 SLMAP ++ + ++ Sarcolemmal membrane-associated protein 
Q9R118 HTRA1 + ++ +++ Serine protease HTRA1 
Q9JLM8 DCLK1 ++ + ++ Serine/threonine-protein kinase DCLK1 
Q5F2E8 TAOK1 ++ + ++ Serine/threonine-protein kinase TAO1 
Q6NZD2 Q6NZD2 +++ + ++ Sorting nexin 1 
O70493 SNX12 +++ ++ +++ Sorting nexin 12 
O70492 SNX3 +++ ++ +++ Sorting nexin 3 
Q91WE1 SNX15 ++ ++ ++ Sorting nexin-15 
Q8C080 SNX16 ++ ++ +++ Sorting nexin-16 
Q8BVL3 SNX17 + + ++ Sorting nexin-17 
Q9CWK8 SNX2 +++ - ++ Sorting nexin-2 
Q3UHD6 SNX27 +++ +++ ++ Sorting nexin-27 
Q8CE50 SNX30 +++ + +++ Sorting nexin-30 
Q9D8U8 SNX5 ++ + ++ Sorting nexin-5 
Q8CFD4 SNX8 ++ ++ ++ Sorting nexin-8 
P58404 STRN4 ++ + ++ Striatin-4 
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Table S.4 - continued:  Proteins recruited with Crb on PI3P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
P70302 STIM1 ++ + ++ Stromal interaction molecule 1 
Q9Z1F9 SAE2 ++ + ++ SUMO-activating enzyme subunit 2 
Q9JIS5 SV2A ++ + ++ Synaptic vesicle glycoprotein 2A 
Q99KW9 TIP ++ + ++ T-cell immunomodulatory protein 
Q80W04 TMCC2 ++ + ++ Transmembrane and coiled-coil domains protein 2 
G3X9Y5 G3X9Y5 + + ++ Ubiquitination factor E4A, UFD2 homolog (S. cerevisiae) 
F6R441 F6R441 + + ++ Uncharacterized protein (Fragment) 
Q3UE31 K0930 + ++ ++ Uncharacterized protein KIAA0930 homolog 
Q922R1 CP070 ++ + ++ UPF0183 protein C16orf70 homolog 
P40336 VP26A ++ +++ ++++ Vacuolar protein sorting-associated protein 26A 
Q8C0E2 VP26B +++ +++ +++ Vacuolar protein sorting-associated protein 26B 
Q9QZ88 VPS29 ++ +++ +++ Vacuolar protein sorting-associated protein 29 
Q9EQH3 VPS35 +++ ++++ +++ Vacuolar protein sorting-associated protein 35 
P97390 VPS45 ++ ++ ++ Vacuolar protein sorting-associated protein 45 
Q60930 VDAC2 +++ + ++ Voltage-dependent anion-selective channel protein 2 
Q3UMB9 WASH7 + + ++ WASH complex subunit 7 
Q6PGL7 FAM21 ++ +++ ++ WASH complex subunit FAM21 
Q8R3E3 WIPI1 ++ +++ +++ WD repeat domain phosphoinositide-interacting protein 1 
Q80W47 WIPI2 +++ ++ +++ WD repeat domain phosphoinositide-interacting protein 2 
Q9CR39 WIPI3 +++ ++ +++ WD repeat domain phosphoinositide-interacting protein 3 
 
Abundance - averaged log2(LFQ)-values of the Crb-triplicates, classified as below 18 and between 18 to 23, 23 
to 28, 28 to 33 and above 33; Ratio - log2-t-test differences, classified as below 1 and between 1 to 3, 3 to 6, 6 
to 9 and above 9; Significance – -log10(p-value),  classified as below 1 and between 1 to 2, 2 to 4, 4 to 6 and 
above 6; all classes were accordingly labeled as: -, +, ++, +++, ++++. The t-test threshold value was hereby set 
to 1.2% and the slope value to 0.2. 
 
 
 
Table S.5:  Sorting nexins recruited on bare PI3P- with respect to  PI4P-containing liposomes. 
AccNo AccStr Abundance Ratio Significance Name 
 
Q6NZD2 Q6NZD2 +++ +++ +++ Sorting nexin-1 
Q9CWK8 SNX2 +++ +++ +++ Sorting nexin-2 
O70492 SNX3 ++ ++ ++ Sorting nexin-3 
Q91YJ2 SNX4 +++ + ++ Sorting nexin-4 
Q9D8U8 SNX5 ++ ++ ++ Sorting nexin-5 
Q6P8X1 SNX6 +++ +++ +++ Sorting nexin-6 
Q9CY18 SNX7 ++ +++ ++ Sorting nexin-7 
Q91VH2 SNX9 ++ ++ + Sorting nexin-9 
O70493 SNX12 ++ ++ ++ Sorting nexin-12 
Q6PHS6 SNX13 ++ + + Sorting nexin-13 
Q91ZR2 SNX18 ++ + + Sorting nexin-18 
Q3ZT31 SNX25 ++ ++ + Sorting nexin-25 
Q8CE50 SNX30 +++ +++ ++ Sorting nexin-30 
 
Abundance - averaged log2(LFQ)-values of the Cys3-triplicates, classified as below 18 and between 18 to 23, 23 
to 28, 28 to 33 and above 33; Ratio - log2-t-test differences, classified as below 1 and between 1 to 3, 3 to 6, 6 
to 9 and above 9; Significance – -log10(p-value),  classified as below 1 and between 1 to 2, 2 to 4, 4 to 6 and 
above 6; all classes were accordingly labeled as: -, +, ++, +++, ++++. The t-test threshold value was hereby set 
to 1.2% and the slope value to 0.2. 
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Table S.6:  Proteins recruited with APP on different liposomes. 
AccNo AccStr Ratio3 Ratio4 Ratio35 Ratio45 Ratio345 Name 
 
Q9Z1T6 FYV1   + + + 1-phosphatidylinositol-3-phosphate 5-kinase 
Q8VDM4 PSMD2     + 26S proteasome non-ATPase regulatory subunit 2 
Q9Z2A0 PDPK1     + 3-phosphoinositide-dependent protein kinase 1 
P14131 RS16 ++    - 40S ribosomal protein S16 
Q9JLJ2 AL9A1    + + 4-trimethylaminobutyraldehyde dehydrogenase 
Q9JM14 NT5C     + 5(3)-deoxyribonucleotidase, cytosolic type 
Q5EG47 AAPK1 +    + 5-AMP-activated protein kinase catalytic subunit alpha-1 
Q6PAM0 AAKB2 +     5-AMP-activated protein kinase subunit beta-2 
O08848 RO60   +   60 kDa SS-A/Ro ribonucleoprotein 
Q9WUA3 K6PP    + + 6-phosphofructokinase type C 
P12382 K6PL    + + 6-phosphofructokinase, liver type 
P47857 K6PF    + + 6-phosphofructokinase, muscle type 
Q9CQ60 6PGL     + 6-phosphogluconolactonase 
P97819 PA2G6 +   + + 85 kDa calcium-independent phospholipase A2 
Q4JIM5 ABL2   + + + Abelson tyrosine-protein kinase 2 
Q8VD66 ABHD4 +     Abhydrolase domain-containing protein 4 
Q9D2R0 AACS   + + + Acetoacetyl-CoA synthetase 
Q8QZT1 THIL   +   Acetyl-CoA acetyltransferase, mitochondrial 
P68033 ACTC    +++ - Actin, alpha cardiac muscle 1 
Q99MR0 ACL6B    + + Actin-like protein 6B 
Q6P4T2 Q6P4T2   ++ -  Activating signal cointegrator 1 complex subunit 3-like 1 
Q9WTL7 LYPA2   ++  ++ Acyl-protein thioesterase 2 
Q9CR95 NECP1 ++    + Adaptin ear-binding coat-associated protein 1 
A2BDX3 MOCS3   +  + Adenylyltransferase and sulfurtransferase MOCS3 
P48962 ADT1 +     ADP/ATP translocase 1 
P61205 ARF3   - +  ADP-ribosylation factor 3 
Q6P5E6 GGA2   + +  ADP-ribosylation factor-binding protein GGA2 
P61211 ARL1     + ADP-ribosylation factor-like protein 1 
Q9QZQ1 AFAD   +   Afadin (Protein Af-6) 
Q8CG76 ARK72     + Aflatoxin B1 aldehyde reductase member 2 
Q80WT5 AFTIN   + +  Aftiphilin 
Q3THG9 AASD1     + Alanyl-tRNA editing protein Aarsd1 
Q9JII6 AK1A1     + Alcohol dehydrogenase [NADP+] 
P28474 ADHX     + Alcohol dehydrogenase class-3 
P45376 ALDR     + Aldose reductase 
P29699 FETUA   +   Alpha-2-HS-glycoprotein 
Q9DBF1 AL7A1     ++ Alpha-aminoadipic semialdehyde dehydrogenase 
P61164 ACTZ   +   Alpha-centractin 
Q8BGW1 FTO   +   Alpha-ketoglutarate-dependent dioxygenase FTO 
Q9D3D0 TTPAL   +   Alpha-tocopherol transfer protein-like 
Q8K341 ATAT    +  Alpha-tubulin N-acetyltransferase 
Q3UH49 Q3UH49 +++ ++++ +++ ++++ ++++ Amyloid beta (A4) protein binding, family A 
P98084 APBA2 +++ +++ +++ +++ +++ Amyloid beta A4 precursor protein-binding family A member 2 
Q9QXJ1 APBB1 +++ ++ ++ ++ ++ Amyloid beta A4 precursor protein-binding family B member 1 
Q3TPE9 ANKY2     + Ankyrin repeat and MYND domain-containing protein 2 
P59672 ANS1A   + + + Ankyrin repeat and SAM domain containing 1 
Q91ZU1 ASB6   ++ +  Ankyrin repeat and SOCS box protein 6 
Q8BIZ1 ANS1B    + + Ankyrin repeat and sterile alpha motif domain…. 
B2RW11 B2RW11    +  Ankyrin repeat domain 34A 
P97384 ANX11 +   - - Annexin A11 
P97429 ANXA4 +   - - Annexin A4 
O88512 AP1G2     + AP-1 complex subunit gamma-like 2 
Q3UHJ0 AAK1    + + AP2-associated protein kinase 1 
B0V3P2 B0V3P2 ++  ++ ++ ++ AP-4 complex subunit beta-1 
Q80V94 AP4E1 ++  ++ ++ ++ AP-4 complex subunit epsilon-1 
Q9JKC7 AP4M1 +  ++ ++ ++ AP-4 complex subunit mu-1 
Q9WVL1 AP4S1 ++  + + ++ AP-4 complex subunit sigma-1 
Q3TAP4 YK046   ++ + ++ AP-5 complex subunit beta-1 
Q8BPD5 APOA1 +     Apolipoprotein A-I 
P33622 APOC3 ++     Apolipoprotein C-III (Apo-CIII) (ApoC-III) (Apolipoprotein C3) 
P51910 APOD +    - Apolipoprotein D 
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Table S.6 – continued:  Proteins recruited with APP on different liposomes. 
AccNo AccStr Ratio3 Ratio4 Ratio35 Ratio45 Ratio345 Name 
 
Q62415 ASPP1   + + + Apoptosis-stimulating of p53 protein 1 
Q80WC7 AGFG2    + + Arf-GAP domain and FG repeat-containing protein 2 
Q8K2K6 AGFG1 ++  +  - Arf-GAP domain and FG repeats-containing protein 1 
Q7SIG6 ASAP2   +   Arf-GAP with SH3 domain, ANK repeat and PH …. 
P16460 ASSY    + + Argininosuccinate synthase 
Q8BNU0 ARMC6   +   Armadillo repeat-containing protein 6 
Q61024 ASNS   + + + Asparagine synthetase [glutamine-hydrolyzing] 
O70305 ATX2    ++ + Ataxin-2 (Spinocerebellar ataxia type 2 protein homolog) 
Q91V92 ACLY   +   ATP citrate lyase 
O54984 ASNA   +   ATPase Asna1 
P61222 ABCE1    + + ATP-binding cassette sub-family E member 1 
Q91VR5 DDX1     + ATP-dependent RNA helicase DDX1 
Q62167 DDX3X    + + ATP-dependent RNA helicase DDX3X 
Q9D8Z6 ATGA1 +     Autophagy-related protein 101 
Q9CQC6 BZW1   +   Basic leucine zipper and W2 domain-containing protein 1 
Q61335 BAP31   - + - B-cell receptor-associated protein 31 
O88597 BECN1     + Beclin-1 
Q8BHT6 B3GLT   +   Beta-1,3-glucosyltransferase 
Q9CWL8 CTBL1   +   Beta-catenin-like protein 1 
Q8R5C5 ACTY   +   Beta-centractin 
Q9DBL7 COASY     + Bifunctional coenzyme A synthase 
Q8C3R1 BRAT1     + BRCA1-associated ATM activator 1 
Q6PAJ1 BCR    + + Breakpoint cluster region protein 
Q8CCN5 BCAS3   +  + Breast carcinoma-amplified sequence 3 homolog 
D3Z6Q9 D3Z6Q9   -  + Bridging integrator 2 
Q8K2Q7 BROX   +   BRO1 domain-containing protein BROX 
Q8K1X1 WDR11 ++  + ++ ++ Bromodomain and WD repeat domain containing 2 
O54825 BYST   +   Bystin 
Q922D8 C1TC   + + + C-1-tetrahydrofolate synthase, cytoplasmic 
Q5HZI2 C2C4C     ++ C2 calcium-dependent domain-containing protein 4C 
P12658 CALB1   +   Calbindin 
B1AUH5 B1AUH5 ++  + +  Calcium/calmodulin-dependent serine protein kinase 
Q9CXW3 CYBP   +   Calcyclin-binding protein 
Q80VC9 CAMP3   + + ++ Calmodulin-regulated spectrin-associated protein 3 
P14211 CALR   +   Calreticulin 
Q9DBC3 MTR1   +  + Cap-specific mRNA (nucleoside-2-O-)-methyltransferase 1 
Q8K354 Q8K354     + Carbonyl reductase 3 
Q00493 CBPE     + Carboxypeptidase E 
Q9DC28 KC1D     ++ Casein kinase 1, delta, isoform CRA_b 
Q9JMK2 KC1E     ++ Casein kinase I isoform epsilon 
B9EJ23 B9EJ23 ++  +++ +++ +++ Cask protein 
Q8BHE3 ATCAY   - - + Caytaxin 
Q5M8N0 CNRP1     + CB1 cannabinoid receptor-interacting protein 1 
Q8BH15 CNOTA    ++ + CCR4-NOT transcription complex subunit 10 
Q8C5L3 CNOT2    +  CCR4-NOT transcription complex subunit 2 
Q8K0V4 CNOT3    + + CCR4-NOT transcription complex subunit 3 
Q60809 CNOT7    +  CCR4-NOT transcription complex subunit 7 
Q9JKC6 CEND -   +  Cell cycle exit and neuronal differentiation protein 1 
Q9JKY0 RCD1    +  Cell differentiation protein RCD1 homolog 
Q6ZQK5 ACAP2    + + Centaurin beta 2 
Q9D8B3 CHM4B   +   Charged multivesicular body protein 4b 
P49025 CTRO     + Citron Rho-interacting kinase (CRIK) 
Q61548 AP180     + Clathrin coat assembly protein AP180 
Q9CQF3 CPSF5    +  Cleavage and polyadenylation specificity factor subunit 5 
Q8BTV2 CPSF7    ++ + Cleavage and polyadenylation specificity factor subunit 7 
Q8BIQ5 CSTF2   + ++ ++ Cleavage stimulation factor subunit 2 
Q99LI7 CSTF3 ++  ++ +++ ++ Cleavage stimulation factor subunit 3 
Q8K1A6 C2D1A +  + ++ ++ Coiled-coil and C2 domain-containing protein 1A 
Q9JIG7 CCD22 ++  ++ +++ ++ Coiled-coil domain-containing protein 22 
Q5SP85 CC85A +     Coiled-coil domain-containing protein 85A 
Q7TQK5 CCD93   ++ ++ ++ Coiled-coil domain-containing protein 93 
Q91W50 CSDE1   +  + Cold shock domain-containing protein E1 
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Table S.6 – continued:  Proteins recruited with APP on different liposomes. 
AccNo AccStr Ratio3 Ratio4 Ratio35 Ratio45 Ratio345 Name 
 
Q9EQG9 C43BP     + Collagen type IV alpha-3-binding protein 
Q8K4M5 COMD1    + ++ COMM domain containing 1 
Q8JZY2 COMDA   + ++ ++ COMM domain-containing protein 10 
Q8BXC6 COMD2   + ++ ++ COMM domain-containing protein 2 
Q63829 COMD3 +  + ++ ++ COMM domain-containing protein 3 
Q9CQ02 COMD4 ++  ++ ++ ++ COMM domain-containing protein 4 
Q8R395 COMD5   ++ ++ +++ COMM domain-containing protein 5 
Q3V4B5 COMD6    +  COMM domain-containing protein 6 
Q8BG94 COMD7 +  ++ ++ ++ COMM domain-containing protein 7 
Q9CZG3 COMD8   + + ++ COMM domain-containing protein 8 
Q8K2Q0 COMD9 ++  ++ ++ ++ COMM domain-containing protein 9 
P84086 CPLX2     ++ Complexin-2 
Q921L5 COG2   +   Conserved oligomeric Golgi complex subunit 2 
Q8CI04 COG3   +  + Conserved oligomeric Golgi complex subunit 3 
Q8C0L8 COG5   + + + Conserved oligomeric Golgi complex subunit 5 
Q3UM29 COG7   + +  Conserved oligomeric Golgi complex subunit 7 
Q9JJA2 COG8   +   Conserved oligomeric Golgi complex subunit 8 
P12960 CNTN1   +   Contactin-1 
Q8C166 CPNE1 +   + + Copine-1 
O89053 COR1A    + + Coronin-1A 
Q9D2V7 CORO7   +   Coronin-7 
P30275 KCRU   ++ ++ + Creatine kinase U-type, mitochondrial 
P45481 CBP   ++ ++ +++ CREB-binding protein (EC 2.3.1.48) 
Q6P1J1 Q6P1J1     + Crmp1 protein 
P70698 PYRG1   + +  CTP synthase 1 
Q9D4H8 CUL2    +  Cullin-2 
Q3TCH7 CUL4A +   +  Cullin-4A 
Q6ZQ38 CAND1    +  Cullin-associated NEDD8-dissociated protein 1 
Q6ZQ73 CAND2   +   Cullin-associated NEDD8-dissociated protein 2 
O35495 CDK14     + Cyclin-dependent kinase 14 
Q04899 CDK18     + Cyclin-dependent kinase 18 
Q99KY4 GAK ++    ++ Cyclin-G-associated kinase 
P62897 CYC   +   Cytochrome c, somatic 
Q8K0T2 DC2L1   ++   Cytoplasmic dynein 2 light intermediate chain 1 
Q9CPY7 AMPL    + + Cytosol aminopeptidase 
Q8R0Y6 AL1L1     + Cytosolic 10-formyltetrahydrofolate dehydrogenase 
Q61753 SERA    + + D-3-phosphoglycerate dehydrogenase 
Q61655 DD19A     + DEAD (Asp-Glu-Ala-Asp) box polypeptide 19b 
Q61656 DDX5     ++ DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
A2AF47 DOC11   + ++ + Dedicator of cytokinesis protein 11 
Q8CIQ7 DOCK3   + + ++ Dedicator of cytokinesis protein 3 
P59764 DOCK4 +  ++ ++ ++ Dedicator of cytokinesis protein 4 
Q8R1A4 DOCK7   + + + Dedicator of cytokinesis protein 7 
Q8BIK4 DOCK9    +  Dedicator of cytokinesis protein 9 
E9Q5T9 E9Q5T9   ++ ++  Deleted. 
Q71KT5 ERG24   +   Delta(14)-sterol reductase 
Q8CHT0 AL4A1   +   Delta-1-pyrroline-5-carboxylate dehydrogenase 
A2RT67 DEND3   +   DENN domain-containing protein 3 
Q6PAL8 DEN5A   + + ++ DENN domain-containing protein 5A 
A2RSQ0 DEN5B     + DENN domain-containing protein 5B 
Q9QXB9 DRG2     + Developmentally-regulated GTP-binding protein 2 
Q9EQF6 DPYL5     + Dihydropyrimidinase-related protein 5 
P50285 FMO1   +   Dimethylaniline monooxygenase [N-oxide-forming] 1 
Q99JF5 MVD1   ++ +  Diphosphomevalonate decarboxylase 
Q3UHC7 DAB2P     + Disabled homolog 2-interacting protein 
Q8BWT5 DIP2A     ++ Disco-interacting protein 2 homolog A 
Q3UH60 DIP2B     ++ Disco-interacting protein 2 homolog B 
P70175 DLG3     + Disks large homolog 3 
Q3U1J4 DDB1 + ++ + ++ ++ DNA damage-binding protein 1 
P54276 MSH6    +  DNA mismatch repair protein Msh6 
P54797 T10     + DNA segment, Chr 16, human D22S680E, expressed 
O35134 RPA1   +   DNA-directed RNA polymerase I subunit RPA1 
Q923G2 RPAB3   +   DNA-directed RNA polymerases I, II, and III subunit RPABC3 
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Q9QYI3 DNJC7   +   DnaJ homolog subfamily C member 7 
P46978 STT3A   +   Dolichyl-diphosphooligosaccharide-protein glycosyltransf…. 
O35075 DSCR3 +  ++ ++ +++ Down syndrome critical region protein 3 homolog 
Q62418 DBNL    +  Drebrin-like protein 
P47809 MP2K4   + + + Dual specificity mitogen-activated protein kinase kinase 4 
Q9WVS7 MP2K5     + Dual specificity mitogen-activated protein kinase kinase 5 
P56387 DYLT3 ++   -  Dynein light chain Tctex-type 3 
Q91ZU6 DYST   - +  Dystonin 
Q9D2N4 DTNA    +  Dystrobrevin alpha, isoform CRA_a 
Q8CHI8 EP400    + + E1A-binding protein p400 
Q5DTM8 BRE1A   ++ ++ ++ E3 ubiquitin-protein ligase BRE1A 
Q3U319 BRE1B   ++ ++ ++ E3 ubiquitin-protein ligase BRE1B 
Q6A009 LTN1   +   E3 ubiquitin-protein ligase listerin 
P46935 NEDD4     + E3 ubiquitin-protein ligase NEDD4 
Q9JI90 RNF14    +  E3 ubiquitin-protein ligase RNF14 
Q69ZI1 SH3R1     + E3 ubiquitin-protein ligase SH3RF1 
Q8CH72 TRI32 ++  + + ++ E3 ubiquitin-protein ligase TRIM32 
Q99LC5 ETFA   +  + Electron transfer flavoprotein subunit alpha, mitochondrial 
P58252 EF2     + Elongation factor 2 
Q8C0D5 ETUD1   +  + Elongation factor Tu GTP-binding domain-containing protein 1 
Q7TT37 ELP1     + Elongator complex protein 1 
Q91WG4 ELP2   +  + Elongator complex protein 2 
Q9ER73 ELP4    +  Elongator complex protein 4 
Q3UJB9 EDC4    +  Enhancer of mRNA decapping 4, isoform CRA_b 
Q8K2D3 EDC3    +  Enhancer of mRNA-decapping protein 3 
P42567 EPS15 +   + + Epidermal growth factor receptor substrate 15 
Q60902 EP15R +     Epidermal growth factor receptor substrate 15-like 1 
Q8VEH5 EPMIP     + EPM2A-interacting protein 1 
Q8CHU3 EPN2 ++    - Epsin-2 
Q91VC3 IF4A3 +    + Eukaryotic initiation factor 4A-III 
Q149F3 ERF3B    +  Eukaryotic peptide chain release factor GTP-binding …. 
Q91WK2 EIF3H   ++  ++ Eukaryotic translation initiation factor 3 subunit H 
Q99JX4 EIF3M   +   Eukaryotic translation initiation factor 3 subunit M 
Q80XI3 IF4G3   +  + Eukaryotic translation initiation factor 4 gamma 3 
Q62448 IF4G2   + + ++ Eukaryotic translation initiation factor 4, gamma 2 
Q9WUK2 IF4H   +   Eukaryotic translation initiation factor 4H 
Q61545 EWS    +++ + Ewing sarcoma breakpoint region 1 
Q8R3S6 EXOC1   +   Exocyst complex component 1 
Q8R313 EXOC6   + + + Exocyst complex component 6 (SEC15-like protein 1) 
Q924C1 XPO5   + + + Exportin-5 
Q924Z6 XPO6   + +  Exportin-6 
Q9EPK7 XPO7     + Exportin-7  
Q9CRT8 XPOT   +   Exportin-T 
Q61553 FSCN1    +  Fascin 
P19096 FAS   + +  Fatty acid synthase 
Q8VDH1 FBX21   +   F-box only protein 21 
Q91W61 FXL15   +   F-box/LRR-repeat protein 15 
Q9QXW2 FBXW5 +   ++ ++ F-box/WD repeat-containing protein 5 
Q9CRA9 FGOP2    +  FGFR1 oncogene partner 2 homolog 
Q8BYN5 FSD1L     + FSD1-like protein 
Q8VEB1 GRK5     + G protein-coupled receptor kinase 5 
Q9R0N0 GALK1     + Galactokinase 
P17183 ENOG   +   Gamma-enolase 
Q99JP7 GGT7   +   Gamma-glutamyltransferase 7 
P58854 GCP3   + ++ + Gamma-tubulin complex component 3 
Q8K0C9 GMDS   + + + GDP-mannose 4,6 dehydratase 
Q9JHK4 PGTA   +  + Geranylgeranyl transferase type-2 subunit alpha 
O55126 NIPS2 +++   + + Glioblastoma amplified sequence 
E9PYV1 E9PYV1     + Glucocorticoid receptor 
P47856 GFPT1     + Glucosamine--fructose-6-phosphate aminotransferase …. 
Q9Z2Z9 GFPT2    ++++ ++++ Glucosamine--fructose-6-phosphate aminotransferase …. 
Q00612 G6PD1    + + Glucose-6-phosphate 1-dehydrogenase X 
D3Z7P3 D3Z7P3   +  + Glutaminase kidney isoform, mitochondrial 
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P15105 GLNA     + Glutamine synthetase 
O70325 GPX41     + Glutathione peroxidase 
Q8QZY2 GLCTK   +   Glycerate kinase 
Q64516 GLPK -    + Glycerol kinase 
Q3ULJ0 GPD1L    + + Glycerol-3-phosphate dehydrogenase 1-like protein 
Q8C0L9 GPCP1    + + Glycerophosphocholine phosphodiesterase GPCPD1 
Q9Z1E4 GYS1   ++ ++ ++ Glycogen [starch] synthase, muscle 
Q8CI94 PYGB     + Glycogen phosphorylase, brain form 
Q2NL51 GSK3A    + + Glycogen synthase kinase-3 alpha 
Q9CZD3 SYG     + Glycyl-tRNA synthetase 
Q9DCZ1 GMPR1   ++  + GMP reductase 1 
Q3THK7 GUAA   + + + GMP synthase [glutamine-hydrolyzing] 
Q8BMP6 GCP60 ++    + Golgi resident protein GCP60 
Q9CW79 GOGA1     + Golgin subfamily A member 1 
Q8BUV3 GEPH   + + + Gphn protein 
Q9JJQ0 PIGB   +  ++ GPI mannosyltransferase 3 
Q9D4H2 GCC1   ++  ++ GRIP and coiled-coil domain-containing protein 1 
Q9JLM9 GRB14 ++  ++ ++  Growth factor receptor-bound protein 14 
Q9WUR9 KAD4   -  ++ GTP:AMP phosphotransferase AK4, mitochondrial 
P08556 RASN +    + GTPase NRas 
Q921J2 RHEB     + GTP-binding protein Rheb 
Q9CQC9 SAR1B +     GTP-binding protein SAR1b 
E9PXE2 E9PXE2   +   Guanine nucleotide exchange factor DBS 
P27601 GNA13   +   Guanine nucleotide-binding protein subunit alpha-13 
Q9D114 MESH1     + Guanosine-3,5-bis(diphosphate) 3-pyrophosphohydrolase …. 
Q9EP53 TSC1   ++ ++ ++ Hamartin 
Q8C547 HTR5B   + +  HEAT repeat-containing protein 5B 
Q6P1G0 HEAT6   +   HEAT repeat-containing protein 6 
P48722 HS74L   +   Heat shock 70 kDa protein 4L 
O35737 HNRH1     + Heterogeneous nuclear ribonucleoprotein H1 
P70333 HNRH2    ++  Heterogeneous nuclear ribonucleoprotein H2 
Q9D0E1 HNRPM +  ++ ++ ++ Heterogeneous nuclear ribonucleoprotein M 
Q8VDM6 HNRL1   + + + Heterogeneous nuclear ribonucleoprotein U-like protein 1 
Q9CPS6 HINT3 +     Histidine triad nucleotide-binding protein 3 
Q61035 SYHC    + + Histidyl-tRNA synthetase, cytoplasmic 
B2RWS6 EP300   + ++ ++ Histone acetyltransferase p300 
P43274 H14   -  + Histone H1.4 
Q9WVG6 CARM1    +  Histone-arginine methyltransferase CARM1 
Q9Z2G9 HTAI2    - + HIV-1 tat interactive protein 2, homolog (Human) 
Q9Z2Y3 HOME1    + + Homer protein homolog 1 
P38060 HMGCL    + + Hydroxymethylglutaryl-CoA lyase, mitochondrial 
Q5D0E0 Q5D0E0     + Ikbkb protein 
O35344 IMA3 +     Importin subunit alpha-3 
P70168 IMB1   +  + Importin subunit beta-1 
Q8K0C1 IPO13    ++  Importin-13 
Q91YE6 IPO9   +  + Importin-9 
P24547 IMDH2    ++ ++ Inosine-5-monophosphate dehydrogenase 2 
Q8BYN3 ITPK1     + Inositol-tetrakisphosphate 1-kinase 
Q6P4S8 INT1   +   Integrator complex subunit 1 
Q7TPD0 INT3   + +  Integrator complex subunit 3 
O55222 ILK    +  Integrin-linked protein kinase 
Q8R3Y8 I2BP1     + Interferon regulatory factor 2-binding protein 1 
Q8K3X4 I2BPL  ++  + + Interferon regulatory factor 2-binding protein-like 
Q6NWV3 IF122    ++  Intraflagellar transport protein 122 homolog 
Q8R0S2 IQEC1 ++  + ++ + IQ motif and SEC7 domain-containing protein 1 
P85094 ISC2A   +  + Isochorismatase domain-containing protein 2A, mitochondrial 
Q04690 NF1   + + ++ Isoform 1 of Neurofibromin 
Q80TQ2 CYLD   + + + Isoform 1 of Ubiquitin carboxyl-terminal hydrolase CYLD 
Q5SWU9 ACACA   + + + Isoform 2 of Acetyl-CoA carboxylase 1 
Q7TQH0 ATX2L   + + ++ Isoform 2 of Ataxin-2-like protein 
Q45VK7 DYHC2   + + + Isoform 2 of Cytoplasmic dynein 2 heavy chain 1 
Q99N11 DUS22     ++ Isoform 2 of Dual specificity protein phosphatase 22 
O08788 DCTN1   +   Isoform 2 of Dynactin subunit 1 
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P58281 OPA1     + Isoform 2 of Dynamin-like 120 kDa protein, mitochondrial 
Q8BHL5 ELMO2     + Isoform 2 of Engulfment and cell motility protein 2 
Q8R123 FAD1    + + Isoform 2 of FAD synthase 
Q99M31 HSP7E   +  + Isoform 2 of Heat shock 70 kDa protein 14 
P61979 HNRPK     + Isoform 2 of Heterogeneous nuclear ribonucleoprotein K 
Q6PAR0 KLD10 ++    + Isoform 2 of Kelch domain-containing protein 10 
Q9DB27 MCTS1     + Isoform 2 of Malignant T cell-amplified sequence 1 
Q8VHN8 SDOS     + Isoform 2 of Protein syndesmos 
Q6ZQ29 TAOK2 +  + ++ ++ Isoform 2 of Serine/threonine-protein kinase TAO2 
Q8CI15 SPHK1    - + Isoform 2 of Sphingosine kinase 1 
Q6P2B1 TNPO3    +  Isoform 2 of Transportin-3 
Q8CGY8 OGT1   + + + Isoform 2 of UDP-N-acetylglucosamine-peptide N-acety... 
P40336 VP26A ++  + + + Isoform 2 of Vacuolar protein sorting-associated protein 26A 
Q9JM52 MINK1    + + Isoform 3 of Misshapen-like kinase 1 
Q9WU78 PDC6I    + + Isoform 3 of Programmed cell death 6-interacting protein 
Q6PDS3 SARM1   + + ++ Isoform 3 of Sterile alpha and TIR motif-containing protein 1 
Q6ZQ08 CNOT1    + + Isoform 4 of CCR4-NOT transcription complex subunit 1 
Q80YX1 TENA   +   Isoform 4 of Tenascin 
Q80X50 UBP2L    +  Isoform 5 of Ubiquitin-associated protein 2-like 
P12023 A4  +++ +++ ++ ++ Isoform APP695 of Amyloid beta A4 protein 
Q99PP7 TRI33   +  + Isoform Beta of E3 ubiquitin-protein ligase TRIM33 
Q5DTN8 JKIP3   ++ ++  Janus kinase and microtubule-interacting protein 3 
Q9CR30 JOS2   - - + Josephin-2 
Q02257 PLAK    +  Junction plakoglobin 
Q8K0T4 KATL1     + Katanin p60 ATPase-containing subunit A-like 1 
Q8BG40 KTNB1     + Katanin p80 WD40-containing subunit B1 
Q99M74 KRT82 -   +++  Keratin, type II cuticular Hb2 
Q60749 KHDR1   + + ++ KH domain-containing, RNA-binding, signal transduction-ass…. 
Q9CPU0 LGUL   +   Lactoylglutathione lyase 
Q80U56 AVL9 +  - - - Late secretory pathway protein AVL9 homolog 
Q6ZPK7 LST2 +     Lateral signaling target protein 2 homolog 
Q80TR1 LPHN1    +  Latrophilin-1 
Q3UGP9 LRC58     + Leucine-rich repeat-containing protein 58 
Q8BMJ2 SYLC   + + + Leucine--tRNA ligase, cytoplasmic 
Q9ESE1 LRBA     ++ Lipopolysaccharide-responsive and beige-like anchor protein 
P41216 ACSL1   +   Long-chain-fatty-acid--CoA ligase 1 
Q99PU5 ACBG1     + Long-chain-fatty-acid--CoA ligase ACSBG1 
Q8C142 ARH ++ ++ + +  Low density lipoprotein receptor adapter protein 1 
Q9D358 PPAC     + Low molecular weight phosphotyrosine protein phosphatase 
Q91X52 DCXR   +  + L-xylulose reductase 
Q9WUC3 LY6H    +  Lymphocyte antigen 6H (Ly-6H) 
P70699 LYAG   ++  + Lysosomal alpha-glucosidase 
Q9WV34 MPP2    + + MAGUK p55 subfamily member 2 
Q9JLB0 MPP6    + + MAGUK p55 subfamily member 6 
Q14BB9 MA6D1     + MAP6 domain-containing protein 1 
A2AG50 MA7D2     + MAP7 domain-containing protein 2 
O89029 MATN4   +   Matrilin-4 (MAT-4) 
Q8C525 M21D2 +++   + ++ MCG125361, isoform CRA_a 
E0CYQ0 E0CYQ0     + MCG13350, isoform CRA_b 
G5E895 G5E895     + MCG142264, isoform CRA_b 
Q9D5R2 WDR20 ++  + + + MCG14935, isoform CRA_a 
A2A8R0 A2A8R0   +  + MCG17975 
Q6ZQG1 Q6ZQG1   +   MCG21756, isoform CRA_a (Fragment) 
Q925J9 MED1    + + Mediator of RNA polymerase II transcription subunit 1 
A2ABV5 MED14 +  ++ +++ ++ Mediator of RNA polymerase II transcription subunit 14 
Q924H2 MED15    - + Mediator of RNA polymerase II transcription subunit 15 
Q8VCD5 MED17    ++ ++ Mediator of RNA polymerase II transcription subunit 17 
Q9CZ82 MED18   +  + Mediator of RNA polymerase II transcription subunit 18 
Q80YQ2 MED23    ++ + Mediator of RNA polymerase II transcription subunit 23 
Q8VCB2 MED25   +  + Mediator of RNA polymerase II transcription subunit 25 
P41242 MATK     + Megakaryocyte-associated tyrosine-protein kinase 
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P70290 EM55    + + Membrane protein, palmitoylated 
Q3UHE1 PITM3   +   Membrane-associated phosphatidylinositol transfer protein 3 
Q99LB6 MAT2B     + Methionine adenosyltransferase 2 subunit beta 
Q9R008 KIME   + + + Mevalonate kinase 
Q7TSJ2 MAP6     + Microtubule-associated protein 6 
Q9R1L5 MAST1     + Microtubule-associated serine/threonine-protein kinase 1 
Q59J78 MIMIT    + - Mimitin, mitochondrial 
Q9CYG7 TOM34    + + Mitochondrial import receptor subunit TOM34 
Q9D6Y7 MSRA +    + Mitochondrial peptide methionine sulfoxide reductase 
Q8VCM5 MUL1 ++   +  Mitochondrial ubiquitin ligase activator of NFKB 1 
P63085 MK01    +  Mitogen-activated protein kinase 1 
Q91Y86 MK08    +  Mitogen-activated protein kinase 8 
Q99JP0 M4K3    + + Mitogen-activated protein kinase kinase kinase kinase 3 
P35282 RAB21    +  MKIAA0118 protein (Fragment) 
Q99P88 NU155 +  + + + MKIAA0791 protein (Fragment) 
O35382 EXOC4   +   MKIAA1699 protein (Fragment) 
Q91WG7 DGKG     + MKIAA4131 protein (Fragment) 
Q9D071 MMS19    + + MMS19 nucleotide excision repair protein homolog 
Q8C570 RAE1L    + + mRNA export factor 
Q9Z2C9 MTMR7     + Myotubularin-related protein 7 
Q68FH4 GALK2   +  + N-acetylgalactosamine kinase 
Q8VDQ8 SIRT2 +  + + + NAD-dependent deacetylase sirtuin-2 
Q6PHQ8 NAA35   +  + N-alpha-acetyltransferase 35, NatC auxiliary subunit 
Q8BG30 NELFA   + + + Negative elongation factor A 
Q8C4Y3 NELFB   + +  Negative elongation factor B 
Q6ZWR6 SYNE1 ++ ++ ++ ++ +++ Nesprin-1 
P13595 NCAM1   +   Neural cell adhesion molecule 1 
Q9EPN1 NBEA     ++ Neurobeachin 
P97300 NPTN   +   Neuroplastin 
Q8R151 ZNFX1   + ++ + NFX1-type zinc finger-containing protein 1 
Q8CC86 PNCB    + + Nicotinate phosphoribosyltransferase 
Q9Z0J4 NOS1   + + ++ Nitric oxide synthase, brain  
Q8K2T1 NMRL1     + NmrA-like family domain-containing protein 1 
Q99K48 NONO +   + + Non-POU domain-containing octamer-binding protein 
A2ANC6 A2ANC6 ++    + Novel protein 
Q8K4Q0 RPTOR +  ++ ++ ++ Novel protein containing six WD40 domains at C-terminus 
Q8R0G9 NU133 +  +   Nuclear pore complex protein Nup133 
Q9Z0W3 NU160   +   Nuclear pore complex protein Nup160 
Q80U93 NU214   +  + Nuclear pore complex protein Nup214 
Q05BA5 Q05BA5     + Nuclear receptor coactivator 3 
Q78ZA7 NP1L4    +  Nucleosome assembly protein 1-like 4 
O08919 NUMBL ++ + + + + Numb-like protein 
Q6NVF0 Q6NVF0   ++ + +++ Oculocerebrorenal syndrome of Lowe 
Q99PG2 OGFR   +   Opioid growth factor receptor 
Q8R326 PSPC1 ++  + ++ + Paraspeckle component 1 
Q8BFQ8 PDDC1    ++ + Parkinson disease 7 domain-containing protein 1 
Q64378 FKBP5    + + Peptidyl-prolyl cis-trans isomerase FKBP5 
Q9DBG5 PLIN3 +  - - - Perilipin-3 
O70589 CSKP ++  +++ +++ +++ Peripheral plasma membrane protein CASK 
O08807 PRDX4   + + + Peroxiredoxin-4 
P98191 CDS1   +   Phosphatidate cytidylyltransferase 1 
Q6PF93 PK3C3   + + + Phosphatidylinositol 3-kinase catalytic subunit type 3 
O08908 P85B   +   Phosphatidylinositol 3-kinase regulatory subunit beta 
Q8BTI9 PK3CB    +  Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic …. 
Q7M6Y3 PICA ++     Phosphatidylinositol-binding clathrin assembly protein 
Q8VD65 PI3R4   + + + Phosphoinositide 3-kinase regulatory subunit 4 
Q91UZ1 Q91UZ1   -  + Phospholipase C beta 4 
Q9D1G2 PMVK     + Phosphomevalonate kinase 
P59114 PCIF1     + Phosphorylated CTD-interacting factor 1 
P20918 PLMN    ++  Plasminogen 
Q8BUL6 PKHA1     + Pleckstrin homology domain-containing family A member 1 
P11103 PARP1   + + + Poly (ADP-ribose) polymerase family, member 1 
Q8BZ20 PAR12    +  Poly [ADP-ribose] polymerase 12 
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Q91WF7 FIG4 +  ++ ++ + Polyphosphoinositide phosphatase 
P54823 DDX6    + + Probable ATP-dependent RNA helicase DDX6 
Q6DIC0 SMCA2   +   Probable global transcription activator SNF2L2 
P12815 PDCD6     + Programmed cell death protein 6 
Q9DB60 PGFS     + Prostamide/prostaglandin F synthase 
Q6PDI5 ECM29   +   Proteasome-associated protein ECM29 homolog 
D3YVV3 D3YVV3   - +  Protein Ankrd29 
O88737 BSN   + ++ ++ Protein bassoon 
Q3V3N7 Q3V3N7 +   + + Protein Bbs1 
E9PV26 E9PV26     + Protein BC068157 
Q8C7D2 CRBN ++ ++ ++ ++ ++ Protein cereblon 
Q80U30 CL16A     + Protein CLEC16A 
D3YXJ0 D3YXJ0     + Protein Dgkh 
Q8BHZ0 FA49A +     Protein FAM49A 
Q9D7I8 FA83D + +++   ++ Protein FAM83D 
Q3UVG3 F91A1 ++  + ++ ++ Protein FAM91A1 
Q80VD1 FA98B   +  + Protein FAM98B 
Q8BIL5 HOOK1     + Protein Hook homolog 1 
Q80U49 K0284    + + Protein KIAA0284 
P23298 KPCL    +  Protein kinase C eta type 
Q02956 KPCZ    +  Protein kinase C zeta type 
Q8JZS0 LIN7A +    + Protein lin-7 homolog A 
O88951 LIN7B ++  + ++ + Protein lin-7 homolog B 
O88952 LIN7C     + Protein lin-7 homolog C 
Q8K2F8 LS14A     + Protein LSM14 homolog A 
O55125 NIPS1 ++   + + Protein NipSnap homolog 1 (NipSnap1) 
D3YVV7 D3YVV7     + Protein Nova2 
Q9QZS3 NUMB ++ ++ + ++ + Protein numb homolog 
Q3TDD9 PPR21    + + Protein phosphatase 1 regulatory subunit 21 
Q60676 PPP5     + Protein phosphatase 5, catalytic subunit 
Q8BVQ5 PPME1    +  Protein phosphatase methylesterase 1 
Q52KR3 PRUN2   -  ++ Protein prune homolog 2 
Q9D394 RUFY3   - +  Protein RUFY3 
Q6DID3 SCAF8     + Protein SCAF8 (RNA-binding motif protein 16) (SR-related …. 
Q8C8N2 SCAI   +  + Protein SCAI 
Q9D1M0 SEC13    +  Protein SEC13 homolog 
Q9DB90 SMG9   ++   Protein SMG9 
Q01405 SC23A    +  Protein transport protein Sec23A 
Q3UPL0 SC31A +  +++ +++ +++ Protein transport protein Sec31A 
O70274 TP4A2   - +  Protein tyrosine phosphatase type IVA 2 
Q99KD5 UN45A   +  ++ Protein unc-45 homolog A 
Q80WQ2 VAC14 +  + ++ + Protein VAC14 homolog 
B1ART2 B1ART2     + Protein Vps13d 
Q80ZJ6 ZER1    +  Protein zer-1 homolog 
Q3UFS0 ZY11B   +   Protein zyg-11 homolog B 
P59913 PCMD1    +  Protein-L-isoaspartate O-methyltransferase domain-…. 
Q9QVP9 FAK2   + + + PTK2 protein tyrosine kinase 2 beta, isoform CRA_a 
Q80SW1 SAHH2 +  + + + Putative adenosylhomocysteinase 2 
Q99K01 PDXD1 +     Pyridoxal-dependent decarboxylase domain-…. 
Q05920 PYC   +   Pyruvate carboxylase, mitochondrial 
P52480 KPYM     + Pyruvate kinase isozymes M1/M2 
P47199 QOR     + Quinone oxidoreductase 
A2AWA9 RBGP1 ++ ++ + + ++ Rab GTPase-activating protein 1 
A6H6A9 RBG1L +    + Rab GTPase-activating protein 1-like 
Q921Q7 RIN1    + + Ras and Rab interactor 1 
Q60790 RASA3     + Ras GTPase-activating protein 3 
Q9QUG9 GRP2    + + RAS guanyl-releasing protein 2 
Q9DD03 RAB13   +++   Ras-related protein Rab-13 
Q9D1G1 RAB1B    +  Ras-related protein Rab-1B 
Q99KL7 RAB28     + Ras-related protein Rab-28 
P62823 RAB3C    +  Ras-related protein Rab-3C 
P35279 RAB6A    +  Ras-related protein Rab-6A 
P61294 RAB6B    +  Ras-related protein Rab-6B 
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P27671 RGRF1   + + + Ras-specific guanine nucleotide-releasing factor 1 
Q9ESK9 RBCC1     + RB1-inducible coiled-coil protein 1 
Q8VE37 RCC1   +   Rcc1 protein 
Q9CSU0 RPR1B    + ++ Regulation of nuclear pre-mRNA domain-containing …. 
Q6NXI6 RPRD2   ++ ++ ++ Regulation of nuclear pre-mRNA domain-containing protein 2 
Q9EPU0 RENT1   +  + Regulator of nonsense transcripts 1 
Q8VEE4 RFA1   + + + Replication protein A1 
Q8BP92 RCN2   +   Reticulocalbin-2 
P24549 AL1A1    + ++ Retinal dehydrogenase 1 
Q9Z275 RLBP1    + + Retinaldehyde-binding protein 1 
O54829 RGS7     + Rgs7 protein 
Q60875 ARHG2   + + + Rho guanine nucleotide exchange factor 2 
Q8BYP3 RHOF +     Rho-related GTP-binding protein RhoF 
Q8CFV9 RIFK     + Riboflavin kinase 
F6Q8A4 F6Q8A4    + + Ribosomal protein S6 kinase 
Q8C050 KS6A5     + Ribosomal protein S6 kinase alpha-5 
Q80TE0 RPAP1   +  + RNA polymerase II-associated protein 1 
Q8R4X3 RBM12   + + ++ RNA-binding protein 12 
Q6NZN0 RBM26     + RNA-binding protein 26 
Q6P5B0 RRP12   + -  RRP12-like protein 
Q8BIJ7 RUFY1    +  RUN and FYVE domain-containing protein 1 
P60122 RUVB1    ++ + RuvB-like 1 
Q9WTM5 RUVB2 +   ++ + RuvB-like 2 
Q9JLC8 SACS   ++ ++ ++ Sacsin 
Q922D4 PP6R3     + SAPS domain family, member 3, isoform CRA_c 
P36536 SAR1A +     SAR1 gene homolog A (S. cerevisiae) 
Q8CFE4 SCYL2     + SCY1-like protein 2 
Q8BTY8 SCFD2   +   Sec1 family domain-containing protein 2 
A2A9B9 A2A9B9     + SEC14-like 1 (S. cerevisiae) 
Q80ZX0 Q80ZX0   +  + Sec24 related gene family, member B (S. cerevisiae) 
Q9DBC0 SELO   ++ + + Selenoprotein O 
Q9QUR8 SEM7A   ++   Semaphorin-7A 
Q64105 SPRE    + + Sepiapterin reductase 
Q9QZX7 SRR     + Serine racemase 
Q9Z2W1 STK25     + Serine/threonine-protein kinase 25 
Q8QZV4 ST32C     + Serine/threonine-protein kinase 32C 
Q7TSE6 ST38L   +  + Serine/threonine-protein kinase 38-like 
Q9JI11 STK4   ++   Serine/threonine-protein kinase 4 
Q9JKK8 ATR   ++ ++  Serine/threonine-protein kinase ATR 
P28028 BRAF    + + Serine/threonine-protein kinase B-raf 
E9QMP6 E9QMP6     + Serine/threonine-protein kinase MARK2 
Q99JT2 MST4     + Serine/threonine-protein kinase MST4 
Q9JLN9 MTOR +  + + + Serine/threonine-protein kinase mTOR 
Q8BTW9 PAK4 +   +  Serine/threonine-protein kinase PAK 4 
E9PU87 E9PU87    + + Serine/threonine-protein kinase SIK3 
Q8BKX6 SMG1 +  ++ ++ ++ Serine/threonine-protein kinase SMG1 
Q3U3Q1 ULK3   ++ + ++ Serine/threonine-protein kinase ULK3 
P58389 PTPA   + +  Serine/threonine-protein phosphatase 2A activator 
Q62388 ATM   ++   Serine-protein kinase ATM 
Q62086 PON2 -  +   Serum paraoxonase/arylesterase 2 
Q9CWR2 SMYD3     + SET and MYND domain-containing protein 3 
Q9R0P3 ESTD     + S-formylglutathione hydrolase 
P14576 SRP54   - ++  Signal recognition particle 54 kDa protein 
P42225 STAT1     + Signal transducer and activator of transcription 1 
P42227 STAT3   + + ++ Signal transducer and activator of transcription 3 
Q9D032 SSBP3   +   Single-stranded DNA-binding protein 3 
Q6A026 PDS5A   + + ++ Sister chromatid cohesion protein PDS5 homolog A 
P63163 RSMN     + Small nuclear ribonucleoprotein-associated protein N 
Q02384 SOS2    + + Son of sevenless homolog 2 
Q91ZR2 SNX18   -  + Sorting nexin 18 
O70492 SNX3 ++    + Sorting nexin 3 
Q9WV80 SNX1   -  ++ Sorting nexin-1 
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Table S.6 – continued:  Proteins recruited with APP on different liposomes. 
AccNo AccStr Ratio3 Ratio4 Ratio35 Ratio45 Ratio345 Name 
 
Q8BVL3 SNX17 +++  + +++ +++ Sorting nexin-17 
Q9CWK8 SNX2   - - +++ Sorting nexin-2 
Q3UHD6 SNX27 ++    ++ Sorting nexin-27 
Q8CE50 SNX30    - + Sorting nexin-30 
Q80ZJ7 SNX32     ++ Sorting nexin-32 
Q9D8U8 SNX5   -  +++ Sorting nexin-5 
Q6P8X1 SNX6   -  ++ Sorting nexin-6 
Q3UHA3 SPTCS +  + + + Spatacsin 
Q9JIA7 SPHK2     + Sphingosine kinase 2 
Q9Z1N5 DX39B   -  + Spliceosome RNA helicase Ddx39b 
Q64213 SF01    + ++ Splicing factor 1 
Q99NB9 SF3B1   +   Splicing factor 3b, subunit 1 
Q8VIJ6 SFPQ ++  + ++ + Splicing factor, proline- and glutamine-rich 
Q78PY7 SND1   + + + Staphylococcal nuclease domain-containing protein 1 
Q6P5D8 SMHD1   + + + Structural maintenance of chromosomes flexible hinge …. 
Q9Z1F9 SAE2     + SUMO-activating enzyme subunit 2 
Q6PDG5 SMRC2   + + + SWI/SNF complex subunit SMARCC2 
Q8BJL0 SMAL1   +  + SWI/SNF-related matrix-associated actin-dependent …. 
Q80X82 SYMPK   + ++ + Symplekin 
O88935 SYN1 ++   + + Synapsin-1 
Q64332 SYN2 +   + + Synapsin-2 
Q8JZP2 SYN3 +   +  Synapsin-3 
Q8R570 SNP47     + Synaptosomal-associated protein 47 
Q61234 SNTA1   +   Syntrophin acidic 1 
P26039 TLN1 -  +   Talin-1 
Q71LX4 TLN2   +   Talin-2 
Q9DCJ1 LST8 +   + + Target of rapamycin complex subunit LST8 
Q3UUG6 TBC24   +  + TBC1 domain family member 24 
Q8BYJ6 TBCD4 +     TBC1 domain family member 4 
Q80XQ2 TBCD5 ++  + + + TBC1 domain family member 5 
Q9D0K0 TBCD7     + TBC1 domain family member 7 
Q9Z1A9 TBCD8     + TBC1 domain family member 8 
Q5SVR0 TBC9B     + TBC1 domain family member 9B 
P80314 TCPB    + + T-complex protein 1 subunit beta 
P80315 TCPD    + + T-complex protein 1 subunit delta 
P80316 TCPE    + + T-complex protein 1 subunit epsilon 
P80313 TCPH     + T-complex protein 1 subunit eta 
Q80VP0 TCPR1   +   Tectonin beta-propeller repeat-containing protein 1 
Q9DC40 TELO2   +  + Telomere length regulation protein TEL2 homolog 
Q5SSZ5 TENS3   +  + Tensin-3 
Q8BYY4 TT39B     ++ Tetratricopeptide repeat protein 39B 
Q810A3 TTC9C    +  Tetratricopeptide repeat protein 9C 
Q60803 TRAF3 +  + +  TNF receptor-associated factor 3 
Q5NCF2 TPPC1 +     Trafficking protein particle complex subunit 1 
Q3TLI0 TPC10   + + + Trafficking protein particle complex subunit 10 
Q8K2L8 TPC12   ++ + ++ Trafficking protein particle complex subunit 12 
Q9CQP2 TPPC2 +     Trafficking protein particle complex subunit 2 
Q9JME7 TPC2L +  +  + Trafficking protein particle complex subunit 2-like protein 
O55013 TPPC3 +  + + + Trafficking protein particle complex subunit 3 
Q9ES56 TPPC4 +  + + + Trafficking protein particle complex subunit 4 
Q9D289 TPC6B +     Trafficking protein particle complex subunit 6B 
Q3U0M1 TPPC9   + + + Trafficking protein particle complex subunit 9 
Q3TKT4 SMCA4   + + + Transcription activator BRG1 
O55201 SPT5H    +  Transcription elongation factor SPT5 
Q8CGF7 TCRG1    +  Transcription elongation regulator 1 
Q3UR70 TGFA1    + ++ Transforming growth factor-beta receptor-associated ….1 
Q4VBD2 TAPT1   +   Transmembrane anterior posterior transformation protein 1 
Q3UBX0 TM109   ++   Transmembrane protein 109 
Q99LG2 TNPO2   + + + Transportin-2 
Q64737 PUR2   + + + Trifunctional purine biosynthetic protein adenosine-3 
Q505D9 TRI67   ++ ++ ++ Tripartite motif-containing protein 67 
Q91XI1 DUS3L    +  tRNA-dihydrouridine synthase 3-like 
Q99LF4 RTCB    + ++ tRNA-splicing ligase RtcB homolog 
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Table S.6 – continued:  Proteins recruited with APP on different liposomes. 
AccNo AccStr Ratio3 Ratio4 Ratio35 Ratio45 Ratio345 Name 
 
P32921 SYWC    + + Tryptophanyl-tRNA synthetase, cytoplasmic 
Q61037 TSC2   + + ++ Tuberin (Tuberous sclerosis 2 protein homolog) 
P68373 TBA1C    +  Tubulin alpha-1C chain 
P05214 TBA3   +  + Tubulin alpha-3 chain 
P68368 TBA4A    +  Tubulin alpha-4A chain 
Q9JJZ2 TBA8    +  Tubulin alpha-8 chain 
Q7TMM9 TBB2A    +  Tubulin beta-2A chain 
Q9ERD7 TBB3    +  Tubulin beta-3 chain 
P68372 TBB4B    +  Tubulin beta-4B chain 
P99024 TBB5    +  Tubulin beta-5 chain 
P83887 TBG1 +  ++ ++ ++ Tubulin gamma-1 chain 
Q921G8 GCP2   + ++ ++ Tubulin, gamma complex associated protein 2, isoform CRA_f 
Q8CIV8 TBCE   + + + Tubulin-specific chaperone E 
Q62393 TPD52 ++  - - - Tumor protein D52 (mD52) 
Q9CYZ2 TPD54 +  - - - Tumor protein D52-like 2 
Q61187 TS101    + + Tumor susceptibility gene 101 protein 
D3Z230 D3Z230   + + + Type I inositol 3,4-bisphosphate 4-phosphatase 
E9PVM1 E9PVM1     + Type II inositol 3,4-bisphosphate 4-phosphatase 
P41241 CSK   +  + Tyrosine-protein kinase CSK 
Q6PB44 PTN23 +  + +  Tyrosine-protein phosphatase non-receptor type 23 
Q80U87 UBP8    +  Ubiquitin carboxyl-terminal hydrolase 
Q99K46 UBP11    +  Ubiquitin carboxyl-terminal hydrolase 11 
Q9D9M2 UBP12 ++     Ubiquitin carboxyl-terminal hydrolase 12 
Q8R5H1 UBP15    + ++ Ubiquitin carboxyl-terminal hydrolase 15 
Q5DU02 UBP22   +  + Ubiquitin carboxyl-terminal hydrolase 22 
P35123 UBP4   +  + Ubiquitin carboxyl-terminal hydrolase 4 
P56399 UBP5   +   Ubiquitin carboxyl-terminal hydrolase 5 
Q9ES00 UBE4B   +   Ubiquitin conjugation factor E4 B 
G3X9Y5 G3X9Y5   +   Ubiquitination factor E4A, UFD2 homolog (S. cerevisiae) 
Q9D906 ATG7    + + Ubiquitin-like modifier-activating enzyme ATG7 
Q9ES34 UBE3B   +   Ubiquitin-protein ligase E3B 
Q80U95 UBE3C     + Ubiquitin-protein ligase E3C 
Q8VCH8 UBXN4     + UBX domain-containing protein 4 
Q8R059 GALE     + UDP-glucose 4-epimerase 
O70475 UGDH   +   UDP-glucose 6-dehydrogenase 
Q8VC42 MIC1   + + + Uncharacterized protein C18orf8 homolog 
Q80TK0 K1107     + Uncharacterized protein KIAA1107 
Q9JK81 MYG1   +  + UPF0160 protein MYG1, mitochondrial 
Q8BWQ6 CP062 ++  ++ +++ +++ UPF0505 protein C16orf62 homolog 
Q9CPT4 CS010   +  + UPF0556 protein C19orf10 homolog 
Q9CWN7 CB029 +   + + UPF0760 protein C2orf29 homolog 
P13439 UMPS    + + Uridine 5-monophosphate synthase 
P52623 UCK1     + Uridine kinase 
Q91YL3 UCKL1    + + Uridine-cytidine kinase-like 1 
Q6PDG8 MON1A   +  + Vacuolar fusion protein MON1 homolog A 
Q91W86 VPS11 +  + + + Vacuolar protein sorting-associated protein 11 homolog 
Q8BX70 VP13C +     Vacuolar protein sorting-associated protein 13C 
Q920Q4 VPS16    + + Vacuolar protein sorting-associated protein 16 homolog 
Q8R307 VPS18   +  + Vacuolar protein sorting-associated protein 18 homolog 
Q8C0E2 VP26B ++   + + Vacuolar protein sorting-associated protein 26B 
Q9QZ88 VPS29 ++  + ++ ++ Vacuolar protein sorting-associated protein 29 
Q9D2N9 VP33A    + + Vacuolar protein sorting-associated protein 33A 
P59016 VP33B +   -  Vacuolar protein sorting-associated protein 33B 
Q9EQH3 VPS35 ++  + + + Vacuolar protein sorting-associated protein 35 
Q8VEJ9 VPS4A    ++  Vacuolar protein sorting-associated protein 4A 
P46467 VPS4B    ++ + Vacuolar protein sorting-associated protein 4B 
Q5SPW0 VPS54   +   Vacuolar protein sorting-associated protein 54 
Q0P5W1 VPS8   + + + Vacuolar protein sorting-associated protein 8 homolog 
Q9CQ80 VPS25     + Vacuolar protein-sorting-associated protein 25 
Q9Z1Q9 SYVC   +   Valyl-tRNA synthetase 
Q8R5L3 VPS39  +  + + Vam6/Vps39-like protein 
P50544 ACADV ++  + +  Very long-chain specific acyl-CoA dehydrogenase …. 
P46460 NSF    + + Vesicle-fusing ATPase 
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Table S.6 – continued:  Proteins recruited with APP on different liposomes. 
AccNo AccStr Ratio3 Ratio4 Ratio35 Ratio45 Ratio345 Name 
 
Q8VDJ3 VIGLN   + + + Vigilin 
P62482 KCAB2 +  + + + Voltage-gated potassium channel subunit beta-2 
Q9Z1G4 VPP1   +   V-type proton ATPase 116 kDa subunit a isoform 1 
Q3UMB9 WASH7     + WASH complex subunit 7 
Q8R3E3 WIPI1 ++  +   WD repeat domain phosphoinositide-interacting protein 1 
Q80W47 WIPI2     ++ WD repeat domain phosphoinositide-interacting protein 2 
Q924H7 WAC   + ++ ++ WW domain-containing adapter protein with coiled-coil 
Q91WL8 WWOX     + WW domain-containing oxidoreductase 
Q6P1B1 XPP1     + Xaa-Pro aminopeptidase 1 
Q6ZPZ3 ZC3H4     + Zinc finger CCCH domain-containing protein 4 
Q810J8 ZFYV1   +  + Zinc finger FYVE domain-containing protein 1 
Q5DU37 ZFY26 +  + ++ + Zinc finger FYVE domain-containing protein 26 
 
 
 
 
 
